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ABSTRACT 
BACKGROUND: Women diagnosed with oestrogen receptor positive breast cancer are prescribed 
endocrine therapies, tamoxifen or aromatase inhibitors (AI), to block the effects of oestrogen on the 
growth of tumour cells. Tamoxifen is known to be associated with an increased risk of venous 
thromboembolic events, but the long-term effect of both tamoxifen and AI use on the risk of a range 
of distinct cardiovascular diseases (CVD) remain unclear.  
METHODS: Two studies were carried out using prospectively collected data from the UK Clinical 
Practice Datalink linked with Hospital Episode Statistics, and data from the US SEER-Medicare 
database, to assemble cohorts of postmenopausal women diagnosed with breast cancer. Cox 
proportional hazards regression models were used to examine the associations between tamoxifen 
and AIs and a comprehensive range of CVDs in both the UK and US study populations. The UK study 
directly compared AI users with tamoxifen users; the US study included a third “unexposed” group of 
women with oestrogen receptor positive breast cancer prescribed no endocrine therapies. 
RESULTS: Results in the UK study suggested a pattern of an increased risk of non-venous CVDs in AI 
compared with tamoxifen users, with evidence of an increased risk of heart failure and arrhythmias 
in AI compared with tamoxifen users (adjusted HR: 1.70, 95% CI: 1.26-2.29; adjusted HR: 1.38, 95% 
CI 1.12-1.70 respectively). The US study then suggested that these associations may be driven by a 
decreased risk of non-venous CVD outcomes in tamoxifen users compared with those unexposed, 
with adjusted HRs ranging from 0.44 (95% CI: 0.30-0.63) in the myocardial infarction analysis to 0.91 
(95% CI: 0.75-1.10) in the peripheral vascular disease analysis. Evidence of a modest reduced risk of 
several non-venous CVD outcomes among AI users compared with those unexposed was also 
observed, but results were suggestive of residual confounding. As expected there were more venous 
thromboembolic events in tamoxifen users compared with both AI users and those unexposed. 
There was a general consistency between comparable results in the two studies.  
CONCLUSIONS: Among postmenopausal women diagnosed with breast cancer, there was convincing 
evidence of a higher risk of several non-venous CVDs in those prescribed an AI compared with those 
prescribed tamoxifen, but this appeared to be driven by protective effects of tamoxifen on these 
outcomes, rather than any toxic effects of AIs. The known association between tamoxifen use and an 
increased risk of venous thromboembolism was also confirmed. As more postmenopausal women 
diagnosed with oestrogen receptor positive breast cancer are prescribed AIs rather than tamoxifen, 
additional large-scale population based studies are needed to better understand the risk-benefit 
balance of endocrine therapies with respect to both cancer and cardiovascular outcomes.  
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1 BACKGROUND 
This chapter will give an overview of the definition and epidemiology of breast cancer and 
cardiovascular disease (CVD), and discuss the overlap between the two diseases with respect to their 
risk factors. This is followed by a description of the aims and objectives of the thesis. 
 
1.1 BREAST CANCER 
1.1.1 Definition and diagnosis 
Breast cancer is the formation of malignant tumours in the breast tissue. The main symptoms of 
breast cancer are a lump in the breast, a change in the shape and size of the breast, nipple 
retraction, dimpling of the skin, or patches of red on the skin of the breast.[1] In patients with 
suspected breast cancer or in those with a possible breast cancer detected through screening, 
investigations include ultrasounds and magnetic resonance imaging (MRI) scans, but final diagnoses 
are normally through a biopsy. Breast cancer can be diagnosed in both men and women, but this 
thesis will cover only breast cancer among female patients.   
 
1.1.2 Stage 
Breast cancer staging refers to the size of the tumour, and if it has spread when diagnosed. The TNM 
classification is widely used to determine the stage of breast cancer at diagnosis. It uses information 
on the following:   
 Tumour size (T) 
 Spread of the cancer to lymph nodes (N) 
 The presence of distant metastases (M) 
The cancer is then given a stage of 0, I, II, III, or IV, with stage 0 being in situ, stage I being early 
locally invasive cancer, and stage IV the most advanced metastatic disease.[2] 
 
1.1.3 Grade 
The Nottingham grading system is a description of breast tumours used to indicate how quickly it is 
likely to grow and spread. The system grades tumours based on the following features:  
 Tubule formation - how much of the tumour tissue has normal breast duct structures 
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 Nuclear grade - an evaluation of the size and shape of the nucleus in the tumour cells 
 Mitotic rate - how many dividing cells are present 
The tumour is then given a grade from 1 to 3, with grade 1 being a low grade or well-differentiated 
tumour, and grade 3 being a high grade or poorly differentiated tumour.[3] Well-differentiated 
cancer cells present like normal cells under a microscope and tend to grow and spread slower than 
poorly differentiated cancer cells. 
 
1.1.4 Molecular subtypes 
There are up to 21 distinct histological subtypes and at least 4 different molecular subtypes of breast 
cancer that differ in terms of risk factors, presentation, response to treatment, and outcomes.[4-6] 
Approximations of molecular subtypes use the biological markers oestrogen receptor (ER), 
progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). The four main 
subtypes are:  
 Luminal A (ER+/PR+ (ER+ or PR+) and HER2-) (73% of breast cancers [7]) - slow growing and 
relatively less aggressive breast cancers, which have the most favourable prognosis, partly 
because they are more responsive to endocrine therapy.[8, 9]  
 Triple negative (ER-, PR- and HER2-) (12% of breast cancers [7]) - Poorer short-term 
prognosis than other subtypes, partly because there are currently no targeted therapies for 
these tumours.[10]  
 Luminal B (ER+/PR+ and HER2+) (10% of breast cancers [7]) - Tend to be higher-grade breast 
cancers and are associated with poorer survival than luminal A cancers.[9]  
 HER 2-enriched (ER-, PR- and HER2+) (5% of breast cancers [7]) - Grow and spread more 
aggressively than other subtypes and are associated with poorer short-term prognosis 
compared with ER+/PR+ breast cancers.[9] 
 
1.1.5  Treatment 
This section will cover the UK guidelines on breast cancer treatment, but any differences in 
guidelines will be taken into account when analysing data from the US. Following diagnosis of an 
early or locally advanced breast cancer, women typically undergo breast-conserving surgery such as 
lumpectomy, partial mastectomy, quadrantectomey, or a complete mastectomy. The extensiveness 
15 
 
of surgery is dependent on the stage, grade, and biology of the tumour; breast size; and other risk 
factors such as germline mutations in the BRCA genes. Whilst waiting for the BRCA status of the 
tumour to return, women will potentially receive neo-adjuvant systemic treatment in an attempt to 
shrink large cancer tumours prior to surgery, or instead of surgery if necessary. Following surgery, a 
decision will be made on the best adjuvant treatment for the woman based on the assessment of 
the prognostic and predictive factors of the cancer, and the potential benefits and side effects of 
treatment. The four main types of treatment are chemotherapy, biological therapy, radiotherapy, 
and endocrine therapy.  
 
1.1.5.1 Chemotherapy 
Chemotherapy agents typically work through inhibition of DNA and RNA synthesis, preventing the 
replication of rapidly growing cancer cells. The decision to offer chemotherapy to a women typically 
depends on the risk of recurrence of breast cancer, age, and personal preferences.[11] Women at 
low risk of recurrence are not recommended chemotherapy as the absolute survival benefit for 
chemotherapy is either unproven or extremely small. The factors contributing to what defines 
women at low or high risk are outlined in Table 1.1. The accepted chemotherapy regimens for 
women at high risk of recurrence are: FEC (-T) (5-fluorouracil, epirubicin, cyclophosphamide (-
docetaxel)); EC (epirubicin, cyclophosphamide); AC (doxorubicin, cyclophosphamide); CMF 
(cyclophosphamide, methotrexate, 5-fluorouracil); TC (docetaxel, cyclophosphamide). The decision 
on whether to administer a regimen containing a taxane (docetaxel, paclitaxel) is dependent on the 
risk of recurrence, with the addition more likely in higher risk breast cancers. However, addition of a 
taxane is likely to induce additional risk of side effects such as neuropathy, neutropenia and 
hypersensitivity. Chemotherapy regimens are given over a period of 9 to 12 weeks (over 3 to 4 
cycles).[12]   
 
Women with more advanced disease may be administered neo-adjuvant chemotherapy to reduce 
tumour size prior to surgery, enabling some women to have breast-conserving surgery who would 
otherwise have a full mastectomy. However, only 17% of women convert from mastectomy to 
breast conservation after neo-adjuvant chemotherapy.[13] Furthermore, it has been suggested that 
neo-adjuvant chemotherapy does not confer any survival benefit compared with adjuvant 
chemotherapy (risk ratio (RR): 1.00, 95% CI: 0.90-1.12).[14] 
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Table 1.1: Overview of what constitutes a low- or high-risk breast 
cancer from the London Cancer Alliance guidelines [11] 
Low risk (all of the following 
factors) 
High risk (any of the following 
factors) 
 Tumour ≤2cm in diameter  Tumour ≥2cm in diameter 
 Oestrogen receptor (ER) 
positive 
 ER negative 
 Grade 1 histology  Grade 2 or 3 histology 
 No lympho-vascular 
invasion 
 Lympho-vascular invasion 
present 
 Negative Lymph nodes  Positive lymph nodes 
 Human Epidermal Growth 
Factor 2 (HER2) negative 
 HER2 positive 
 
 Younger than 35 years old 
 
1.1.5.2 Biological Therapy 
At diagnosis of breast cancer, the tumour tissue is tested for HER2 expression and women with 
overexpression should be considered for therapy with trastuzumab.[12] Trastuzumab is a 
monoclonal antibody that works by blocking the HER2 pathway, essentially stalling the growth of 
HER2 positive breast cancers. If required, adjuvant trastuzumab is given at 3-week intervals for one 
year in combination with surgery and other treatments. However, due to the known cardiotoxicities 
of trastuzumab, it is not recommended for use among women who have any of the following: 
 Left ventricular ejection fraction (LVEF) of 55% or less 
 History of documented congestive heart failure 
 High-risk uncontrolled arrhythmias 
 Angina pectoris requiring medication 
 Clinically significant valvular disease 
 Evidence of transmural infarction on electrocardiograph 
 Poorly controlled hypertension 
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Cardiac functional assessments are carried out prior to treatment initiation and then repeated every 
three months during treatment. If LVEF drops by 10% from baseline or to below 50%, suspension of 
trastuzumab is recommended.[12]   
 
1.1.5.3 Radiotherapy 
Radiation uses high-energy x-ray beams, such as photon beams, to damage the DNA of cancerous 
cells, so they are unable to replicate, and stopping further tumour growth. Radiotherapy is normally 
offered to women after breast conserving surgery, however, in women with a very low absolute risk 
of recurrence (over the age of 65 years with tumours that are early stage, grade 1-2, HER2-, and 
ER+/PR+) there is no evidence that radiotherapy increases overall survival, so any therapy is 
potentially omitted. In women who have a mastectomy, radiotherapy is given to those in which the 
cancer has spread to the under arm lymph nodes. However, among those with lymph node negative 
breast cancer only those that are stage III or IV are given radiotherapy due to limited evidence on 
decreased recurrence (RR for breast cancer recurrence in those irradiated vs not: 1.06, 95% CI: 0.76-
1.48), and worries of lung and cardiac morbidity being associated with radiotherapy due to the 
breasts being situated within close proximity of the heart and lungs.[15]  
 
1.1.5.4 Endocrine Therapies 
Oestrogen promotes the growth of ER+ breast cancers, and all patients with these tumours are 
indicated endocrine therapies to lower oestrogen, or block the effects of oestrogen on the growth of 
tumour cells. UK guidelines state that women with ER+ breast cancers (regardless of PR status) 
should be offered tamoxifen or aromatase inhibitors (AI) within 2-3 weeks after the completion of 
chemotherapy, or as soon as convenient after surgery if chemotherapy is not administered.[16] 
However, in routine practice endocrine therapies are prescribed to women with ER+/PR+ breast 
cancer as it has been shown that they are efficacious in certain sub-populations of with an ER- and 
PR+ diagnosis.[17] The remainder of this thesis will assume endocrine therapies are given to women 
with an ER+/PR+ breast cancer.  
 
Tamoxifen 
Tamoxifen is a selective oestrogen receptor modulator that works in breast tissue by inhibiting the 
growth of the tumour through competitive antagonism of oestrogen at its receptor. Premenopausal 
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women with invasive ER+/PR+ breast cancer are offered tamoxifen for an initial 5 years, which can 
be extended if the benefits of further therapy outweighs the risk of side effects such as thrombosis, 
endometrial cancer, and possible bone density loss.[12] Evidence suggests that 5 years of tamoxifen 
reduces the rate of breast cancer recurrence (RR: 0.53, 95% CI: 0.47-0.59) and breast cancer 
mortality (RR: 0.71, 95% CI: 0.61-0.80) in the decade following diagnosis, regardless of menopausal 
status.[18] However, there is no clear evidence of a benefit in disease recurrence (OR: 0.89, 95% CI: 
0.76-1.05) or overall survival (OR: 0.99, 95% CI: 0.84-1.16) from continuing tamoxifen for over 5 
years compared with stopping therapy after 5 years.[19] Postmenopausal women that are at low risk 
of disease recurrence, or those in whom AIs are not tolerated, are also offered tamoxifen.  
 
AIs 
Aromatase is responsible for the conversion of the adrenal androgen substrate androstenedione to 
oestrogen in the breast tissue, which is the main source of oestrogen in postmenopausal women. By 
inhibiting this process, AIs can reduce oestrogen production by over 90%.[20] As of 2006, when 
guidelines were changed, postmenopausal women with invasive ER+/PR+ breast cancer are offered 
AIs for an initial 5 years.[21] Prior to 2006, all women now eligible for AI therapy were offered 
tamoxifen. AIs are associated with a decrease in breast cancer recurrence in comparison with 
tamoxifen in postmenopausal women (RR: 0.78, 95% CI: 0.68-0.89).[22] Evidence also suggests that 
both extending therapy beyond 5 years instead of stopping, and switching to AIs after 2-3 years of 
tamoxifen therapy instead of continuing tamoxifen, decreases the risk of breast cancer recurrence 
(RR: 0.75, 95% CI: 0.65-0.86; and RR: 0.79, 95% CI: 0.65-0.92, respectively).[22, 23] Women with a 
high risk of recurrence are therefore recommended to continue treatment after the initial 5-year 
treatment, or switch from tamoxifen.  
 
1.1.6 Epidemiology 
Breast cancer remains the most common cancer worldwide, with the highest incidence in Europe, 
North America, and Australasia. Latest statistics reported an estimated 84,272 new cases per year in 
the UK, and 262,347 new cases per year in the US in 2018.[24] However, earlier detection through 
screening programs and the advent of new treatments has facilitated an increase in 5-year survival 
rate from 53% and 75% in the 1970’s to 87% and 91% in the 2010’s in the UK and US 
respectively.[25, 26] 
 
It is suggested that 23% of all breast cancers are preventable through modification of risk 
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factors.[27] There is evidence that increasing body mass index (BMI), alcohol use, and tobacco use is 
associated with breast cancer risk,[28-30] and 8% of all cases in the UK can be attributed to obesity 
and alcohol use individually.[27] There is also evidence that not breastfeeding and oral contraceptive 
use is associated with a 22% (95% CI: 18-26%) and 24% (95% CI: 15-33%) increased risk of breast 
cancer respectively.[31, 32] Women with one first degree relative who had breast cancer are known 
to have an 85% (95% CI: 69-91%) higher risk of breast cancer in comparison with those without,[33] 
and women carrying the BRCA1/2 gene mutations have a 45-65% increased risk by age 70.[34] 
Finally, several reproductive factors such as older age at first giving birth, younger age at menarche, 
older age at menopause, and not having children are known to be associated with an increased risk 
of breast cancer.[35] 
 
1.2 CVD 
1.2.1 Definition and diagnosis 
This thesis will focus on a range of clinically specific CVD outcomes. The World Health Organization 
(WHO) defines CVDs as a group of disorders of the heart and blood vessels. CVD can broadly be 
broken down into three main types: vascular disease, myocardial disease, and venous 
thromboembolism.  
 Vascular disease – disease of the blood vessels, arteries and, and veins of the circulatory 
system. 
 Myocardial disease – conditions which affect heart muscle but spare other anatomic 
structures within the cardiovascular system. 
 Venous thromboembolism – blood clots in the veins, which can dislodge and move into the 
heart and lungs. 
 
CVD is a disease of many different sub-types, and there is not one homogenous diagnosis. This thesis 
will explore 12 clinically specific CVD outcomes that are defined below. Throughout the thesis the 
outcomes will regularly be grouped into venous and non-venous CVD. Venous outcomes refer to all 
venous thromboembolic events such as deep vein thrombosis and pulmonary embolism, and non-
venous outcomes refer to all other CVD outcomes described below. The reason for this binary 
distinction is due to the known increased risk of venous CVD outcomes associated with tamoxifen 
use, and the homogenous direction of effect when exploring the risk of endocrine therapy use on all 
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other non-venous CVD outcomes. Although grouping all non-venous CVDs is not standard within the 
cardiology literature, it is relevant for this study question and will allow ease of reporting within the 
thesis.  
 
1.2.1.1 Angina 
Angina is characterised by discomfort that occurs when myocardial oxygen demand exceeds the 
supply, and can generally by classified into stable and unstable angina. Unstable angina, an attack 
usually follows a precipitating event (climbing stairs, a heavy meal, emotional stress etc.) and has the 
same severity as previous attacks. The onset of stable angina is due to fixed narrowing or stenosis of 
the coronary blood vessels. Unstable angina occurs because of incomplete or temporary coronary 
artery occlusion from plaque rupture, and has increasing severity, duration, or frequency over 
time.[36, 37] Common symptoms of angina are chest pain, breathlessness, and nausea.  
 
Patients with suspected stable angina normally undergo an initial clinical assessment that includes 
physical examination and an assessment of blood pressure, haemoglobin, thyroid function, 
cholesterol and glucose levels. Patients then undergo a series of diagnostic tests including a 12-lead 
electrocardiography (ECG), exercise tolerance testing, and myocardial perfusion scintigraphy,[38] 
and those with abnormal measures are diagnosed by clinicians. ECG, high-sensitivity troponin tests, 
and computed tomography (CT) angiography are used to diagnose unstable angina.[38] 
 
1.2.1.2 Myocardial Infarction (MI) 
Coronary artery occlusion, due to rupture of built up plaques in coronary blood vessels and resulting 
blockage, causes most cases of MI.[39]. Common symptoms of an MI include severe chest pain, pain 
in other parts of the body, dizziness, shortness of breath, and nausea. 
 
Investigation of MI includes ECG and measurements of high sensitivity cardiac troponin, which are 
biomarkers indicative of tissue death. A diagnosis requires at least abnormal ECG readings, and rise 
or fall of  cardiac troponin above the 99th percentile.[40] 
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1.2.1.3 Revascularisation 
Following occlusion of coronary blood vessels, coronary revascularisation is the process of restoring 
the flow of blood to the heart. The most common procedure is coronary artery bypass grafting 
(CABG), where vessels from other parts of the body (usually chest, leg, or arm) are used to surgically 
divert blood around the occlusion. Another method of revascularisation is Percutaneous Coronary 
Intervention (PCI), which is a non-surgical procedure that uses a catheter to place a stent to open up 
blood vessels in the heart that have been narrowed by plaque build-up. In CABG, bypass grafts are 
placed to the mid-coronary vessel beyond the “culprit” lesion, providing extra sources of blood flow 
to the myocardium and offering protection against the consequences of further obstructive disease. 
In contrast, coronary stents aim to restore the normal flow of the coronary vessel without offering 
protection against new disease proximal to the stent.[41] 
 
Revascularisation procedures can be offered to patients presenting with stable multi-vessel and/or 
left main coronary artery disease. Although revascularisation is essentially an intervention, it can 
help to capture coronary artery diseases that are otherwise not captured by general practitioner 
(GP) or hospital systems when identifying outcomes in routinely collected data.  
 
1.2.1.4 Sudden Cardiac Arrest (SCA) 
SCA is absent or inadequate contraction of the ventricles of the heart that immediately causes 
circulatory failure. If not treated immediately, SCA usually results in death. Most commonly, the 
sequence of events leading to arrhythmic SCA is the degeneration of ventricular tachycardia (VT) 
into ventricular fibrillation (VF), followed by asystole or pulseless electric activity.[42] Pre-existing 
coronary artery disease (acute myocardial ischemia, scarring from previous myocardial infarction, 
heart failure) are present in 80% of SCAs. Dilated non-ischemic and hypertrophic cardiomyopathies 
account for the second largest number of SCAs, whereas other cardiac disorders such as congenital 
heart disease and underlying genetically determined ion channel anomalies account for 5% to 10% 
of SCAs.[43] Signs and symptoms include loss of consciousness, rapid shallow breathing progressing 
to apnea, and profoundly low blood pressure. 
 
1.2.1.5 Peripheral Vascular Disease (PVD) 
PVD is facilitated through atherosclerotic plaque causing arterial stenosis or occlusion and reducing 
blood flow and oxygen supply to the body. Critical limb ischemia happens when reduction of blood 
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loss is so severe that there is pain during rest, ulceration, or gangrene.[44] Although asymptomatic 
in many people, some may experience intermittent claudication (muscle pain on mild exertion). 
 
Initial exploration of PVD is through the use of the ankle-brachial index (ABI) that compares the 
blood pressure in the feet to the blood pressure in the arms and determines how well blood is 
flowing. If a patient records an ABI score of below 0.9 or above 1 .4, which is considered abnormal, 
they are referred for further testing through Doppler and Ultrasound imaging, CT Angiography, 
Magnetic Resonance Angiography, or Angiography.[45]  
 
1.2.1.6 Stroke 
Stroke is characterised as a neurological deficit attributed to an acute injury of the central nervous 
system by a vascular cause lasting more than 24 hours or leading to death, and can be due to 
cerebral infarction, intracerebral haemorrhage, and subarachnoid haemorrhage. Ischemic strokes 
are an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction, 
where blood flow is to the brain is restricted. Strokes caused by intracerebral haemorrhage show 
rapidly developing clinical signs of neurological dysfunction attributable to a focal collection of blood 
within the brain parenchyma or ventricular system that cannot be attributed to trauma. Stroke 
caused by subarachnoid haemorrhage show rapidly developing signs of neurological dysfunction 
and/or headache because of bleeding into the subarachnoid space that also cannot be attributed to 
trauma. Transient ischemic attacks are those episodes of temporary and focal dysfunction of 
vascular origin that leave no persistent neurological deficit and are variable in duration, commonly 
lasting from 2 to 15 minutes, but occasionally lasting as long as a day.[46] Symptoms of a stroke 
include a drooped face on one side, weak or numb arms, slurred speech, paralysis of one side of the 
body, dizziness, and balance or coordination problems. 
 
CT scanning and magnetic resonance imaging of the brain are the main methods used to diagnose a 
stroke and identify if the source is ischemic or haemorrhagic. Although commonly measured 
markers include S100 calcium binding protein B or S100B, glial fibrillary acidic protein, brain 
natriuretic peptide, and matrix metalloproteinase-9, none of these biomarkers are routinely 
measured to inform diagnoses.[46]  
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1.2.1.7 Arrhythmia 
Arrhythmias occur due to the heart rate being too fast (tachycardia, >90-100 beats per minute 
(bpm)), too slow (bradycardia, <50-60 bpm), or beating irregularly. The three main mechanisms of 
arrhythmias are: abnormal automaticity due to creation of electrical impulses by non-pacemaker 
cells of the myocardium because they acquire automaticity and spontaneously depolarize; triggered 
electrical activity which is the abnormal propagation of electrical activity in individual heart cells and 
are often due to problems in the ion channels in the heart muscle cells; and re-entry that happens 
when the electrical impulse travels backwards from the ventricles to the atria, initiating another 
heartbeat while the first heartbeat is still descending into the ventricles.[47] Common symptoms of 
arrhythmia include palpitations, dizziness, fainting, and breathlessness.  
 
The most common method used to diagnose arrhythmias is through electrocardiograms, allowing 
clinical evaluation of the electrical activity of the heart within each contraction.  
 
1.2.1.8 Heart failure (HF) 
HF is the pathophysiological process in which the heart is unable to meet the metabolic 
requirements of the tissue for oxygen and substrates. Broadly, HF is due to abnormalities in the 
myocardium leading to inabilities to fulfil its function in pumping blood around the body. Systolic HF 
is characterised by a reduced ejection fraction (a measurement, expressed as a percentage, of how 
much blood the left ventricle pumps out with each contraction) and an enlarged left ventricular 
chamber, and is clinically associated with left ventricular failure in the presence of cardiomegaly. 
Diastolic HF is characterised by an increased resistance to filling with increased filling pressure, 
which is accompanied by pulmonary congestion with a normal or slightly enlarged ventricle.[48] 
Common symptoms of HF include breathlessness, fatigue, and swollen ankles and legs.  
 
Diagnosis is through echocardiogram coupled with Doppler flow studies and measurement of B-type 
natriuretic peptide. Based on left ventricular ejection fraction, HF is defined as follows:[49]  
1. HF with reduced ejection fraction: symptoms and signs with LVEF <40%. 
2. HF with mid-range ejection fraction: symptoms and signs with LVEF 40% to 49%. Other 
features include elevated natriuretic peptides (B-type natriuretic peptide (BNP) >35 
nanograms/L (>35 picograms/mL) or N-terminal pro-brain natriuretic peptide (NT-pro-BNP) 
>125 nanograms/L (125 picograms/mL)) and at least one additional criterion: (a) relevant 
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structural heart disease (e.g., left ventricular hypertrophy (LVH) or left atrial enlargement), 
(b) diastolic dysfunction. 
3. HF with preserved ejection fraction: symptoms and signs with LVEF >50%. Other features 
include elevated natriuretic peptides (BNP >35 nanograms/L (>35 picograms/mL) or NT-pro-
BNP >125 nanograms/L (>125 picograms/mL)) and at least one additional criteria: (a) 
relevant structural heart disease (e.g., LVH or left atrial enlargement), (b) diastolic 
dysfunction. 
 
1.2.1.9 Pericarditis 
The pericardium is a fibroelastic sac made up of visceral and parietal layers separated by the 
pericardial cavity. In healthy individuals, the pericardial cavity contains 15-50 ml of an ultrafiltrate of 
plasma. Pericarditis is the inflammation of the pericardial sac. Common symptoms include sharp 
chest pain, breathlessness, palpitations, fever, and fatigue.  
 
Diagnoses are normally made through electrocardiogram, chest radiography, biomarker count 
(troponin level, erythrocyte sedimentation rate, and C-reactive protein level), and echocardiogram. 
Pericarditis can be diagnosed with at least two of: pericarditic chest pain; pericardial rubs; new 
widespread ST-elevation or PR depression on electrocardiogram; or pericardial effusion. Additional 
supporting findings include elevation of the biomarkers outlined above. Pericarditis can be acute (<4 
weeks), incessant (>4 weeks but <3 months, without remission), recurrent (recurrence of an episode 
with a symptom-free interval of >4 weeks), or chronic (lasting longer than 3 months).[50]  
 
1.2.1.10 Valvular Heart Disease (VHD) 
VHD is caused by either damage or defect in one of the four heart valves (aortic, mitral, tricuspid or 
pulmonary), which can be either congenital or acquired. The dominant functional and anatomic 
consequences of VHD are stenosis and insufficiency. Stenosis is a mild thickening of the valve, which 
results in severe impairment of the valve motion, and insufficiency describes the inability of the 
valve to close properly and prevent back flow of blood.[51] Common symptoms of VHD are 
breathlessness, swelling of feet and ankles, and tiredness.  
 
Echocardiography is the key technique used to confirm a diagnosis of all types of VHD,[52] allowing 
assessment of the appearance and mobility of valves. Other techniques consist of Doppler 
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parameters including peak velocity, mean gradient, and effective orifice area; aortic size 
measurement; left ventricular geometry and function; pulmonary artery size and pressure; and 
colour mapping of the valves.  
 
1.2.1.11 Deep Vein Thrombosis (DVT) 
DVT refers to one or more thrombi in one of the body’s large veins, most commonly in the lower 
limbs, that cause partial or complete blocking of the circulation of the vein. Virchow’s triad described 
the three broad categories that contribute to thrombosis: venous stasis, vascular injury, and 
hypercoagulability. The presence of venous stasis and either of the other two factors greatly 
increases the risk of clot formation. VTE regularly occurs in areas with decreased or altered blood 
flow, such as pockets adjacent to valves in the deep veins of the leg.[53] Common symptoms of DVT 
include pain in legs, and warm or red skin around affected area.  
 
Diagnosis of DVT is initiated though a d-dimer test, that allows people who are unlikely to have DVT 
to be ruled out. Doppler venous ultrasound is then the first line DVT imaging modality and allows 
detection of thrombi. If a diagnosis cannot be confirmed, patients then undergo venous CT 
scans.[54]  
 
1.2.1.12 Pulmonary Embolism (PE) 
Pulmonary embolism occurs when a deep vein thrombosis breaks free, passes through the right side 
of the heart, and lodges in the pulmonary arteries, resulting in partial or complete occlusion.[55] 
Evidence of DVT in the legs is found in around 70% of patients with PE. Patients with PE most 
regularly present with dyspnoea with or without pleuritic pain and haemoptysis (acute minor 
pulmonary embolism). The second most common presentation is haemodynamic instability, which is 
associated with acute massive pulmonary embolism. The third and least common presentation 
mimics heart failure or indolent pneumonia, especially in the elderly.[56] Common symptoms of PE 
include breathlessness and chest pain.  
 
D-dimer tests are again used to rule out a PE diagnosis, and CT scans are the primary diagnostic test 
for PE, allowing thrombi to be identified in the pulmonary arteries.[57]   
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1.2.2 Treatment 
Drug treatment for CVD has two main aims: relieve symptoms of the diagnosis, and reduce the risk 
of recurrence or worsening. Treatments can also be used for CVD prevention measures. The main 
drug treatments are:  
 Angiotensin-converting enzyme (ACE) inhibitors – decrease blood pressure by reducing the 
activity of the renin–angiotensin–aldosterone system through blocking the conversion of 
Angiotensin I to Angiotensin II.[58] 
 Statins – reduce cholesterol by competitively inhibiting HMG-CoA reductase.[59] 
 Angiotensin-II antagonists – decrease blood pressure by blocking the activation angiotensin 
II receptors, causing vasodilation.[60] 
 Beta blockers – decrease blood pressure by reducing the heart rate through inhibition of β-
adrenergic receptors.[61] 
 Calcium channel blockers – decrease blood pressure by disrupting the movement of calcium 
though calcium channels.[62] 
 
1.2.3 Epidemiology 
CVD causes 17.9 million deaths worldwide every year, which accounts for 31% of all global 
deaths.[63] There are around 7 and 92 million people living with CVD in the UK and US 
respectively.[64, 65] Although CVD continues to be large burden on the health of society, age 
standardised mortality from CVD has fallen 70% over the last 30 years in the UK, from 1,152 per 
100,000 in 1979 to 333 per 100,000 in 2013.[66] 
 
High blood pressure, increasing BMI, high cholesterol levels, unhealthy diet, physical inactivity, and 
tobacco and alcohol use are known to be associated with an increased risk of CVD, with 49% of all 
coronary artery diseases attributable to high blood pressure, 56% to high cholesterol, 21% to high 
BMI, 31% to unhealthy diet, 22% to physical inactivity, 12% to tobacco, and 2% to alcohol.[67] 
Overall, it is estimated that 83–89% of all coronary heart diseases and 70-76% of all strokes could be 
prevented and are attributable to the joint effects of these modifiable risk factors.[67] There is an 
increasing prevalence of CVD as age increases,[66] and evidence also suggests that type 2 diabetes is 
associated with an increased risk of all CVD outcomes other than arrhythmia and sudden cardiac 
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arrest.[68] A CVD diagnosis in at least one parent is also known to be associated with an increased 
risk of the disease.[69] 
 
1.3 INTERSECTION OF BREAST CANCER AND CVD 
In older women diagnosed with breast cancer, there is a greater likelihood of dying of diseases other 
than cancer itself, with CVD being the most frequent other cause.[70, 71] The risk of CVD is also 
higher in women with a breast cancer diagnosis compared with those without.[72] This overlap 
between breast cancer and risk of CVD is likely to be due to either similar risk factors, cardiotoxicity 
of treatments, or a combination of the two.  
 
1.3.1 Risk factors 
CVD may be a particular problem for those breast cancer survivors with existing CVD risk factors as 
many of these overlap with the risk factors of breast cancer (Figure 1.1). Uptake of a number of 
behaviours aimed at increased CVD health, such as diet, activity, and smoking, have also been shown 
to be associated with a lower incidence of breast cancer.[73] Lifestyle changes can therefore be a 
means by which women diagnosed with breast cancer are able to reduce the risk of breast cancer 
recurrence, as well as the risk of CVD. 
 
Figure 1.1: Risk factors for CVD and breast cancer [74] 
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1.3.2 Cardiotoxicity of treatments 
As women are living longer following a diagnosis of breast cancer, there are more opportunities for 
any medium- to long-term adverse effects of treatments to manifest, be those effects of individual 
therapies or regimens incorporating multiple agents. Evidence suggests both early and delayed toxic 
effects of several breast cancer therapies. For example, there is known to be no safe dose 
anthracycline (doxorubicin, epirubicin), as even women administered the lower doses of the drug 
are at risk of experiencing cardiotoxicity such as heart failure, arrhythmias, atrial fibrillation, and left 
ventricular dysfunction.[75-77] Administration of the taxane paclitaxel has been shown to be 
associated with bradycardia, with patients in a clinical trial experiencing heart rates of <40 bpm.[78] 
MI, HF, and arrhythmias have been reported as side effects of 5-fluorouracil, but evidence is not 
conclusive,[79-81] and any effects are thought to be acute, with long-term cardiotoxicity 
uncommon.[82] There is also a known association between trastuzumab, used in women with 
HER2+ breast cancer, and heart failure. However, this toxic effect is mostly reversible.[83] Finally, 
there was an excess of non–breast cancer deaths after 5 years among patients receiving 
radiotherapy, with CVD being one of the main causes of death.[84] Left-sided breast cancer patients 
treated with radiotherapy have a 90% (95% CI: 52-137%) increased risk of CVD mortality over 20 
years compared with those treated with radiotherapy for right-sided breast cancer.[85] 
 
This thesis will focus on the cardiotoxicities associated with endocrine therapy use. Several 
systematic reviews and meta-analyses have attempted to map out the risk of CVD associated with 
use of tamoxifen, AIs, and the comparative risk between the two drugs.[86-91] The systematic 
review in Chapter 2 fully reviews all currently available evidence, but broadly, these reviews have 
suggested that tamoxifen use is associated with an increased risk of venous thromboembolic events 
such as DVT, and potentially a decreased risk of coronary heart disease outcomes in comparison 
with both AI use and no tamoxifen or placebo. Little conclusive evidence is available on the 
associations between AI use and CVD. Many of the randomised controlled trials (RCT) that have 
explored the cardiotoxicity associated with AI use have included CVD events as a secondary 
consideration, with breast cancer recurrence being the primary outcome. Several observational 
studies have also explored this association, but the majority of these studies have used composite 
CVD outcome definitions, which do not take into account the clinical nuances between specific 
CVDs. 
 
It is known that tamoxifen use lowers total serum cholesterol by 10-20% and low-density lipoprotein 
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levels by 15-22%, but there is no known effect on high-density lipoprotein cholesterol.[92-95]. The 
reduction in cholesterol may therefore explain any protective effects of tamoxifen on CVD. However, 
the oestrogen agonistic effects of tamoxifen and resulting increase in thrombogenicity, through a 
reduction in antithrombin and protein C levels,[96, 97] could also explain a toxic effect on the risk of 
venous thromboembolic events. Furthermore, AIs work by inhibiting the aromatase enzyme and 
depleting oestrogen levels, which are known to be protective of CVD. There is therefore a biological 
explanation for any increased risk of CVD associated with AI use.   
 
Fully understanding the cardiotoxicities of AIs is increasingly important in post-menopausal women 
as guideline changes in 2006 suggested that these women are primarily given AIs rather than 
tamoxifen. A full understanding of the risk of clinically specific CVDs associated with AI in comparison 
with tamoxifen use, as well as the risks associated with both treatments alone, is crucial in 
understanding the full safety profile of endocrine therapies in post-menopausal women.   
 
1.4 AIMS AND OBJECTIVES 
The overall aim of this thesis is to assess the effect of endocrine therapy use on the risk of a range of 
CVD outcomes in female breast cancer survivors. The specific objectives are:  
1. Review RCT and observational evidence regarding the association between endocrine 
therapy use and a range of clinically specific CVD outcomes in female breast cancer 
survivors. 
2. Explore codes and algorithms to define and detect CVD outcomes in primary and secondary 
care in routinely collected UK data.  
3. Assess the effect of AI in comparison with tamoxifen use on the risk of a range of clinically 
specific CVD outcomes in a cohort of post-menopausal female breast cancer survivors in the 
UK. 
4. Assess the effect of AI use, tamoxifen use, and the comparative effect between use of the 
two endocrine therapies on the risk of a range of clinically specific CVD outcomes in a cohort 
of post-menopausal female breast cancer survivors in the US. 
5. Compare the methodology, results, and conclusions between the studies in the UK and US, 
then modify the methodology of both studies until they are as similar as possible, and 
compare modified results.    
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1.5 OUTLINE OF THESIS 
This thesis follows the research paper style format, with articles incorporated into chapters, and 
other chapters written in a more traditional style. Three articles have been written, one of which has 
been published, and two that are formatted as pre-submission manuscript drafts. The thesis will be 
organised as follows:  
 Chapter 2 – a published systematic review of long-term adjuvant endocrine therapy use and 
the risk of cardiovascular disease in female breast cancer survivors. 
 Chapter 3 – an overview of the data sources used for the original analyses in the thesis. 
 Chapter 4 – investigation into how CVD outcomes are captured in UK primary and secondary 
care data, followed by development and assessment of CVD outcome definitions. 
 Chapter 5 – final draft of a paper assessing the effect of endocrine therapy use on the risk of 
CVD in the UK. 
 Chapter 6 - final draft of a paper assessing the effect of endocrine therapy use on the risk of 
CVD in the US. 
 Chapter 7 – comparison of the UK and US studies, and analysis in which both studies are 
modified to make them as similar as possible 
 Chapter 8 – summary of the main results in the context of what is already known, discussion 
of the strengths and limitations of the studies, and implications for clinical practice and 
future work.  
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1.6 SUMMARY  
 
 
  
 Breast cancer is the most common cancer worldwide, but advances in detection and 
treatment has meant there is now a relatively high five-year survival rate.  
 Breast cancer is the formation malignant tumours in the breast tissue and has a variety of 
subtypes based on stage, grade, and biology of the tumour.  
 The main treatment modalities are chemotherapy, biological therapy, radiotherapy, and 
endocrine therapy. 
 Over 80% of breast cancers are defined as ER+/PR+ 
 Endocrine therapies (tamoxifen and AIs) are used to reduce the recurrence of ER+/PR+ 
breast cancer for at least five years following surgery. 
 Breast cancer survivors may be at a higher risk of CVD, a group of disorders of the heart 
and blood vessels, due to shared risk factors, cardiotoxicity of treatments, or a 
combination of the two.  
 Previous evidence has suggested that tamoxifen use is associated with an increased risk of 
venous thromboembolic events, and potentially a decreased risk of coronary heart disease 
outcomes in comparison with both AI use and no tamoxifen or placebo. Little conclusive 
evidence is available on the associations between AI use and CVD.  
 This thesis will investigate the effects of tamoxifen and AI use on a range of clinically 
specific CVD outcomes, first through a review of existing evidence, then through analysis 
of data from the UK and US.   
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2 LONG TERM ADJUVANT ENDOCRINE THERAPY AND RISK OF 
CARDIOVASCULAR DISEASE IN FEMALE BREAST CANCER 
SURVIVORS: SYSTEMATIC REVIEW  
 
This chapter includes a systematic review that collated all available evidence on the risk of 
cardiovascular disease associated with endocrine therapy used in female breast cancer survivors. 
This review was published in the British Medical Journal in October 2018. Online appendices that 
were published alongside the review are available at the end of the thesis.  
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2.2 MOTIVATION FOR THESIS 
Given the results of the systematic review, it is clear that there are several gaps in knowledge for the 
association between endocrine therapies and the risk of CVD. There is a lot of evidence available for 
the effect of both endocrine therapies (both comparatively and individually) on the risk of some 
clinically specific CVD events (MI, stroke, and VTE), but there are still several outcomes for which 
there is little or no evidence (HF, arrhythmia, angina, revascularisation, SCA, cardiomyopathy, VHD). 
Given the widespread use of AIs in postmenopausal women diagnosed with ER+/PR+ breast cancer, 
it is important to fully classify such risks. The remainder of this thesis will therefore aim to assess the 
risk of a full range of clinically specific CVD outcomes associated with endocrine therapy use in 
postmenopausal women diagnosed with ER+/PR+ breast cancer.  
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3 DATA SOURCES 
3.1 INTRODUCTION 
This chapter summarises the data sources used in the UK and US studies, as well as an outline of my 
contribution to the data acquisition, cleaning, and curating.  
 
3.2 UK STUDY   
3.2.1 Data sources 
Analyses carried out in UK data for this project utilised two EHR databases: the UK Clinical Practice 
Research Datalink (CPRD) and linked Hospital Episode Statistics (HES).  
 
3.2.1.1 CPRD 
The CPRD Gold (hereafter referred to as the CPRD) is a primary care database containing 
anonymised data from over 700 GP practices in the UK that use the Vision IT system, covering 
around 6.9% of the UK population.[98] Those included have been shown to be broadly 
representative of the UK population in terms of age, sex and ethnicity.[99]  The CPRD includes 
patient-level information from GP surgeries such as consultations, clinical diagnoses, prescriptions in 
primary care, tests, immunisations, and referral to hospitals. There is also information on lifestyle 
measures that are collected by GPs such as smoking, alcohol use, and BMI. In addition to these 
routinely collected data, there may be records of information from some secondary sources that 
have been passed on to GPs, such as major diagnoses made in hospitals. All diagnoses in the CPRD 
are recorded using the hierarchical Read code classification system. Read codes have a 
corresponding description, allowing users of these data to identify diagnoses and their related 
codes. However, GPs can also input patient information in the form of free text and scans of hospital 
letters without coding, which could lead to missing information as these data are not available for 
research. Prescription records are created automatically when a GP issues a prescription, so capture 
of primary care prescriptions should be almost 100%. Prescription drugs are recorded with a unique 
CPRD generated product code and description of the drug for each type of prescription. Once data 
are recorded by GP practices, they undergo a series of validity checks, both at the patient and 
practice level. Patient level acceptability is based on their registration status, recording of events in 
the patient record, and valid age and gender. Each practice is also given an ‘up to standard date’, 
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which indicates the date from which an individual practice includes reliable data.[98] In depth 
documentation provided by CPRD on the definition of patient and practice level acceptability is 
available in Appendix 3.1. CPRD data have been shown to be highly valid in regards to most clinical 
diagnoses. A systematic review of validation studies reported that the median proportion of 
neoplasm and circulatory system cases in CPRD confirmed by another source was 95% and 85% 
respectively.[100] Specifically breast cancer diagnoses are highly valid, with 96% of cases in CPRD 
also being recorded in either the UK national cancer registry or another data source.[101] Lifestyle 
measures such as smoking and BMI have also been shown to be highly valid in the CPRD,[102, 103] 
but can be prone to substantial missingness.   
 
Data Structure 
Each patient in the CPRD has a unique patient identifier (patient ID), which can be used to link the 
files in which all data are stored to build a chronological set of records for each patient. The patient 
ID is present in all files that provide patient level data. An overview of all data files is included in 
Table 3.1.  
 
Table 3.1: Description of CPRD data files 
File Description 
Patient Patient level demographic data: year of birth, gender, date of death, date of transfer out of the 
practice. 
Clinical Patient level clinical diagnoses: date of event and diagnostic code. 
Therapy Patient level information on prescriptions: date of prescription, related drug identifier code, 
strength, and formulation. 
Test Patient level information on tests: date of test, test type, and result. 
Referral Patient level referrals: date of referral, diagnosis give, method of referral, referral specialty. 
Additional Further information relating to clinical events. This includes information that cannot be stored 
within the Clinical file such as blood pressure readings, number of cigarettes smokes, BMI, level of 
alcohol drinking etc.  
Consultation Patient level data on consultations within the GP surgery: date of consultation, type of consultation, 
and duration of consultation.  
Practice Practice level information on the GP surgery: geographical region, up to standard date, last data 
collection date . 
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3.2.1.2 Linked HES 
HES is an administrative secondary care database that contains information on admissions from all 
National Health Service (NHS) hospitals in England. A subset of English GP practices that contribute 
data to the CPRD take part in a linkage scheme where their patients’ records are linked to HES data 
(75% of practices in England, which equates to 56% of practices in the whole of the UK).[104] These 
data are linked through deterministic matching using a combination of the patients’ NHS number, 
gender, date of birth, and postcode. The linkage is undertaken by NHS Digital, acting as a trusted 
third party, on behalf of CPRD. No personal identifiers are held by CPRD. Information on inpatient 
and day care admissions, outpatient appointments, and accident and emergencies, with 
comprehensive information on diagnoses, are available in the linkage scheme. However, no 
information is currently available on prescriptions given to patients in hospital. Once diagnoses are 
input into hospital systems by clinicians, clinical coders convert these unstructured clinical notes into 
International Classification of Diseases 10th revision (ICD-10) codes. Procedures are coded using the 
Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 
(OPCS-4) coding system.  
 
Data structure  
As part of the linkage process outlined above, each patient’s HES data are tied to the appropriate 
CPRD identifier (patient ID). The data are arranged into files relating to hospitalisations, episodes, 
and files for events that are linked to specific episodes. Hospitalisations refer to the total period of 
inpatient hospital stay from admission to discharge. When a hospitalisation spans the end of the HES 
year, it is artificially modelled as two hospitalisations, from admission to end of HES year (in the first 
year’s HES data) and from start of the HES year to final discharge (in the second HES year). An 
episode is a time-period within a hospitalisation, which corresponds to the period where the patient 
is in the continuous care of one consultant using the beds of one health care provider. This is not 
always the same as a single stay in hospital, because a patient may be transferred from one 
consultant to another during their stay. In these cases, there will be two or more episode records for 
the hospitalisation. Consultant episodes will also terminate when a patient is transferred between 
health care provider organisations, even though their inpatient care may be continuous. Each 
patient may have one or more HES hospitalisations. Each hospitalisation can consist of one or more 
episodes. For each episode, up to 20 diagnoses and 24 procedures may be recorded. Additionally, 
each episode can have up to nine periods of augmented care. Each episode has one primary 
diagnosis, and can have several secondary diagnoses, with the primary diagnosis relating to the main 
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reason for that episode occurring.[105]  
 
In this thesis, a CVD diagnosis in HES was classed as an event if it was within any episode of a 
hospitalisation. The diagnosis could also be either the primary or secondary diagnosis of that episode 
(see Chapter 4). Furthermore, the incident event of interest was captured, but no further events. 
However, the aim of the thesis is to explore the effect of endocrine therapies on incident CVD 
events, so further events would not matter in the context of the research question. Figure 3.1 gives   
three examples of how CVD events were identified in HES. 
 
3.2.2 Other potential data sources 
There are several other data sources within the UK that could have been used to answer the 
research question of the thesis. It would be possible to use RCT data, and there have been results 
from RCT studies reported for the effect of endocrine therapies on several CVD outcomes, as 
outlined in the systematic review. However, none of these RCTs reported the information on the full 
range of CVD outcomes, and they were mainly set up to assess the efficacy of tamoxifen or AIs, so 
are prone to several sources of bias when attempting to explore the CVD side effects of treatment. It 
would not be possible to set up an RCT to answer the research question due to ethical 
considerations as AIs have already shown to be more efficacious in comparison with tamoxifen in 
post-menopausal women diagnosed with ER+/PR+ breast cancer.  
 
Figure 3.1: Examples of how CVD events were identified in HES 
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Although I have used the CPRD and HES data, which are routinely collected health records, it would 
also have been possible to use The Health Improvement Network database (THIN).[106] This 
database is comparable to the CPRD, but the process of linking data to HES is easier for CPRD as it is 
done in house at CPRD. A third-party company needs to link THIN to HES, which can be expensive 
and time consuming. LSHTM also has a license with CPRD, but not with THIN, which means CPRD 
data were cheaper and more easily accessible.  
 
There are currently no appropriate registries in the UK (other than the UK cancer registry, which is 
discussed later) that would be suitable to identify the source population and answer this research 
question. However, if there was such a registry it would likely include information on a wider 
selection of potential confounders that are not available in the CPRD, such as breast cancer stage, 
grade, and other treatments that were administered. It also should include 100% of all breast 
cancers diagnosed in the UK. 
 
It would be possible to answer the research question by using data from a prospective cohort study. 
Although there are several prospective cohort studies currently taking place in the general area of 
breast cancer research (such as the Generations Study,[107] which examines breast cancer risk and 
recruited both women with and without a breast cancer diagnosis), none are suitable for answering 
this specific research question.  A prospective study set up to answer this question would require 
follow up of women diagnosed with breast cancer, with information on their treatment and 
subsequent CVD outcomes. It is likely that study populations for any prospective study set up to 
answer this question would be too small to have adequate statistical power to detect an effect of 
endocrine therapies on each CVD of interest.  
 
There are no suitable administrative databases in the UK that will give sufficient information to 
answer this research question. Such databases could be from healthcare insurance providers that 
are mainly used for administrative rather than care purposes. However, the size of these databases 
would be small given the proportionally small number of people covered by private healthcare 
insurers in the UK, and the cost of accessing these data for research purposes are likely expensive.  
 
3.2.3 Contribution 
I led all data acquisition, cleaning, and curating throughout the duration of the UK study. This 
included conceptualising and writing a protocol for the study to submit to the Independent Scientific 
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Advisory Committee board. Approval is required from this board prior to access to anonymised 
patient level CPRD data for research purposes. LSHTM holds a CPRD license, so once I gained 
protocol approval, I was able to extract the defined dataset from the files held at LSHTM and begin 
the cleaning and curating process. I was solely responsible for this process, which included defining 
and creating the study population, exposure, outcome, and covariates within the data. This was also 
the stage at which several of the study decisions were taken. Although I initiated all decisions, I also 
had conversations with both of my supervisors to get their opinions on several of the decisions 
made. This process took around 8 months to a year from the beginning of the PhD (2016) before I 
was able to start the main analyses.  
 
3.3  US STUDY 
3.3.1 Data sources 
Analyses carried out in the US utilised the linkage of two large population-based databases: the 
Surveillance, Epidemiology and End Results Program (SEER) and Medicare parts A, B, and D.   
 
3.3.1.1 SEER 
The SEER program of the US National Cancer Institute is a surveillance system that began collecting 
information in 1973 on demographics, clinical and tumour characteristics, initial surgical and 
Figure 3.2: SEER reporting states 
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radiation treatment, vital status, and cause of death for all individuals who are diagnosed with 
cancer and reside within one of the 12 SEER states (Figure 3.1). Geographic areas were selected for 
inclusion in the SEER Program based on their ability to operate and maintain a high quality 
population-based cancer reporting system and for their epidemiologically significant population 
subgroups. The program covers approximately 34.6% of the US population. Although it is only 
collected from 12 states and is not a nationwide sample, SEER is representative of the wider US 
population in terms of poverty and education, but includes more urban areas and a greater 
proportion of foreign-born residents.[108, 109] SEER is considered the gold standard for data quality 
among cancer registries in the US, with a 95% complete case identification and a 95% annual rate of 
follow-up to determine survival.[110]  
 
3.3.1.2 Medicare parts A, B, and D 
The Medicare systems provides governmental funded health insurance for approximately 97% of US 
citizens aged 65 years and over.[111] Medicare health insurance is also available to individuals under 
65 years if they have been diagnosed with end-stage renal disease or medical disability. As of 2016, 
57 million people were covered by Medicare, of whom 48 million were age 65 years or over (84%). 
Everyone covered by Medicare is entitled to Part A coverage, which includes hospital inpatient care. 
Around 96% of people then pay for Part B coverage, which covers physician and outpatient 
services.[112] Claims data from Medicare Parts A and B are available from 1998 onwards. 52% of 
Medicare beneficiaries also have Part D enrolment, which began in 2007 and offers outpatient 
coverage for medications. There is an extra cost for Medicare parts B and D, meaning this may only 
cover a more affluent population. Figure 3.3 gives an outline of how Medicare Parts A, B, and D are 
Figure 3.3: Medicare coverage overview 
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related. Medicare data are highly accurate due to being claims based and the centres for Medicare 
services regularly evaluating accuracy of billing information by taking random samples of medical 
records, and reviewing them against the claim for accuracy. Hospitals are subject to penalties if they 
have up-coded claims.[113] Several CVD outcomes from Medicare have been externally validated: 
heart failure claims were validated against medical discharge records from the Atherosclerosis Risk 
in Communities Study with high levels of agreement (Kappa coefficient (κ) 0.92);[114] and 
myocardial infarction and coronary revascularisation were validated against data from the Women’s 
Health Initiative with equally high agreement (κ=0.74 and κ=0.91, respectively).[115]  
 
3.3.1.3 Linked SEER-Medicare 
The SEER-Medicare database is a linkage of the two above databases using a deterministic algorithm 
based on name, social security number, sex, and date of birth, and includes cancer cases until 2013 
and Medicare claims until 2014. This time restriction could mean that any results are not 
generalisable to the post-menopausal women diagnosed with ER+/PR+ breast cancer today because 
there are likely less women being prescribed tamoxifen due to the changing use of endocrine 
therapies. 
  
3.3.2 Contribution 
This study was a collaboration with colleagues from the Department of Epidemiology at the 
University of North Carolina (UNC), Chapel Hill in the US. I led on the study design and protocol 
development, supported by advisors at both institutions. The protocol was submitted to and 
approved by the SEER advisory board prior to any work began. Sharon Peacock Hinton, an employee 
at UNC, then produced the specified dataset from the raw data, with guidance from myself. In depth 
information on the data structure is therefore not provided. As this was a collaboration with UNC, 
variables were defined using their well-established definitions, hence there was less scope for 
validation of variables (i.e. as in chapter 4 for CVD outcomes in the UK study). Once I received the 
cleaned dataset, I was then responsible for identifying the correct exposures and exposure 
categories. The project required me to spend three months in at UNC in Chapel Hill, North Carolina, 
where I was a fully integrated member of the Department of Epidemiology. The collaboration with 
colleagues at UNC began at the beginning of 2017. Protocol and study development took place 
throughout 2017, then I visited North Carolina from March-June 2018 to carry out all data analyses.  
 
Prior to forming the collaboration with UNC, I had originally planned to collaborate with the 
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Department of Clinical Epidemiology at Aarhus University in Denmark. The project was very similar 
to the one that I eventually carried out in the US. I, again, wrote a protocol for the project which was 
approved in Denmark. However, following this approval there was a change of the laws in Denmark, 
which made it illegal for non-Danish researchers to access prescription data. This meant it would not 
have been possible for me to carry out any analyses. The project was therefore put on hold, and we 
have applied for funding to hire a Danish researcher to carry out the analyses.   
 
3.4 SUMMARY 
 
  
 This thesis utilises linked data from the CPRD and HES for the UK study. 
 75% of GP practices that contribute data to the CPRD in England have linked HES data, 
which equates to 56% of practices in the whole of the UK. 
 CPRD data have been shown to be highly valid in regards to most clinical diagnoses. 
 Linked SEER-Medicare claims data were used for the US study. 
 SEER-Medicare include all cancer cases from 1973 until 2013, and Medicare claims from 
1998 until 2014. 
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4 CAPTURE OF CVD OUTCOMES IN THE UK STUDY 
 
4.1 INTRODUCTION 
A range of clinical CVDs make up the main outcomes to be explored within this thesis. This chapter 
contains a series of exploratory analyses using both CPRD and HES with the aim of developing CVD 
outcome definitions in UK data, assessing the validity of UK primary and secondary care data to 
detect CVD outcomes, and deciding if the main analyses in the UK should use either the CPRD data 
alone or the CPRD and HES linked data. This will be achieved through the following objectives.  
 
4.2 OBJECTIVES 
1. Describe the process of creating CVD outcome code lists in CPRD. 
2. Identify and describe definite and possible CVD events in the CPRD data. 
3. Examine the concordance of events between CPRD and HES. 
4. Identify events recorded in HES alone, and explore CPRD data around this time to see if any 
diagnoses in primary care were originally missed. 
5. Assess the validity of CVD events in HES. 
6. Calculate the statistical power of analyses using either CPRD data alone, or linked CPRD and 
HES data. 
 
4.3 METHODS 
4.3.1 Study population  
The following analyses use the study population definition that is fully outlined in the UK study in 
Chapter 5. For objective 2, all eligible patients in the CPRD were included (until 2017). The study 
population was then restricted for objectives 3-5 to only include those eligible for the CPRD and HES 
linkage scheme, and for follow up time up until the latest CPRD and HES linkage date (2016).  
 
4.3.2 CVD outcomes 
A list of clinical CVD outcomes was created to explore in all future analyses (both UK and US). These 
outcomes were discussed with a cardiologist and GP and included both composite and specific 
outcomes. The final agreed outcomes were as follows: 
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 Coronary artery disease 
o Angina 
o Myocardial infarction 
o Revascularisation procedures 
o Sudden cardiac arrest  
 Peripheral vascular disease  
 Stroke 
 Arrhythmia 
 Heart failure (consisting of heart failure and cardiomyopathy) 
 Pericarditis 
 Valvular heart disease  
 Venous thromboembolism  
o Deep vein thrombosis  
o Pulmonary embolism  
 
Although it would have been possible to include hypertension as an outcome, the study team 
decided that hypertension contributes to CVD, rather than being a clear clinical CVD outcome itself. 
If endocrine therapies altered blood pressure, it is possible that hypertension could partly mediate 
any effect of endocrine therapies on CVD.  
 
4.3.3 Identification of codes used to define CVD outcomes 
4.3.3.1 CPRD 
CPRD uses Read codes to identify clinical events that have been diagnosed in primary care. Read 
codes are a coded thesaurus of clinical terms that have been used in the National Health Service 
(NHS) since 1985, which provide a standard vocabulary by which clinicians can record patient 
findings and procedures in health and social care IT systems across primary and secondary care. 
Creation of Read code lists representing a certain disease allows identification of patients in CPRD 
with a diagnosis of that disease by merging the code lists with the patients’ raw data files.  
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A systematic approach was used to define code lists in order to identify clinical diagnoses of CVD 
outcomes. The dictionaries of codes were searched using STATA do files,[116] so that all decisions on 
inclusion and exclusion criteria were recorded and easily replicated.  
 
A code list for each clinical diagnosis was created using the following algorithm:  
 A list of inclusion search terms, which were synonyms of the medical event, was agreed 
through discussion with the clinical collaborators involved in the study.  
 The CPRD Read code dictionary was then searched to identify any codes with one of the 
search terms in the read term field, which is used to describe the Read code. 
 Using a list of pre-specified terms and scanning the codes initially identified, a list of 
exclusion terms was created and applied. 
 Codes and their descriptors were manually reviewed to decide if they were appropriate for 
the final code list . 
 
Initial inclusion terms to create CVD code lists utilised the search terms in the CALIBER study, where 
available.[117] These search terms were reviewed and expanded if necessary.  
 
4.3.3.2 HES 
HES uses ICD-10 codes to identify clinical events diagnosed in secondary care. ICD-10 codes are a 
comprehensive classification of causes of morbidity and mortality that is published by the World 
Health Organisation (WHO). The 10th revision of ICD codes was published in April 1995, and followed 
the 9th revision (ICD-9) that was published in 1975 and came into use in hospital health systems in 
1979. Furthermore, OPCS-4 codes are used to classify interventions and procedures, and were 
originally published in 1987 by the Office of Population Censuses and Surveys, and was followed by a 
4th revision in 1992. 
 
CVD outcome events were identified in HES. Clinicians guided the creation of ICD-10 code lists 
relating to all CVD outcomes. OPCS-4 codes lists were also created to identify revascularisation 
procedures carried out in secondary care. These codes lists were then used to search for relevant 
diagnoses in the patients’ raw HES data.  
 
59 
 
4.3.4 Definite, possible, and history of events 
For all CVD events in CPRD, the final Read code list was reviewed and all codes were categorised as 
either a definite event, a possible event, or history of an event. Codes indicating a definite event 
were those showing a clear clinical diagnosis. Possible event codes were those codes in which a 
diagnosis was not clear, but there was an indication that the patient suffered from the related CVD. 
For example, a possible stroke Read code had the description “stroke self-management plan 
agreed”, which is a process of care code and shows that the patient has most probably suffered from 
a stroke, and is now been given guidance on how to deal with the consequences. This could also 
come in the form of a code indicating the patient had been referred to a clinic relating to the 
diagnosis. For some CVD outcomes, there were also other closely related diagnoses that were 
classed as possible codes. For example, a pulmonary oedema diagnosis usually occurs when the 
diseased or overworked left ventricle cannot pump out enough of the blood it receives from the 
lungs, which is essentially congestive HF. So, Read codes relating to pulmonary oedema were 
considered as possible HF codes. All Read codes that indicated a “suspected” event were also classed 
as possible codes. Finally, a code was classified as a history of event code if the Read code indicated 
an event that had happened in the past, or it showed monitoring or review of a past diagnosis.  
 
4.3.5 Analysis  
4.3.5.1 Objective 1 - Describe the process of creating CVD outcome code lists in CPRD 
For each CVD outcome, the number of codes identified at each stage of the CPRD code list creation 
algorithm (as above) was outlined. This included this number of codes identified: after inclusion 
terms had been applied; after exclusion terms had been applied; and after the resulting code list had 
been manually reviewed. A full list of inclusion and exclusion terms for each CVD outcome are 
available in Appendix 4.1, and the final Read code lists created are available in appendices 4.2-4.13. 
 
4.3.5.2 Objective 2 - Identify and describe definite and possible CVD events in the CPRD data 
After excluding those with a past event (a diagnosis with any code in the final code list), incident CVD 
events in CPRD during follow up were identified from patients’ Clinical and Referral files using the 
Read code lists created in objective 1 (excluding diagnoses recorded with “history of” codes). All CVD 
outcomes were assessed separately. The number of events classed as definite and possible events 
was calculated. If an incident event was classed as possible, the patients’ files were further explored 
to identify how many of these possible events were followed by a definite event within the following 
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year. The top five Read codes and descriptions that identified incident events for each CVD outcome 
were then presented. 
 
4.3.5.3 Objective 3 - Concordance of CVD outcomes in linked CPRD and HES data 
The study population was restricted to those in the linkage scheme, and women were excluded if 
they had been diagnosed with a CVD event prior to the index date in either CPRD or HES. Incident 
CVD events during follow up were identified from an appropriate Read code in patients’ Clinical and 
Referral files (again excluding diagnoses recorded with “history of”‘ codes), and from patients’ HES 
diagnosis files using the ICD-10/OPCS-4 codes in appendix 4.14. The number of events during follow 
up were initially identified using CPRD and HES records separately, and then when using both CPRD 
and HES records together. This allowed the overlap between the two databases to be calculated. The 
median time between events that occurred in both CPRD and HES (in either direction) was also 
calculated.  
 
4.3.5.4 Objective 4 - Exploration of primary care codes recorded around the time of HES only events  
To identify Read codes missed in the original code lists, all diagnoses occurring in CPRD within a six-
month period around an event (three months before and after) that only occurred in HES were 
identified for each outcome. All events and related Read codes in this period were then accumulated 
and manually scanned to find any Read codes that were missing from the original Read code list. For 
outcomes in which new Read codes were found, above analyses examining the concordance 
between CPRD and HES were repeated. Furthermore, for the four CVD outcomes in which the 
smallest proportion of total events could be identified in CPRD alone (angina, pericarditis, SCA, and 
VHD), five women were picked at random, and their individual CPRD diagnosis, prescription, and test 
records were explored in detail for a year around the time of the HES event. This helped to 
understand if there was any other way to identify a record in primary care records that was 
otherwise only recorded in a woman’s HES records.  
 
4.3.5.5 Objective 5 - Validity of HES events 
For each episode in HES, there can up to 20 diagnoses, with one primary diagnosis and several 
secondary diagnoses. When originally identifying incident CVD events in HES, all recorded diagnoses 
were used, regardless of if the event was the primary or secondary diagnosis of the episode. To 
understand how many events were the main reason for the time in hospital, and to help decide if 
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only primary events should be used, the proportion of events recorded as the primary diagnosis of 
that episode were calculated. The ICD-10 letter of the primary diagnoses for that episode was 
tabulated for all events for which the diagnosis was not the primary diagnosis (i.e. events that 
indicated a secondary diagnosis). This process was replicated for all outcomes other than 
revascularisation, as this is classed as a procedure not a diagnosis. 
 
4.3.5.6 Objective 6 - Calculate the statistical power of analyses using either CPRD data alone or 
linked CPRD and HES data 
Detectable hazard ratios for survival analysis were calculated based on the sample size, event 
numbers, and standard deviation of endocrine therapy exposure (calculated from those exposed to 
tamoxifen or AIs in the study population) for analyses using CPRD data alone to define the study 
population and capture CVD events, and analyses that defined the study population in the linked 
CPRD and HES data, but captured events that were in either CPRD or HES. All detectable hazard 
ratios were calculated with a statistical power of 80% and type 1 error rate of 5%. The detectable 
hazard ratio calculates the minimum possible hazard ratio that is detectable based on the sample 
size and number of events and gives a good indication of size of effects that could be found with the 
available data. Given there are two potential data sources, comparing the minimum detectable 
hazard ratio between the two sources enables one to see the source in which smaller effect sizes can 
be detected.  
 
4.4 FINDINGS 
4.4.1 Objective 1 - Describe the process of creating CVD outcome Read code lists in CPRD 
After initial inclusion and exclusion criteria were applied, and the codes had been manually scanned 
to remove any that were inappropriate, the final number of Read codes ranged from 128 in the 
revascularisation outcome to 20 in the PE outcome (Table 4.1). All Read code created are available in 
appendices 4.2-4.13. 
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4.4.2 Objective 2 - Identify and describe definite and possible CVD events in the CPRD data 
Once women with prior CVD events in CPRD were excluded, the final number of women included in 
the study population ranged from 15,262 in the arrhythmia analysis to 16,568 in the pericarditis 
analysis. Table 4.2 outlines the total number of incident events, the proportion of those that were 
definite, and the proportion of possible events followed by a definite event within a year. For the 
majority of outcomes, all incident events were definite, with stroke reporting the lowest number of 
incident events that were definite (73%). However, 15% of the possible stroke events were followed 
by a definite event within a year. Furthermore, over 59% of all incident events were captured by 5 
Read codes for all outcomes (Table 4.3), with over 90% of all events being captured by 5 Read codes 
for 6/12 of the outcomes. 
Table 4.2: Events in CPRD between 2002 and 2017 
Outcome  Women in study 
population  
Total number of 
incident events in 
follow up (% of 
total in study pop) 
Definite 
incident events 
(% of all events) 
Possible events that 
were confirmed by a 
definite event within 
a year (% of all 
possible events)*† 
Angina 15655 97 (0.62) 97 (100) N/A 
MI 16206 162 (1.00) 162 (100) N/A 
Revascularisation 16484 36 (0.22) 36 (100) N/A 
SCA 16564 18 (0.11) 18 (100) N/A 
PVD 16260 123 (0.76) 119 (97) 0 (0.00) 
Stroke 15934 365 (2.29) 267 (73) 15 (15.31) 
Arrhythmia 15262 635 (4.16) 635 (100) N/A 
HF 15997 318 (1.99) 277 (87) 7 (17.07) 
Pericarditis 16568 6 (0.04) 6 (100) N/A 
VHD 16413 113 (0.69) 113 (100) N/A 
DVT 16115 284 (1.76) 232 (82) 6 (11.54) 
Pulmonary Embolism 16324 189 (1.16) 188 (99) 0 (0.00) 
* N/A if all incident events were definite events 
† 0 if there are some incidents events are possible events, but none of them have a definite event within a year 
 
Table 4.1: Number of codes within CVD code lists after inclusion, exclusion, 
and manual searching 
Outcome After inclusion After exclusion 
Number manually 
excluded Final 
Angina 71 43  2 41 
MI 217 82 9 73 
Revascularisation 142 128 0 128 
SCA 62 24 6 18 
PVD 1874 87 0 87 
Stroke 250 250 126 124 
Arrhythmia 85 72 1 71 
HF 186 150 17 133 
Pericarditis  38 37 0 37 
VHD 53 48 0 48 
DVT  72 55 12 43 
PE 22 21 1 20 
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Table 4.3: Top five Read codes used to identify incident CVD events between 2002 and 2017  
Outcome Read 
code 
Description Definite 
/possible 
events 
Number 
of 
incident 
events 
Proportion 
of all 
incident 
events 
Cumulative 
proportion 
of all 
incident 
events 
Angina G33..00 angina pectoris Definite 75 77.3 77.3 
G311100 unstable angina Definite 7 7.2 84.5 
G311.13 unstable angina Definite 5 5.2 89.7 
G332.00 coronary artery spasm Definite 2 2.1 91.8 
G311200 angina at rest Definite 2 2.1 93.8 
MI G307100 acute non-st segment elevation myocardial 
infarction 
Definite 67 41.4 41.4 
G30..00 acute myocardial infarction Definite 42 25.9 67.3 
G30..15 mi - acute myocardial infarction Definite 31 19.1 86.4 
G30X000 acute st segment elevation myocardial infarction Definite 12 7.4 93.8 
G30z.00 acute myocardial infarction nos Definite 5 3.1 96.9 
Revascularisation 7911300 replacement of aortic valve nec Definite 13 21.7 21.7 
 7911.12 replacement of aortic valve Definite 10 16.7 38.3 
 792..11 coronary artery bypass graft operations Definite 10 16.7 55 
 792E.00 percutaneous coronary intervention Definite 8 13.3 68.3 
 7911.00 plastic repair of aortic valve Definite 6 10 78.3 
SCA G575.00 cardiac arrest Definite 11 61.1 61.1 
 7937500 implantation of internal cardiac defibrillator Definite 4 22.2 83.3 
 8532.11 cardiopulmonary resuscitation Definite 1 5.6 88.9 
 2241.00 o/e - collapse -cardiac arrest Definite 1 5.6 94.4 
 G575.12 asystole Definite 1 5.6 100 
PVD G73z000 intermittent claudication Definite 34 27.6 27.6 
 G73z.00 peripheral vascular disease nos Definite 13 10.6 38.2 
 G73..00 other peripheral vascular disease Definite 12 9.8 48 
 G73zz00 peripheral vascular disease nos Definite 7 5.7 53.7 
 C107.00 diabetes mellitus with peripheral circulatory 
disorder 
Definite 7 5.7 59.3 
Stroke G66..00 stroke and cerebrovascular accident unspecified Definite 73 20 20 
 G66..11 cva unspecified Definite 63 17.3 37.3 
 8HBJ.00 stroke / transient ischaemic attack referral Possible 62 17 54.2 
 8HTQ.00 referral to stroke clinic Possible 32 8.8 63 
 G64z.00 cerebral infarction nos Definite 25 6.8 69.9 
Arrhythmia 181..00 palpitations Definite 386 42.5 42.5 
 G573000 atrial fibrillation Definite 236 26 68.5 
 G573.00 atrial fibrillation and flutter Definite 86 9.5 78 
 G573200 paroxysmal atrial fibrillation Definite 27 3 80.9 
 R050.00 [d]tachycardia, unspecified Definite 24 2.6 83.6 
HF G58..00 heart failure Definite 77 23.1 23.1 
 G580.11 congestive cardiac failure Definite 44 13.2 36.3 
 G581.00 left ventricular failure Definite 40 12 48.3 
 G580.00 congestive heart failure Definite 34 10.2 58.6 
 G5yy900 left ventricular systolic dysfunction Definite 23 6.9 65.5 
Pericarditis G534.00 pericardial effusion - acute Definite 8 36.4 36.4 
 G536.00 pericardial effusion Definite 6 27.3 63.6 
 G50..00 acute pericarditis Definite 3 13.6 77.3 
 G50z.00 other and unspecified acute pericarditis Definite 3 13.6 90.9 
 G50..11 pericardial effusion - acute Definite 1 4.5 95.5 
VHD G540.16 mitral regurgitation Definite 58 30.9 30.9 
 G541500 aortic stenosis Definite 53 28.2 59 
 G541100 aortic stenosis, non-rheumatic Definite 25 13.3 72.3 
 G541012 aortic regurgitation, non-rheumatic Definite 10 5.3 77.7 
 G540.14 mitral valve regurgitation Definite 10 5.3 83 
DVT G801.11 deep vein thrombosis Definite 202 71.1 71.1 
 1JH..00 suspected deep vein thrombosis Possible 42 14.8 85.9 
 G801.13 dvt - deep vein thrombosis Possible 10 3.5 89.4 
 8HTm.00 referral to deep vein thrombosis clinic Definite 10 3.5 93 
 G801.00 deep vein phlebitis and thrombophlebitis of the 
leg 
Definite 7 2.5 95.4 
Pulmonary 
Embolism 
G401.00 pulmonary embolism Definite 182 96.3 96.3 
G401.12 pulmonary embolus Definite 6 3.2 99.5 
 1JC..00 suspected pulmonary embolism Possible 1 .5 100 
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4.4.3 Objective 3 - Concordance of CVD outcomes in linked CPRD and HES data 
The pulmonary embolism outcome demonstrated the largest overlap between events in CPRD and 
HES (49.66%, Figure 4.1. Table 4.4), and pericarditis the smallest (4.55%). Generally, a larger 
proportion of incident events could be identified using only HES in comparison with using only CPRD, 
with over 70% of all events in 8/12 of the CVD outcomes identified when using only HES. Whereas 
over 70% of all events were identified in 5/12 of the CVD outcomes when using only CPRD. Using 
only HES also captured a higher proportion of the total incident events in comparison with using only 
CPRD in 8/12 of the CVD outcomes. When there were events in both CPRD and HES, the median time 
between those events was zero days for both SCA and stroke (Table 4.4). However, the median time 
between events was 311.5 days for VHD events, which could either be due to delayed input into the 
patients’ records, or the record of a different, unrelated event that followed the incident event.  
 
 
 
 
A C B 
Figure 4.1: Overlap of incident CVD events between CPRD and HES 
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4.4.4 Objective 4 - Exploration of CPRD file around the time of HES only events  
After assessing all Read codes in the CPRD clinical and referral files within a 6-month period around 
an event that was only recorded in HES, new Read codes were identified for arrhythmia, valvular 
heart disease, and revascularisation. The additional Read codes and descriptions were as follows: 
 Arrhythmia 
o 181..00 – Palpitations 
 Pericarditis 
o G536.00 – Pericardial effusion 
o G50..11 – Pericardial effusion – acute 
o G534.00 - Pericardial effusion – acute 
o G533.00 – Pericardial effusion – non-inflammatory 
o G536000 – Chronic pericardial effusion  
 Valvular heart disease 
o 7911300 - Replacement of aortic valve NEC 
o G541500 - Aortic stenosis 
o G541100 - Aortic stenosis, non-rheumatic 
 Revascularisation 
o 7911300 - Replacement of aortic valve NEC 
o 7911.00 - Plastic repair of aortic valve 
Table 4.4: Concordance of CVD outcomes in linked CPRD and HES* 
Outcome  Women in 
study 
population 
Incident events 
when using both 
CPRD and HES 
(A+B+C); (% of 
study population) 
Incident events 
identified from 
CPRD (A+B); (% 
of total events 
from both 
sources) 
Incident events 
identified from 
HES (A+C): (% 
of total events 
from both 
sources) 
Overlap 
between CPRD 
and HES (C); (% 
of total events 
from both 
sources), C) 
Median time 
between events 
in CPRD and 
HES 
Angina 9234 167 (1.81) 46 (27.54) 149 (89.22) 32 (19.16) 82 
MI 9779 132 (1.35) 99 (75.00) 97 (73.48) 64 (48.48) 1 
Revascularisation 9916 44 (0.44) 21 (47.73) 37 (84.09) 14 (31.82) 5 
SCA 9995 39 (0.39) 11 (28.21) 31 (79.49) 3 (7.69) 0 
PVD 9772 98 (1.00) 73 (74.49) 38 (38.78) 13 (13.27) 103 
Stroke 9582 296 (3.09) 222 (75.00) 163 (55.07) 91 (30.74) 0 
Arrhythmia 9060 542 (5.98) 344 (63.47) 359 (66.24) 184 (33.95) 102.5 
HF 9532 344 (3.61) 173 (50.29) 249 (72.38) 89 (25.87) 33 
Pericarditis 9986 22 (0.22) 1 (4.55) 22 (100.00) 1 (4.55) 12 
VHD 9755 223 (2.29) 70 (31.39) 166 (74.44) 18 (8.07) 311.5 
DVT 9681 204 (2.11) 170 (83.33) 86 (42.16) 52 (25.49) 2 
Pulmonary 
Embolism 
9832 149 (1.52) 108 (72.48) 112 (75.17) 74 (49.66) 5 
*Coverage for CPRD (B) 2002-2017, coverage for HES (C) 2002-2016, and coverage for both data sets (A) 2002-2016 
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o 7911.12 - Replacement of aortic valve 
 
The concordance of CPRD and HES events following the addition of these codes to the original Read 
code lists are outlined in Appendix 4.15. The addition of one new Read code in the arrhythmia code 
list made the largest difference, identifying 137 additional events in CPRD. However, the addition of 
new codes for the other three outcomes had minimal impact (between three and nine further 
events identified in CPRD).  
 
For the five patients that were picked at random for each of the four CVD outcomes with low 
coverage of events in CPRD (angina, pericarditis, SCA, and VHD, Table 4.5), there was generally no 
firm conclusions as to why events were recorded in HES, but not CPRD. All patients had evidence of 
CVD related problems and/or prescriptions for CVD-related drugs, but the specific outcome of 
interest, as identified in their HES records, could not be ascertained in their CPRD records.  
 
 
 
Table 4.5: Overview of the exploration of patients CPRD records around the time of a 
HES event between 2002 and 2016 
Outcome Patient Overview of what was found in CPRD 
Angina 1 Been in hospital, on other CVD drugs 
 2 Had a fall and seen in casualty, on other CVD drugs 
 3 Lots of tests in primary care, pain killers and GI drugs 
 4 Other CVD drugs prescribed 
 5 Prescribed digoxin for AF, had a stroke not long after 
Hypothesis for no Read 
code 
Patients have many other problems. Hard to identify if not coded specifically as angina 
Pericarditis 1 Admitted to hospital and had endoscopy, there was a gastric outlet 
obstruction 
 2 A lot of indigestion tablets, but no other information. Cancer may have 
gone metastatic 
 3 Meningococcal diagnosis 
 4 Painkiller prescriptions, and not any diagnoses 
 5 Diabetic, and other CVD drugs 
Hypothesis for no Read 
code  
Very hard to identify these events in CPRD, with very little evidence of the HES diagnosis 
SCA 1 A lot of tests not long after HES diagnosis, including CVD related tests 
 2 Other CVD diagnoses such as heart failure and atrial fibrillation. Also had 
chest x-rays.  
 3 A lot of painkiller prescriptions, and kidney function tests, seems like 
they have a lot of other problems 
 4 A lot of CVD related prescriptions,  but no diagnoses 
 5 Had a mammography the same day, so possible re-diagnosis of breast 
cancer 
Hypothesis for no Read 
code  
Women seem to have a lot of other problems, so possible that the SCA hasn't been 
transferred to GPs records 
VHD 1 On several CVD drugs and CVD monitoring 
 2 On several CVD drugs 
 3 On several CVD drugs, and has diabetes 
 4 Has epilepsy and on pain killers for what seems like musculoskeletal 
problems 
 5 On painkillers, and had an x-ray not long after date of VHD 
Hypothesis for no Read 
code  
Women have a lot of CVD related problems, but no evidence of VHD diagnoses 
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4.4.5 Objective 5 - Validity of HES events  
The proportion of all HES events that were classed as the primary diagnosis of the episode ranged 
from 8.9% for VHD to 69.5% for stroke (Table 4.6). For those events that were classed as the 
secondary diagnosis, the most common related primary diagnosis within the same episode was from 
the same ICD-10 chapter as the intended outcome (chapter I) for all outcomes, except pulmonary 
embolism (Appendix 4.16).  
 
Table 4.6: Total number of HES events, and proportion of 
events that were the primary diagnoses of the episode 
between 2002 and 2016 
Outcome (ICD letter of 
outcome) 
Total number of events 
in HES 
Number of HES events 
that were the primary 
diagnosis (proportion of 
all HES events) 
Angina (I) 167 42 (25.10) 
MI (I) 132 79 (59.80) 
SCA (I) 38 10 (26.30) 
PVD (I) 41 10 (24.40) 
Stroke (I) 197 137 (69.50) 
Arrhythmia (I) 416 68 (16.30) 
HF (I) 322 75 (23.30) 
Pericarditis (I) 33 3 (9.10) 
VHD (I) 192 17 (8.90) 
DVT (I) 100 57 (57.00) 
Pulmonary Embolism (I) 147 79 (53.70) 
 
 
4.4.6 Objective 6 - Calculate the statistical power of analyses using either CPRD data alone or linked 
CPRD and HES data 
The CPRD and HES linked population includes a subset of around 56% of the CPRD population. 
However, additionally including events recorded in HES allowed accumulation of events not 
identified in CPRD. Therefore, although there were fewer women in the study population, the 
statistical power of analyses was generally similar when using the CPRD and HES linked population 
and identifying CVD events in either CPRD or HES, compared with using CPRD alone to generate the 
study population and identify CVD events. A lower HR was detectable for 5/12 of the CVD outcomes 
when using the linked population (Table 4.7). However, the differences for many other outcomes 
were negligible. 
 
68 
 
 
4.5 DISCUSSION 
The analyses in this chapter carried out a full exploration of CVD outcomes in the UK data, allowing 
decisions to be made on how to define these outcomes when exploring the effect of endocrine 
therapies.  
 
When exploring CVD events in CPRD alone, most of the incident events within follow-up were 
classed as definite (based on the definition of definite and possible events outlined in the methods). 
However, even if the incident event was a possible event, a large proportion of these events were 
confirmed with a definite event within a year. It was therefore decided to include both definite and 
possible codes in the Read code lists used to identify CVD events in CPRD going forward. Although 
possible events are not clear clinical diagnoses, the most regularly used possible codes indicate a 
diagnosis or referral that represents a diagnosis of the CVD of interest, so events will be identified 
when the GP has not clearly coded the required outcome.  
 
There was generally a low proportion of overlapping events between CPRD and HES when including 
HES data to identify CVD events. HES captured a larger proportion of events for a small majority of 
the outcomes, which demonstrates the advantage of including HES data to identify events. However, 
it also shows that some events may have been missed within CPRD due to incomplete Read code 
lists. Read code lists were therefore explored further, and additional Read codes for four CVD 
Table 4.7: Detectable HRs for all CVD outcomes 
when using CPRD alone and linked CPRD and HES 
data between 2002 and 2016 
 
Outcome 
Detectable HR 
CPRD only 
(events) 
CPRD and HES 
(events) 
Angina 1.77 (97) 1.54 (167) 
MI 1.56 (162) 1.63 (132) 
Revascularisation 2.07 (60) 2.27 (47) 
SCA 3.78 (18) 2.46 (39) 
PVD 1.66 (123) 1.76 (98) 
Stroke 1.34 (365) 1.39 (296) 
Arrhythmia 1.21 (908) 1.24 (679) 
HF 1.36 (333) 1.35 (344) 
Pericarditis 3.33 (22) 2.94 (27) 
VHD 1.51 (188) 1.45 (232) 
DVT 1.4 (284) 1.48 (204) 
Pulmonary Embolism 1.51 (189) 1.58 (149) 
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outcomes were identified when exploring the time around HES events. However, when further 
exploring patients’ individual records, it was clear that for many patients with an event in HES but no 
corresponding CPRD record, it would be extremely hard to confidently define the event in CPRD. 
There are several reasons that an event could be in HES but not CPRD.  Firstly, the event in HES could 
be real, but never fed back to the GP. As there is a distinct disconnect between primary and 
secondary care in the UK healthcare system, it is possible that a patient received a diagnosis of a 
disease or condition in hospital, without the GP being made aware. This scenario is even more likely 
if the patient has several comorbidities, which is probable in older patients diagnosed with breast 
cancer. Secondly, information of the diagnosis was fed back to the GP, but did they not code the 
diagnosis correctly in their electronic health record system. Letters from hospital clinicians to 
patients’ GPs inform them of patients’ clinical diagnosis in hospital, but if the GP only saves the letter 
on file, or writes a note in their records, without assigning a Read code, there will be no capture of 
the diagnosis in CPRD data. Finally, the event may have been miscoded in HES, so the records do not 
represent a real event. Although possible due to errors by clinicians or coders in hospitals, it is 
unlikely that this will happen regularly, and any miscoded events are likely to be random.  
 
For many of the outcomes, a low proportion of the events in HES were the primary diagnosis of that 
episode. However, if the event was a secondary diagnosis, the primary diagnosis of that episode was 
regularly from the same ICD chapter as the intended outcome. Secondary diagnoses describe those 
conditions that coexist at the time of admission, or develop subsequently and affect the patient care 
for the current episode. It is therefore plausible that a secondary diagnosis could be an historical 
rather than incident event, and it is not possible to distinguish between the two in HES data. 
However, if the secondary diagnosis was an historical event, then the patient should have records of 
this event (at the time it occurred) in either their hospital or GP records. As women with historical 
CVD events are excluded from the study population, it is likely that secondary diagnoses represent 
conditions that developed subsequently after admission to the hospital, so multiple counting of HES 
secondary diagnoses is avoided (further diagrammatical explanation in Figure 4.2). Therefore, it was 
decided to include both primary and secondary diagnoses events identified in HES, as only including 
primary diagnoses would mean missing a large proportion of genuine incident events.  
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There were minimal differences in the detectable hazard ratios for most outcomes when using the 
linked dataset to identify CVD events in CPRD or HES, in comparison with only identifying CVD events 
from CPRD records in the full CPRD population alone. As including events recorded in HES gives a 
higher probability of identifying CVD events, with minimal or no loss in statistical power, it was 
decided that the UK study should use linked CPRD and HES data for all analyses, whilst identifying 
events that were recorded in either CPRD or HES. This method will likely have higher sensitivity but 
lower specificity of outcome detection compared with only using events recorded in both CPRD and 
HES, as there is a higher probability that the women has had the event if it was recorded in both 
databases. However, only using events that are in both CPRD and HES could cause under 
ascertainment of the outcome, potentially missing legitimate events only recorded in one database, 
and would severely affect statistical power. Using events recorded in either CPRD or HES (more 
sensitive method) could cause over ascertainment of CVD outcomes, as it is possible that an event is 
not real if only recorded in one database. However, given the problems previously discussed 
(reasons that events are in HES but not CPRD), and as women may never go to hospital for less 
severe CVDs (only to the GP), it was considered that over ascertainment would be less of a problem 
for this study.   
Figure 4.2: Exclusions of women based on historical CVD events in HES 
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4.6 CONCLUSION 
This chapter showed that the original algorithm for creating Read code lists found most events 
identifiable in the CPRD, but it is not possible to identify all events using CPRD alone. The inclusion of 
possible CVD events in CPRD and events recorded in either CPRD or HES increases the sensitivity of 
CVD outcome identification in the UK study, with limited impact on statistical power due to having 
to restrict the study population to women included in the CPRD and HES linkage scheme.  
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4.7 SUMMARY 
 The aim of this chapter was to develop CVD outcome definitions in UK data, assess the 
validity of UK primary and secondary care data to detect CVD outcomes, and decide if 
the main analyses in the UK should use either the CPRD data alone or the CPRD and HES 
linked data. 
  The algorithm used to create the original CVD Read code lists was presented, and the 
number of codes detected to identify CVD outcomes ranged from 128 in the 
revascularisation outcome to 20 in the PE outcome. 
 Most incident CVD events in CPRD were definite events, and a large proportion of 
possible events were followed by a definite event within a year, so it was decided to 
include both definite and possible codes in the Read code lists used to identify CVD 
events in CPRD going forward. 
 There was generally a low proportion of overlapping events in both CPRD and HES. 
However, additional Read codes were identified for four outcomes by exploring 
diagnoses in CPRD in the time around an event that only occurred in HES, which 
increased the proportion of events identified using CPRD.  
 There were still some outcomes for which few events could be identified in CPRD in 
comparison with HES, however, there were no clear ways to identify these diagnoses in 
CPRD. It is likely that these events are missed in CPRD due to records not being fed back 
to the GP, or the information not being coded correctly by the GP surgery.  
 For many CVD events identified in HES, a low proportion were the primary diagnosis of 
the episode. However, for those that were the secondary diagnosis, the primary 
diagnosis of the episode was regularly from the same ICD chapter as the intended 
outcome. The decision was therefore made to include both primary and secondary 
diagnoses as CVD outcomes in HES.  
 Analyses that defined the study population in linked CPRD and HES data, whilst 
identifying CVD events in either CPRD or HES, had minimal differences in statistical 
power compared with analyses that only used CPRD to both define the study population 
and identify CVD events. As including events recorded in HES gives a higher probability of 
identifying CVD events, with minimal or no loss in statistical power, it was decided that 
the UK study should use linked CPRD and HES data for all analyses, whilst identifying 
events that were recorded in either CPRD or HES. 
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5 ASSESSING THE EFFECT OF ENDOCRINE THERAPY USE ON THE 
RISK OF CARDIOVASCULAR DISEASE: A COHORT STUDY IN THE 
UK  
 
This chapter is the final draft of a paper assessing the effect of endocrine therapy use on the risk of 
cardiovascular disease in a UK population. This draft will soon be submitted to PLOS Medicine. All 
appendices that will be submitted alongside the paper are available at the end of the thesis.  
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 ABSTRACT 
Background 
Tamoxifen is known to be associated with an increased risk of thromboembolic events, but the long-
term effect of aromatase inhibitor (AI) use on risk of cardiovascular diseases are unclear. We aimed 
to examine the effect of AIs in comparison with tamoxifen on the risk of a comprehensive range of 
cardiovascular outcomes in postmenopausal breast cancer survivors. 
 
Methods 
Using UK primary and secondary care data, we assembled a cohort of postmenopausal female breast 
cancer survivors, who were prescribed tamoxifen or AIs from 2002-2016. The outcomes were a 
range of incident cardiovascular events. Associations between endocrine therapy (AI vs tamoxifen) 
and CVD outcomes were analysed using Cox regression, adjusted for potential confounders. 
 
Results 
10005 women were included: 4716 and 5289 were originally prescribed tamoxifen and AIs 
respectively. There was a pattern of an increased risk of non-venous CVDs in AI compared with 
tamoxifen users, with evidence of an increased risk of heart failure and arrhythmias in women ever 
exposed to AI compared with tamoxifen (adjusted hazard ratio (HR): 1.70, 95% confidence interval 
(CI): 1.26-2.29; adjusted HR: 1.38, 95% CI 1.12-1.70 respectively), which may be driven by cardio-
protective effects of tamoxifen use, as we also found past tamoxifen users at a higher risk of both 
outcomes compared with current users. As expected, AI use was associated with a lower risk of deep 
vein thrombosis than tamoxifen    
 
Conclusion 
We found results that suggest an increased risk of several non-venous CVD outcomes associated 
with AI in comparison with tamoxifen use, with varying levels of precision, and evidence of an 
increased risk of heart failure and arrhythmia during AI use in comparison with tamoxifen use, which 
is likely driven by a protective effect of tamoxifen. Our results also confirmed the established 
increased risk of VTE associated with tamoxifen use. 
 
78 
 
BACKGROUND 
Endocrine therapies, namely tamoxifen and aromatase inhibitors (AIs), reduce the recurrence rate of 
oestrogen and progesterone receptor (ER) positive breast cancer, with AIs being more efficacious in 
postmenopausal women.1-3 Tamoxifen use is known to be associated with an increased risk of 
venous thromboembolic events,4-14  but there have been recent concerns about excess 
cardiovascular disease (CVD) side effects of AIs in comparison with tamoxifen.  
 
Several randomised control trials (RCTs) have compared tamoxifen with AIs for efficacy;7-10 15-23 some 
have compared CVD risks as a secondary outcome, but there has generally been inadequate 
statistical power to detect associations; more recently a few observational studies have attempted 
to explore the long-term CVD effect of AIs relative to tamoxifen;24 25 but most previous work has 
focused on composite CVD outcomes, with little evidence available on specific CVDs. A recent meta-
analysis of RCTs reported an increased risk of non-venous CVDs in comparison with tamoxifen (RR: 
1.19, 95% confidence interval (CI): 1.07–1.34), with authors concluding that this is likely due to 
cardio-protective effects of tamoxifen.15 Another systematic review also collated RCT and 
observational evidence on the effect of endocrine therapies on the risk of specific CVD outcomes, 
and results were consistent with a higher risk of the vascular CVDs myocardial infarction and angina 
in AI compared with tamoxifen users, which is again likely due to a protective effect of tamoxifen on 
these outcomes. The review also suggested an increased risk of venous thromboembolic outcomes 
in tamoxifen users compared with both non-users and AI users.26  
 
Given the ongoing uncertainty, limited real world evidence, and clinical importance, we aimed to 
examine the effect of AIs in comparison with tamoxifen on the risk of a comprehensive range of CVD 
outcomes in female post-menopausal breast cancer survivors in the UK.   
 
METHODS 
Study Design and Data Source 
We carried out a cohort study using prospectively collected data from the UK Clinical Practice 
Research Datalink (CPRD) and linked Hospital Episode Statistics (HES). The CPRD contains 
anonymised primary care data from general practitioners (GPs) who agreed at the practice level to 
participate.27 CPRD covers 7% of the UK population and is broadly representative of the wider 
population.28 The database includes diagnoses, prescriptions and tests from primary care, referrals 
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to specialists, as well as diagnoses and outcomes from secondary care, which are fed back to GPs. 
Lifestyle and anthropometric measurements are also recorded. Around 56% of practices in the CPRD 
have linked data available in HES, all of which are in England. HES includes detailed information on 
hospitalisations.  
 
Study Population 
We identified female patients with linked CPRD and HES data aged 54 years and over (median age of 
the menopause in Europe 29) with an incident breast cancer diagnosis in CPRD (at least one year of 
CPRD follow-up prior to first breast cancer for an incident diagnosis, further information on breast 
cancer definition in Appendix 5.1), who were newly prescribed an AI or tamoxifen in primary care 
after their diagnosis, from 1st January 2002 (although national recommendations suggested use of 
AIs for this population from 2006, preliminary analysis showed that third generation aromatase 
inhibitors anastrozole, exemestane, and letrozole came into widespread use in 2002) to 31st March 
2015 (one year prior to the latest date at which CPRD and HES was linked). Follow-up began either 
one year after the date of breast cancer (to ensure we were studying breast cancer survivors and to 
separate any acute cardiotoxic effects of other systemic treatments), or at the date of first AI or 
tamoxifen prescription, whichever occurred latest (hereafter the ‘index date’). Patients were 
excluded if prior to their index date they: died or transferred out of the CPRD; were diagnosed with 
the CVD event of interest; or had any other cancer diagnoses.  
 
Exposures 
Incident tamoxifen and AI exposures were identified using an appropriate prescription code (code 
lists available at https://doi.org/10.17037/DATA.177, and information on how drug code lists were 
created is available in Appendix 5.2). The primary exposure was AI use relative to tamoxifen use. To 
help elucidate how drug exposure is associated with risk, exposure was parameterised in two ways. 
First, we considered ever exposure to endocrine therapy (ever use of tamoxifen, ever use of AI, ever 
use of both drugs, Appendix 5.3). If a woman moved between tamoxifen and AI prescriptions, 
records were time-updated to indicate they had ever been exposed to both drugs from this point 
forward. Secondly, current exposure to endocrine therapy (categorised as current tamoxifen use, 
current AI use, no current therapy and previously ever exposed to an AI, no current therapy and 
previously exposed to tamoxifen only, Appendix 5.4) was time-updated at any changes in therapy. A 
prescription was defined as continuous if a further prescription followed within 30-days of the 
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original prescription ending. Appendix 5.5 contains further information on how length of endocrine 
therapy prescriptions were defined.  
 
Primary Outcomes 
The main CVD outcomes of interest were: coronary artery disease (angina, myocardial infarction 
(MI), revascularisation procedures, sudden cardiac arrest (SCA)); peripheral vascular disease (PVD); 
stroke; arrhythmia; heart failure (HF, consisting of HF and cardiomyopathy); pericarditis, valvular 
heart disease (VHD); and venous thromboembolism (VTE) (deep vein thrombosis (DVT), pulmonary 
embolism (PE)). Composite CVD outcomes and all individual components of the composite outcomes 
were analysed separately. Events were identified through clinical diagnoses using NHS Read codes in 
the CPRD and ICD-10 codes in HES (code lists are available at https://doi.org/10.17037/DATA.177, 
and information on how clinical diagnosis codes were identified are available in Appendix 5.6). Codes 
that indicated history of an event were included in the code list used to capture past events prior to 
index date, but were not included when identifying incident events during follow up.   
 
Covariates 
Data on the following covariates at index date were extracted from patients’ CPRD files for use in the 
analyses: age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); BMI 
(underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-
drinker); Index of Multiple Deprivation (IMD) score (level 1-5 based on GP level IMD data); use of 
statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor 
blockers (ARB); use of anti-platelets; diabetes; chronic kidney disease; rheumatoid arthritis; systolic 
blood pressure (low/normal, pre-high, high); diastolic blood pressure (low/normal, pre-high, high); 
history of non-venous CVD (all outcomes except those within the VTE outcome); history of any VTE 
outcome; year of breast cancer diagnosis; time since index date (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); 
and current year. (Algorithms and code lists used to define confounders in CPRD can be found in 
Appendix 5.7, and at https://doi.org/10.17037/DATA.177 respectively). Covariate selection of the 
most important potential confounders was made through discussions with oncologists and 
cardiologists to understand the variables that may distort the association between the exposure and 
outcomes due to being independently associated with both the exposure and outcome, and is not an 
intermediate factor on the causal pathway.  
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Statistical Analysis 
Observation time began at index date and ended at earliest of the following: a CVD event of interest, 
diagnosis of another cancer, death, transfer out of the CPRD network, or end of follow-up (31st 
March 2016, the latest date at which CPRD and HES was linked). Prior to exploring the relationship 
between endocrine therapies and CVD, baseline characteristic distributions of patients who were 
initially prescribed tamoxifen or AIs were described.  
 
Primary analyses 
Number of events and crude incident rates of each outcome of interest were calculated for both 
parameterisations of the primary exposures. The primary exposure variables were then included in 
unadjusted (which was adjusted for age due to using age as a timescale, but referred to as 
unadjusted throughout) and adjusted (accounting for all covariates) Cox regression models with an 
underlying age timescale, to obtain hazard ratios. Women with missing BMI, smoking status, or 
alcohol use data (8.7% overall) were excluded (complete case analysis), which is valid in a regression 
context if missingness is conditionally independent of the outcome.30  
 
Secondary analyses 
Effect modification 
Ever exposure analyses were tested for evidence of effect modification by any prior CVD, age at 
index (54-59, 60-69, 70+), and time since index date (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs, which also 
implicitly tests the proportional hazards assumption), in all outcomes. Effect modification was tested 
by including an interaction term between the primary exposure and the potential effect modifier in 
the fully adjusted models, which was then tested using a Wald test on the interaction term (this 
tests if each value of the interaction is equal to zero (on the log scale) and gives the corresponding p 
value, and was carried out using the Stata testparm command). Results were not presented if there 
were no events within any categorisation of a stratified analysis. 
 
Sensitivity and post-hoc and analyses 
As guidelines recommended use of AIs in this study population from 2006, and tamoxifen prior to 
2006, baseline characteristic distributions of patients who were initially prescribed tamoxifen or AIs 
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were described before and after the changes in guidelines.  
 
In case of misclassification of exposure status due to delays in patients obtaining their prescriptions, 
the grace period used to define a continuous prescription was extended from 30 days to 3 months, 6 
months, and 1 year in the current prescription analyses in outcomes that showed evidence of effect 
in primary analyses.  
 
Primary analyses suggested an increased risk of certain outcomes in time previously exposed to 
endocrine therapies in comparison with time currently exposed tamoxifen. To explore whether this 
might be driven by reverse causality (i.e. precursors of the outcome causing the patient to stop 
therapy), we divided the past endocrine therapy categories into recent past use (<6m from stopping) 
and distant past use (>6m from stopping); we hypothesised that any reverse causality would only 
affect the recent past use exposure category.    
 
Ever exposure analyses were additionally adjusted for hormone replacement therapy (HRT) use 
before index date. Women with ER+/PR+ breast cancer are recommended to stop any hormone 
replacement therapy (HRT) once diagnosed with ER+/PR+ breast cancer, but any long-term effects 
could potentially act as a confounder (HRT code list are available at 
https://doi.org/10.17037/DATA.177).  
 
All analyses were performed in STATA 15.31, and further discussion regarding the choice of study 
design, covariate adjustment, and model selection is included in Appendix 5.8.  
 
RESULTS 
A total of 10005 women aged 54 years and over were prescribed either tamoxifen or an AI following 
a breast cancer diagnosis during the study period. A STROBE flow diagram is provided in Appendix 
5.9. 4716 (47%) and 5289 (53%) women were initially prescribed tamoxifen or an AI respectively. The 
characteristics of women based on their initial exposure are shown in Table 1. Women originally 
prescribed AIs were slightly older, with more comorbidities, prior CVDs, and CVD related 
prescriptions compared with women originally prescribed tamoxifen. 
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Primary analyses  
Ever exposure analyses 
Mean follow-up per person for individual clinical CVD outcomes ranged from 3.98 years in 
arrhythmia analyses to 4.07 years in stroke analyses. After adjustment for all potential confounders, 
there was evidence of an increased risk of HF and arrhythmia associated with ever AI in comparison 
with tamoxifen use (adjusted HR: 1.70, 95% CI: 1.26-2.29; adjusted HR: 1.38, 95% CI 1.12-1.70 
respectively; Figure 1, Appendix 5.10). A similar pattern was also seen for other non-venous CVDs 
(other than stroke), albeit with 95% CIs that crossed unity. There was evidence of a decreased risk of 
DVT associated with ever AI compared with tamoxifen use following adjustment for all potential 
confounders at baseline (adjusted HR: 0.63, 95% CI: 0.43-0.93).  
 
Current exposure analyses 
There was evidence of an increased risk of arrhythmia in all categories in comparison with current 
tamoxifen use (current AI vs current tamoxifen adjusted HR: 1.45, 95% CI: 1.17-1.81, Figure 2, 
Appendix 5.11). A similar pattern was seen for coronary artery disease and most of the outcomes 
that made up this composite outcome (angina, revascularisation, SCA), but precision was limited for 
these outcomes as 95% CIs crossed unity. There was also an increased risk of HF associated with 
current AI in comparison with tamoxifen use (adjusted HR: 1.48, 95% CI: 1.07-2.04). In contrast with 
other outcomes, the highest incidence in the DVT outcome was within the current tamoxifen 
category; with evidence of a lower risk of DVT associated with current AI use and patients with in 
those with past exposure to tamoxifen, compared with current tamoxifen use (current AI  vs current 
tamoxifen adjusted HR: 0.50, 95% CI: 0.35-0.72; past tamoxifen only vs current tamoxifen adjusted 
HR: 0.50, 95% CI: 0.26-0.98), but estimates were less precise for the association between past use of 
AI and current tamoxifen. 
 
Secondary analyses 
Effect modification 
All effect modification analyses are presented in Appendices 5.12-5.23. Within the arrhythmia 
outcome, there was weak evidence of effect modification between ever exposure to endocrine 
therapy and both time since index date and past CVD (p=0.07 and p=0.06 respectively, Appendix 
5.18), with a higher risk of arrhythmia associated with ever AI compared with tamoxifen use in 
women shortly after index date, and in those with a CVD event prior to index date. There was also 
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evidence of effect modification between ever exposure to endocrine therapy and time since index 
date in the composite coronary artery disease outcome (p=0.03, Appendix 5.12), with a higher risk of 
coronary artery disease associated with ever AI compared with tamoxifen use in women shortly 
after index date, which attenuated towards the null in later years. There was no further evidence of 
effect modification by age, past CVD, or time since index date in any other outcome. However, there 
were generally few events within the stratified analyses for the majority of outcomes, meaning 
results were not presented for many analyses due to no events within one arm, and little statistical 
power to estimate effect modification for those that were, including no results for any stratified 
analyses for the SCA and pericarditis outcomes.  
 
Sensitivity and Post hoc analyses 
Characteristics before and after guideline changes 
The characteristics of women based on their initial exposure before and after the changes in 
guidelines in 2006, are shown in Appendix 5.24. Prior to the guideline changes, women that were 
prescribed AIs were generally older than those prescribed tamoxifen (median age of AI users prior to 
2006: 74 years, IQR 65-83; median age of tamoxifen users prior to 2006: 68 years, IQR: 61-77), 
whereas after the guideline changes women were generally of a similar age (median age of AI users 
after 2006: 69 years, IQR 63-67; median age of tamoxifen users prior to 2006: 68 years, IQR: 62-75). 
Women prescribed AIs prior to the guideline changes were also more likely to have prior CVD, both 
venous and non-venous, compared with AI users after the changes. 
 
Differing grace periods 
Evidence of an increased risk of arrhythmia and HF in time previously exposed to both AI and 
tamoxifen persisted in all grace period variations year (Appendix 5.25). However, the risk of DVT 
moved away from the null as the grace period length increased when comparing time previously 
exposed to both AI and tamoxifen only.  
 
Risk of event in first six months after stopping therapy 
There continued to be evidence of an increased risk of arrhythmia associated with past use of AI and 
tamoxifen therapy compared with current tamoxifen use, even >6 months after stopping therapy 
(Table 2). There also continued to be an increased risk of HF in all time after stopping AI therapy, 
with a larger HR in the time <6m following prescription end in comparison with the time >6m 
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following prescription end. There was weak evidence of a small increase in risk of HF in all time after 
stopping tamoxifen therapy, albeit with 95% CIs that crossed unity.  
 
Additional adjustment for prior HRT use 
All ever exposure analyses were the same or extremely similar to the original results after 
additionally adjusting for HRT use prior to index date (Appendix 5.26). 
 
DISCUSSION 
Main findings  
In this large population-based cohort study, there was an overall trend of an increased risk of non-
venous CVD outcomes (expect stroke) in ever AI compared with tamoxifen users, with 95% CIs that 
did not cross unity in the arrhythmia and HF outcomes. The risk of arrhythmia and HF was also 
sustained in the time after AI prescription had ended. However, the increased risk of these 
outcomes may be due to cardio-protective effects of tamoxifen use as there was evidence of an 
increased risk of arrhythmia and HF associated with time after exposure to tamoxifen compared 
with time currently exposed, which was not due to women stopping their prescription shortly before 
an event. There was also evidence of a decreased risk of DVT in ever and current AI compared with 
tamoxifen users, which is likely driven by the known increased risk in tamoxifen users.  
 
Another possible explanation for the for the increased risk of arrhythmias and HF in AI users 
compared with tamoxifen, other than cardio-protective effects of tamoxifen, includes confounding 
by other cardio-toxic cancer treatments, such as anthracycline chemotherapy and radiotherapy, due 
to more advanced disease in AI users. We could not explore this possibility as we did not have access 
to information on cancer treatment or stage and grade of cancer, and although there is no reason to 
believe that these factors would differ systematically between the comparison groups, any 
differences in other treatments may explain part of the association. Furthermore, given that more 
women who initiate AIs have CVD diagnoses prior to index date in comparison with those that 
initiate tamoxifen (Table 1), it is conceivable that a possible explanation of the results may be 
confounding by prior CVD. The persistence of an effect in those without any prior CVDs in the 
stratified HF analyses (Appendix 5.18) suggests that this not be the case for HF, but the attenuation 
towards the null in those without prior CVD in the stratified arrhythmia analysis (Appendix 5.17) 
suggests that such confounding may explain at least part of this association. Moreover, as of 2006, it 
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has been recommended that post-menopausal women diagnosed with ER+ breast cancer be 
prescribed AIs over tamoxifen.32 Although the proportion of all users that initiate tamoxifen is 
decreasing over time, there are still many women that are given this drug over AIs. This may be 
because of other conditions such low bone mineral density as women prescribed AIs are at an 
increased risk of fracture in comparison with those prescribed tamoxifen.33 There may therefore also 
be residual confounding by reason for initiation of either tamoxifen or AI, which could not be 
explored, as GP records contain no information on reason for initiation of a certain drug. Finally, 
there was some evidence of reverse causality in the HF analysis, as there was an inflated increased 
risk of HF in the first six months after stopping AIs in comparison with the time greater than six 
months after stopping. This provides some evidence that women stopped their AI treatment due to 
the precursors of HF, but this did not change any overall conclusions.  
 
Comparison with other studies  
Two recent studies by Abdel-Qadir and Haque are the only observational studies to date that have 
directly compared the use of tamoxifen and AIs associated with the risk of specific CVD outcomes.24 
25 Abdel-Qadir reported an increased risk of hospitalisation for MI in AI users compared with 
tamoxifen users (HR: 2.02, 95% CI: 1.16-3.53).24 We found a similar trend (adjusted HR for ever AI 
use vs. ever tamoxifen use: 1.53, 95% CI: 0.95-2.48), albeit with a non-significant effect. Further 
observational evidence have suggested that this effect may be due to a cardio-protective effect of 
MI in tamoxifen users as two out of four observational studies reported a decreased risk in 
tamoxifen users compared with non-users.34-37 Haque reported no evidence of a difference in risk of 
HF between those exposed to AI and tamoxifen (HR: 0.96, 95% CI: 0.77-1.08),25 whereas this study 
reported an increased risk of heart failure in AI users (adjusted HR for ever AI use vs. ever tamoxifen 
use: 1.70, 95% CI: 1.26, 2.29), but in the Haque study, all women over the age of 18 years were 
included and follow-up started at breast cancer diagnosis. Haque also reported evidence of an 
increased risk of a composite outcome that included arrhythmia, dysrhythmia, and pericarditis in AI 
users compared with tamoxifen users (HR: 1.29, 95% CI: 1.11-1.50), which is similar to the effect we 
reported in the arrhythmia analysis. Finally, Haque reported weak evidence of a decreased risk of 
stroke associated with AI compared with tamoxifen use (HR: 0.82, 95% CI: 0.63-1.06), which we did 
not find.  
 
A meta-analysis of RCTs by Khosrow-Khavar reported an increased risk of a composite non-venous 
CVD outcome associated with AI compared with tamoxifen use (RR: 1.18, 95% CI: 1.05-1.33),15 which 
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was likely the result of a cardio-protective effect of tamoxifen. This is similar to the trend seen in the 
non-venous CVD outcomes in this study. Most other meta-analyses focused on composite CVD 
outcomes, but like this study, four out of five individual RCTs reported evidence of a decreased risk 
of VTE in AI users compared with tamoxifen users, with relative risks ranging from 0.25-0.61.7-10 20 
One RCT also reported evidence of an increased of heart failure in AI users compared with tamoxifen 
users (RR: 1.20, 95% CI: 1.04-1.38),10 which is the same direction of effect seen in this study. 
 
A recent systematic review collated all RCT observational evidence and concluded that AI users were 
at a higher risk of MI and angina in comparison with tamoxifen users, which is again likely driven by a 
protective effect of tamoxifen.26 Although we had little precision for these outcomes, the directions 
of effect in both the ever and current exposure analyses for MI and angina was in a similar to that 
suggested in the systematic review. The review also suggested an increased risk of VTE outcomes in 
tamoxifen users compared with AI users, which is consistent with DVT results in this study. However, 
the results for PE were not precise enough to provide conclusive evidence of an effect in either 
direction.  
 
Strengths and limitations 
As the CPRD is a large dataset and broadly represents the UK population,28 the findings are likely to 
be generalisable to postmenopausal women diagnosed with ER+/PR+ breast cancer in both the UK 
and other developed populations due to the homogenous indication of endocrine therapy 
worldwide.  
 
ER+/PR status was not available, but it is likely that all breast cancers were ER+/PR+ as such a 
diagnosis is a prerequisite of being prescribed endocrine therapies. This also meant that we were 
unable to identify a population of women diagnosed with ER+/PR+ breast cancer who were 
unexposed to any endocrine therapy to act as a control group. Having such a group would have 
allowed us detect the effect of both drugs in comparison with those who were free of any potential 
CVD effect of endocrine therapies. However, this categorisation may also be problematic due to 
potential differences between those that do and do not initiate endocrine therapies. It would also 
not be appropriate to compare women diagnosed with ER+/PR+ breast cancer to those with other 
subtypes of breast cancer (i.e. triple negative) because of the different treatment regimens given to 
these women and the resulting potential differences in toxicity.  
 
CPRD captures prescriptions at the point of issue, but we had no data on whether prescriptions were 
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filled, or the drug taken, which could lead to potential misclassification of exposure status. However, 
further descriptive analyses, using a 6-month grace period to define a continuous prescription, 
indicated that 97% of women remained on therapy within 1 year of starting, 95% within 3 years, 85% 
within 5 years, and 29% within 6 years. Hence, it is likely that most women adhered to therapy for 
the recommended 5-year treatment because if they are continuing to pick up their prescriptions 
then it is reasonable to assume that they are using the drugs.  
 
It is possible that some of the difference in CVD risk between AI and tamoxifen users is due to the 
heterogeneous characteristics of tamoxifen and AI users before and after the guideline changes in 
2006. AI users prior to 2006 were older with more prevalent CVD, so are likely at a higher risk of 
further events.  
 
Within women included in the ‘past with AI’ group in the current exposure analyses, 20% of the time 
exposed to any endocrine therapy was exposed to tamoxifen. This time was included within `past 
with AI’ group because the primary aim of the analyses was to investigate the CVD effects of AIs. 
This could help explain the unexpected lack of difference in DVT risk between the past AI and current 
tamoxifen groups.  
 
Within the patients diagnosed with arrhythmia, 10% had a previous HF diagnosis. It is therefore not 
surprising to see the association in a similar direction for both arrhythmia and HF, and some of the 
association between AI use and arrhythmia may be explained by the increased risk of HF with AI use 
in comparison with tamoxifen.  
 
CONCLUSION 
This large population based cohort using data from UK primary and secondary care is the first to 
explore the relative effect of endocrine therapies on the whole range of clinically specific CVD 
outcomes. There was a general pattern of an increased risk of non-venous CVDs in AI compared with 
tamoxifen users, with varying levels of precision. However, results suggested evidence of an 
increased risk of HF and arrhythmia in AI compared with tamoxifen users. It is thought that the 
increased risk in AI users is likely due to cardio-protective effects of tamoxifen. A decreased risk of 
DVT in AI compared with tamoxifen users is also reported, which is likely due to the well-established 
increased risk associated with tamoxifen use. Although there are several advantages in 
understanding the effect of endocrine therapies on CVD as whole, such as the potential to change 
modifiable risk factors such as weight, smoking and alcohol intake, this study shows that these drugs 
89 
 
are not homogenous in their effects on more clinically specific CVD outcomes. Knowledge of these 
effects is also increasingly important in post-menopausal women diagnosed with ER+/PR+ breast 
cancer because of the current recommendations to prescribe AIs to this population, and the growing 
numbers of older women surviving their initial breast cancer diagnosis.  
 
CONFLICTS OF INTEREST 
AM has nothing to disclose. SS reports personal fees from Roche, Clinigen, Eli Lilly, and Novartis, 
outside the submitted work. AL reports personal fees from Servier, Novartis, Pfizer, Roche, Ferring 
Pharmaceuticals, Clinigen Group, Boehringer Ingelheim, Amgen, Eli Lily, and BMS, outside the 
submitted work. LS reports grants from Wellcome, during the conduct of the study; grants from 
Wellcome, MRC, NIHR, BHF, Diabetes UK, and grants and personal fees from GSK, outside the 
submitted work; and is a trustee of the British Heart Foundation. KB reports grants from Wellcome 
Trust and the Royal Society, during the conduct of the study. 
 
CONTRIBUTIONS 
Study design was decided on by AM and KB. AM carried out all data extraction, manipulation, and 
analyses. AM wrote the first draft. All authors contributed to further drafts and approved the final 
manuscript.  
 
FUNDING 
This study was supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and 
the Royal Society (grant No 107731/Z/15/Z) held by KB. The Wellcome Trust and the Royal Society 
had no role in the design, analysis, or writing up of this study. 
 
 
 
 
90 
 
REFERENCES 
1. Early Breast Cancer Trialists' Collaborative G, Davies C, Godwin J, et al. Relevance of breast cancer 
hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level 
meta-analysis of randomised trials. Lancet 2011;378(9793):771-84. doi: 
http://dx.doi.org/10.1016/S0140-6736(11)60993-8 
2. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for 
early-stage breast cancer: 10-year analysis of the ATAC trial. The Lancet Oncology 
2010;11(12):1135-41. doi: 10.1016/S1470-2045(10)70257-6 
3. Early Breast Cancer Trialists' Collaborative G, Dowsett M, Forbes JF, et al. Aromatase inhibitors 
versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. 
Lancet 2015;386(10001):1341-52. doi: 10.1016/S0140-6736(15)61074-1 
4. Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. British journal of 
clinical pharmacology 1998;45(6):608-12. 
5. Hernandez RK, Sorensen HT, Pedersen L, et al. Tamoxifen treatment and risk of deep venous 
thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 
2009;115(19):4442-9. doi: http://dx.doi.org/10.1002/cncr.24508 
6. van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast 
cancer (TEAM): a randomised phase 3 trial. Lancet 2011;377(9762):321-31. doi: 
10.1016/S0140-6736(10)62312-4 
7. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-
responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined 
results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366(9484):455-62. doi: 
10.1016/S0140-6736(05)67059-6 
8. Boccardo F, Rubagotti A, Guglielmini P, et al. Switching to anastrozole versus continued tamoxifen 
treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) 
trial. Annals of oncology : official journal of the European Society for Medical Oncology / 
ESMO 2006;17 Suppl 7:vii10-4. doi: 10.1093/annonc/mdl941 
9. Arimidex TAoiCTG, Forbes JF, Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant 
treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet 
Oncology 2008;9(1):45-53. 
10. Colleoni M, Giobbie-Hurder A, Regan MM, et al. Analyses adjusting for selective crossover show 
improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 
study. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology 2011;29(9):1117-24. doi: 10.1200/JCO.2010.31.6455 [published Online First: 
2011/02/16] 
11. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving 
adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast 
Group. Bmj 1995;311(7011):977-80. 
12. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: 
National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 
1999;353(9169):1993-2000. doi: 10.1016/S0140-6736(99)05036-9 
13. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women 
with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm 
Breast Cancer Study Group. Journal of the National Cancer Institute 1993;85(17):1398-406. 
14. Fisher B, Anderson S, Tan-Chiu E, et al. Tamoxifen and chemotherapy for axillary node-negative, 
estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast 
and Bowel Project B-23. J Clin Oncol 2001;19(4):931-42. doi: 10.1200/JCO.2001.19.4.931 
91 
 
15. Khosrow-Khavar F, Filion KB, Al-Qurashi S, et al. Cardiotoxicity of aromatase inhibitors and 
tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-
analysis of randomized controlled trials. Ann Oncol 2017;28(3):487-96. doi: 
10.1093/annonc/mdw673 
16. Ryden L, Heibert Arnlind M, Vitols S, et al. Aromatase inhibitors alone or sequentially combined 
with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo 
- Meta-analyses on efficacy and adverse events based on randomized clinical trials. Breast 
2016;26:106-14. doi: 10.1016/j.breast.2016.01.006 
17. Cuppone F, Bria E, Verma S, et al. Do adjuvant aromatase inhibitors increase the cardiovascular 
risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. 
Cancer 2008;112(2):260-7. 
18. Aydiner A. Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase 
inhibitors in postmenopausal women. Breast 2013;22(2):121-9. doi: 
http://dx.doi.org/10.1016/j.breast.2013.01.014 
19. Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal 
breast cancer patients: a systematic review and meta-analysis. Journal of the National 
Cancer Institute 2011;103(17):1299-309. doi: http://dx.doi.org/10.1093/jnci/djr242 
20. Bliss JM, Kilburn LS, Coleman RE, et al. Disease-related outcomes with long-term follow-up: an 
updated analysis of the intergroup exemestane study. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology 2012;30(7):709-17. doi: 
10.1200/JCO.2010.33.7899 
21. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen 
after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised 
controlled trial. Lancet 2007;369(9561):559-70. doi: 10.1016/S0140-6736(07)60200-1 
22. Abo-Touk NA, Sakr HA, Abd El-Lattef A. Switching to letrozole versus continued tamoxifen 
therapy in treatment of postmenopausal women with early breast cancer. J Egypt Natl Canc 
Inst 2010;22(1):79-85. [published Online First: 2011/04/20] 
23. Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with 
early breast cancer after anastrozole initiated after treatment with tamoxifen compared 
with continued tamoxifen: the ARNO 95 Study. Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology 2007;25(19):2664-70. doi: 
10.1200/JCO.2006.08.8054 
24. Abdel-Qadir H, Amir E, Fischer HD, et al. The risk of myocardial infarction with aromatase 
inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer. 
Eur J Cancer 2016;68:11-21. doi: 10.1016/j.ejca.2016.08.022 
25. Haque R, Shi J, Schottinger JE, et al. Cardiovascular Disease After Aromatase Inhibitor Use. JAMA 
oncology 2016 doi: 10.1001/jamaoncol.2016.0429 
26. Matthews A, Stanway S, Farmer RE, et al. Long term adjuvant endocrine therapy and risk of 
cardiovascular disease in female breast cancer survivors: systematic review. Bmj 
2018;363:k3845. doi: 10.1136/bmj.k3845 
27. Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research 
Datalink (CPRD). International journal of epidemiology 2015;44(3):827-36. doi: 
10.1093/ije/dyv098 
28. Campbell JD, D.J. Eaton, S.C. Gallagher, A.M. Williams, T.J. Is the CPRD GOLD Population 
Comparable to the U.K. Population? Pharmacoepidemiology and Drug Safety 2013;22(Suppl 
1):280. 
29. Dratva J, Gomez Real F, Schindler C, et al. Is age at menopause increasing across Europe? Results 
on age at menopause and determinants from two population-based studies. Menopause 
2009;16(2):385-94. doi: 10.1097/gme.0b013e31818aefef 
92 
 
30. White IR, Carlin JB. Bias and efficiency of multiple imputation compared with complete-case 
analysis for missing covariate values. Stat Med 2010;29(28):2920-31. doi: 10.1002/sim.3944 
31. Stata Statistical Software: Release 15 [program]. College Station, TX: StataCorp LLC, 2017. 
32. National Institute for Health and Care Excellence. Hormonal therapies for the adjuvant treatment 
of early oestrogen-receptor-positive breast cancer 2006 [Available from: 
https://www.nice.org.uk/guidance/TA112/documents/final-appraisal-determination2 
accessed 14/04/2016. 
33. Tseng OL, Spinelli JJ, Gotay CC, et al. Aromatase inhibitors are associated with a higher fracture 
risk than tamoxifen: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis 
2018;10(4):71-90. doi: 10.1177/1759720X18759291 
34. Bradbury BD, Lash TL, Kaye JA, et al. Tamoxifen-treated breast carcinoma patients and the risk of 
acute myocardial infarction and newly-diagnosed angina. Cancer 2005;103(6):1114-21. 
35. Yang TL, Wu TC, Huang CC, et al. Association of tamoxifen use and reduced cardiovascular events 
among asian females with breast cancer. Circulation Journal 2014;78(1):135-40. 
36. Ligibel JA, James O'Malley A, Fisher M, et al. Risk of myocardial infarction, stroke, and fracture in 
a cohort of community-based breast cancer patients. Breast Cancer Research & Treatment 
2012;131(2):589-97. doi: http://dx.doi.org/10.1007/s10549-011-1754-1 
37. Geiger AM, Chen W, Bernstein L. Myocardial infarction risk and tamoxifen therapy for breast 
cancer. British journal of cancer 2005;92(9):1614-20. 
 
 
93 
 
 
 
 
Table 1: Characteristics of study population based on their initial exposure 
 Tamoxifen  AI Total 
N 4716 (100) 5289 (100) 10005 (100) 
Age (yrs)    
54-59 911 (19.3) 716 (13.5) 1627 (16.3) 
60-69 1850 (39.2) 1972 (37.3) 3822 (38.2) 
70+ 1955 (41.5) 2601 (49.2) 4556 (45.5) 
Median (IQR) 68 (62-76) 70 (63-79) 69 (62-78) 
Year of breast cancer    
2002 579 (12.3) 72 (1.4) 651 (6.5) 
2003 605 (12.8) 123 (2.3) 728 (7.3) 
2004 571 (12.1) 186 (3.5) 757 (7.6) 
2005 512 (10.9) 289 (5.5) 801 (8) 
2006 467 (9.9) 370 (7) 837 (8.4) 
2007 386 (8.2) 448 (8.5) 834 (8.3) 
2008 380 (8.1) 495 (9.4) 875 (8.7) 
2009 290 (6.1) 533 (10.1) 823 (8.2) 
2010 223 (4.7) 586 (11.1) 809 (8.1) 
2011 216 (4.6) 619 (11.7) 835 (8.3) 
2012 210 (4.5) 539 (10.2) 749 (7.5) 
2013 174 (3.7) 504 (9.5) 678 (6.8) 
2014 93 (2) 451 (8.5) 544 (5.4) 
2015 10 (.2) 74 (1.4) 84 (.8) 
BMI (kg/m2)    
<18 59 (1.3) 63 (1.2) 122 (1.2) 
18-24 1693 (35.9) 1619 (30.6) 3312 (33.1) 
25-29 1549 (32.8) 1801 (34.1) 3350 (33.5) 
30-34 800 (17) 979 (18.5) 1779 (17.8) 
≥35 345 (7.3) 548 (10.4) 893 (8.9) 
Missing 270 (5.7) 279 (5.3) 549 (5.5) 
Median (IQR) 26 (23-30) 27 (24-31) 27 (24-31) 
Smoking status    
Never smoker 2423 (51.4) 2517 (47.6) 4940 (49.4) 
Current smoker 503 (10.7) 482 (9.1) 985 (9.8) 
Ex-smoker 1761 (37.3) 2268 (42.9) 4029 (40.3) 
Missing 29 (.6) 22 (.4) 51 (.5) 
Alcohol use    
Non drinker 618 (13.1) 613 (11.6) 1231 (12.3) 
Current 3320 (70.4) 3628 (68.6) 6948 (69.4) 
Ex-drinker 480 (10.2) 715 (13.5) 1195 (11.9) 
Missing 298 (6.3) 333 (6.3) 631 (6.3) 
Systolic BP    
Low/ideal 530 (11.2) 599 (11.3) 1129 (11.3) 
Pre-high 1862 (39.5) 2327 (44) 4189 (41.9) 
High 2314 (49.1) 2355 (44.5) 4669 (46.7) 
Missing 10 (.2) 8 (.2) 18 (.2) 
Diastolic BP    
Low/ideal 2130 (45.2) 2650 (50.1) 4780 (47.8) 
Pre-high 1988 (42.2) 2058 (38.9) 4046 (40.4) 
High 588 (12.5) 573 (10.8) 1161 (11.6) 
Missing 10 (.2) 8 (.2) 18 (.2) 
IMD category    
1 870 (18.4) 962 (18.2) 1832 (18.3) 
2 943 (20) 1214 (23) 2157 (21.6) 
3 925 (19.6) 1054 (19.9) 1979 (19.8) 
4 1052 (22.3) 936 (17.7) 1988 (19.9) 
5 926 (19.6) 1122 (21.2) 2048 (20.5) 
Missing 0 (0) 1 (0) 1 (0) 
Statins before index 1100 (23.3) 1903 (36) 3003 (30) 
ACEI before index 1195 (25.3) 1823 (34.5) 3018 (30.2) 
CCB before index 1195 (25.3) 1764 (33.4) 2959 (29.6) 
ARB before index 493 (10.5) 795 (15) 1288 (12.9) 
Anti-platelets before index 1132 (24) 1639 (31) 2771 (27.7) 
RA before index 138 (2.9) 137 (2.6) 275 (2.7) 
Diabetes before index 462 (9.8) 728 (13.8) 1190 (11.9) 
CKD before index 867 (18.4) 1090 (20.6) 1957 (19.6) 
Non-venous CVD before index 1031 (21.9) 1636 (30.9) 2667 (26.7) 
VTE before index 144 (3.1) 324 (6.1) 468 (4.7) 
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Table 2: Adjusted HRs for the risk of event 
with time after stopping prescription split 
into <6m and >6m after stopping  
Outcome Current exposure  Adjusted HR 
Arrhythmia Tamoxifen 1 
 AI 1.47 (1.18, 1.83) 
Past with AI <6m 1.70 (1.11, 2.61) 
Past with AI >6m 2.10 (1.50, 2.94) 
 Past with tam <6m 1.25 (0.67, 2.33) 
 Past with tam >6m 2.19 (1.54, 3.11) 
HF 
 
 
 
Tamoxifen 1 
AI 1.49 (1.08, 2.06) 
Past with AI <6m 2.09 (1.20, 3.64) 
Past with AI >6m 1.55 (0.95, 2.54) 
Past with tam <6m 1.17 (0.46, 2.98) 
Past with tam >6m 1.29 (0.75, 2.22) 
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Figure 1: Adjusted HRs, events, and crude rate for the association between ever exposure to endocrine 
therapy and a range of clinical CVD outcomes 
 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-
smoker); BMI (underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score 
(level 1-5 based on GP level IMD data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of 
angiotensin II receptor blockers (ARB); diabetes; chronic kidney disease; rheumatoid arthritis; systolic blood pressure (low/normal, 
pre-high, high); diastolic blood pressure (low/normal, pre-high, high); history of VTE; history of non-venous CVD year of breast 
cancer diagnosis; time since index (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); and current year. 
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Figure 2: Adjusted HRs, events, and crude rate for the association between current exposure to 
endocrine therapy and a range of clinical CVD outcomes 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-
smoker); BMI (underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score 
(level 1-5 based on GP level IMD data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of 
angiotensin II receptor blockers (ARB); diabetes; chronic kidney disease; rheumatoid arthritis; systolic blood pressure (low/normal, 
pre-high, high); diastolic blood pressure (low/normal, pre-high, high); history of VTE; history of non-venous CVD year of breast 
cancer diagnosis; time since index (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); and current year. 
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6 ASSESSING THE EFFECT OF ENDOCRINE THERAPY USE ON THE 
RISK OF CARDIOVASCULAR DISEASE: A COHORT STUDY USING 
THE US SEER-MEDICARE LINKED DATABASE  
 
 This chapter is the final draft of a paper assessing the effect endocrine therapy use on the risk of 
cardiovascular disease in a US population. This draft will soon be submitted to JAMA Oncology. All 
appendices that will be submitted alongside the paper are available at the end of the thesis.  
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ABSTRACT 
Background 
The long-term adverse cardiovascular consequences of endocrine therapies, including tamoxifen and 
aromatase inhibitors, remain unclear, and clinical trials have not been statistically powered to detect 
adverse cardiovascular effects. We aimed to examine the effect of tamoxifen and aromatase 
inhibitors (AI) on the risk of a comprehensive range of cardiovascular disease (CVD) outcomes in 
female breast cancer survivors aged 66 years and over in the United States. 
Methods 
We carried out a cohort study using prospectively collected data from the US SEER-Medicare linked 
database. We identified all women with Medicare Parts A, B and D coverage, aged 66 years and over 
with, with an incident ER or PR positive and stage 1-3 breast cancer diagnosis between 1st January 
2008 and 31st December 2013. Women with endocrine therapy prescriptions prior to their breast 
cancer diagnosis were excluded. Tamoxifen and AI exposures and CVD outcomes were identified 
using National Drug Codes, diagnosis codes, and procedure codes. Cox proportional hazards 
regression models were fitted adjusted for a priori-specified potential confounders. 
Results 
22027 women with hormone-receptor positive breast cancer were included; initial endocrine 
treatment was an AI for 15074 (68%), tamoxifen for 2286 (10%) and no endocrine therapy for 4667 
(22%) women. There was generally a pattern of a decreased risk of non-venous CVD outcomes 
associated with ever tamoxifen use with adjusted hazard ratios (HR) ranging from 0.44 (95% 
confidence interval (CI): 0.30-0.63) in the MI analysis to 0.91 (95% CI: 0.75-1.10) in the PVD analysis. 
There was also evidence of a lower risk of several non-venous CVD outcomes among AI users 
compared with the unexposed. As expected there were more deep vein thromboses (DVT) in women 
ever exposed to tamoxifen compared with the unexposed (adjusted HR and 95% CI: 1.41, 0.98-2.04), 
but no evidence of association between AI use and DVT (adjusted HR and 95% CI: 1.14, 0.86-1.52).   
Conclusions 
Apart from the established association between tamoxifen and increased risk of DVT, there was no 
evidence of increased CVD risk with either tamoxifen or AI use compared with no endocrine therapy. 
Our results suggested a protective effect of tamoxifen use on the risk of the major arterial 
cardiovascular diseases. A similar, but weaker, protective association was also seen for arterial 
disease during AI use, but there was a possibility of residual confounding that bring questions to the 
causality of these associations.  
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INTRODUCTION 
Breast cancer remains the most common cancer among women worldwide and recent advances in 
treatment mean that cancer-free survival is increasing.1-3 However, prolonged survival also means 
that adverse effects and delayed toxicities of treatment have the potential to substantially impact 
both patient outcomes and medical resources. 
 
A particular concern regarding treatment effects centres upon CVD risk of endocrine therapies, 
which are widely used in women with oestrogen or progesterone receptor positive (ER+/PR+) 
tumours. Several trials, in which the primary outcome was breast cancer reoccurrence, have 
compared the use of the endocrine therapies tamoxifen and AIs,4-11 and it has been consistently 
shown that AIs increase survival compared with tamoxifen in post-menopausal women diagnosed 
with ER+/PR+ breast cancer. Many of these trials also reported the CVD effects of these drugs, but 
they were regularly underpowered to detect such associations and reported effects on composite 
CVD outcomes, with little evidence available for specific CVD events. The most recent meta-analysis 
of RCTs reported an increased risk of non-venous CVDs in comparison with tamoxifen (RR: 1.19, 95% 
confidence interval (CI): 1.07–1.34), with authors concluding that this is likely due to cardio-
protective effects of tamoxifen.12 Recent observational evidence has begun to focus on more specific 
CVD outcomes,13-19 with many studies showing a protective association between tamoxifen use 
compared with non-users and the risk of non-venous CVDs, but little conclusive evidence on the risks 
associated with AI use. Another recent systematic review collated all RCT and observational evidence 
on the effect of endocrine therapies on the risk of specific CVD outcomes, and results were 
consistent with a higher risk of the vascular CVDs myocardial infarction and angina in AI compared 
with tamoxifen users, which is again likely due to a protective effect of tamoxifen on these 
outcomes. The review also suggested an increased risk of venous thromboembolic outcomes in 
tamoxifen users compared with both non-users and AI users.20 To date, no study has explored the 
effect of endocrine therapies on the risk of the whole range of clinically specific CVD outcomes in 
postmenopausal ER+/PR+ breast cancer survivors. 
 
Given the ongoing uncertainty, limited real world evidence, and clinical importance, we aimed to 
examine the effects of tamoxifen and AIs on a comprehensive range of CVD outcomes in female 
breast cancer survivors aged 66 years and over in the US. 
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METHODS 
Study design and data source  
We conducted a cohort study using the Surveillance, Epidemiology, and End Results program (SEER)–
Medicare database, a linkage of cancer registry and Medicare enrolment and claims data. This linked 
database includes cancer cases through 2013 and Medicare claims through 2014. Medicare Part A 
and B claims provide information on diagnoses and procedures in the hospital and outpatient setting 
and Part D claims provide information on prescription drug dispensing. SEER data along with 
Medicare parts A, B, and D claims are used in this study from 2008 (which is the year Medicare Part 
D data came available to researchers). The data cover 12 states, which are covered by the SEER 
registry. These states equate to approximately 35% of the US population and have been shown to be 
highly representative of the wider US population in terms of poverty and education.21 
 
Study population 
We identified all women with Medicare Parts A, B and D enrolment and no managed care coverage 
for the 12-months before the month of cancer diagnosis. We included all women aged 66 years and 
over (Medicare coverage starts at age 65 years), with an incident ER+/PR+ and stage 1-3 breast 
cancer diagnosed between 1st January 2008 and 31st December 2013. Women were excluded if they 
had an endocrine therapy prescription prior to their breast cancer diagnosis. Follow up began one 
year after the date of breast cancer (hereafter the index date). Women were excluded if prior to 
their index date they: died, discontinued from Medicare Parts A, B, or D, were diagnosed with any 
cancer relating to sites other than the breast (excluding non-melanoma skin cancer), or were 
diagnosed with the CVD event of interest (within a 3-year look back period). 
 
Exposures 
Incident tamoxifen and AI exposures were identified using claims with the Healthcare Common 
Procedural Coding System (HCPCS) procedure codes and National Drug Codes (NDCs) included in 
Appendix 6.1. To help elucidate how drug exposure is associated with CVD risk, exposure was 
parameterised in two ways. First, we considered ever exposure to endocrine therapy (categorised as 
unexposed, ever use of tamoxifen, ever use of AI, or ever use of both drugs). If a woman moved 
between tamoxifen and AI exposure, their records were time-updated to indicate they had ever 
been exposed to both drugs from this point forward. They could also begin follow up as unexposed 
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and later move to any of the other exposure categories. A woman’s exposure when they began 
follow up was the relevant categorisation at time of index date (Appendix 6.2). Second, we looked at 
current exposure to endocrine therapy (categorised as unexposed, current tamoxifen use, current AI 
use, no current therapy and any prior AI use, no current therapy and prior tamoxifen use only). 
Current exposure status was time-updated at any change in therapy (Appendix 6.3). An exposure 
was defined as continuous if a further claim for the same endocrine therapy followed within 30 days 
(i.e., the grace period) of the end of the prescription dispensing date plus the days supplied.  
 
Outcomes 
The main CVD outcomes of interest were: coronary artery disease (angina, myocardial infarction 
(MI), revascularisation procedures, sudden cardiac arrest (SCA)); peripheral vascular disease (PVD); 
stroke; arrhythmia; heart failure (HF, including cardiomyopathy), pericarditis; valvular heart disease 
(VHD); and venous thromboembolism (VTE) (deep vein thrombosis (DVT), pulmonary embolism 
(PE)). Composite CVD outcomes and all individual components of the composite outcomes were 
analysed separately.  Events were identified using International Classification of Disease, 9th edition 
(ICD-9) diagnosis codes and HCPCS codes outlined in Appendix 6.4. 
 
Covariates 
Data on the following covariates were extracted for use in the analysis: year of breast cancer 
diagnosis (2008-2013); age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, 
Native American, other); SEER region (North East, South, North Central, West); breast cancer stage 
(1-3); breast cancer grade (1-3); time since index date (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); and 
current calendar year. The following covariates were defined using ICD-9 diagnosis and procedure 
codes, NDC codes, and HCPCS codes based on a 3-year look back period prior to the index date: use 
of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-
hypertensive drugs, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; 
diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, diabetes, VTE, and non-
venous CVD. All codes used to identify prescribed drugs are outlined in Appendix 6.5. Diagnoses of 
comorbid conditions were based on the Klabunde adaptation of the Charlson comorbidity index,22 
which searches across the patients inpatient and outpatient claims to retain diagnosis codes that are 
either in the inpatient setting, or on two outpatient visits separated by over 30 days. All 
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comorbidities were adjusted for individually. Covariate selection was made through discussions with 
oncologists and cardiologists to understand the variables that are the most important potential 
confounders. 
 
Statistical analysis 
Observation time began at the index date and ended at the earliest of the following: a CVD event of 
interest, diagnosis of another non-breast cancer event, death, end of enrolment in Medicare Parts A, 
B, or D, or end of study period (December 13, 2014). Prior to exploring the relationship between 
endocrine therapies and CVD, distributions of baseline characteristics of patients who were 
unexposed at one year after diagnosis, or initially exposed to tamoxifen or AIs were described. 
 
Primary analyses 
Number of events and crude incident rates of each outcome of interest were calculated for all 
parameterizations of the primary exposures. The primary exposure variables were then included in 
unadjusted (which was adjusted for age due to using age as a timescale, but referred to as 
unadjusted throughout) and adjusted (accounting for all potential confounders) Cox proportional 
hazards regression models with an underlying age timescale, to obtain cause specific hazard ratios 
(HR). By changing the reference category, we calculated HRs both for AI and tamoxifen compared 
with the unexposed group, and for the direct comparison between AI and tamoxifen. Women with 
missing data for any covariate (5.1% overall) were excluded (complete case analysis), which is valid 
in a regression context if missingness is conditionally independent of the outcome.23 
 
Secondary Analyses 
Effect measure modification 
For all outcomes, ever exposure analyses were tested for evidence of effect modification by any CVD 
(except for the event of interest) prior to index date; current age (66-74, 75-84, 85+; which was time-
updated); and time since index date (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs, which also implicitly tests 
the proportional hazards assumption). Effect modification was tested by including an interaction 
term between the primary exposure and the potential effect modifier in the fully adjusted models, 
which was then tested using a Wald test. Results were not presented if there were no events within 
any categorisation of a stratified analyses, and 3 to <5yrs and 5+yrs were combined in the time since 
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index analysis if there were no events in the 5+yrs category.  
 
Sensitivity analyses 
A secondary study population was created, which was a subset of the original population, including 
only women prescribed either tamoxifen or AIs to address residual confounding by reasons for not 
initiating any endocrine therapy. Follow up began one year after the date of breast cancer, or at first 
prescription of tamoxifen or AI (whichever occurred latest). This population was then used to build 
an adjusted Cox proportional hazards model with an underlying age timescale, to obtain HRs for the 
association between the ever exposure variable outlined above and all CVD outcomes. Results were 
compared with those of the original ever exposure model including the unexposed group. 
 
In case of misclassification of exposure status due to delays in patients obtaining their prescriptions, 
the grace period used to define a continuous prescription was extended from 30 days to 3 months, 6 
months, and 1 year in the current prescription analyses.  
 
To ensure results were not driven by additional unmeasured residual confounding, which is more 
likely in older women included in the study as they have a higher likelihood of being pre-disposed to 
CVD events given they have survived longer, the ever exposure analyses were repeated, excluding all 
women over the age of 85.  
 
RESULTS 
A total of 22027 women aged 66 and over were diagnosed with ER+/PR+ breast cancer during the 
study period. A STROBE flow diagram is provided in Appendix 6.6. At the index date, 4667 (22%) 
women were unexposed to any endocrine therapy, whereas 2286 (10%) and 15074 (68%) were 
initially exposed to tamoxifen and AIs respectively. The characteristics of women initially in each 
exposure group are shown in Table 1. Women initially exposed to AIs were generally younger, with 
later stages of breast cancer, and more systemic cancer treatment compared with women that were 
initially unexposed or exposed to tamoxifen. There was also an increase in the proportion of women 
initiating AIs over the study period (of all initiators, 83% were AI in 2008 and 89% were AI in 2013), 
along with a decrease in the proportion of women initiating tamoxifen (of all initiators, 17% were 
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tamoxifen in 2008 and 11% were tamoxifen in 2013). There was generally a high proportion of 
women that were previously diagnosed with non-venous CVD (60% overall), with more prior disease 
in those unexposed at index (64%) in comparison with those exposed to either tamoxifen or AIs (56% 
and 59% respectively).  
 
Primary analyses 
Ever exposure analyses 
Mean follow up per person ranged from 2.26 years in the arrhythmia analysis to 2.50 years in the 
pulmonary embolism analysis. After adjustment for potential confounders, there was evidence of a 
decreased risk of MI associated with ever exposure to either tamoxifen or AIs compared with those 
unexposed to any endocrine therapy (ever tamoxifen vs unexposed adjusted HR: 0.44, 95% CI: 0.30-
0.63; ever AI vs unexposed adjusted HR: 0.79, 95% CI: 0.64-0.97, Figure 1, Appendix 6.7), with a 
larger decreased risk in tamoxifen users (AI vs tamoxifen adjusted HR: 1.81, 95% CI: 1.28-2.58, 
Appendix 6.7). A similar pattern of a decreased risk in those exposed to tamoxifen was seen across 
all outcomes that made up the coronary artery disease outcome, albeit with 95% CIs that crossed 
unity for some outcomes. However, the evidence of a decreased risk in those ever exposed to AIs 
was not seen in all coronary artery disease outcomes (angina and revascularisation). Across the 
other non-venous CVD outcomes, there was generally evidence of a decreased risk associated with 
ever exposure to tamoxifen in comparison with the unexposed group, with varying strength and 
some 95% CIs that crossed unity. However, there was mixed evidence as to the relationship between 
ever exposure to AI and the other non-venous CVD outcomes, with some outcomes showing 
evidence of a decreased risk (stroke, arrhythmia, HF, and pericarditis), and others showing no 
evidence of effect (PVD, VHD). Within the outcomes that made up the composite VTE outcome, 
there was weak evidence of an increased risk of DVT associated with ever exposure to tamoxifen 
compared with those unexposed (adjusted HR: 1.42, 95% CI: 0.98-2.04), and no evidence of effect in 
those ever exposed to AIs compared with those unexposed (adjusted HR: 1.14, 95% CI: 0.86-1.52). 
Few PE events led to imprecise estimation of associations for this outcome.  
 
Current exposure analyses 
Within the coronary artery disease composite outcome, there was evidence of a decreased risk of 
both MI and SCA associated with being currently exposed to either tamoxifen or AIs compared with 
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being unexposed, with the lowest risk consistently in those currently exposed to tamoxifen. The 
decreased risk of MI persisted when women stopped tamoxifen, but there was no evidence of a 
difference in risk of MI with past exposure to AIs, and also no difference in risk of SCA with past 
exposure to either tamoxifen or AIs. Within the other non-venous CVD outcomes, there was 
consistent evidence of a decreased risk associated with current exposure to both tamoxifen and AIs 
compared with being unexposed (with less evidence of effect for the association with current 
exposure to AIs and the outcomes PVD and VHD), with the lowest risk being with exposure to 
tamoxifen for arrhythmia and HF. However, once exposure stopped, the risk of an outcome typically 
attenuated towards the null (except for the risk of stroke once stopping tamoxifen). There was 
evidence of an increased risk of DVT during exposure to tamoxifen compared with being unexposed 
(adjusted HR: 1.74, 95% CI: 1.23-2.46, Figure 2, Appendix 6.8), which attenuated towards the null 
among those who had stopped therapy (adjusted HR: 1.31, 95% CI: 0.93-1.84). But there was no 
evidence of a difference in the risk of DVT with current exposure to AIs compared with being 
unexposed (adjusted HR: 1.11, 95% CI: 0.83-1.49).  
 
Secondary analyses 
Effect modification  
Effect modification analyses are presented in Appendices 6.9-6.21. There were generally few events 
within the stratified analyses for the majority of outcomes, meaning little statistical power to 
estimate effect modification. No results were presented for the PE outcome, as there were groups 
with no events for each stratified analysis. There was, however, evidence of effect modification by 
both time since index date and age within the HF analysis (p for interaction=0.04 and 0.07 
respectively). Although there was weak evidence of a decreased risk of HF associated with exposure 
to both tamoxifen and AIs in the time leading up to 5 years after index, the direction of association 
changed after this point, albeit with 95% CIs that crossed unity. There was also evidence of effect 
modification by current age within the VHD outcome (p for interaction=0.04), with a decreasing risk 
of VHD as age increased.  
 
Sensitivity analyses 
Direct comparison of AI vs tamoxifen 
There was evidence of an increased risk of angina, MI, arrhythmia, pericarditis, and VHD associated 
with ever exposure to AI compared with tamoxifen in the head-to-head comparison (Appendix 6.22). 
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Results were similar in the primary analyses when the reference category was ever tamoxifen use 
and in the sensitivity analysis restricted to those only given endocrine therapy. 
 
Differing grace periods 
Evidence of all effects within all current exposure and outcome analyses persisted when the grace 
period was extended to 3 months, 6 months, and one year (Appendix 6.23). 
 
Exclusion of women over the age of 85 years 
The direction and trend of associations for all outcomes remained the same in the ever exposure 
analysis when women over the age of 85 years were excluded (Appendix 6.24). However, 
associations generally moved towards the null for all outcomes within the coronary artery disease 
and VTE composite outcomes (angina, MI, revascularisation, SCA, DVT, and PE), and away from the 
null for other non-venous CVD outcomes (stroke, arrhythmia, HF, and pericarditis).  
 
DISCUSSION  
Main Findings 
In this large, cancer registry-based study in women aged 66 years and over diagnosed with ER+/PR+ 
breast cancer in the US, there was no evidence of increased non-venous CVD risk associated with 
either tamoxifen or AI use compared with no endocrine therapy. However, the risk of all non-venous 
CVD outcomes was lower in those ever exposed to tamoxifen compared with those unexposed, and 
for six out of 11 of the non-venous outcomes (including the composite coronary outcome), there 
was good statistical evidence of a protective effect with 95% CIs not including the null association. 
The largest decreased risk was reported in the MI analysis, with those ever exposed to tamoxifen 
being at a 56% (95% CI: 37-70%) lower risk of an outcome in comparison with those unexposed. 
There was mixed evidence on the relationship between exposure to AIs and risk of non-venous CVD 
outcomes, with evidence of a decreased risk of some outcomes with exposure to AI (MI, stroke, HF, 
and pericarditis), and no evidence of a difference, or 95% CIs that crossed unity, for other outcomes. 
However, women exposed to tamoxifen were consistently at the lowest risk of all non-venous CVD 
outcomes (except for HF, where all endocrine therapy exposed groups had a similar reduced risk in 
comparison with those unexposed). For those outcomes in which there was a protective effect 
during exposure to either tamoxifen or AI, the risk of non-venous CVDs typically increased towards 
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the level of those unexposed once exposure ended. There was also evidence of an increased risk of 
DVT during time currently exposed to tamoxifen, which decreased when women stopped tamoxifen.   
 
There is biological rationale that tamoxifen possesses cardio-protective effects due to decreasing 
lipid levels, with evidence of reductions in total serum cholesterol (between 10% and 15%) and low-
density lipoprotein cholesterol (between 15% and 22%).24 25 It has also been suggested that AIs could 
increase the risk of CVD outcomes in comparison with tamoxifen as they reduce oestrogen levels 
and therefore the oestrogen-mediated protective CVD effects such as regulation of serum lipid 
metabolism, increasing vasodilation, and inhibition of the development of atherosclerosis,26 but 
several RCTs have compared hypercholesterolemia between AI and tamoxifen users, with 
inconclusive results.27-29  
 
Comparison with other studies 
This is the first study to our knowledge to assess the effect of endocrine therapies in comparison 
with an unexposed breast cancer population on a full range of clinically relevant CVD outcomes. 
Seven studies (five observational and two RCTs) directly compared tamoxifen use to either no 
tamoxifen or placebo and the risk of MI, 13-17 30 31 with four studies reporting relative risks in a similar 
protective direction as reported in our study (RRs ranged from 0.20-0.83).13 14 30 31 Similar to our 
study, one observational study and one RCT have reported protective effects of AI use versus no use 
associated with the risk of MI, albeit with less precise estimates in which the 95% CI crossed unity 
(RR: 0.90, 95% CI: 0.65-1.25, RR: 0.82, 95% CI: 0.55-1.22 respectively).16 29 Three out of five studies 
(four observational and one RCT) exploring the effect of tamoxifen use on risk of stroke also 
reported a similar protective direction of effect (RRs ranged from 0.52-0.81),14-16 19 30 but two studies 
reported effects in opposite directions for the effect of AI use on the risk of stroke,16 29 whereas we 
reported a protective effect. Our results are also consistent with the established increased risk of 
VTE outcomes associated with tamoxifen use, 30 32-35 but we did not find a similar increased risk in AI 
users reported in one previous RCT.29 All previous observational and RCT evidence was collated in a 
recent systematic review.20 Similar to this study, it concluded that AI users are at a higher risk of 
several vascular diseases including MI and angina in comparison with tamoxifen users, which may be 
partly driven by a protective effect of tamoxifen, and tamoxifen users are at a higher risk of VTE 
outcomes in comparison with both AI users and those unexposed. However, our results also suggest 
that AI use may have cardio-protective effects versus no endocrine therapy use for some specific 
111 
 
 
CVD outcomes (MI, SCA, stroke, angina, HF, arrhythmia, pericarditis), but to a lesser extent than 
tamoxifen. 
 
Strengths and limitations  
SEER-Medicare includes a large, diverse population of older women diagnosed with breast cancer 
and treated in real world settings, in which we were able to account for several potentially cardio-
toxic treatments such as anthracyclines and trastuzumab. The inclusion of those with Medicare Part 
D coverage also allowed adjustment for CVD-related prescription medications. These results likely to 
be generalisable to women aged 66 and over diagnosed with ER+/PR+ breast cancer in both the US 
and other developed countries due to the homogenous indication of endocrine therapy worldwide.  
 
Several limitations of the study could be non-causal explanations of the observed associations. The 
inclusion of only women with ER+/PR+ breast cancer meant we were able to compare CVD risk in 
those with a clinically similar breast cancer diagnosis. The proportion of women that were 
unexposed to any therapy at index date in this study (21%) was similar to the proportion of non-
initiators reported in a similar population of women diagnosed with ER+/PR+ breast cancer by Farias 
et al (25%).36 However, the non-initiators may have an elevated CVD risk at baseline in comparison 
with women that initiated endocrine therapy due to being generally older, and having more 
comorbidities such as CKD, and a higher proportion of previous CVD (Table 1). Although, when 
assessing effect modification by prior CVD for most outcomes in which there was evidence of an 
effect of tamoxifen use, the protective association mostly persisted in those without previous CVD or 
there was no evidence of effect modification, which argues against residual confounding by prior 
CVD. Other reasons for non-initiation could include frailty, poor CVD preventative care, and high 
BMI, which are also risk factors for CVD. The very large protective effect of tamoxifen use on risk of 
MI (HR: 0.44, 95% CI: 0.30-0.63), which is beyond even the most established CVD drugs such as 
statins, or the decreased risk of several outcomes associated with AI use, could therefore be partly 
explained by unmeasured confounding of these factors, which could not be directly measured in 
these data. Although it is unlikely that this residual confounding explains all of the observed 
association for the protective effects of tamoxifen on several non-venous CVD outcomes, it is 
possible that some of the observed associations with AI use are non-causal. 
 
Within unexposed patients, no information was available on the other reason for non-initiation. This 
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could be due to patient’s individual factors (e.g., beliefs about therapy effectiveness, financial 
barriers, access to care), physician recommendations, or potential medical contraindications. We 
were also not able to account for contraindications such as hot flushes and night sweats. The model 
using the restricted study population without non-initiators (Appendix 6.22) had less potential for 
confounding due to factors related to reasons for non-initiation,37 and reported similar results to the 
original model when directly comparing the difference between ever AI and tamoxifen use.  
 
SEER-Medicare data has no information on patients’ lifestyle measures such as smoking, BMI, and 
alcohol use, which are overlapping risk factors of both breast cancer and CVD. Any differences in 
these factors between initiators and non-initiators of endocrine therapy will result in residual 
confounding. However, although there is evidence to suggest that smoking and alcohol use influence 
adherence to endocrine therapy,38 there is currently no evidence that any of these factors affect 
choice of endocrine therapy.  
 
In the interest of minimising the number of exposure arms in the current exposure analysis, all 
women previously exposed to an AI contributed time to the ‘past with AI’ group, regardless of if they 
were also previously exposed to tamoxifen. Within all women included in the ‘past with AI group’, 
10% of the time exposed to any endocrine therapy was exposed to tamoxifen. This could help 
explain why there are slightly greater protective and toxic effects in the ‘past with AI group’ in 
comparison with the current AI group in the angina and DVT current exposure analyses respectively.  
 
CONCLUSION 
This large cancer registry-based cohort study in the US is the first to explore the relative effect of 
tamoxifen and AI use compared with an unexposed population on the risk of a range of clinically 
specific CVD outcomes in ER+/PR+ older breast cancer survivors. It has been widely suggested that 
AIs users are at increased risk of non-venous CVDs in comparison with tamoxifen users.  Results 
suggest evidence of a protective effect of tamoxifen therapy on the risk of the non-venous CVDs: MI, 
SCA, stroke, arrhythmia, HF, pericarditis, and VHD. However, we also report evidence of a decreased 
risk of several non-venous CVDs during AI use, albeit less than with tamoxifen use, but there is a 
possibility of residual confounding due to a potentially increased risk of non-venous CVDs in non-
initiators of endocrine therapy at baseline, that brings questions to the causality of these 
associations. The established increased risk of DVT with tamoxifen use is also confirmed. While 
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choice of AI or tamoxifen will primarily be based on the effectiveness against breast cancer 
recurrence, the individual’s risk of both venous and non-venous CVDs are important secondary 
considerations, and these results will thus help inform clinical decision-making in women with 
ER+/PR+ breast cancer.  
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Table 1:  Characteristics of study population based on their initial exposure 
 Unexposed (%) Tamoxifen (%) AI (%) Total (%) 
N 4667 (100) 2286 (100) 15074 
(100) 
22027 (100) 
Age at index date (yrs)     
66-74 1538 (33) 897 (39.2) 7505 
(49.8) 
9940 (45.1) 
75-84 1937 (41.5) 994 (43.5) 5894 
(39.1) 
8825 (40.1) 
85+ 1192 (25.5) 395 (17.3) 1675 
(11.1) 
3262 (14.8) 
Median (IQR) 79 (73-85) 77 (72-83) 75 (71-
81) 
76 (71-82) 
Ethnicity     
White  4002 (85.8) 2028 (88.7) 12782 
(84.8) 
18812 (85.4) 
Black 360 (7.7) 102 (4.5) 1099 
(7.3) 
1561 (7.1) 
Other  93 (2) 47 (2.1) 335 (2.2) 475 (2.2) 
Asian 123 (2.6) 68 (3) 498 (3.3) 689 (3.1) 
Hispanic 71 (1.5) 32 (1.4) 294 (2) 397 (1.8) 
Native American - - - 52 (.2) 
Missing - - - 41 (.2) 
SEER Region     
North East  760 (16.3) 283 (12.4) 3320 
(22) 
4363 (19.8) 
South 1023 (21.9) 605 (26.5) 3778 
(25.1) 
5406 (24.5) 
North Central 695 (14.9) 448 (19.6) 1761 
(11.7) 
2904 (13.2) 
West 2157 (46.2) 939 (41.1) 6130 
(40.7) 
9226 (41.9) 
Missing 32 (.7) 11 (.5) 85 (.6) 128 (.6) 
Year of breast cancer diagnosis     
2008 847 (18.1) 414 (18.1) 2075 
(13.8) 
3336 (15.1) 
2009 831 (17.8) 449 (19.6) 2140 
(14.2) 
3420 (15.5) 
2010 729 (15.6) 368 (16.1) 2394 
(15.9) 
3491 (15.8) 
2011 744 (15.9) 333 (14.6) 2625 
(17.4) 
3702 (16.8) 
2012 756 (16.2) 350 (15.3) 2709 
(18) 
3815 (17.3) 
2013 760 (16.3) 372 (16.3) 3131 
(20.8) 
4263 (19.4) 
Stage of breast cancer     
Stage I 3034 (65) 1486 (65) 8379 
(55.6) 
12899 (58.6) 
Stage II 1275 (27.3) 660 (28.9) 5267 
(34.9) 
7202 (32.7) 
Stage III 358 (7.7) 140 (6.1) 1428 
(9.5) 
1926 (8.7) 
Grade of breast cancer     
1 1522 (32.6) 765 (33.5) 4273 
(28.3) 
6560 (29.8) 
2 2071 (44.4) 1109 (48.5) 7350 
(48.8) 
10530 (47.8) 
3 853 (18.3) 324 (14.2) 2810 
(18.6) 
3987 (18.1) 
Missing 221 (4.7) 88 (3.8) 641 (4.3) 950 (4.3) 
Cancer treatments     
Taxane 570 (12.2) 162 (7.1) 2415 
(16) 
3147 (14.3) 
Anthracyclines 259 (5.5) 68 (3) 820 (5.4) 1147 (5.2) 
Trastuzumab 226 (4.8) 39 (1.7) 687 (4.6) 952 (4.3) 
Other treatment 753 (16.1) 244 (10.7) 2992 
(19.8) 
3989 (18.1) 
Comorbidities     
RA  185 (4) 103 (4.5) 547 (3.6) 835 (3.8) 
CKD  383 (8.2) 155 (6.8) 1113 
(7.4) 
1651 (7.5) 
Hypertension  3426 (73.4) 1612 (70.5) 11113 
(73.7) 
16151 (73.3) 
Diabetes  1313 (28.1) 598 (26.2) 4545 
(30.2) 
6456 (29.3) 
CVD related treatment     
Statins 1778 (38.1) 948 (41.5) 6988 
(46.4) 
9714 (44.1) 
Hypertensives 169 (3.6) 83 (3.6) 577 (3.8) 829 (3.8) 
ACEi 962 (20.6) 477 (20.9) 3251 
(21.6) 
4690 (21.3) 
CCB 850 (18.2) 364 (15.9) 2696 
(17.9) 
3910 (17.8) 
ARB 593 (12.7) 255 (11.2) 2063 
(13.7) 
2911 (13.2) 
Past CVD     
Non venous CVD 2989 (64) 1281 (56) 8896 
(59) 
13166 (59.8) 
VTE 162 (3.5) 31 (1.4) 385 (2.6) 578 (2.6) 
*Cells with ‘–‘ represent those with numbers suppressed due to some cells containing numbers <11   
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Figure 1: Adjusted HRs, events, and crude rate per 1000 person-years for the association 
between ever exposure to endocrine therapy and a range of clinical CVD outcomes 
*Events suppressed if number of events < 11 
† HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native 
American, other); SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since 
index date (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer 
treatments, statins, anti-hypertensive drugs, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of 
rheumatoid arthritis, chronic kidney disease, hypertension, diabetes, VTE, and non-venous CVD 
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Figure 2: Adjusted HRs, events, and crude rate per 1000 person-years for the association 
between current exposure to endocrine therapy and a range of clinical CVD outcomes 
*Events suppressed if number of events < 11 
† HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, 
Native American, other); SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-
3); time since index date (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, 
other systemic cancer treatments, statins, anti-hypertensive drugs, ACE inhibitors, calcium channel blockers, angiotensin receptor 
blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, diabetes, VTE, and non-venous CVD 
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7 ZCOMPARISON OF UK AND US STUDIES 
 
7.1 INTRODUCTION 
The main aims of both the UK and US studies were to assess the cardiotoxicity of endocrine 
therapies in breast cancer survivors. However, given the differences between the CPRD/HES and 
SEER-Medicare data, there were differences in the methods used to achieve this aim in the two 
studies. This chapter will compare the methodology of the original studies and their respective 
results, then re-analyse both studies to make them as similar as possible and allow for a direct 
comparison.  
 
7.2 COMPARISON OF METHODOLOGY 
This section will give an overview of the difference in study designs between the UK and US study, as 
well as explanations of why differences arose.  
 
7.2.1 Study populations 
Table 7.1 outlines the concordance of inclusion and exclusion criteria and start of follow up for both 
studies. In the UK study, all women aged 54 years and over with a breast cancer diagnosis between 
2002 and 2013 who received a tamoxifen or AI prescription were included. Whereas, women aged 
66 years and over with an ER+/PR+ breast cancer diagnosis between 2008 and 2013 were included in 
the US study, regardless of if they were prescribed an endocrine therapy. These differences were 
because SEER-Medicare follow up starts at the age of 65 years (then women needed a year of follow 
up prior to their breast cancer diagnosis), Medicare part D follow up is complete from 2008, and 
ER/PR status is not available in CPRD or HES. The only difference in exclusion criteria was that 
women were excluded from analysis if they had the CVD event of interest at any point prior to index 
date in the UK, but only within a 3-year look back period in the US. This was because Medicare 
follow up only starts at the age of 65 years, so the likelihood of identifying prior events would 
depend on age if there was a longer look back period because older women would have the most 
prior follow up available. If women were aged 66 or 67 years, their look back period was only 1 and 2 
years respectively. 
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7.2.2 Exposure 
To define recorded prescriptions, CPRD uses its own product code system and SEER-Medicare uses 
HCPCS and NDCs. It is not possible to map these systems to each other, so in each study, 
Table 7.1: Concordance of study populations between UK and US studies 
 UK study US study Concordant Reason 
Inclusion criteria 
 
Gender 
 
Female Female 

 
Age 54 years and over 66 years and over 
X 
Only data from those aged of 
65 year and over available in 
SEER-Medicare 
Cancer diagnosis Breast cancer with one 
year of follow up prior to 
diagnosis 
 
ER+/PR+ breast cancer with 
one year of follow up prior to 
diagnosis 
X 
ER/PR status not available in 
CPRD or HES 
Date Breast cancer diagnosis 
between 1/1/2002 and 
31/3/2015 
 
Breast cancer diagnosis 
between 1/1/2008 and 
31/12/2013 X 
Medicare Part D was complete 
from 2008 and was needed to 
identify prescriptions 
 
Endocrine therapy 
prescription 
Only women with a 
tamoxifen or AI 
prescription after their 
breast cancer diagnosis 
All women with ER+/PR+ 
breast cancer, regardless of if 
they were prescribed 
tamoxifen, AIs, or neither. 
Prescriptions had to be after 
breast cancer diagnosis 
X 
As ER/PR status was not 
available in CPRD or HES, it 
was impossible to identify an 
unexposed population with a 
similar breast cancer diagnosis 
Exclusion criteria 
 
Died or discontinued 
follow up in database 
At any point prior to 
index date 
At any point prior to index 
date  
 
Diagnosed with 
another cancer 
 
At any point prior to 
index date 
At any point prior to index 
date  
 
Diagnosed with CVD 
event of interest 
At any point prior to 
index date 
Within 3 years prior to index 
date 
X 
Women are only eligible for 
Medicare from the age of 65 
years in the US, so including a 
longer look back period would 
mean the likelihood of 
identifying prior events would 
depend on age because older 
women would have the most 
prior follow up available 
Start of follow up Latest of 1 year after 
breast cancer diagnosis or 
first prescription 
1 year after breast cancer 
diagnosis 
X
Under the inclusion criteria in 
the UK study, women needed a 
prescription enter study, so 
couldn’t enter prior to this 
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independent code lists were created that were as similar as possible.  
 
The ever and current exposure to endocrine therapy variables were created in the same way for 
both studies, but the US study included an unexposed group. The only difference was how length of 
prescription was calculated. CPRD supplies information on the number of drugs prescribed and the 
recommended daily dose, so it was possible to calculate the length of each prescription, whereas 
Medicare part D directly supplies the number of days for which the drug was supplied. Regardless of 
how length of prescription was calculated, a 30-day grace period from the end of the prescription 
defined a continuous prescription; if there was another prescription within this period, prescription 
continuity was assumed. Both studies also included sensitivity analyses that varied the grace periods.  
 
7.2.3  Outcomes 
The UK study used Read codes in CPRD and ICD-10 codes in HES to identify CVD diagnoses, whereas 
the US study used ICD-9 codes in SEER-Medicare. The ICD-10 codes used in the UK study were 
provided to UNC as part of the data specification, and were mapped to ICD-9 codes by a UNC 
student as part of the dataset preparation to ensure concordance between the outcome definitions 
in both studies. Both studies identified outcomes in both primary and secondary care.  
 
7.2.4 Covariates 
Table 7.2 shows the covariates adjusted for in both studies, along with an overview of their 
definitions. The following section includes further explanations for any differences in covariate 
definitions.  
 
7.2.4.1 Demographics 
IMD score was available in the UK study, but was not available in SEER-Medicare data. Race is 
available in the CPRD, however there is poor completeness and consistency of this variable, 
especially prior to 2006,[118] so the decision was taken not to include it. Furthermore, region was 
not considered an important confounder in the UK due to the smaller geographical differences in the 
UK.  
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Table 7.2: Covariates adjusted for in UK and US studies 
Covariate UK study US study 
 Adjusted  Definition  Adjusted Definition  
Demographic    
Age at index  54-59, 60-69, 70+  66-74, 75-84, 85+ 
IMD score  level 1-5 based on GP level IMD data X N/A 
Race X N/A  White, Black Asian, Hispanic, Native 
American, other 
Region X N/A  North East, South, North Central, West 
Lifestyle measures     
Smoking status  At index (non-smoker, current 
smoker, ex-smoker)
X N/A 
BMI  At index (underweight/healthy 
weight, overweight, obese)
X N/A 
Alcohol status  At index (non-drinker, current 
drinker, ex-drinker)
X N/A 
Treatments     
Use of statins  Ever use prior to index  Use within 3-years prior to index 
Use of ACE inhibitors  Ever use prior to index  Use within 3-years prior to index 
Use of CCBs  Ever use prior to index  Use within 3-years prior to index 
Use of ARBs  Ever use prior to index  Use within 3-years prior to index 
Use of antiplatelets  Ever use prior to index X N/A
Use of anti-
hypertensive drugs 
X N/A  Use within 3-years prior to index 
Use of taxanes X N/A  Use within 3-years prior to index 
Use of anthracyclines X N/A  Use within 3-years prior to index 
Use of trastuzumab X N/A  Use within 3-years prior to index 
Use of other systemic 
cancer therapies 
X N/A  Use within 3-years prior to index 
Comorbidity 
diagnoses 
   
Diabetes  Ever diagnosed prior to index  Diagnosed within 3-years prior to index 
CKD  Ever diagnosed prior to index  Diagnosed within 3-years prior to index 
Rheumatoid arthritis  Ever diagnosed prior to index  Diagnosed within 3-years prior to index 
Systolic blood 
pressure 
 At index (low/normal, pre-high, 
high) 
X N/A 
Diastolic blood 
pressure 
 At index (low/normal, pre-high, 
high)
X N/A 
Hypertension X N/A  Diagnosed within 3-years prior to index 
History of non-venous 
CVD 
 Ever diagnosed prior to index  Diagnosed within 3-years prior to index 
History of any VTE 
outcome 
 Ever diagnosed prior to index  Diagnosed within 3-years prior to index 
Information relating 
to breast cancer 
   
Year of breast cancer 
diagnosis 
 2002-2015  2007-2013 
Breast cancer stage X N/A  1-3 
Breast cancer grade X N/A  1-3 
Other information    
Time since index date  0-1yr, 1-3yrs, 3-5yrs, 5+yrs  0-1yr, 1-3yrs, 3-5yrs, 5+yrs 
Current year  2002-2017  2007-2014 
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7.2.4.2 Lifestyle measures 
No lifestyle measures such as smoking status, BMI, and alcohol status were available in SEER-
Medicare data.  
 
7.2.4.3 Treatments 
No reliable data on cancer treatments (other than endocrine therapy) were available in the CPRD or 
HES data. The US study adjusted for use of anti-hypertensive drugs, but the UK study did not, as the 
presence of hypertension was measured using systolic and diastolic blood pressure. Furthermore, 
the UK study adjusted for use of anti-platelets, but the US study did not. However, in the UK study, 
there was minimal difference between the crude HRs and the HRs after adjustment for antiplatelet 
use. The biggest difference was in the angina analysis, where the absolute difference between the 
crude and the adjusted HR was 7% (Appendix 7.1). However, the absolute difference between the 
crude and adjusted HRs was less than 5% for 12/14 of the outcomes. Antiplatelet use was therefore 
not considered an important confounder.  
 
In the UK study, women were defined as previously being exposed to any of these drugs at index if 
they had a prescription at any point between their entry into the CPRD network and index date. 
Whereas in the US study, women were defined as being previously exposed at index if they had a 
prescription within the three years prior to index date (or between entry into the network and index 
if this period was less than three years). Like prior CVD events, this was because Medicare follow up 
only starts at the age of 65 years, so the likelihood of identifying prior prescriptions would depend 
on age if there was a longer look back period because older women would have the most prior 
follow up available.   
 
7.2.4.4 Diagnoses 
Systolic and diastolic blood pressure readings were not available in SEER-Medicare data, so a record 
of a hypertension diagnosis, as well as prescription of an anti-hypertensive drug (above) was used as 
a proxy for hypertension in the US study.   
 
As with treatments above, women in the UK study were defined as previously having a diagnosis of a 
125 
 
 
comorbidity at index if they had a record at any point between their entry into the CPRD network 
and index date. Whereas in the US study, women were defined as previously having a diagnosis of a 
comorbidity at index if they had a record within the three years prior to index date (or between 
entry into the network and index if this period was less than three years).  
 
7.2.4.5 Information relating to breast cancer 
Breast cancer stage and grade was not available in CPRD or HES. It is possible to link the CPRD and 
HES data to the UK Cancer Registry, but there is a high level of missingness of stage and grade, which 
has the potential to impact statistical power and bias any results if missingness is dependent on the 
outcome (in a complete case analysis). It was therefore decided not to link these data. 
 
7.2.4.6 Other information 
Both studies adjusted for time since index date and current year. 
 
7.2.5 Statistical Analysis 
For both studies, observation time began at index date and ended at earliest of the following: a CVD 
event of interest, diagnosis of another cancer, death (from CPRD records in the UK study, and 
Medicare records in the US study), transfer out of the CPRD network/end of enrolment in Medicare 
Parts A, B, or D, or end of follow-up. Data from both the UK and US studies are from routinely 
collected data, so complete ascertainment of outcomes during defined follow up can be reasonably 
assumed, other than misclassification due to improper coding.  Although the exposure 
categorisations were different in the two studies, they both used the same statistical methodology. 
The primary exposure variables were always included in unadjusted and adjusted (accounting for all 
covariates) Cox regression models with an underlying age timescale, to obtain hazard ratios. 
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7.3 COMPARISON OF RESULTS 
This section aims to compare the results of the UK and US studies, both as they were reported in 
chapters 5 and 6, and when re-analysed so the methodology and analyses in each study were 
modified to make them as similar as possible. To allow for the modified comparison, both study 
populations were restricted until they were as similar, analyses were adjusted for covariates that 
were included in both studies, and covariates were identified were using the same methodology. 
 
7.3.1 Methods 
7.3.1.1 Comparison of results as originally reported in studies  
The primary analysis of the ever exposure analysis in the US study was also carried out with the 
baseline exposure changed to ever tamoxifen use, so it was possible to make a direct comparison 
between both ever exposure analyses in the UK and US studies, retaining the original methodology 
from each study. For simplicity, only the results comparing the risk of CVD outcomes in ever AI 
compared with tamoxifen users were presented.  
 
7.3.1.2 Modified comparison of results 
This section outlines the modified study population, exposures, outcomes, covariates, and analyses 
used to re-analyse both studies to make them as comparable as possible. The methodology 
presented below was applied to both the UK and US studies separately, and results were compared.   
 
Study population 
Both study populations were modified to include all women with follow up in the data for 12-
months before an incident breast cancer diagnosis. All women had to be aged 66 and over, with an 
incident ER+/PR+ and stage 1-3 breast cancer (in the US study, any breast cancer in the UK study) 
diagnosed between from 1st January 2002 and 31st March 2015 in the UK and 1st January 2008 and 
31st December 2013 in the US, and be newly prescribed an AI or tamoxifen after their diagnosis. In 
addition, women were excluded if they had an endocrine therapy prescription prior to their breast 
cancer diagnosis. Follow-up began either one year after the date of breast cancer or at the date of 
first AI or tamoxifen prescription, whichever occurred latest (hereafter the ‘index date’). Women 
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were excluded if prior to their index date they: died, discontinued from Medicare Parts A, B, or 
D/transferred out of the CPRD, were diagnosed with any cancer relating to sites other than the 
breast, or were diagnosed with the CVD event of interest (within a 3-year period prior to index). 
Overall, in the UK the requirements that were modified from the original study were: age was 
restricted to 66 years and over, rather than 54 years and over; and women were excluded if they 
had a CVD event of interest within 3 years prior to the index date rather than at any point prior to 
the index date. The only modification in the US was that all women were required to have an 
ER+/PR+ breast cancer diagnosis and an endocrine therapy prescription, rather than just an ER+/PR+ 
breast cancer diagnosis regardless of if they were prescribed an endocrine therapy.  
 
Exposures 
In both UK and US study populations, identification of incident tamoxifen and AI exposures used an 
appropriate prescription code (based on the code lists outlined in chapters 5 and 6 for CPRD and 
SEER-Medicare respectively). The primary exposure was AI use relative to tamoxifen use. To help 
elucidate how drug exposure is associated with risk, exposure was parameterised in two ways. First, 
ever exposure to endocrine therapy (ever use of tamoxifen, ever use of AI, ever use of both drugs). If 
a woman moved between tamoxifen and AI prescriptions, records were time-updated to indicate 
they had been exposed to both drugs from this point forward. Secondly, current exposure to 
endocrine therapy (categorised as current tamoxifen use, current AI use, no current therapy and 
previously ever exposed to an AI, no current therapy and previously exposed to tamoxifen only) was 
time-updated at any changes in therapy. A prescription was continuous if a further prescription 
followed within 30-days of the original prescription ending. Overall, the exposure groups in the UK 
were the same as the original study; and exposure groups in the US omitted the unexposed group 
and was parameterised like the UK version.  
 
Outcomes 
The full range of CVD outcomes explored in both the UK and US studies remained the primary 
outcomes of interest for this comparison analysis. Events were identified using Read/ICD-10 codes in 
CPRD/HES respectively, and ICD-9 codes in SEER-Medicare.  
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Covariates 
A common set of covariates, available in both datasets, was adjusted for: year of breast cancer; age 
at index date (66-74, 75-84, 85+); time since index date ((<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); current 
calendar year; use of statins; use of ACE inhibitors; use of calcium channel blockers; use of 
angiotensin receptor blockers; rheumatoid arthritis; chronic kidney disease; diabetes; VTE; and non-
venous CVD. Identification of diagnoses and prescriptions were restricted to a 3-year look back 
window prior to index date.  
 
Analysis 
Observation time began at index date and ended at earliest of the following: a CVD event of interest, 
diagnosis of another cancer, death, transfer out of the CPRD network/end of enrolment in Medicare 
Parts A, B, or D, or end of follow-up (31st March 2016 in the UK and 31st December 2014 in the US). 
Prior to exploring the relationship between endocrine therapies and CVD, baseline characteristic 
distributions of patients who were initially prescribed tamoxifen or AIs were described. The primary 
exposure variables were then included in unadjusted and adjusted (accounting for all covariates) Cox 
regression models with an underlying age timescale, to obtain hazard ratios. 
 
7.3.2 Results 
7.3.2.1 Comparison of results as originally reported in studies  
Generally, the original study results comparing the risk of outcomes associated with ever AI 
compared with tamoxifen use from the UK and US studies reported effect estimates that were in the 
same direction, with similar strengths (Figure 7.1).  However, the results for HF were not consistent, 
with the UK study reporting an increased risk of HF associated with ever AI in comparison tamoxifen 
use (HR: 1.68, 95% CI: 1.24-2.26), and the US study reporting no evidence of an association (HR: 
0.96, 95% CI: 0.83-1.12). There were also point estimates in opposing directions for the PE analysis, 
however 95% CIs crossed unity for both studies due to few outcomes (UK HR: 1.21, 95% CI: 0.79-
2.04; US HR: 0.77, 95% CI: 0.29-2.04). Associations were in the same direction for both the UK and 
US studies for all other outcomes. For all but one of the outcomes (MI), the HR in the US study was 
slightly closer to the null association. The US study also generally had more precision due to the 
larger study population and resulting higher number of events  
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Figure 7.1: Adjusted HRs (adjusted for variables originally reported in each study) for the 
association between originally reported results for ever AI use compared with ever 
tamoxifen use and the risk of a range of clinical CVD outcomes in the UK and US studies 
(with baseline group changed to ever tamoxifen use) 
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7.3.2.2  Modified comparison of results 
There were more women in the US study population in comparison with the UK study population 
when modified to allow for direct comparison (5665 and 18248 women in the UK and US study 
populations respectively, Table 7.3). A higher proportion of women were initially prescribed 
tamoxifen in the UK (44%) compared with the US (13%). Women in the US were generally younger 
(median age in US: 75 years, IQR: 71-81; median age in UK: 77 years, IQR: 71-83), but tamoxifen 
users were older in the US, whereas AI users were older in the UK. The proportion of initial 
tamoxifen users steadily decreased the later the breast cancer diagnosis in the UK, whereas the 
decline was not as sharp in the US. There was a higher total proportion of ACEi, CCB, and ARB users 
in the UK in comparison with the US, with a higher proportion of prescriptions in AI users in 
comparison with tamoxifen users in both countries. The total proportion of women diagnosed with 
diabetes and non-venous CVDs was much higher in the US in comparison with the UK, but the 
proportion of women diagnosed with both diabetes and non-venous CVD was higher in AI users in 
comparison with tamoxifen users in both the UK and the US. Finally, there was a higher total 
proportion of women diagnosed with CKD in the UK in comparison with the US, with a higher 
proportion of CKD diagnoses in AI users in comparison with tamoxifen users in both countries.  
  
Ever exposure analyses 
Associations between ever AI compared with ever tamoxifen use and the risk of all CVD outcomes 
were generally in the same direction for both the US and UK studies (Figure 7.2). There was evidence 
of an increased risk of MI, arrhythmia, pericarditis, and VHD associated with ever AI in comparison 
with tamoxifen use in the US study, and although there were associations in a similar direction in the 
UK study, estimates were less precise. The HF analysis was the only analysis in the UK study that 
showed evidence of an increased risk associated with ever AI compared with tamoxifen use (with a 
95% CI that did not cross the null association), but in the US study there was no association. All other 
effect estimates were generally in the same direction and consistent between the two studies (apart 
from revascularisation). There were differences in the size of the effect estimates for the stroke, 
pericarditis, and DVT analyses, but the UK study lacked precision for these outcomes, and the US 
estimate was contained within the UK 95% CI. In this modified analysis, the precision of the UK study 
was considerably restricted due to a fewer women eligible for the final study population, and fewer 
resulting outcome events. There were also no events in the ever tamoxifen arm of the SCA analysis 
in the modified UK study, so effect measures could not be estimated.  
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Current exposure analyses 
Associations between current AI compared with tamoxifen use and the risk of all CVD outcomes 
were again generally in the same direction for both the UK and US studies (Figure 7.3). There was 
evidence of an increased risk of MI, arrhythmia, pericarditis, and VHD associated with current AI 
compared with tamoxifen use in the US study, with the UK study reporting associations in a similar 
direction for all these outcomes. However, in the HF analysis, there was again evidence of an 
increased risk of an event associated with current AI compared with current tamoxifen use in the UK 
study, but no evidence of a difference in the US study. Although effect estimates were in a similar 
direction, there were some differences in effect sizes between the UK and US for the stroke, VHD, 
and SCA analyses, but the UK study again lacked precision for these outcomes. Within the modified 
analyses exploring the associations between both past with AI and past tamoxifen only, compared 
with current tamoxifen use, and the risk of all CVD outcomes (Appendix 7.2), there were generally 
few CVD events in the two past use categorisations, leading to low precision in the analyses from the 
UK study. However, most effect estimates were consistently in the same direction in the UK and US 
studies. 
Table 7.3: Characteristics of modified study populations based on their initial exposure for both UK and 
US studies 
 UK   US   
 Tamoxifen (%) AI (%) Total (%) Tamoxifen (%) AI (%) Total (%) 
N 2504 (100) 3161 (100) 5665 (100) 2410 (100) 15838 (100) 18248 (100) 
Age at index (yrs)       
66-74 1222 (48.8) 1245 (39.4) 2467 (43.5) 944 (39.2) 7879 (49.7) 8823 (48.4) 
75-84 896 (35.8) 1282 (40.6) 2178 (38.4) 1047 (43.4) 6181 (39) 7228 (39.6) 
85+ 286 (15.4) 632 (20.1) 1020 (18) 419 (17.4) 1778 (11.2) 2197 (12) 
Median (IQR) 75 (70-82) 78 (71-84) 77 (71-83) 77 (72-83) 75 (71-81) 75 (71-81) 
Year of breast cancer diagnosis       
2002 320 (12.8) 48 (1.5) 368 (6.5)    
2003 297 (11.9)  84 (2.7) 381 (6.7)    
2004 295 (11.8) 135 (4.3) 430 (7.6)    
2005 278 (11.1) 181 (5.7) 459 (8.1)    
2006 245 (9.8) 234 (7.4) 479 (8.5)    
2007 202 (8.1) 265 (8.4) 466 (8.2)    
2008 215 (8.6) 297 (9.4) 512 (9) 449 (18.6) 2244 (14.2) 2693 (14.8) 
2009 149 (6) 304 (9.6) 453 (9) 477 (19.8) 2304 (14.5) 2781 (15.2) 
2010 111 (4.4) 340 (10.8) 451 (8) 395 (16.4) 2513 (15.9) 2908 (15.9) 
2011 134 (5.4) 353 (11.2) 487 (8.6) 346 (14.4) 2733 (17.3) 3079 (16.9) 
2012 109 (4.4) 296 (9.4) 405 (7.1) 360 (14.9) 2839 (17.9) 3199 (17.5) 
2013 88 (3.5) 301 (9.5) 389 (6.9) 383 (15.9) 3205 (20.2) 3588 (19.7) 
2014 53 (2.1) 280 (8.9) 333 (5.9)    
2015 8 (0.3) 44 (1.4) 52 (0.9)    
Statins before index 685 (27.4) 1232 (39) 1917 (33.8) 840 (34.9) 6274 (39.6) 7114 (39) 
ACEi before index 617 (24.6) 966 (30.6) 1583 (27.9) 425 (17.6) 2804 (17.7) 3229 (17.7) 
CCB before index 680 (27.2) 1035 (32.7) 1715 (30.3) 307 (12.7) 2267 (14.3) 2574 (14.1) 
ARB before index 330 (13.2) 516 (16.3) 846 (14.9) 219 (9.1) 1694 (10.7) 1913 (10.5) 
RA before index 26 (1) 24 (0.8) 50 (0.9) 111 (4.6) 583 (3.7) 694 (3.8) 
Diabetes before index 306 (12.2) 499 (15.8) 805 (14.2) 626 (26) 4809 (30.4) 5435 (29.8) 
CKD before index 692 (27.6) 954 (30.2) 1646 (29.1) 170 (7.1) 1184 (7.5) 1354 (7.4) 
Non-venous CVD before index 422 (16.9) 806 (25.5) 1228 (21.7) 1356 (56.3) 9429 (59.5) 10785 (59.1) 
VTE before index 65 (2.6) 104 (3.3) 169 (3) 35 (1.5) 430 (2.7) 465 (2.5) 
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 Figure 7.2: Adjusted HRs for the association between ever AI compared with ever tamoxifen use and a range of 
clinical CVD outcomes in modified analyses in both the UK and US 
 
†Adjusted for: year of breast cancer; age at index date (66-74, 75-84, 85+); time since index date (<1yr, 1 to <3yrs, 3 to <5yrs, 
5+yrs); current calendar year; use of statins; use of ACE inhibitors; use of calcium channel blockers; use of angiotensin 
receptor blockers; rheumatoid arthritis; chronic kidney disease; diabetes; VTE; and non-venous CVD 
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Figure 7.3: Adjusted HRs for the association between current AI compared with current tamoxifen 
use and a range of clinical CVD outcomes in modified analyses in both the UK and US 
 
†Adjusted for: year of breast cancer; age at index date (66-74, 75-84, 85+); time since index date (<1yr, 1 to <3yrs, 3 to <5yrs, 
5+yrs); current calendar year; use of statins; use of ACE inhibitors; use of calcium channel blockers; use of angiotensin receptor 
blockers; rheumatoid arthritis; chronic kidney disease; diabetes; VTE; and non-venous CVD 
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7.3.3 Discussion 
7.3.3.1 Main findings 
This section enabled a comparison of results from the UK and US studies, both as they were 
presented in chapters 5 and 6, and after modifying methodology to allow for a more direct 
comparison. The comparison of the original results generally reported agreement between the UK 
and US studies, with some small differences in effect sizes. In the analysis that modified both the UK 
and US study populations, covariates, and analyses, the final restricted population in the UK study 
was a lot smaller than the US study population, so there was less statistical power to detect 
associations and some effect estimates had 95% CIs that crossed unity. However, the directions of 
effect continued to stay the same in both the UK and US studies for most outcomes in both the ever 
and current exposure analyses.  
 
The main difference in results between the two studies was when directly comparing the use of AI in 
comparison with tamoxifen and the risk of HF. In both the comparison of the original results, and the 
modified comparison, there was consistently a greater risk of HF associated with AI compared with 
tamoxifen use in the UK study, and no difference between the two groups in the US study. Results of 
secondary analyses from the original UK study suggested that the increased risk associated with AI 
compared with tamoxifen use was likely due to cardio-protective effects of tamoxifen, and results in 
the original US study suggested that tamoxifen use was indeed associated with a reduced risk of HF 
in comparison with an unexposed population. However, the US study also suggested a reduced risk 
of HF associated with AI use compared with an unexposed population, with no difference in the risk 
of HF between AI and tamoxifen users. Therefore, although the original US study agreed with the UK 
study that there is evidence that tamoxifen reduced the risk of HF and AI use does not increase the 
risk of HF, it also reported contrasting results for the relative difference in risk of HF when comparing 
AI and tamoxifen use.   
 
7.3.3.2 Possible reasons for differences between studies 
Study populations 
There were more than double the number of women included in the original US study compared 
with the UK study, even though the study population was restricted to older women (aged 66 years 
and over in the US, aged 54 years and over in the UK), and those who were diagnosed with breast 
cancer within a shorter time period (2008-2013 in the US, 2002-2016 in the UK). There was a similar 
 
135 
 
discrepancy in size in the modified study populations, although the number of women included in 
the UK study nearly halved, whereas the US study was around 84% of the original size. The larger 
drop in size of study populations in the UK compared with the US after modification was due to the 
revised UK study excluding all women diagnosed with breast cancer between the ages of 54 and 66 
years, whereas the US study only excluded women diagnosed with ER+/PR+ breast cancer that were 
not prescribed endocrine therapy.  
 
In the modified study populations, the US population had a higher proportion of women with CVD 
diagnoses in the 3 years prior to index date, but the revised UK population had a higher proportion 
of CVD related prescriptions (ACEi, CCB, ARB), which is somewhat contradictory. However, the 
higher proportion of CVD related drug prescriptions in the UK could be given for the primary 
prevention of CVD, which is consequently reducing the burden of CVD. Furthermore, the study 
starting earlier in the UK may explain the higher proportion of women that were originally 
prescribed tamoxifen in the UK compared with the US, with women initiating tamoxifen in the 
earlier years due to limited knowledge of the additional efficacy of AIs over tamoxifen in 
postmenopausal women. However, the higher proportion of women with previous CVD in the 
revised US population, and the known association between tamoxifen and VTE could also influence 
the difference between AI and tamoxifen initiators. Clinicians are less likely to prescribe tamoxifen to 
those with prior CVD, even though this thesis suggests a protective association between tamoxifen 
and certain CVD outcomes.  
 
AI users were older than tamoxifen users in the UK study, in both the original and modified analyses, 
with both a higher median age, and more women in the oldest age category. However, in the US 
study, tamoxifen users were older than AI users. Results show that for several non-venous CVD 
outcomes in both the ever and current exposure analyses, the effect estimates for events when 
comparing AI and tamoxifen users were larger in the UK compared with the US study, albeit with 
95% CIs that crossed unity. The higher proportion of older AI compared with tamoxifen users could 
explain these differences due to the increased risk of CVD associated with increasing age.[119] 
 
Confounding 
There were several potential confounders unaccounted for in the modified analyses as the aim was 
to make the analyses as similar as possible, adjusting only for variables that were available in both 
studies. Residual confounding due to these variables that were not accounted for could therefore 
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explain any differences seen between the studies. The most prominent potential confounders 
omitted from the modified studies, and the original US study, were lifestyle factors such as BMI. 
Organisation for Economic Cooperation and Development (OECD) data show that the proportion of 
the population defined as obese is higher in the US (38.2%) than the UK (26.9%).[120] The original 
UK study reported that the BMI of AI users was higher than that of tamoxifen users. Although 
adjusting for BMI in the original UK study did not largely influence effect estimates, if there was a 
greater difference between BMI in AI and tamoxifen users in the US, then not adjusting for BMI 
could cause considerable residual confounding, and may explain any differences between effect 
estimated in both the original and modified UK and US studies. 
 
The difference in HF results could be due to AI users receiving more cardio-toxic chemotherapy 
treatments, such as anthracyclines, compared with tamoxifen users in the UK, as there is a known 
increased risk of HF associated with increasing cumulative doses of anthracyclines.[75] The US study 
only included women diagnosed with stages 1-3 breast cancer, which may be a factor for any 
differences in treatment, as the UK study included all women with a breast cancer diagnosis 
recorded in the CPRD during the study period. Those diagnosed with DCIS or stage 4 breast cancer, 
who could be included in the UK study, are likely given different treatment regimens to those with 
stages 1-3 breast cancer. There were more anthracyclines administered to AI users compared with 
tamoxifen users in the US study. However, there was generally a low proportion of all women given 
these agents (5.2% of women overall given an anthracycline). If more women in the UK were given 
these anthracyclines, which included a higher proportion of AI users compared with tamoxifen users, 
then it is conceivable that this is driving an increased risk of HF in AI users. Although it is not possible 
to test this hypothesis within the UK data as information on cancer treatments were not available, 
the UK National Cancer Registration and Analysis Service reported that approximately 33% of all 
women diagnosed with breast cancer in the UK were administered any chemotherapy agent in 2013-
2014.[121] It is likely that the proportion of post-menopausal women diagnosed with stage 1-3 
ER+/PR+ breast cancer who are given an anthracycline is less than 33% as such therapy will not be 
given to those diagnosed with earlier stage and less aggressive breast cancers, and they could be 
treated with other, non-anthracycline based, chemotherapy agents. However, it is highly unlikely 
that the proportion of women given an anthracycline will be as low at the 5.2% reported in the US 
study. It is therefore reasonable to assume that more treatment was given in the UK compared with 
the US study population, although inferences into the difference of treatments between AI and 
tamoxifen users in the UK cannot be made.  
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Outcome definitions 
Another reason for the difference in the HF results in the UK and US studies could be that the 
definition of HF within the two studies is slightly different. The UK study used Read codes to identify 
events in primary care, and ICD-10 codes to identify results in secondary care, whereas the US study 
only used ICD-9 codes. Although this was also case for all other CVD outcomes, a HF diagnosis has a 
more nuanced diagnosis, with the European Society of Cardiology stating that a HF diagnosis 
requires: symptoms typical of heart failure (breathlessness at rest or on exercise, tiredness, fatigue, 
ankle swelling); signs typical of heart failure (tachycardia, tachypnoea, pulmonary rales, pleural 
effusion, raised jugular venous pressure, hepatomegaly, peripheral oedema); and objective evidence 
of a structural or functional abnormality of the heart at rest (cardiomegaly, third heart sound, 
cardiac murmurs, abnormality on echocardiogram, raised B-type natriuretic peptides).[122] To help 
understand if potentially varying HF definitions were the reason for the differences in results, the UK 
analysis was replicated using restricted code lists which only included Read codes that fall under the 
Quality and Outcomes Framework (QOF) definition of HF (Appendix 7.3), and specifically HF ICD-10 
codes (as original code list also included cardiomyopathy outcomes). However, even with the 
restricted outcome definition, ever AI users continued to have an increased risk of HF in comparison 
with ever tamoxifen users in the UK (adjusted HR: 1.95, 96% CI: 1.42-2.69).  
 
Statistical chance 
Statistical chance is also a possible explanation of the difference in HF results, or the results of any 
other CVD outcomes in both the original and modified analyses. If the true effect estimates for the 
ever-exposed analyses comparing AI to tamoxifen use and the risk of HF in either the UK or US 
studies were at the extremities of the 95% CIs, then results could be similar.  
  
Differences in the nature of data 
More generally, the nature of the data used could contribute towards differences in both study 
populations and results. Data from the UK CPRD and HES are EHRs recorded by clinicians in GP 
surgeries and hospitals, whereas data from SEER-Medicare in the US are claims based. GP surgeries 
and hospitals use EHRs to record details of all encounters with patients, allowing for a complete 
overview of their care, whereas generation of claims data come from bills submitted by physicians 
and hospitals for payment by commercial and government health plans.  
 
Claims based data accurately record filled drug prescriptions as a record generation only happens 
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after payment for the prescribed drug. However, EHR records contains information on all drugs 
prescribed by the clinician, regardless of if that prescription was filled, which could lead to an 
overestimation of what was actually filled and eventually taken by the patient. This could explain the 
higher proportion of women prescribed statins, ACEis, ARBs, and CCBs in the UK study compared 
with the US study.  
 
On the other hand, EHRs can extract information that may not be available in claims data. For 
example, EHRs record lab and test results, which allows a deeper understanding of diagnoses such as 
hypertension. The original US study used a combination of records of an ICD-9 code for hypertension 
and prescription of anti-hypertensive to identify hypertension, whereas the UK study used records of 
the patients’ systolic and diastolic blood pressure in the UK. Although both methods will correctly 
identify if a woman was hypertensive, the method used in the UK will allows for more granular 
detail, and the US method may be prone to residual confounding as the risk of CVD is known to 
increase with increasing blood pressure.[123]  
 
Claims data are also more temporally limited than EHR data as a claim reflects the diagnoses and 
services that occurred on the date the claim was submitted, meaning only incident diagnoses are 
usually recorded. Claims data do not to convey information about what happened in the past. 
However, UK based EHRs can capture historical diagnoses, and when a patient registers at a new GP, 
the standard process is to update their records to include all diagnoses from their previous surgeries. 
All analyses excluded women with a previous diagnosis of the outcome of interest, and the 
exclusions in the modified analyses were restricted to CVD diagnoses within three years prior to 
index date. If a woman registered with a new GP within this three-year period, or the GP had 
updated their records within this time, it is possible that women with prevalent diagnoses that 
occurred prior to this three-year period were not included due to GPs back-dating their records. 
However, exclusions only applied to those with an incident CVD event in the three-years prior to 
index date in the US study due to the nature of claims data. This could explain some of the 
differences between results in the two studies if the proportion of women excluded because of a 
historical, rather than an incident, diagnosis differed between those prescribed tamoxifen and AI in 
the UK study. It could also explain differences between other diagnoses such as RA, diabetes, and 
CKD. Theoretically, the difference between prevalent and incident disease should not be a problem 
when identifying CVD events during follow up, as the UK study dropped all Read codes that 
represented historical events when identifying events during follow up in CPRD. However, there is a 
possibility that GPs incorrectly coded historical events as incident events, in which case some events 
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in follow up may represent prevalent disease.  
 
7.3.4 Conclusion 
Overall, although restricting the study populations and methodology of the two studies allowed for a 
direct comparison between results, it also introduced more uncertainty. Smaller study populations 
and fewer events meant effect estimates were less precise than in the original studies, especially in 
the UK. However, there was general agreement between the results in the modified analyses of the 
UK and US studies, much like the comparison of the original results. HF remained the one outcome 
in which the studies disagreed, and residual confounding by variables not available in both datasets, 
such as lifestyle measures and other cancer treatments, or statistical chance, may drive this 
difference.  
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7.4  SUMMARY 
 A comparison was made of the study populations and covariates adjusted in the UK and 
US studies. There was longer follow up and a wider age range in the UK study, but 
women diagnosed with ER+/PR+ breast cancer that were unexposed to any endocrine 
therapy were included in the US study. Information on breast cancer treatments and 
severity were not available in the UK data, whereas lifestyle measures were not available 
in the US data 
 There was general agreement for the results of the ever-exposed analyses as originally 
presented in the UK and US studies. HF was the only outcome for which the two studies 
were in disagreement, with the UK study reporting evidence of an increased risk of HF 
associated with AI compared with tamoxifen use, and the US study reporting no 
association.  
 After the modification of both study populations and analyses, making them as similar as 
possible, effect estimates were generally in the same direction, with some differences in 
effect sizes. The US study generally reported more precise effect estimates that were 
closer to the null association. However, there continued to be inconsistent results for the 
HF analyses. 
 The difference in HF results may to be due to different definitions for HF, more cardio-
toxic treatments used in AI users compared with tamoxifen users in the UK, or statistical 
chance.  
 
 
141 
 
8 SUMMARY AND CONCLUSIONS 
 
8.1 INTRODUCTION 
This chapter will begin with a concise overview of the findings of the main thesis, followed by 
comparing the findings of all individual CVD outcomes with previous literature identified in the 
systematic review in chapter 2. A discussion of the biological plausibility and overall strengths and 
limitations will follow. Finally, the work of the thesis will be contextualised in relation to its 
implications and the future research that should follow.  
 
8.2 OVERVIEW OF RESEARCH  
This section will provide an overview of what was included and the conclusions of each chapter. 
Section 8.3 will give further detail on the findings of the individual studies.  
 
8.2.1 Chapter 2 - Systematic review 
 A systematic review aimed to collate the current literature on the effect of both tamoxifen 
and AIs on the range of specific clinical CVD outcomes in women with a history of non-
metastatic breast cancer. 
 26 eligible studies were identified that investigated the risk of seven specific CVD outcomes 
(venous thromboembolism, 15 studies; MI, 14 studies; stroke, 12 studies; angina, 4 studies; 
HF, 4 studies; arrhythmia, 1 study; and PVD, 1 study) associated with either tamoxifen use, 
aromatase inhibitor use, or a comparison of the two treatments, in all women with a history 
of non-metastatic breast cancer.  
 There were no studies identified investigating revascularisation, SCA, pericarditis, or VHD. 
 Results suggested an increased risk of VTE in tamoxifen users compared with both non-users 
and aromatase inhibitor users. Results were also consistent with a higher risk of the vascular 
diseases MI and angina in aromatase inhibitor users compared with tamoxifen users, but 
there was also a suggestion that this may be partly driven by a protective effect of tamoxifen 
on these outcomes. Data were limited, and evidence was generally inconsistent for all other 
cardiovascular disease outcomes. 
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 The main problem in RCTs was incomplete reporting of methods, which made it impossible 
to judge whether studies were prone to certain biases.  
 All observational studies had at least one domain categorised as being at high risk of bias.  
 
8.2.2 Chapter 3 - Data sources and creation of code lists 
 All databases that were to be used in the PhD were introduced, including the CPRD and HES 
from the UK, and SEER-Medicare from the US, and my contribution in each study was 
documented.  
 
8.2.3 Chapter 4 – Capture of CVD outcomes in the UK study 
 A series of exploratory analyses using both CPRD and HES in the UK data were undertaken 
with aim of assessing the validity of CPRD to detect CVD outcomes, identifying missing Read 
codes and finalising code lists, and deciding on the use of CPRD and HES linkage data 
 Events in the CPRD are identified using Read code lists. The algorithm used to create the 
original CVD Read code lists was presented, and the number of codes detected to identify 
CVD outcomes ranged from 128 in the revascularisation outcome to 20 in the PE outcome. 
 A description was given of the proportion of definite and possible CVD events in the CPRD 
data. It was observed that most incident CVD outcomes in the CPRD were classed as definite 
events, and a large proportion of possible events were followed up by a definite event 
within a year. The decision was therefore made to include both types of events in all further 
analyses.  
 The concordance of events between CPRD and HES was observed, and there was generally a 
low proportion of overlapping events in both CPRD and HES. Additional codes were then 
identified for arrhythmia, pericarditis, VHD, and revascularisation outcomes by exploring 
diagnoses in CPRD in the time around an event that only occurred in HES.  
 There was similar statistical power to detect associations for all CVD outcomes if the linked 
CPRD and HES study population was used, rather than CPRD alone. To maximize sensitivity 
of outcome ascertainment, the decision was therefore made to restrict the study population 
to those that had linked HES data and include CVD outcome events identified from either 
CPRD or HES, rather than CPRD alone. 
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8.2.4 Chapter 5 - Assessing the effect of endocrine therapy use on the risk of cardiovascular disease: 
A cohort study in the UK  
 Routinely collected primary care data from the UK CPRD database were used to assemble a 
cohort of post-menopausal female breast cancer survivors, who were prescribed tamoxifen 
or an AI from 2002-2016.  
 The effect of endocrine therapy use (AI vs tamoxifen) on the risk of a range of clinically 
specific CVD outcomes were analysed using Cox regression, adjusted for potential 
confounders including year of breast cancer diagnosis, age, time since index date, current 
year smoking, BMI, alcohol status, IMD score, statins, ACE inhibitors, CCBs, ARBs, anti-
platelets, diabetes; chronic kidney disease, rheumatoid arthritis, systolic blood pressure, 
diastolic blood pressure, history of VTE, and history of non-venous CVD. 
 There was a pattern of an increased risk of non-venous CVDs in AI compared with tamoxifen 
users, with evidence of an increased risk of heart failure and arrhythmias in women ever 
exposed to AI compared with tamoxifen (adjusted HR: 1.70, 95% CI: 1.26-2.29; adjusted HR: 
1.38, 95% CI 1.12-1.70 respectively). It is likely that these associations are driven by a 
protective effect associated with tamoxifen use as results also suggested past tamoxifen 
users were at a higher risk of both outcomes compared with current users.  Results also 
confirmed the established reduced risk of DVT associated with AI in comparison with 
tamoxifen use (adjusted HR: 0.54, 95% CI: 0.36-0.83). 
 A key limitation was that ER/PR status was not available in the CPRD data to allow an 
unexposed population of women diagnosed with ER+/PR+ breast cancer to be identified. 
Having these data would have meant the individual effects of tamoxifen and AI could have 
been disentangled, rather than just comparing the two treatments against each other.  
 
8.2.5 Chapter 6 - Assessing the effect of endocrine therapy use on the risk of cardiovascular disease: 
a cohort study using the US SEER-Medicare linked database  
 Claims based data from the US SEER-Medicare database were used to assemble a cohort of 
female ER+/PR+ stage 1-3 breast cancer survivors aged 66 and over from 2008-2013. 
 The effect of endocrine therapy use (AI or tamoxifen) compared with non-use of any 
endocrine therapy on the risk of a range of clinically specific CVD outcomes were analysed 
using Cox regression, adjusted for potential confounders including year of breast cancer 
diagnosis, age, time since index date, current calendar year, race, SEER region, breast cancer 
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stage, breast cancer grade, taxanes, anthracyclines, trastuzumab, other systemic cancer 
treatments, statins, anti-hypertensive drugs, ACE inhibitors, CCBs, ARBs, rheumatoid 
arthritis, chronic kidney disease, hypertension, diabetes, history of VTE, and history of non-
venous CVD. 
 Apart from the established association between tamoxifen use and increased risk of DVT, 
there was no evidence of increased CVD risk with either tamoxifen or AI use compared with 
no endocrine therapy use. Results also suggested a protective association between 
tamoxifen use and risk of several non-venous CVDs with adjusted HRs ranging from 0.44 
(95% CI: 0.30-0.63) in the MI analysis to 0.91 (95% CI: 0.75-1.10) in the PVD analysis.  
 A similar, but weaker, protective association was also seen for non-venous CVDs during AI 
use, but there was a possibility of residual confounding due to an artificial increased risk of 
CVD in women that never initiated endocrine therapy that brings questions to the causality 
of these associations.  
 
8.2.6 Chapter 7 - Comparison of UK and US studies 
 The pattern of results in the UK study suggested that any difference in risk of non-venous 
CVD between AI and tamoxifen users may be driven by a protective effect of tamoxifen. The 
US study then provided evidence of a decreased risk of several non-venous CVDs associated 
with tamoxifen use. However, the US study also reported a reported a protective association 
between AI use and several non-venous CVDs, albeit less protective that tamoxifen.  
 When directly comparing ever AI to tamoxifen use, the UK and US studies reported similar 
effect estimates for all CVD outcomes other than HF. The evidence of an increased risk of HF 
in AI compared with tamoxifen reported in the UK study, was not replicated in the US, which 
reported evidence of a similar strength of a protective association between both AI and 
tamoxifen use and the risk of HF.  
 Study populations, covariate adjustments, and analyses were then modified so the studies 
were as similar as possible. Results were again generally consistent, even though there was a 
lack of precision for the some of the outcomes in the modified UK analysis. Even when 
analyses were modified, there continued to be a distinctive difference between the results 
reported for HF. 
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 It is thought that the difference in HF results between the UK and US studies could be due to 
either: more cardio-toxic chemotherapy agents being administered to AI users compared 
with tamoxifen users in the UK; residual confounding by BMI, smoking, or alcohol use in the 
US; or statistical chance.  
 Differences in the nature of the data (EHRs in the UK and claims based data in the US) could 
also contribute towards any differences in results. For example, EHRs records lab and test 
results allowing for additional adjustment of potential confounders that are not recorded in 
claims data. Claims data accurately records filled drug prescriptions, whereas EHRs only 
record information of what has been prescribed, but not filled. Claims are also more 
temporally limited in comparison with EHRs.  
 
8.3 OVERVIEW OF RESULTS FOR INDIVIDUAL CVD OUTCOMES AND COMPARISON 
WITH PREVIOUS LITERATURE 
Of the CVD outcomes outlined in chapter 4, which were all explored in the UK and US studies, no 
previous literature was identified for the systematic review in chapter 2 for the association between 
endocrine therapy use and the risk of revascularisation, SCA, pericarditis, or VHD. The studies in this 
thesis are therefore the first to study the effect of endocrine therapy use on the risk of these CVD 
outcomes. However, results in both the UK and US studies for the effect of endocrine therapy use on 
the risk of all other CVD outcomes will be discussed in the context of previous literature.  
 
8.3.1 Angina 
 Results from the UK and US studies suggested HRs in the direction of a slightly increased risk 
of angina associated with ever AI compared with tamoxifen use (adjusted UK HR: 1.31, 95% 
CI: 0.88-1.97; adjusted US HR: 1.19, 95% CI: 0.95-1.50), although the 95% CIs were also 
compatible with no association. This was similar to results reported by one previous RCT 
that compared AI to tamoxifen use (RR: 1.37, 95% CI: 0.92-2.05).[124]  
 The US study reported an effect estimate that suggested evidence a protective association 
between ever tamoxifen use and the risk of angina (ever tamoxifen vs unexposed adjusted 
HR: 0.88, 95% CI: 0.68-1.10), albeit with little precision and again with a 95% CI that is 
compatible with no association. Although two previous observational studies disagreed on 
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effect size, they both reported point estimates that also suggested a protective effect of 
tamoxifen (tamoxifen vs no tamoxifen RR: 0 40, 95% CI: 0.20-0.80; and RR: 0.88, 95% CI: 
0.65-1.20).[125, 126] In the US study there was no evidence that any protective effects of 
tamoxifen persisted once tamoxifen prescription is stopped (adjusted HR for past tamoxifen 
vs unexposed: 0.93, 95% CI: 0.61-1.41), although there was little precision in the current 
exposure analysis.  
 The US study reported no evidence of association between ever AI use and risk of angina 
(ever AI vs unexposed adjusted HR: 1.05, 95% CI: 0.89-1.35), which did not agree with the 
increased risk in AI users suggested in a previous RCT (AI vs placebo RR: 1.35, 95% CI: 1.17-
1.56).[127]  
 Overall, there is no statistical evidence to suggest that is a difference in risk of angina 
between AI and tamoxifen users. However, point estimates are consistent with the pattern 
seen in some other non-venous CVDs, whereby there is a higher risk in AI compared with 
tamoxifen users, which is driven by a protective effect of tamoxifen, but more statistical 
power is required to confirm within the data presented in this thesis. The effect of AIs on 
angina remains unclear, but any difference in risk of angina associated with AI use is likely to 
be minimal.  
 
8.3.2 MI 
 Both the UK and US studies suggested evidence of an increased risk of MI associated with 
ever AI compared with tamoxifen use (adjusted UK HR: 1.56, 95% CI: 0.96-2.52, adjusted US 
HR: 1.81, 95% CI: 1.28-2.58), with greater statistical power to detect an association in the US 
study. A similar direction and strength of association was reported in all but one of five 
previous studies that compared AI to tamoxifen use (RRs ranged from 1.50-2.29 in both RCT 
and observational studies).[128-132] 
 The US study suggested evidence of a large protective effect of ever tamoxifen use 
associated with the risk of MI (ever tamoxifen vs unexposed adjusted HR: 0.44, 95% CI: 0.30-
0.63). Three RCTs and two prior observational studies reported effect estimates in the same 
direction when comparing tamoxifen use to either placebo or no tamoxifen, but the strength 
of associations reported varied greatly (RRs ranged from 0.20-0.83).[125, 133-136] However, 
three observational studies also reported effect estimates suggesting either no difference in 
risk of MI associated with tamoxifen use, or a toxic effect of tamoxifen.[126, 137, 138]  
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 The US study also suggested that any protective association between tamoxifen use and MI 
may persist once tamoxifen use has ended (past tamoxifen vs unexposed adjusted HR: 0.46, 
95% CI: 0.25-0.85), which is a possible argument against a causal effect as results may be 
due to residual confounding.  
 The US study goes further to suggest evidence of a small protective effect of ever AI use 
associated with the risk of MI (ever AI vs unexposed adjusted HR: 0.79, 95% CI: 0.64-0.97). A 
similar association was alluded to in a previous RCT and observational study (AI vs placebo 
RR: 0.82, 95% CI: 0.55-1.22; AI vs no AI RR: 0.90, 95% CI: 0.65-1.25 respectively), but both 
results were also consistent with no association.[127, 137]  
 This thesis has suggested an increased risk of MI in AI compared with tamoxifen users. It also 
suggests that this difference in risk is likely driven by a protective effect of tamoxifen on MI 
risk, because although there is mixed evidence of the effect of tamoxifen use on the risk of 
MI, there is no evidence in either the US study or any prior studies, that AI use increased risk 
of MI. In fact, the US study suggests a small protective effect of AI use on the risk of MI, but 
it unclear if this relationship is causal due to potential residual confounding because of 
unmeasured variables such as frailty, poor CVD preventative care, and high BMI which may 
be more likely in non-initiators of endocrine therapy, and could mean an artificially 
increased risk of MI in non-initiators at beginning of follow up. This residual cofounding 
could also explain part of the large protective association between tamoxifen use and MI 
reported in the US study.  
 
8.3.3 Revascularisation (no previous evidence) 
 Both the UK and US studies suggested effect estimates that pointed towards an increased 
risk of revascularisation procedures associated with ever AI compared with tamoxifen use 
(adjusted UK HR: 1.84, 95% CI: 0.85-4.02, adjusted US HR: 1.46, 95% CI: 0.95, 2.24), albeit 
with 95% CIs that crossed unity.  
 Results from the US study also suggested weak evidence of a decreased risk of 
revascularisation associated with ever tamoxifen use compared with non-users of any 
endocrine therapies (ever tamoxifen vs unexposed adjusted HR: 0.63, 95% CIL 0.39-1.01). 
There was, however, an attenuation of this effect estimate when comparing risk in the time 
currently exposed to tamoxifen to time unexposed to any endocrine therapy (current 
tamoxifen vs unexposed adjusted HR: 0.89, 95% CI: 0.59-1.35). 
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 There was no evidence of an association between ever AI use and revascularisation in the US 
study (ever AI vs unexposed adjusted HR: 0.91, 95% CI: 0.68-1.23). 
 Both studies reported effect estimates that suggested an increased risk of revascularisation 
in AI compared with tamoxifen users, which is likely driven by a decreased risk in tamoxifen 
users rather than any toxic effect of AI use. However, there were too few events to precisely 
estimate the reported effect estimates in both studies, so all results were generally 
inconclusive.  
 
8.3.4 Sudden cardiac arrest (no previous evidence) 
 Both the UK and US studies suggested HRs in the direction of an increased risk of SCA 
associated with ever AI compared with tamoxifen use (adjusted UK HR: 1.65, 95% CI: 0.65-
4.49, adjusted US HR: 1.17 95% CI: 0.78-1.76), although the 95% CIs were also compatible 
with no association.  
 The US study suggested some evidence of a decreased risk of SCA associated with both ever 
tamoxifen and AI use, when compared with non-users (ever tamoxifen vs unexposed 
adjusted HR: 0.67, 95% CI: 0.43-1.04; ever AI vs unexposed adjusted HR: 0.78, 95% CI: 0.59-
1.04). Effect estimates were similar during time currently exposed to either drug (current 
tamoxifen vs unexposed adjusted HR: 0.58, 95% CI: 0.36-0.92; current AI vs unexposed 
adjusted HR: 0.64, 95% CI; 0.48-0.87), and attenuated towards the null once exposure 
ended. The UK study also suggested a direction of association that was consistent with an 
increased risk of SCA associated with time after stopping tamoxifen in comparison with time 
currently exposed (past tamoxifen only vs current tamoxifen adjusted HR: 3.47, 95% CI: 0.70-
17.04), and although this would also suggest a decreased risk during time currently exposed 
to tamoxifen, there were too few events to draw conclusions.  
 To summarise, the US study suggested weak evidence that use of both drugs individually 
lowered risk of SCA, but tamoxifen use may have larger decreased risks. However, problems 
around residual confounding leading to an artificial increased risk of SCA in those that do not 
initiate therapy (outlined in the MI section above) still persist, and all results are fairly 
inconclusive given the lack of precision.  
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8.3.5 PVD 
 Only one RCT has previously explored the effect of endocrine therapies on the risk of PVD, 
which reported an inconclusive association between AI and tamoxifen use, but the direction 
of the effect estimate alluded to an increased risk of PVD associated with in AI in comparison 
with tamoxifen use (RR: 1.25, 95% CI: 0.68-2.29).[130] Both the UK and US studies suggested 
similar effect estimates in the same direction and of a similar strength (adjusted UK HR: 1.31, 
95% CI: 0.67-2.25; adjusted US HR: 1.10, 95% CI: 0.92-1.31), but results were again 
imprecise. 
 Although the effect estimate in the US study suggested a protective association between 
both ever and current tamoxifen use, and the risk of PVD, the strength of association was 
small, and the estimate had 95% CIs that crossed unity (ever tamoxifen vs unexposed 
adjusted HR: 0.91, 95% CI: 0.75-1.10; current tamoxifen vs unexposed adjusted HR: 0.85, 
95% CI: 0.70-1.03). 
 There was no evidence of association between AI use and the risk of PVD reported in the US 
study in both ever and current users of AIs (ever AI vs unexposed adjusted HR: 1.00, 95% CI: 
0.87-1.14; current AI use vs unexposed adjusted HR: 0.95, 95% CI: 0.82-1.09) 
 Although all results are somewhat imprecise, the addition of the UK and US study, with 
similar effect sizes, increases the evidence that there may be a small increased risk of PVD in 
AI compared with tamoxifen users. Any increase in risk is likely to be driven by a protective 
effect of tamoxifen on PVD risk, but it is possible that all reported associations could be due 
to chance because few events and a lack of precision.  
 
8.3.6 Stroke 
 Both the UK and US study suggested no evidence for an association between ever AI 
compared with tamoxifen use, and the risk of stroke (UK adjusted HR: 1.11, 95% CI: 0.81-
1.52; US adjusted HR: 1.05, 95% CI: 0.90-1.24). Although effect estimates pointed in a 
direction that suggested an increased risk associated with AI use, effect estimates were 
small and imprecise. Previous evidence on the association between AI compared with 
tamoxifen users and the risk of stroke was mixed, with three studies reporting effect 
estimates suggesting an lower risk of stroke in AI users,[128, 133, 139] and three studies 
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reporting effect estimates suggesting a higher risk in AI users.[140-142] Two of the studies 
suggesting a higher risk in AI users were extremely imprecise.   
 The US study suggested evidence of a decreased risk of stroke associated with both ever 
tamoxifen and AI use (ever-tamoxifen vs unexposed adjusted HR: 0.82, 95% CI: 0.69-0.98; 
ever-AI vs unexposed adjusted HR: 0.87, 95% CI: 0.76-0.98), which was also observed when 
comparing current tamoxifen and AI use to those unexposed (current tamoxifen vs 
unexposed adjusted HR: 0.83, 95% CI: 0.69-0.99; current AI vs unexposed adjusted HR: 0.81, 
95% CI; 0.71-0.93). It was also suggested that the effect persisted once tamoxifen exposure 
ended, but not when AI exposure ended (past tamoxifen vs unexposed adjusted HR: 0.73, 
95% CI: 0.54-1.00; past AI use vs unexposed adjusted HR: 1.02, 95% CI: 0.89-1.18).  
 Six previous studies, one RCT and five observational, reported evidence for the effect of 
tamoxifen use on the risk of stroke, with effect estimates generally pointing towards a 
reduced risk associated with tamoxifen use.[126, 133, 136, 137, 139, 143] However, the 
strength of association varied (RR’s for tamoxifen vs either placebo no tamoxifen ranged 
from 0.52-1.15), and only one observational study that reported a decreased risk associated 
with tamoxifen use was statistically powered to detect an association. One RCT and one 
observational study also reported effect estimates in opposing directions for the effect of AI 
use on the risk of stroke (RCT, AI vs placebo RR: 1.14, 95% CI:.89-1.45; observational study, 
AI vs no AI RR: 0.71, 95% CI: 0.43-1.03). 
 The addition of evidence from this thesis intersects the previous evidence and suggests no 
difference in the risk of stroke between AI and tamoxifen users. However, the US study 
suggests that this is in the context of a small reduction in risk of stroke in both tamoxifen 
and AI users. As previous evidence on the effect of both tamoxifen and AIs on this risk of 
stroke is mixed, no definite conclusion can be made regarding these effects. 
 
8.3.7 Arrhythmia 
 Both the UK and US studies suggested an increased risk of arrhythmia associated with ever 
AI compared with tamoxifen use (UK adjusted HR: 1.37, 95% CI: 1.11-1.68; US adjusted HR: 
1.22 95% CI: 1.05-1.41), and no other study had previously made this comparison. 
 The US study suggested evidence of a decreased risk of arrhythmia associated with both 
ever tamoxifen and AI use (ever tamoxifen vs unexposed adjusted HR: 0.75, 95% CI: 0.63-
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0.88; ever-AI vs unexposed adjusted HR: 0.91, 95% CI: 0.81-1.01). The US study also 
observed an increased risk of arrhythmia associated with current tamoxifen and AI use in 
comparison with those unexposed (current tamoxifen vs unexposed adjusted HR: 0.72, 95% 
CI: 0.61-0.84; current AI vs unexposed adjusted HR: 0.86, 95% CI: 0.77-0.97), which did not 
persist once exposure ended (past tamoxifen only vs unexposed adjusted HR: 0.99, 95% CI: 
0.77-1.26; past with AI vs unexposed adjusted HR: 1.02, 95% CI: 0.89-1.17). The UK study 
also suggested evidence of an increased risk of arrhythmia associated with time after 
stopping tamoxifen therapy, in comparison with time currently exposed (past tamoxifen only 
vs current tamoxifen adjusted HR: 1.90, 95% CI: 1.38-2.62), suggesting a decreased risk 
during time exposed. One previous RCT also reported an effect estimate, albeit imprecise, 
suggesting a decreased risk of arrhythmia associated with tamoxifen use (RR: 0.79, 95% CI: 
0.64-1.14).[134] 
 Evidence presented in this thesis is consistent with an increased risk of arrhythmia in AI 
users compared with tamoxifen users, and there is increasing evidence to suggest that this is 
likely driven by a protective effect of tamoxifen. However, this is the first place that has also 
suggested that a small protective effect of AI use on the risk of arrhythmia. All protective 
effects reported are also prone to the residual confounding issues described in the MI 
outcome above, which may wholly explain the association between AI use and risk of 
arrhythmia, due to the effect estimate being closer to the null association in comparison 
with the association between tamoxifen use and risk of arrhythmia.  
 
8.3.8 HF 
 HF is the only outcome in which the UK and US studies reported results with differing 
conclusions when comparing the risk of HF in AI compared with tamoxifen users. The UK 
study suggested evidence of an increased risk of HF associated with ever AI compared with 
tamoxifen use (adjusted HR: 1.68, 95% CI: 1.24-2.26), and the US study suggested no 
difference in risk of HF between users of the two types of endocrine therapy (adjusted HR: 
0.96, 95% CI: 0.83-1.12). There is a similarly mixed picture in the previous literature; one RCT 
reported evidence of an increased risk of HF associated with AI compared with tamoxifen 
use with a smaller effect estimate than the UK study (RR: 1.20, 95% CI:.04-1.38);[140] and an 
observational study reported no difference in risk between users of the two types of 
endocrine therapy (RR: 0.96, 95% CI: 0.77-1.08).[139] 
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 In the US study, the above association was in the context of evidence of a decreased risk of 
HF associated with both ever tamoxifen and AI use (ever tamoxifen vs unexposed adjusted 
HR: 0.87, 95% CI: 0.74-1.02; ever AI vs unexposed adjusted HR: 0.84, 95% CI: 0.75-0.94). 
Similar effect estimates were observed when comparing current tamoxifen and AI use to 
non-use (current tamoxifen vs unexposed adjusted HR: 0.77, 95% CI: 0.65-0.91; current AI vs 
unexposed adjusted HR: 0.79, 95% CI: 0.70-0.89), which was not preserved during time after 
exposure had ended (past tamoxifen only vs unexposed adjusted HR: 1.05, 95% CI: 0.82-
1.34; past with AI vs unexposed adjusted HR: 0.99, 95% CI: 0.86-1.14). The UK study 
correspondingly reported an effect estimate, albeit imprecise, that suggested evidence of an 
increased risk of HF associated with time after tamoxifen exposure compared with time 
currently exposed (past tamoxifen only vs current tamoxifen adjusted HR: 1.33, 95% CI: 0.81-
2.18). Previous evidence is mixed, with an RCT and observational study reporting evidence 
pointing towards a protective association between tamoxifen use and HF,[134, 139] but 
another observational study reporting no evidence of an association.[126]   
 Although the UK study suggested evidence of an increased risk of HF in AI users compared 
with tamoxifen users, the US study suggested that, any difference in risk is not due to a toxic 
effect associated with AI use, and rather a protective effect of tamoxifen use. However, 
although the US study adds to the evidence that tamoxifen use decreases risk of HF, there 
still continues to be uncertainty because of mixed evidence in previous studies. The 
association between AI use and risk of HF is also still unclear due to the differing results in 
the UK and US studies, and no previous studies having assessed this association.  
 
8.3.9 Pericarditis (no previous evidence) 
 The US study suggested an increased risk of pericarditis associated with ever AI compared 
with tamoxifen use (adjusted HR: 1.81, 95% CI: 1.06-3.08). The direction of effect was 
replicated in the UK study, however fewer events meant less precision and an inconclusive 
result (ever AI vs ever tamoxifen adjusted HR: 3.25, 95% CI: 0.86-12.23). 
 The US study suggested evidence of a decreased risk of pericarditis associated with both 
ever tamoxifen and AI use when compared with non-users, which was considerably larger in 
tamoxifen users (ever tamoxifen vs unexposed adjusted HR: 0.37, 95% CI: 0.21-0.65; ever AI 
vs unexposed adjusted HR: 0.67, 95% CI: 0.50-0.90). There was evidence of effect estimates 
in a similar direction when comparing the risk of pericarditis during time currently exposed 
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to tamoxifen or AI to non-use (current tamoxifen vs unexposed adjusted HR: 0.77, 95% CI: 
0.65-0.91; current AI vs unexposed adjusted HR: 0.79, 95% CI: 0.70-0.89). 
 If a real difference in the risk of pericarditis exists between AI and tamoxifen users, the US 
study suggests that use of both drugs individually have a protective effect on pericarditis, 
but tamoxifen may have a larger effect. However, the size of the protective effect of 
tamoxifen appears implausibly large, which raises questions about the causality of the 
association and reasons for non-causality outlined in the MI outcome could also be present 
in this outcome. Furthermore, cancer can present with pericarditis,[144] which may explain 
some of the protective association if the pericarditis recording was delayed and was 
associated with not being prescribed any endocrine therapy. The UK study was also severely 
underpowered to detect any associations, meaning the evidence from this study was 
inconclusive.  
 
8.3.10 Valvular heart disease (no previous evidence) 
 The UK and US studies reported effect estimates that pointed towards an increased risk of 
VHD associated with ever AI compared with tamoxifen use (UK adjusted HR: 1.30, 95% CI: 
0.92-1.85; US adjusted HR: 1.21, 95% CI: 1.04, 1.41).  
 The US study suggested evidence of a protective association between ever tamoxifen use 
and risk of VHD (ever tamoxifen vs unexposed adjusted HR: 0.81, 95% CI: 0.68-0.96). There 
was a similar association when comparing time currently exposed to tamoxifen to non-use 
(current tamoxifen vs unexposed adjusted HR: 0.82, 95% CI: 0.69-0.97), which attenuated 
towards the null once exposure finished (past tamoxifen only vs unexposed adjusted HR: 
0.92, 95% CI: 0.70-1.20). There was also evidence of effect modification by current age (p for 
effect modification = 0.04), with no evidence of association between tamoxifen use and risk 
of VHD in the younger age group (ever tamoxifen vs unexposed adjusted HR in women 
currently aged 66-74: 1.10, 95% CI: 0.80-1.52), and a decreased risk of VHD associated with 
tamoxifen use in the oldest age group (ever tamoxifen vs unexposed adjusted HD in women 
currently aged 85+: 0.56, 95% CI: 0.39-0.80). The UK study also suggested weak evidence of 
an increased risk of VHD associated with time after tamoxifen exposure compared with time 
currently exposed (adjusted HR: 1.66, 95% CI: 0.95-2.91), implying a potential increased risk 
associated with current tamoxifen use.  
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 There was no evidence of an association between ever AI use and risk of VHD in the US study 
(ever AI vs unexposed adjusted HR: 0.98, 95% CI: 0.87-1.13).   
 Evidence in both the UK and US studies suggests an increased risk of VHD in AI users 
compared with tamoxifen users, which is likely driven by the protective effect of tamoxifen 
uses and VHD risk as observed in the US study. However, the US study also suggested that 
this protective effect was driven by those in the older age groups, with no protective effects 
seen in younger women. There was also no evidence of any toxic or protective effects 
associated with AI use. As these studies are the first to report results on these effects, and 
there is the possibility of residual confounding by factors such as frailty are even greater in 
older populations, causality of any protective effects of tamoxifen cannot be assumed.  
 
8.3.11 Venous Thromboembolism 
 This comparison will focus on the composite VTE outcome, which is consistent with the VTE 
outcome in the systematic review that included DVT individually, or both DVT and PE 
together 
 Both the UK and US studies suggested effect estimates pointing towards evidence of a 
decreased risk of VTE associated with ever AI compared with tamoxifen use (UK adjusted HR: 
0.82, 95% CI: 0.61-1.10; US adjusted HR: 0.80, 95% CI: 0.59-1.07). Six out of seven previous 
RCTs reported effect estimates in the same direction, but with effect estimates further away 
from the null association (RRs comparing AI to tamoxifen use ranged from 0.26-0.61),[128, 
129, 131, 140, 145] and another RCT reported no evidence of association.[124] 
 The US study suggested evidence of an increased risk of VTE associated with ever tamoxifen 
use (ever tamoxifen vs unexposed adjusted HR: 1.39, 95% CI: 0.98-1.98), and a larger effect 
estimate was reported when comparing time currently exposed to non-use (current 
tamoxifen vs unexposed adjusted HR: 1.68, 95% CI: 1.21-2.35). The apparent toxic effect 
associated with tamoxifen use also disappeared once tamoxifen exposure ended (past 
tamoxifen only vs unexposed adjusted HR: 1.04. 95% CI: 0.56-1.92), although few events 
meant this estimate was imprecise. The UK study also observed a decreased risk of a VTE 
associated with time after tamoxifen exposure compared with time currently exposed 
(adjusted HR: 0.74, 95% CI: 0.44-1.23), suggesting an increased risk during time exposed, but 
results were consistent with chance variation. An increased risk of VTE associated with 
tamoxifen use was reported in five out of six previous RCTs and two out of three 
 
155 
 
observational studies, with varying levels of precision (RRs comparing tamoxifen use to 
placebo or no tamoxifen ranged from 1.64-7.10).[133-135, 146-150]  
 There was no evidence of association between ever AI use and risk of VTE in the US study 
(ever AI vs unexposed adjusted HR: 1.11, 95% CI: 0.84-1.46), which contradicts the one 
previous RCT that indicated an increased risk associated with AI use (AI vs placebo RR: 1.84. 
95% CI: 1.11-3.04).[127]  
 The majority of evidence, including that reported in this thesis, suggests that AI users are at 
a decreased risk of VTE outcomes in comparison with tamoxifen users, which is likely driven 
by the long established increased risk of VTE in tamoxifen use. This thesis also hypothesises 
that any toxic effects may stop when exposure ends, but evidence on this effect is not 
conclusive. Effect sizes presented in this thesis were smaller than in previous studies that 
reported evidence of effect between both AI compared with tamoxifen use and tamoxifen 
use compared with non-use, on the risk of VTE. The potential underestimation in risk of VTE 
in tamoxifen users in comparison with several previous studies could be further evidence of 
an artificially increased risk of CVD in non-initiators of endocrine therapy due to residual 
confounding, suggested as a possible reason for non-causal relationships within other CVD 
outcomes.  There is still uncertainty of the effect of AI use and one the risk of VTE outcomes.  
 
8.4 BIOLOGICAL PLAUSIBILITY 
As outlined in the introduction, It is known that tamoxifen use lowers total serum cholesterol by 10-
20% and low-density lipoprotein levels by 15-22%,[92-95]. This suggests that the results reported in 
the US study suggesting a possible protective effect associated with tamoxifen use on the risk of 
several non-venous CVD outcomes may be mediated through tamoxifen reducing the level of CVD 
risk factors such as cholesterol. The heterogeneous protective effect sizes reported between 
tamoxifen use and the different non-venous CVD outcomes may therefore partly be a product of any 
differing effects of cholesterol on the different outcomes. Tamoxifen also has oestrogen agonistic 
effects that could increase the risk of in thrombogenicity through a reduction in antithrombin and 
protein C levels, [96, 97] which may explain the reported increased risk of VTE outcomes associated 
with tamoxifen use in both this thesis, and previous studies.  
 
AIs work by inhibiting the aromatase enzyme and depleting oestrogen levels, which are known to be 
protective of CVD. Evidence regarding the effect of AIs on cholesterol levels is inconclusive, with two 
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RCTs reporting a higher incidence of hypercholesterolemia in AI compared with tamoxifen 
users,[151, 152] but another study finding no differences.[127] However, neither of the studies 
within the thesis reported evidence that the oestrogen depleting effects of AIs translated into an 
increased risk of any CVD outcome associated with AI use. There were some results that suggested 
evidence of decreased risk of some CVD events associated with AI use, but if true, there is no current 
understanding of a biological mechanism through which such an effect is mediated. 
 
8.5 STRENGTHS AND LIMITATIONS 
The study specific strengths and limitations were outlined within individual studies. This section will 
reiterate and expand on these points as well as discussing the wider implications of using routinely 
collected data for research and the potential problems of cross-country comparisons.  
8.5.1 Strengths 
 A key strength of using routinely collected data for research is the large size of the many 
available data sources and breadth of these data, which allows studies of exposures and 
outcome combinations that are otherwise too rare to study. It would be extremely 
expensive and time consuming to carry out a prospective cohort study to detect the effect of 
endocrine therapies in breast cancer survivors on the risk of each individual CVD outcome 
outlined in previous chapters.  
 Unlike traditional prospective cohort studies that require participants to agree to be 
followed up, potentially inducing healthy participator bias, data used in this thesis are 
collected routinely, and are highly representative of the populations from which they 
originate. 
 This thesis used data from two independent databases in the UK and US to address the same 
research question. This approach helps to guard against incorrect conclusions due to biases 
present in a single database, and consistent patterns of results increases the confidence in 
the conclusions.   
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8.5.2 Limitations 
8.5.2.1 Misclassification 
Exposure 
 Although all prescriptions are captured in primary care in the CPRD and Medicare Part D, no 
information is recorded on the administration of these drugs. Women who are prescribed 
endocrine therapies (or any other prescription used as a covariate in each study) but do not 
take the drug, would be misclassified as exposed. However, given the severity of a breast 
cancer diagnosis, and the current evidence that endocrine therapies reduce recurrence, 
women will likely be mindful to take prescribed drugs. Furthermore, 97% of women in the 
UK and 90% in the US continued to pick up repeat prescriptions 1 year after starting therapy, 
which is an indication that most prescriptions were being filled and taken.  
 Endocrine therapies could be prescribed in hospital at the first instance, followed by 
prescriptions in primary care. These prescriptions were not included in the UK as HES data 
does not include information on hospital prescribing, which could have led to delayed date 
of initiation in CPRD records. However, follow up started one year after breast cancer 
diagnosis, and any misclassification in regards to time to exposure in CPRD will likely be non-
differential as time between breast cancer diagnosis and first prescription in primary care 
was similar in initiators of both tamoxifen and AIs (median time to initiation was 57 and 63 
days in tamoxifen and AI initiators respectively). Missing such prescriptions was not a 
problem in the US study as prescriptions from both hospital and primary care are captured 
in either Medicare Parts A, B, or D.  
 In the ever exposure analyses in both studies, women were defined as exposed from the 
point of their first tamoxifen or AI prescription until they were either censored or switched 
between drugs (at which point their exposure were time updated to be ever exposure to 
both drugs). Women could therefore receive only one prescription, but stay within the ever 
exposed group. Although this remains within the definition of being ever being exposed to 
the drug, it is unlikely that women who were exposed to only one endocrine therapy 
prescription received any protective or toxic effects of the drug. However, stopping therapy 
after one prescription is also unlikely given the known reduction in breast cancer recurrence 
associated with use of both tamoxifen and AIs, and again, descriptive analyses in both 
studies showed that 97% and 90% of women were exposed for at least 1 year in the UK and 
US studies respectively.  
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Outcome 
 EHRs may not record acute CVD events that result in death prior to admission to hospital, so 
some women with an event could have been incorrectly censored at death when they 
actually suffered a CVD event of interest. This differential misclassification could have biased 
results if the proportion of acute CVD events leading immediately to death that were not 
recorded as CVD events varied between exposure groups. Such variation is conceivable given 
the differences in characteristics that may be associated with a higher risk of acute CVD 
between exposure groups (higher BMI and more smoking in AI initiators in the UK study, and 
more taxanes, anthracyclines, and trastuzumab in the AI initiators in the US study), but the 
assumption is not testable due to no information on events that occurred outside of the 
hospital resulting in death. This misclassification is likely to be more problematic for 
outcomes such as sudden cardiac arrest, where overall survival following an out of hospital 
event is approximately 8.3% in the US.[153] Although some of these events will be missed, 
many of them will still be recorded in patients’ records alongside their record for death. The 
inclusion of primary care records increases the likelihood of the correct recording of an out 
of hospital CVD event resulting in death, but the best way to overcome such problems in the 
UK would be to use the Office of National Statistics mortality data, which includes 
information on cause of death. These data were not utilised in this thesis, but would be 
advantageous to any future work.   
 This thesis explored a range of clinically specific CVD outcomes, which had varying degrees 
of severity, and as the study populations included older women, it is likely that those 
included had several comorbidities. It plausible that less severe CVD outcomes may not be 
recorded or recognised by clinicians if the woman also has any other, more severe, 
comorbidities. Women that initiated AIs in both the UK and US study had more 
comorbidities such as RA, CKD, and diabetes in comparison with tamoxifen initiators. If less 
CVD events were recorded in the women exposed to AI, then it is possible that there is an 
underestimation of effect size when comparing AI to tamoxifen use. In the US study, women 
unexposed to any endocrine therapy generally also had more comorbidities than those that 
initiated tamoxifen or AIs, which could again have led to underestimation of effect sizes.  
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Covariates 
 Patients are not required to update their lifestyle choice records every time they visit a GP 
surgery in the UK. For example, a woman’s latest record could indicate they currently 
smoke, but their cancer diagnosis caused them to stop. If they have not been questioned as 
to their change in habit, their records would not reflect this change. However, given women 
diagnosed with breast cancer are likely to have regular contact with the GP following their 
diagnosis, the likelihood of full and up to date lifestyle measures is high, which is also 
reflected in the low number of missing data within these variables.  
 Prescriptions of drugs other than endocrine therapy were identified using the same method 
as the exposure (a record of a prescription in the patients’ files based on a pre-specified list 
of codes). Therefore, there is still a risk of women being prescribed, but never actually 
dispensing and taking the drug. However, given that all women were then diagnosed with 
breast cancer, it is likely that they reviewed their medication with a GP and were 
encouraged to take any drugs that they had ben indicated.  
 Diagnoses of the potential comorbidities diabetes, CKD, and rheumatoid arthritis were 
identified using only the CPRD in the UK study. It is therefore possible for patients to be 
misclassified as not being diagnosed with the comorbidity if they had only been diagnosed in 
secondary care. However, all comorbidities in this thesis were chronic and of sufficient 
significance that they are likely recorded in the primary care record, regardless of if they 
were initially diagnosed in secondary care. Such misclassification would be more 
problematic for acute events.  
 The UK and US health systems are set up in very different ways. For example, the Quality 
and Outcomes Framework financially incentivises all GPs in the NHS to diagnose, give drugs 
or take readings based on certain recommendations (such as BP recordings in all patients 
over the age of 45).[154] This does not happen in the US due to the more fragmented nature 
of the healthcare system. Any difference in recording is, however, likely to be non-
differential in relation to exposure to endocrine therapy.   
 
8.5.2.2 Missing data 
 Routinely collected health records can be prone to missing data. A complete case analysis, in 
which crude and adjusted analyses only included women without missing data was carried 
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out in both the UK and US studies. This approach is valid in a regression context if 
missingness is conditionally independent of the outcome.[155] In the context of the UK 
study, this means that the assumption was made of no association between having 
complete data on BMI (5.5% missing), smoking (0.5% missing), alcohol use (6.3% missing), 
and blood pressure (0.2% missing for systolic and diastolic) and developing any of the CVD 
outcomes given fixed covariate values. Although this is an untestable assumption, it is more 
plausible than the missing at random assumption required for multiple imputation, as 
recording of lifestyle variables may be associated with the value of the variable itself (those 
with high or low BMI are more likely to have their BMI recorded). In comparison, the 
variables with missingness in the US study were region (0.6% missing), ethnicity (0.2% 
missing), and grade of breast cancer (4.3% missing). Although it is plausible that these 
variables could be missing at random, meaning multiple imputation would be a valid 
approach; missingness is likely independent of the CVD outcomes, so a complete case 
analysis is also valid.   
 Diagnoses in EHR studies are defined by either the presence or absence of a clinical code. 
Therefore, not having a diagnosis is defined by an absence of evidence of disease, rather 
than an assessment of disease that indicates the person does not have a certain diagnosis. 
However, it is possible that those with absence of a clinical code were assessed for the 
disease, but had missing data in relation to the diagnosis. Due to this method of identifying 
diagnoses, there is no way to identify true missingness. 
 
8.5.2.3 Confounding 
 The main potential source of confounding in the US study was likely due to reasons for non-
initiation of endocrine therapy. If women did not initiate either tamoxifen or AIs due to 
reasons that are also associated with the risk of a CVD event (BMI, smoking, alcohol use, 
financial barriers, access to care), then it is likely that non-initiators are at an increased risk 
of an event at baseline compared with those that initiate therapy. If this is true, then any 
protective effect of either endocrine therapy could be over-estimated. Protective effects 
were generally small when comparing the association between AI use and non-venous CVDs, 
so residual confounding due to reasons for non-initiation could explain the effects. The 
measures outlined above that could potentially influence non-initiation were not available in 
SEER-Medicare data, so it was not possible to explore reasons for non-initiation.  
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 The increased risk of VTE events associated with tamoxifen use, which was observed in both 
the UK and US studies, has been reported in other studies and is well known to clinicians. If 
this known association also meant women at a high risk of CVDs other than VTE were more 
likely to be prescribed AIs instead of tamoxifen, then the AI users would have higher risk of 
non-venous CVD at therapy initiation. This could explain some of the increased risk of non-
venous CVD outcomes in AI compared with tamoxifen users observed in both studies. 
However, adjustments were made for many CVD risk factors in both studies; in the UK study 
it was also possible to further include lifestyle variables that were not available in the US.  
 Residual confounding could have also originated from the categorisation of covariates. All 
prior diagnoses (chronic kidney disease, rheumatoid arthritis, diabetes) were included as 
binary variables, but the disease severity could differ greatly within those diagnosed. For 
example, those with mild diabetes have a very different biomarkers and treatment regimens 
to those with severe diabetes, causing residual confounding within this group of patients. 
This mechanism of residual confounding is also applicable to all other treatment and lifestyle 
covariates.  
 All adjustments made in analyses are only as good as the data from which they originated. 
So, any misclassification described above that may lead to measurement error, has the 
potential to cause residual confounding.  
 Hypertension (or blood pressure) was included as a potential confounder. It is however 
possible that changes in cholesterol levels due to endocrine therapy use could cause 
hypertension, which is known to contribute to CVD prevalence. If this is the case, then 
hypertension could be a partial mediator of any association between endocrine therapy and 
CVD. Adjusting for a potential mediator could therefore bias any reported associations. A 
possible way to explore this would be to include hypertension as an outcome, but the study 
team decided not to do so as I wanted to explore clear clinical cardiovascular end points 
rather than disease that contributes to and causes these outcomes. A limitation of this 
approach is that by not including hypertension as an outcome, some adverse CVD 
consequences of therapy that had not yet led to harder CVD diagnoses may be missed.  
 
8.5.2.4 Multiple testing  
 As a large range of outcomes are collected in routinely collected EHR data, there can be a 
tendency to test for a wide range of associations within one study population, which could 
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potentially lead to an increased risk of false positive results. Study populations for each 
individual CVD analysis are not identical in both the UK and US studies as they exclude 
women with the specific CVD outcome of interest prior to index. Caution should therefore 
be taken when interpreting 95% CIs that are close to the null association, due to problems 
associated with multiple testing. However, there were consistent patterns of results for the 
association between endocrine therapies and non-venous CVD outcomes, so for the results 
of non-venous CVD outcomes where the 95% CI was close to the null association, it unlikely 
that chance is the full explanation.  A way to correct for multiple testing is to apply the 
Bonferroni correction.[156] However, this correction is usually over-conservative and only 
changes the significance cut off. This would also place a lot of emphasis on arbitrary p values 
to assess statistical significance. Furthermore, Bonferroni correction should only be 
considered if: (1) a single test of the ‘universal null hypothesis’ that all tests are not 
significant is required, (2) it is imperative to avoid a type I error, and (3) a large number of 
tests are carried out without pre-planned hypotheses.[157] Although type I errors should be 
avoided, requirements 1 and 3 are not satisfied in this context as I was not exploring the 
possibility that all tests were simultaneously “non-significant” and all association assessed 
had pre-planned hypotheses. 
 
8.5.2.5 Statistical power 
 Although EHR databases are usually very large in comparison with traditional cohort studies, 
lack of statistical power to detect small associations is still sometimes problematic. In 
survival analysis, the number of events has a high impact on statistical power. The number 
of events in some analyses assessing the risk of relatively rare CVD outcomes such as 
pericarditis and SCA was small in the study populations of female breast cancer survivors. 
 
8.5.2.6 Generalisability 
 The study populations of the two studies within this thesis originate from countries that 
have a high incidence of both breast cancer and CVD in comparison with many other 
countries in the world. Although these results are likely generalisable to women in other 
high-income countries, further understanding of the associations are needed in low and 
middle-income settings. 
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8.6 BRADFORD-HILL CRITERIA FOR CAUSALITY 
The implicit comparison for the question of causality is each endocrine therapy (tamoxifen and AIs) 
vs no endocrine therapy, which was explored in the US study, because the comparison between AI 
and tamoxifen is secondary to the causal effects of each drug vs no endocrine therapy. 
 
8.6.1 Does tamoxifen causally affect the risk of CVD outcomes? 
The strength of association between tamoxifen and non-venous CVD outcomes varied based on the 
specific outcome. Some outcomes, such as MI, showed evidence of a very strong protective effect 
(ever tamoxifen vs no endocrine therapy US HR: 0.44, 95% CI: 0.30-0.63), whereas others, such as 
PVD, showed weaker evidence of a protective effect (ever tamoxifen vs no endocrine therapy US HR: 
0.91, 95% CI: 0.75-1.10). Furthermore, consistency of effects has been discussed in detail in section 
8.3, and for the outcomes in which there is a considerable amount of previous literature, results are 
generally consistent with what has been found in this thesis. Temporality is assumed for the 
associations between tamoxifen and non-venous CVD outcomes (and all other exposure outcome 
relationships in this thesis) due to the prospective nature of the cohort studies that have been 
designed, leading to little risk of reverse causality. Biological gradient was not explicitly tested (do 
increasing doses of tamoxifen give further non-venous CVD protection? Similar for all other exposure 
outcome associations) because of limited power, but within patients diagnosed with ER+/PR+ breast 
cancer, the dose of tamoxifen will likely not be increased due to its known efficacy on reducing the 
risk of breast cancer recurrence. However, the effect of increasing length of tamoxifen prescription 
on the risk of non-venous CVD outcomes was explored, and it was generally found that there was no 
further protection as length of prescription increased. Finally, there is a biological explanation of a 
protective effect of tamoxifen on non-venous CVD outcomes through lowering of cholesterol (full 
explanation in section 8.4).  
 
The strength of association between tamoxifen and venous CVD outcomes is reasonably large, with 
evidence of an increased risk of VTE associated with ever tamoxifen use (ever tamoxifen vs no 
endocrine therapy US HR: 1.39, 95% CI: 0.98-1.98) which is consistent with most previous RCTs and 
observational studies (fully outlined in chapter 2 and section 8.3). There was, however, little 
evidence of an increasing risk of VTE as length of prescription increased, but this could be due to 
limited power. Finally, there is biological plausibility of this association as tamoxifen has oestrogen 
agonistic effects that could increase the risk of in thrombogenicity through a reduction in 
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antithrombin and protein C levels.  
 
8.6.2 Do AIs causally affect the risk of CVD outcomes?  
The strength of association between AIs and non-venous CVD outcomes was considerably weaker in 
comparison with the association between tamoxifen and non-venous CVD outcomes. Some 
outcomes, such as pericarditis, showed evidence of a reasonably strong protective effect (ever AI vs 
no endocrine therapy US HR: 0.67, 95% CI: 0.50-0.90), whereas others, such as PVD, showed no 
evidence of an effect (ever AI vs no endocrine therapy US HR: 1,00, 95% CI: 0.87-1.14). Relatively few 
previous studies have explored the effect of AIs on the risk of non-venous CVD outcomes, and for 
those that have, there have been mixed results, with some showing small protective effects and 
others showing no association. Again, there was little evidence that increasing length of prescription 
affected the protective effects of AIs. Finally, there is no biological reasoning behind a protective 
effect of AIs on non-venous CVD outcomes, but instead a plausible mechanism that suggests an 
increased risk of these outcomes with AI use as they deplete oestrogen levels, which are known to 
be protective of CVD. 
 
There is little evidence of an association between AI use and venous CVD outcomes in this thesis and 
only one previous RCT reporting an increased risk of VTE in AI users. There is also no evidence of a 
dose-response relationship, but it is there is a possible biological mechanism to an increased risk of 
VTE in AI users through depletion of oestrogen levels.  
 
8.7 IMPLICATIONS FOR CLINICAL PRACTICE AND FUTURE WORK 
 This thesis has shown that the hypothesised mechanism for an increased risk of CVD events 
with AI use does not appear to translate into an increased risk of CVD events associated with 
AI use, and any difference in CVD risk in AI users compared with tamoxifen users is likely to 
be predominantly driven by the cardiac effects of tamoxifen (be that a possibly protective of 
some non-venous CVDs, or toxic of venous CVDs). Therefore the call for clinicians to 
prioritise assessment and reduction of CVD risk in AI users may not be as important as was 
previously thought.[158]  
 Descriptive analyses reported a marked yearly decrease in the proportion of women 
initiating tamoxifen, coupled with an increase in women initiating AIs after a breast cancer 
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diagnosis in both the UK and US studies. This is likely due to the evidence that AIs increase 
disease free and overall survival in comparison with tamoxifen in post-menopausal women 
diagnosed with ER+ breast cancer.[159] Although this change will likely mean less VTE 
events in post-menopausal survivors of ER+/PR+ breast cancer, it is unclear how the loss of 
an apparently protective effect of some non-venous CVD associated with tamoxifen use will 
affect the population as a whole. Clinicians should therefore be wary of this possible loss in 
protection of any women at high risk of CVD who are switching form tamoxifen to AIs.  
 As tamoxifen use is becoming less prevalent in post-menopausal women diagnosed with 
ER+/PR+ breast cancer, and older women diagnosed with breast cancer are dying from 
causes other than the cancer itself, it would be informative to know if the cardio-protective 
effects of tamoxifen outweigh the excess reduction in risk of breast cancer recurrence 
associated with AI use compared with tamoxifen use. A meta-analysis of RCTs showed that 
there was no difference in overall mortality between those given tamoxifen compared AIs 
for 5 years, and further understanding of the CVD and breast cancer specific mortality 
associated with both tamoxifen and AI use is needed.[22] If the long term CVD benefits of 
tamoxifen outweigh the excess protection effect of breast cancer reoccurrence with AI use, 
it is conceivable that post-menopausal women diagnosed with ER+/PR+ breast cancer who 
are at high risk of CVD may receive more benefit from taking tamoxifen rather than AIs.  
 The effect of AI use and CVD risk should be explored further. This includes further 
understanding of the viability of a plausible biological mechanism for a reduced risk of 
certain non-venous CVD events associated with AI use, and if these reported associations are 
causal or a result of biases. This could be progressed through the following questions: 
o Are the CVD effects of AI use the same within all types of third generation AIs 
(anastrozole, letrozole, and exemestane)?  
o What are the risk factors of non-initiation of any endocrine therapy in women 
diagnosed with ER+/PR+ breast cancer and how similar are these to the risk factors 
of CVD? 
o Does AI use effect the risk of CVD risk factors such as cholesterol level and blood 
pressure? 
 The studies within this thesis suggested that the individual effect of both tamoxifen and AIs 
on the risk of stroke are similar to the effect on other non-venous CVDs. However, due to 
conflicting results in previous research, there is still uncertainty on the association between 
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both endocrine therapies individually and the risk of stroke. Further large population-based 
studies that focus on the effect of these drugs on the risk of stroke (overall, and both 
haemorrhagic and ischaemic stroke individually) would allow a deeper understanding of 
these associations.  
 There was little statistical power to detect an association for several specific CVD outcomes 
although the broad populations from which the study populations originated were large. It 
may be possible to further explore some of the outcomes for which there was statistical 
little power if there was a possibility for collaborative international work combining data 
from several sources. Greater statistical power would also mean that effect modification and 
the cumulative effect of treatment could also be assessed in more detail.  
 A data source that allows for adjustment of all potential confounders would enable potential 
residual confounding problems to be addressed. A potential dataset that would address the 
current problem of being unable to adjust for other cancer therapies in the UK data would 
be the CPRD and HES linked to the Systemic Anti-Cancer Therapy (SACT) dataset, which has 
recently become available to researchers. SACT collects information routinely reported by 
NHS trusts on the treatment of malignant disease in secondary care in England. Submission 
of SACT data was only mandatory from 2014, and these data have only recently been linked 
to the CPRD. It was therefore not possible to use these data for the purpose of analysis in 
this thesis, but may be possible in the future once time since mandatory follow up increases.  
 
8.8 CONCLUSIONS  
This thesis focused on the effect of endocrine therapy use on the risk of a range of CVD outcomes. 
Based on the totality of information presented from the studies in this thesis, along with previous 
RCT and observational studies, there is convincing evidence of an increased risk of several non-
venous CVDs in AI compared with to tamoxifen users in post-menopausal women diagnosed with 
ER+/PR+ breast cancer, with varying effect sizes for different clinically specific outcomes. However, 
the associations are likely due to protective effects of tamoxifen on these outcomes, rather than any 
toxic effects of AIs. There was also evidence of AI use being associated with a small decreased risk of 
several non-venous CVD events, but a causal effect cannot be assumed due to no current 
understanding of a biological mechanism, and a possible overestimation of any protective effect due 
to residual confounding. The studies within this thesis also confirmed the known effect of tamoxifen 
use (compared with both AI use and non-use of any endocrine therapy) on increased risk of VTE, 
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which was previously evident from the accumulation of evidence in the systematic review. No 
evidence of effect was observed between AI use and the risk of VTE. Overall, the effects of 
tamoxifen use on the risk of CVD are becoming clearer. However, as more postmenopausal women 
are prescribed AIs rather than tamoxifen, additional large-scale population based studies are needed 
to understand if any observed cardio-protective effects of AI are causal, as well as further 
understanding the risk-benefit balance of endocrine therapies with respect to both cancer and 
cardiovascular outcomes. 
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APPENDICES 
CHAPTER 2 
Appendix 2.1 – Overview of previous meta-analyses 
 
Author Year Inclusion criteria Main comparison Main Cardiovascular 
Outcomes 
Meta-analysis 
result RR (95% CI)  
Notes 
Khosrow-
Khavar 
2016 Phase III RCTs examining third 
generation AIs and tamoxifen 
among post-menopausal women 
with a diagnosis of breast cancer, 
with CVD or cerebrovascular 
adverse events reported. 
AI vs Tam CVD events  1.19 (1.07-1.34) Result from AI vs Tam monotherapy. 
Concluded that the cardio-protective 
effects of tamoxifen accounted for the 
increase in CVD risk. Also explored 
sequenced therapy.  
Cerebrovascular 
events 
0.96 (0.61-1.51) 
Ryden 2016 RCTs with long-term (at least 5 
years) follow-up data of AI 
compared with tamoxifen or 
placebo with either efficacy (DFS 
and OS) or side effect outcomes   
AI vs Tam CVD events  1.13 (0.96-1.33) Result from AI vs Tam monotherapy. 
Only one study in AI vs Tam analysis. 
Also explored sequenced therapy, and 
looked at time on and off treatment 
Aydiner 2013 RCTs that included 
postmenopausal women that 
had undergone surgery for 
estrogen-sensitive early breast 
cancer, and examined the 
comparative effects of AIs and 
tamoxifen (either as 
monotherapy, sequenced 
therapy, or extended therapy) in 
relation to efficacy outcomes 
AI vs Tam CVD events  1.23 (0.95-1.60) Result from AI vs Tam monotherapy. 
Also explored sequenced therapy.  
Thromboembolic 
events 
0.61 (0.47-0.80) 
Amir 2011 Phase III RCTs that compared AIs 
with tamoxifen as initial adjuvant 
therapy in postmenopausal 
women with early stage breast 
cancer. Only trials that had 
treatment durations longer than 
5 years were included.  
AI vs Tam CVD events (including 
MI, angina, and 
cardiac failure) 
1.26 (1.10-1.43) Result includes direct AI vs Tam, Tam 
to AI vs AI alone, and tam to AI vs AI 
alone 
Cerebrovascular 
events (including 
cerebrovascular 
accident and transient 
ischemic attack) 
1.01 (0.81-1.26) 
Venous Thrombosis 
(any venous 
thromboembolic 
episode) 
0.55 (0.46-0.64) 
Cuppone 2007 Phase III RCTs that explored the 
cardiovascular risk of adjuvant AI 
compared with tamoxifen as an 
early switch strategy (after 2-3 
years’ tamoxifen) or as an 
upfront strategy (starting at the 
time of surgery and planned for 3 
years. All trails must have 
included women who were 
previously untreated and had 
undergone surgical resection for 
early breast cancer.  
AI vs Tam CVD events 1.30 (1.07-1.60) Result Includes both upfront and early 
switch comparisons of AI and 
tamoxifen 
 Thromboembolic 
events  
0.53 (0.42-0.65) 
Cerebrovascular 
events 
0.84 (0.68-1.05) 
Braithwaite 2003 Breast cancer treatment RCTs 
that explored the effect of 
tamoxifen on vascular  outcomes 
Tam vs No tam/ 
placebo 
MI  0.74 (0.47-1.16) Also explored some outcomes in trials 
of post-menopausal women, breast 
cancer reduction trials, and trials with 
tamoxifen as only treatment 
Stroke 1.48 (1.07-2.04) 
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Appendix 2.2 - Systematic review search strategy 
 
 
Medline 
Breast Cancer 
MeSH terms breast neoplasms or carcinoma, ductal, breast or carcinoma, lobular or inflammatory breast neoplasms or 
unilateral breast neoplasms or triple negative breast neoplasms 
Keywords breast cancer or breast neoplasm* or breast tumour or breast adenocarcinoma or breast carcinogenesis or 
breast carcinoma or breast sarcoma 
Endocrine Therapy 
MeSH terms tamoxifen or aromatase inhibitors 
Keywords tamoxifen or aromatase inhibitor* or anastrazole or exemestane or letrozole or endocrine therapy  
Cardiovascular Disease 
MeSH terms cardiovascular diseases or heart diseases or cardiotoxicity or coronary artery disease or cardiomyopathies or 
heart arrest or heart failure or heart failure, diastolic or heart failure, systolic or heart valve diseases or aortic 
valve insufficiency or aortic valve stenosis or mitral valve insufficiency or mitral valve stenosis or pulmonary 
valve insufficiency or pulmonary valve stenosis or tricuspid valve insufficiency or tricuspid valve stenosis or 
angina pectoris or angina, unstable or angina, stable or myocardial infarction or stroke or venous 
thromboembolism or pulmonary embolism or pericarditis or peripheral vascular disease or arrhythmias, cardiac 
Keywords cardiovascular* or CVD or cardiac or cardiotoxi* or heart disease* or coronary artery dis* or revascular* or 
coronary bypass or artery bypass or aorta bypass or cardiomyopathy* or cardiopulmonary arrest* or cardiac 
arrest* or heart arrest* or heart failure or valvular*disease or valve disease or valve stenosis or valve 
insufficiency or angina* or heart infarc* or myocardial infarc* or heart attack or coronary infarc* or stroke or 
tia or transient ischemic attack or cerebrovascular accident or venous thromboembolism or deep*thrombo* or 
thromboem* or pulmonary embolism or pericarditis or peripheral vascular or peripheral art* or arrhythmia* or 
fibrillation or heart*flutter 
 
Limits 
  English language 
 Humans 
 1960 –Current year  
Embase 
Breast Cancer 
Indexed terms breast cancer or breast tumour or basal like breast cancer or breast adenocarcinoma or breast carcinogenesis 
or breast carcinoma or breast sarcoma or estrogen receptor positive breast cancer or inflammatory breast 
cancer or triple negative breast cancer 
Keywords breast cancer or breast neoplasm* or breast neoplasm or breast tumour or breast adenocarcinoma or breast 
carcinogenesis or breast carcinoma or breast sarcoma 
Endocrine Therapy 
Indexed terms aromatase inhibitor or anastrozole or exemestane or letrozole or tamoxifen 
Keywords chemotherapy or anthracycline or daunorubicin or doxorubicin or epirubicin or cyclophosphamide or 
fluorouracil or methotrexate or taxoid* or taxane* or paclitaxel or docetaxel or tamoxifen or aromatase 
inhibitor* or anastrazole or exemestane or letrozole or endocrine therapy or trastuzumab or Herceptin or 
breast cancer treatment 
Cardiovascular Disease 
Indexed terms heart disease/ or cardiovascular disease/ or cardiotoxicity/ or heart arrhythmia/ or heart atrium arrhythmia/ or 
heart ventricle arrhythmia/ or atrial fibrillation/ or heart atrium flutter/ or heart ventricle arrhythmia/ or heart 
ventricle flutter/ or heart ventricle fibrillation/ or heart fibrillation/ or heart failure/ or acute heart failure/ or 
congestive heart failure/ or diastolic heart failure/ or systolic heart failure/ or heart ventricle failure/ or heart 
left ventricle failure/ or heart right ventricle failure/ or Ischemic cardiomyopathy/ or cardiomyopathy/ or 
congestive cardiomyopathy/ angina pectoris/ or stable angina pectoris/ or unstable angina pectoris/ or heart 
infarction/ or acute heart infarction/ or heart atrium infarction/ or pericarditis/ or valvular heart disease/ or 
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aorta valve disease/ or mitral valve disease/ or pulmonary valve disease/ or tricuspid valve disease/ or aorta 
valve stenosis/ or mitral valve stenosis/ or heart valve stenosis/ or pulmonary valve stenosis/ or tricuspid valve 
stenosis/ or revascularization/ or heart arrest/ or cardiopulmonary arrest/ or cerebrovascular accident/ or 
venous thromboembolism/ or deep vein thrombosis/ or thromboembolism/ or embolism/ or vein thrombosis/ 
or peripheral vascular disease/ 
Keywords cardiovascular* or CVD or cardiac or cardiotoxi* or heart disease* or coronary artery dis* or arrhythmia* or 
fibrillation or heart*flutter or heart failure or cardiomyopathy or angina or heart*infarc* or myocardial infarc* 
or heart attack or coronary infarc* or pericarditis or valvular*disease or valve disease or valve stenosis or valve 
insufficiency or revascular* or coronary bypass or artery bypass or aorta bypass or cardiopulmonary arrest* or 
cardiac arrest* or heart arrest* or cerebrovascular accident or stroke or tia or transient ischaemic attack or 
venous thromboembolism or deep*thrombo* or thromboem* or pulmonary embolism or peripheral vascular 
or peripheral art*  
Limits 
  English language 
 Human  
 Embase  
 1960 –Current year  
 Article or review 
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Appendix 2.3 - Bias assessment criteria – cohort studies 
 
Exposure 
 
Low  
 Minimum exposure period or need for several prescriptions before classified 
 Exposure ascertained through prescription or pharmacy records 
High 
 Exposure ascertainment not clearly defined, or defined by patient or physician 
recall 
 Future information used to inform exposure status at baseline 
 Potential for exposure misclassification due to no information of exposure prior 
to index 
 No minimum exposure period or need for several prescriptions 
 Non exposed or referent group from a different population to exposed  
Outcome Assessment 
Low  
 Well defined diagnosis using hospital records, GP diagnosis, or similar methods 
 Method of outcome ascertainment has been clearly validated  
High  
 Unclear method of diagnosis, or diagnosis defined by patient or physician recall 
 Potential for differential misclassification due to different methods of outcome 
ascertainment being used for different exposure groups 
Adjustments 
Low 
 IPTW adjustment for CVD risk factors, CVD related treatment, cancer severity, 
major non-CVD comorbidities, other cancer treatments 
 Adjustment for most or all of the risk factors outlined above at baseline 
High 
 Minimal adjustment for one or two of the risk factors outlined above at baseline 
 No adjustment  
Missing data 
Low  
 None or low percentage of missing data, or appropriate missing data technique 
used such as multiple imputation 
High 
 Substantial amount of missing data (>20%) with no methods applied to deal with 
missingness 
 A missing category fitted to deal with missing data 
Censoring 
Low 
 No censoring/loss to follow up  
 Appropriate method of adjustment or sensitivity analysis if censoring or loss to 
follow up present 
 Censoring unlikely to have impact on results 
High 
 No adjustment or additional analysis where censoring/loss to follow up may 
cause bias 
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Appendix 2.4 - Bias assessment criteria – case-control studies 
 
 
Case Definition 
Low 
 Well defined diagnosis using hospital records, GP diagnosis, or similar methods 
 Method of case definition ascertainment has been clearly validated  
High 
 Unclear method of diagnosis, or diagnosis defined by patient or physician recall 
 Potential for differential misclassification due to different methods of case 
ascertainment between exposure groups 
 Likely that outcome can occur at time that is not appropriate to risk period 
relative to exposure 
Control Selection 
Low 
 Controls comparable to and chosen from the same population as cases 
High 
 Controls systematically different to cases due to being selected from a different 
population, or have very different characteristics that have not been adjusted 
for 
Exposure Assessment 
 
Low  
 Exposure ascertained through prescription or pharmacy records 
 Same method for exposure ascertainment used for cases and controls 
High 
 Exposure ascertainment not clearly defined, or defined by patient or physician 
recall 
 Risk of misclassification due to incomplete records on past exposure 
 Potential for misclassification of exposure based on outcome, or different 
methods used for exposure ascertainment between cases and controls 
Adjustments 
Low 
 Detailed adjustment for CVD risk factors, CVD related treatment, cancer 
severity, major non-CVD comorbidities, other cancer treatments 
 Adjustment for most or all of the risk factors outlined above, in less detail 
High 
 Minimal adjustment for one or two of the risk factors outlined above 
 No adjustment  
 Risk factors ascertained through recall by patient or physician 
Missing data 
Low  
 None or low percentage of missing data, or appropriate missing data technique 
used 
High 
 Substantial amount of missing data (>20%) with no methods applied to deal with 
missingness 
 A missing category fitted to deal with missing data 
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Appendix 2.5 – Overview of included studies 
Author Meier Geiger Bradbury 
Year 1998 2004 2005 
Title 
Tamoxifen and risk of idiopathic venous thromboembolism Stroke risk and tamoxifen therapy for breast cancer Tamoxifen-treated breast carcinoma patients and the risk of 
acute myocardial infarction and newly-diagnosed angina 
Country UK USA UK 
Study Type Observational Observational Observational 
Data source GPRD Kaiser Permanente Southern California GPRD 
Study Design Case control Case control Nested case control 
Age <70 (at time of outcome) All patients 35-80 years old 
Inclusions 
Women who had a computer-recorded diagnosis of breast 
cancer in or after 1980 and who were hospitalised for a first-
time diagnosis of deep vein thrombosis or pulmonary 
embolism between January 1, 1991 and December 31, 1996. 
For each case, up to 10 control women with breast cancer 
were randomly selected, matched on age (within two years), 
duration of breast cancer (same year of breast cancer) and 
calendar year of VTE (same index date). Women were 
ineligible to be controls if they had—according to the 
computerized medical record—recurrent or metastatic breast 
cancer, died within 6 month after the index date, or 
underwent mastectomy, chemotherapy, radiotherapy, 
trauma, or major surgery within 6 months prior to the index 
date. 
All women with a first invasive breast cancer diagnosed at 
KPSC between January 1, 1980, and July 1, 2000. 
Women with a first-time diagnosis of breast carcinoma who 
were treated with tamoxifen or with bladder carcinoma, 
colorectal carcinoma, or non-melanoma skin cancer between 
January 1, 1991 and December 31, 1999. Women with other 
cancers (bladder, colorectal, and non-melanoma skin cancer), 
were selected to provide an unexposed population, because 
most women with breast carcinoma in the GPRD were treated 
with tamoxifen, and to increase the comparability of the 
exposure reference group to the tamoxifen-exposed group 
with respect to ongoing medical surveillance.  
Exclusions 
Any other malignancies besides breast cancer, a history of VTE 
or thrombophlebitis, stroke, angina pectoris, myocardial 
infarction, diabetes mellitus, chronic renal disease, 
hypertension, hyperlipidaemia, intermittent claudication, 
systemic lupus erythematosus, epilepsy, connective tissue 
disorders or cystic fibrosis. Furthermore, all potential cases 
were excluded if they underwent mastectomy, chemotherapy, 
radiotherapy, trauma (i.e. accident, bone fracture) or major 
Patients with a subsequent primary cancer diagnosis (other 
than a second primary breast cancer, cervical cancer in situ, or 
basal or squamous cell skin cancer) before their stroke 
diagnoses were excluded from the study because the other 
cancer could alter their breast cancer treatment or their 
stroke risk. Patients with thromboembolic disease diagnoses 
other than stroke (i.e., myocardial infarction, venous 
Women were excluded if they had a history of cancer, MI, 
angina pectoris, congestive heart failure, or HIV/acquired 
immunodeficiency syndrome before the study entry date. 
Women with known HIV infection were excluded because HIV 
infection may complicate cancer therapy, including adjuvant 
therapy. Women were required to have at least 1 year of 
recorded follow-up after their study entry date to assure 
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surgery (i.e. abdominal surgery, hip replacement) within 6 
months prior to the index date, who had recurrent or 
metastatic breast cancer, or who were in their terminal phase 
and died within 6 months after the index date (subjects who 
died from pulmonary embolism were included).  
thromboembolism, or pulmonary embolism) were excluded. adequate follow-up. 
Intervention arm 
Tamoxifen (any, currently exposed in VTE case-control analysis 
at index date) (n=133)  
Any tamoxifen (in stroke case-control analysis) (n=286) Current tamoxifen. Women who received 2 or more tamoxifen 
prescriptions within 1 year of their index date were 
considered current users   (n=49) 
Reference arm 
Never or past tamoxifen (in VTE case-control analysis at index 
date) (n=64) 
Unexposed to tamoxifen (in stroke case-control analysis). 
Unlikely to have been prescribed AIs due to study period being 
before approval of AIs (n=246) 
Unexposed to tamoxifen. Unlikely to have been prescribed AIs 
due to study period being before approval of AI  (n=158) 
Primary end point VTE Stroke (hospitalisation) Ischaemic heart disease diagnosis in primary care 
Follow up time 
Mean follow up  49.2 months (range 12-144) Mean at-risk period 68.4 months (standard deviation 54 
months) 
N/A 
Statistical methods 
(if available for CVD 
outcome) 
A matched analysis was conducted by using conditional 
logistic regression models, and relative risk estimates (odds 
ratios) of developing VTE with regard to current and past use 
were obtained, using never users as reference group.  
Case patients were compared with their individually matched 
control subjects using univariate and multivariable conditional 
logistic regression methods. Crude and adjusted odds ratios 
were estimated, and 95% confidence intervals were 
calculated. These analyses were limited to case patients who 
had their first stroke after their breast cancer diagnosis and 
their matched control subjects. 
The risk of IHD was assessed for current tamoxifen users and 
according to the dose-response measures among all cases 
combined and among cases stratified by diagnosis of angina or 
MI. Odds ratios and 95% CIs were estimated using conditional 
logistic regression modelling 
Adjustments 
Cases and controls matched on age (within two years), 
duration of breast cancer (same year of breast cancer) and 
calendar year of VTE (same index date). Then analyses 
adjusted for BMI ( < 30, 30+ kg m−2, unknown), smoking 
status (never, ex, current, unknown), and hysterectomy status 
(yes, no) 
Menopausal status (pre- or perimenopausal, naturally 
postmenopausal, or menopausal because of surgery); history 
of hypertension (no, yes but not requiring medication, and yes 
requiring medication); history of diabetes (no, yes but not 
requiring medication, and yes requiring medication); 
chemotherapy (yes, no)  
Cases and controls were matched on the date of the case’s 
IHD diagnosis, age (1 year), and study entry date (6 months). 
Analyses were further adjusted for BMI (kg/m2), treated 
hypertension, use of hormone replacement therapy, and 
smoking status. Information concerning these risk factors was 
ascertained from the data base on or before the index date 
Relative risk taken 
from paper, or 
calculated from raw 
numbers 
Paper Paper Paper 
CVDs outcome(s) Thromboembolic events Stroke Angina, MI 
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Author Geiger Hernandez Ligibel 
Year 2005 2009 2012 
Title 
Myocardial infarction risk and tamoxifen therapy for breast 
cancer 
Tamoxifen treatment and risk of deep venous thrombosis and 
pulmonary embolism: a Danish population-based cohort study 
Risk of myocardial infarction, stroke, and fracture in a cohort of 
community-based breast cancer patients 
Country USA Denmark USA 
Study Type Observational Observational Observational 
Data source Kaiser Permanente Southern California Danish Registries HealthCore Integrated Research Database 
Study Design Case control Cohort Cohort 
Age All patients 45-69 years old Post-menopausal 
Inclusions 
All women with a first invasive breast cancer diagnosed at 
KPSC between January 1, 1980, and July 1, 2000. 
Women eligible for the study were diagnosed with 
International Union Against Cancer stage I or stage II oestrogen 
receptor-positive breast cancer between 1990 and 2004 at 
ages 45 to 69 years, as reported to the Danish Breast Cancer 
Cooperative Group (DBCG) clinical database 
Women who were enrolled a minimum of 6–12 months before 
the first of at least 2 diagnosis codes for breast cancer during 
2001–2007 and women with no diagnosis codes for breast 
cancer who were used as controls 
Exclusions 
Patients with another cancer diagnosis (other than second 
primary breast cancer, cervical cancer in situ or basal or 
squamous cell skin cancer) or thromboembolic disease (stroke, 
venous thromboembolism or pulmonary embolism) occurring 
before their MI were excluded 
Women with no existing cardiovascular disease (defined using 
ICD-8 and ICD-10 codes) as of the date of breast cancer surgery 
Metastatic cancer 
Intervention arm 
Any tamoxifen (in MI case-control analysis) (n=216) Any tamoxifen during follow up (n=8232) Currently exposed to Tamoxifen (n=4710) or AI (n=9067). 
Patients who were simultaneously prescribed both drugs 
contributed analysis time to both the tamoxifen and AI group.  
Reference arm 
Unexposed to tamoxifen (in case-control analysis). Unlikely to 
have been prescribed AIs due to study period being before 
approval of AIs (n=165) 
Unexposed to tamoxifen. Unlikely to have been prescribed AIs 
due to study period being before approval of AIs (n=8057) 
Not currently exposed to either tamoxifen or AI therapy 
(n=29497) 
Primary end point 
Myocardial infarction (hospitalisation) DVT/PE (ICD-8 and -10 codes 45,099; 45,100; DI260; DI269; 
DI269A; DI801; DI802; DI802B; DI803; and DI803E) 
Myocardial infarction, ischemic stroke, and fractures 
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Follow up time 
Mean at-risk period 64.4 months (standard deviation 58.8 
months) 
Median follow up 48 months (range 0-174) Median follow up 30 months for breast cancer patients and 
33.5 months for non-breast-cancer patients 
Statistical methods 
(if 
applicable/available 
for CVD outcome) 
Case patients were compared with their individually matched 
control subjects using univariate and multivariable conditional 
logistic regression methods. Crude and adjusted odds ratios 
were estimated, and 95% confidence intervals were calculated. 
These analyses were limited to case patients who had their 
first stroke after their breast cancer diagnosis and their 
matched control subjects. 
Follow-up was initiated 3 months after the surgery date. 
Follow-up ended on December 31, 2005. Risks of events were 
analysed individually by year for the first 5 years of follow-up, 
and then cumulatively for Years 1 to 5. RRs and 95% 
confidence intervals were calculated as estimates of the 
association between tamoxifen therapy and incident 
thromboembolic events. Cox proportional hazards models 
were used to estimate crude HRs and adjusted HRs controlling 
for confounding, for years 1 to 5 individually, and for Years 5 to 
10 taken together. the proportional hazards assumption was 
tested by adding a covariate to the model to represent the 
interaction between exposure and the log of survival time 
Propensity score matching was used. Cox proportional hazards 
models with time varying treatment variables were used to 
assess whether treatment with AIs or tamoxifen was 
associated with MI and stroke among women with breast 
cancer and to assess the association of breast cancer with the 
outcomes of interest. The time-varying treatment variables 
allowed women to contribute information to the treatment 
group when on treatment and to the control group when not 
on treatment; women who received both AIs and tamoxifen 
contributed to both groups. For each outcome event, women 
were followed from the time of their first diagnosis code only 
until the occurrence of the event or the censoring of their 
observation.  
Adjustments 
Menopausal status (pre- or perimenopausal, naturally 
postmenopausal, or menopausal because of surgery); history 
of hypertension (no, yes but not requiring medication, and yes 
requiring medication); history of diabetes (no, yes but not 
requiring medication, and yes requiring medication); 
chemotherapy (yes, no)  
Age, surgical procedures (other than breast cancer surgery), 
metastatic tumours other than breast cancer, radiotherapy, 
chemotherapy, diabetes, stroke, chronic obstructive 
pulmonary disease, and heart failure were assessed at baseline 
Age, census region, index year, Charlson index, number of drug 
classes used, statin use at baseline, PPI use at baseline, 
insurance produce, urban/rural residence, median household 
income in zip code, % in high school education in zip, % blacks 
in zip, % Hispanics in zip. 
Relative risk taken 
from paper, or 
calculated from raw 
numbers 
Paper Paper Paper 
CVD outcome(s) MI Thromboembolic events Stroke, MI 
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Author Chen Yang Abdel-Qadir 
Year 2014 2014 2016 
Title 
No increased venous thromboembolism risk in Asian 
breast cancer patients receiving adjuvant tamoxifen 
Association of tamoxifen use and reduced cardiovascular events 
among Asian females with breast cancer 
The risk of myocardial infarction with aromatase inhibitors 
relative to tamoxifen in post-menopausal women with early 
stage breast cancer 
Country Taiwan Taiwan Canada 
Study Type Observational Observational Observational 
Data source Taiwan Cancer Registry Database NHI Research Database Taiwan Canadian administrative databases 
Study Design Cohort Cohort Cohort 
Age All patients All patients Post-menopausal 
Inclusions 
Diagnosed with stage I, II, or III breast cancer, according to 
the American Joint Committee on Cancer staging system 
(sixth version) criteria between January 1, 2004 and 
December 31, 2009; and received curative breast cancer 
surgery (lumpectomy or mastectomy) within 1 year after 
diagnosis 
Patients who were newly diagnosed with breast cancer Women with a first diagnosis of stage I-III breast cancer r 
between January 1, 2005 and December 
31, 2010, who were dispensed a prescription for tamoxifen, or 
an aromatase inhibitor (i.e. anastrozole, letrozole or 
exemestane) within 1 year of cancer diagnosis, along with a 
second prescription dispensed within 1.5-times the number of 
days of the preceding prescription’s supply 
Exclusions 
Women with history of other types of cancer or multiple 
primary invasive breast cancer; the presence of lymphoma 
(ICD-O-3 morphology code, 9590-9989), Kaposi’s sarcoma 
(ICD-O-3 morphology code, 9140), and phyllodes tumour 
(IDC-O-3 morphology code, 9020) of the breast; received 
tamoxifen treatment prior to the operation date; and 
death within 28 days after the operation. 
Patients with pre-existing cardiovascular disease, such as 
coronary artery disease, ischemic stroke, haemorrhagic stroke or 
peripheral artery disease  were excluded 
Women were excluded if they were treated with tamoxifen or 
AIs in the year preceding breast cancer diagnosis. Women were 
also excluded if they had substantial exposure to both tamoxifen 
and an aromatase inhibitor. This was defined as >10% of the 
days during which either tamoxifen or an aromatase inhibitor 
was prescribed. Accordingly, women were only included if they 
were exposed to one of the drug categories for 90% of the days 
during which a study drug was dispensed. 
Intervention arm 
At least one tamoxifen prescription after the index date  
(n=17874) 
at least one tamoxifen prescription associated with the breast 
cancer diagnosis (n=2056) 
Aromatase inhibitors at index date (n=7049). Patients were 
analysed based on the drug category they were predominantly 
exposed to. 
Reference arm 
No tamoxifen prescriptions after the index date (n=10155). 
No information about AI prescriptions.  
No tamoxifen (n=1634). No information about AI prescriptions.  Tamoxifen at index date (n=1941) 
Primary end point 
Deep vein thrombosis/Pulmonary embolism. DVT 
estimates used in systematic review results 
AMI, ischemic stroke, haemorrhagic stroke and total 
cardiovascular events 
Myocardial infarction (hospitalisation) 
Follow up time Median follow up 48 months (range 0 -96) Mean follow up 82.8 months Mean follow up 39.9 months 
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Statistical methods (if 
applicable/available for 
CVD outcome) 
Outcomes were compared using the Cox proportional 
hazard model for estimating hazard ratios and 95 % 
confidence intervals. 
Survival analysis was assessed using Kaplan-Meier analysis, with 
the significance based on the log-rank test. The survival time was 
calculated from the date of enrolment to the development of 
AMI, ischemic stroke or haemorrhagic stroke. Multiple regression 
analysis was carried out using Cox proportional hazard regression 
analysis to evaluate the effect of tamoxifen use on determining 
the occurrence of AMI, stroke, or total cardiovascular events. 
Time-to-event analyses were performed for MI, using tamoxifen 
as the reference treatment. Cumulative incidence function 
curves were used to estimate the cumulative incidence of MI 
over time after accounting for the competing risk of death. This 
allowed us to estimate the incidence of MI, given that some 
subjects will die before the occurrence of a cardiac event. IPTW 
using the propensity score was used to reduce the effects of 
measured confounding variables when estimating the effect of 
AIs versus tamoxifen. The PS model was estimated using a 
logistic regression model with receipt of AIs as the dependent 
variable and all covariates as the independent or explanatory 
variables. The variables that were chosen included markers of 
cardiovascular disease, cardiovascular risk factors, cancer 
severity, major non-cardiovascular co-morbidities, health care 
utilisation, factors that increase risk of adverse cardiac events 
with breast cancer (left-sided disease, chemotherapy, 
trastuzumab, radiation), as well as medications that could 
impact risk of cardiovascular disease. Truncated weights were 
used to minimise undue influence from atypical individuals with 
very high weights. The distribution of measured baseline 
covariates was compared between treatment groups in the 
sample weighted by the inverse probability of treatment using 
standardised differences. Variables were determined to be well 
balanced if the standardised difference was 
Adjustments 
Congestive heart failure, rheumatic disease, renal disease, 
diabetes mellitus, hypertension, Charlson comorbidity 
index. Patients had to have been diagnosed with the 
comorbidity within 1 year prior to the index date. 
Information was obtained from the NHI database, and all 
of the diagnoses were identified from either a single report 
in the inpatient medicinal claims file or from no less than 
two reports in the outpatient medicinal claims files 
Diabetes mellitus, cardiac arrhythmia, hyperlipidaemia, 
congestive heart failure, and chronic obstructive pulmonary 
disease, 365 days before the date of diagnosis of breast cancer. 
The diagnosis code of any comorbidity must have appeared at 
least twice and lasted longer than 30 days before officially being 
regarded as a comorbidity. Medications before enrolment were 
also reviewed within the database, which included angiotensin-
converting enzyme inhibitors, β-adrenergic antagonists, calcium-
channel blockers, diuretics, statins, antiplatelet agents (aspirin or 
clopidogrel) and thiazides. 
Factors used in IPTW were: age, income quintile, rural residence, 
year of cohort entry, breast cancer side, chemotherapy, 
radiation, trastuzumab, CVD (other than MI), diabetes, 
dyslipidaemia, hypertension, venous thromboembolism, 
fracture, renal disease, dialysis, prior malignancy, Charlson 
index, primary care visits in past year, specialist visits in past 
year, total physician visits in past year, medications dispensed in 
past year, ACE inhibitor, ARB, aspirin,  thienopyridines, beta-
blockers, calcium channel blockers, digoxin, aldosterone 
antagonists, diuretics, statins, oral hypoglycaemics, insulin, 
vitamin K antagonists, low molecular weight heparin, nitrates, 
NSAIDs 
Relative risk taken from 
paper, or calculated 
from raw numbers 
Paper Paper Paper 
CVD outcome(s) Thromboembolic events Stroke, MI MI 
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Author Haque Rutqvist McDonald 
Year 2016 1993 1995 
Title 
Cardiovascular Disease After Aromatase Inhibitor Use Cardiac and thromboembolic morbidity among 
postmenopausal women with early-stage breast cancer in 
a randomized trial of adjuvant tamoxifen. The Stockholm 
Breast Cancer Study Group 
Cardiac and vascular morbidity in women receiving adjuvant tamoxifen 
for breast cancer in a randomised trial. The Scottish Cancer Trials Breast 
Group 
Country USA Sweden Scotland 
Study Type Observational RCT RCT 
Data source Kaiser Permanente Southern California   
Study Design Cohort   
Age Post-menopausal Post-menopausal <80 years old 
Inclusions 
Women with a first diagnosis of primary breast cancer 
between 1991 and 2010 and observed them through 
December 2011. For eligibility, women had to have 
pharmacy benefits, and have oestrogen– or 
progesterone receptor–positive breast cancer. 
Histologically verified invasive breast cancer, and no 
previous history of cancer 
Early invasive breast cancer suitable for mastectomy 
Exclusions 
Prior CVD (cardiac ischemia (acute myocardial 
infarction 
and angina), stroke, heart failure and cardiomyopathy, 
and other events (dysrhythmia, valvular dysfunction, 
and pericarditis)) 
Inoperable local disease or distant metastasis at the time 
of primary diagnosis, other concurrent cancers, medical 
contraindications to the therapy, and operation which 
deviated from the protocol 
T4, N2, N3 or Mi lesions, more than one palpable malignant lesion or 
bilateral breast cancer, In-situ carcinoma (including Paget’s disease) 
without proof of underlying or associated invasive carcinoma, Patients 
who were or wished to become pregnant, Those unwilling to discontinue 
unrelated hormone therapy including the contraceptive pill, Previous 
malignant disease other than successfully treated squamous or basal cell 
carcinoma of skin, Previous systemic therapy for breast cancer, Any cause 
likely to compromise adequate review, premenopausal women with 
proven involvement of axillary lymph nodes who were enrolled in a trial 
comparing ovarian ablation with chemotherapy as adjuvant treatment 
Intervention arm Current aromatase inhibitors only (n=3807) Tamoxifen (40mg) daily for 2 years (n=203) 20mg tamoxifen daily for 5 years (n=661) 
Reference arm 
Current tamoxifen only (n=4207) No tamoxifen (n=219). Unlikely to have been prescribed 
AIs due to study period being before approval of AIs. 
No tamoxifen (n=651). Unlikely to have been prescribed AIs due to study 
period being before approval of AIs.  
Primary end point 
CVD events (cardiac ischemia (acute myocardial 
infarction 
and angina), stroke, heart failure and cardiomyopathy, 
Cardiac and thromboembolic morbidity Adverse events, including CVD 
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and other events (dysrhythmia, valvular dysfunction, 
and pericarditis) 
Follow up time 
72886 person-years of follow-up Median follow up 60 months 5 years of tamoxifen, then could be randomized to receive more 
tamoxifen after this 
Statistical methods (if 
applicable/available for 
CVD outcome) 
Follow-up commenced on the breast cancer diagnosis 
date and ended on the date of one of the study end 
points (first CVD diagnosis date, death, termination of 
health plan membership, or study’s end [December 
31, 2011]), whichever occurred first. Hazard ratios 
(HRs) and 95% CIs were estimated using 
Cox proportional hazards models with time-
dependent medication use variables 
All analyses were on the basis of "intention to treat." All 
patient data were analysed according to the allocated 
treatment regardless of whether the patient actually 
received that treatment. No patient randomly assigned to 
treatment was excluded from analysis.  Number of 
outcomes reported for adverse events.  
Cox proportional hazards with censoring at date of systemic relapse, 
death, or at follow up to 31 December 1992. 
Adjustments 
Age at diagnosis, diagnosis year, breast cancer stage, 
race/ethnicity (from the SEER registry), geocoded 
median household income, body mass index, medical 
centre, tumour characteristics, and primary cancer 
treatment (surgery, radiotherapy, and 
chemotherapy). Comorbidities, captured in the year 
before breast cancer diagnosis, included 
hypertension, diabetes mellitus, and the Charlson 
comorbidity index score. Data on pharmacy use 
related to CVD therapy and/or prevention were also 
extracted. These drug covariates were coded as binary 
(ever or never) 
  
Relative risk taken from 
paper, or calculated from 
raw numbers 
Paper Calculated Calculated (HR calculated, but using incorrect reference group) 
CVD outcome(s) MI Stroke, Heart failure MI, Thromboembolic events 
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Author Fisher Fisher Jakesz 
Year 1999 2001 2005 
Title 
Tamoxifen in treatment of intra-ductal breast cancer: 
National Surgical Adjuvant Breast and Bowel Project B-24 
randomised controlled trial 
Tamoxifen and chemotherapy for axillary node-negative, 
oestrogen receptor-negative breast cancer: findings from 
National Surgical Adjuvant Breast and Bowel Project B-23 
Switching of postmenopausal women with endocrine-
responsive early breast cancer to anastrozole after 2 years' 
adjuvant tamoxifen: combined results of ABCSG trial 8 and 
ARNO 95 trial 
Country USA USA and Canada Europe 
Study Type RCT RCT RCT 
Data source    
Study Design    
Age All patients All patients Post-menopausal 
Inclusions 
Women with DCIS were eligible for inclusion if their life 
expectancy was at least 10 years. Women with tumours 
that also consisted of DCIS and lobular carcinoma in situ 
(LCIS) were eligible. Women had to undergo lumpectomy.  
primary operable, histologically node-negative, ER-
negative breast cancer and a life expectancy of at least 
10 years 
Eligible patients were postmenopausal women aged 80 years 
or younger (ABCSG trial 8) or 75 years or younger (ARNO 95) 
with histologically verified, locally radically treated invasive or 
minimally invasive breast cancer without previous 
chemotherapy, hormone therapy, or radiotherapy, and 
absence of organ metastases. Women must have had 2yrs of 
tamoxifen (20mg ) daily. 
Exclusions 
Women who had previously been diagnosed with cancer, 
except for those who had had in-situ carcinoma of the 
cervix or squamous-cell or basal-cell carcinoma of the skin, 
were not eligible. 
No information given indeterminate menopausal status (or menopausal status 
maintained by medication), presence of secondary malignant 
disease, tumour infiltration of skin or breast muscle (T4 
tumours), and presence of other concomitant serious medical 
conditions— eg. those involving bone marrow function, the 
central nervous system, uncompensated cardiac insufficiency, 
or uncontrolled local or systemic infection. 
Intervention arm 
Radiation therapy followed by tamoxifen (10mg) twice daily 
for 5yrs (n=891) 
CMF and tamoxifen (10 mg) twice a day (n=498) Anastrozole (1mg) daily for remainder of 5-year endocrine 
treatment following 2 years of tamoxifen (n=1602). Follow up 
began after initial tamoxifen.  
Reference arm Radiation therapy followed by placebo (n=890). Unlikely to 
have been prescribed AIs due to study period being before 
CMF and placebo (n=499). Unlikely to have been 
prescribed AIs due to study period being before approval 
Tamoxifen (20mg) daily for remainder of 5yr endocrine 
treatment following 2 initial years of tamoxifen (n=1597). 
 
191 
 
approval of AIs. of AIs. Follow up began after initial tamoxifen. 
Primary end point Disease free survival Disease free survival Disease free survival 
Follow up time Median follow up 74 months (range = 57-93 months) Mean follow up 65 months (range 10 to 102 months) Median follow-up 28 months (95% CI: 26–30) 
Statistical methods 
(if applicable 
/available for CVD 
outcome) 
Number of outcomes reported for adverse events.  Number of outcomes reported for adverse events.   Adverse events were only counted once per patient, and are 
described with absolute frequencies and proportions. 
Differences in the adverse event rates were estimated with 
exact odds ratios (OR) and corresponding 95% CIs. Exact ORs 
stratified by country were calculated for the five types of 
serious adverse events available for Austrian and German 
patients (myocardial infarct, embolism, thromboses, fractures, 
and endometrial cancer). 
Adjustments    
Relative risk taken 
from paper, or 
calculated from raw 
numbers 
Calculated Calculated Paper 
CVD outcome(s) Stroke, MI, Thromboembolic events Thromboembolic events Thromboembolic events, MI 
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Author Goss Boccardo Coombes 
Year 2005 2006 2007 
Title 
 Randomized Trial of Letrozole Following Tamoxifen as 
Extended Adjuvant Therapy in Receptor-Positive Breast 
Cancer: Updated Findings from NCIC CTG MA.17 
Switching to anastrozole versus continued tamoxifen 
treatment of early breast cancer. Updated results of 
the Italian tamoxifen anastrozole (ITA) trial 
Survival and safety of exemestane versus tamoxifen 
after 2-3 years' tamoxifen treatment (Intergroup 
Exemestane Study): a randomised controlled trial 
Country Canada Italy UK 
Study Type RCT RCT RCT 
Data source    
Study Design    
Age Post-menopausal Post-menopausal All patients 
Inclusions 
Previous adjuvant tamoxifen therapy lasting 4.5 – 6 years; 
histologically confirmed primary breast cancer; a tumour 
that was positive for oestrogen receptor, progesterone 
receptor, or both (defined by a level of 10 fmol/mg protein 
or a positive result on immunohistochemical analysis of ER 
or PR); discontinuation of tamoxifen therapy less than 3 
months before enrolment; an Eastern Cooperative 
Oncology Group performance status of 0, 1, or 2 (scored on 
a scale of 0 to 4, with lower scores indicating better 
function); a life expectancy of more than 5 years; and 
postmenopausal status. Women were defined as being 
postmenopausal if they were at least 50 years of age at the 
start of adjuvant tamoxifen therapy, were younger than 50 
years at the start of tamoxifen therapy but postmenopausal 
at the initiation of tamoxifen therapy, were younger than 
50 years at the start of tamoxifen therapy but had 
undergone bilateral oophorectomy, were premenopausal 
and younger than 50 years of age at the start of tamoxifen 
therapy but became amenorrheic during chemotherapy or 
treatment with tamoxifen, or were any age but had 
postmenopausal levels of luteinizing hormone or follicle-
stimulating hormone prior to study enrolment. Women 
with unknown hormone receptor status were eligible, 
provided an effort was made to determine the receptor 
status of the primary tumour. 
Histologically confirmed primary breast cancer, tumour 
oestrogen receptor positivity , positive axillary nodes, 
and no evidence of recurrent or metastatic disease, 
who were receiving adjuvant treatment with tamoxifen 
for the last 2–3 years 
Patients were eligible if they had histologically 
confirmed, completely resected unilateral invasive 
breast carcinoma that was positive for oestrogen 
receptors or that was of unknown receptor status. 
Patients were postmenopausal and had received 
adjuvant tamoxifen therapy for at least two years but 
not more than three years and one month. Patients 
were required to have adequate hematologic, renal, 
and liver function at the time of randomization. b     
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Exclusions 
No information given Patients with a history or presence of any other cancer 
(except adequately treated skin cancer or carcinoma-
in-situ of the cervix) and patients with any condition 
that may jeopardize their compliance to treatment or 
follow-up 
The presence of a tumour with known negative 
oestrogen-receptor status; evidence of local relapse or 
a distant metastasis since the time of diagnosis; a 
clinically significant skeletal, cardiac, or endocrine 
disorder; and the use of hormone-replacement therapy 
within four weeks before randomization. Patients were 
also excluded if they had clinical evidence of severe 
osteoporosis or a history of a previous neoplasm other 
than carcinoma in situ of the cervix or basal-cell skin 
carcinoma or if they were taking concomitant 
anticoagulant agents, a selective oestrogen-receptor 
modulator other than tamoxifen, or any other form 
of hormonal therapy. 
Intervention arm 
Letrozole (2.5mg) daily for 5 years, following previous 
adjuvant tamoxifen for 4.5-6 years. Follow up began after 
initial tamoxifen. 
1mg of anastrozole daily for remainder of 5yr 
endocrine treatment following 2-3yrs of tamoxifen 
(n=223). Follow up began after initial tamoxifen. 
Exemestane (25mg) daily for remainder of 5yr 
endocrine treatment following 2-3 years of tamoxifen 
(n=2320). Follow up began after initial tamoxifen. 
Reference arm 
Placebo daily for 5 years, following previous adjuvant 
tamoxifen for 4.5-6 years. Follow up began after initial 
tamoxifen. 
20mg of tamoxifen daily for the remainder of their 5yr 
endocrine treatment following 2-3 initial yrs of 
tamoxifen (n=225). Follow up began after initial 
tamoxifen. 
Tamoxifen (20 or 30mg) daily for the remainder of 
their of 5yr endocrine treatment following 2-3 initial 
years of tamoxifen (n=2338). Follow up began after 
initial tamoxifen. 
Primary end point Disease free survival Disease free survival Disease free survival 
Follow up time Median follow-up 30 months (range 1.5 - 61.4 months) Median follow up 64 months (range = 12-92 months) Median follow up 55.7 months (range = 0-89.7 months) 
Statistical methods 
(if available for CVD 
outcome) 
Number of outcomes reported for adverse events.   Number of outcomes reported for adverse events.   Number of outcomes reported for adverse events.    
Adjustments    
Relative risk taken 
from paper, or 
calculated from raw 
numbers 
Calculated Calculated  Calculated 
CVD outcome(s) Angina, Stoke, MI, Thromboembolic events Thromboembolic events MI, PVD 
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Author Kaufmann  Forbes Abo-Touk 
Year 2007  2008 2010 
Title 
Improved survival in postmenopausal 
women with early breast cancer after 
anastrozole initiated after treatment with 
tamoxifen compared with continued 
tamoxifen: The ARNO 95 study 
 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage 
breast cancer: 100-month analysis of the ATAC trial 
Switching to Letrozole Versus Continued 
Tamoxifen Therapy in Treatment of 
Postmenopausal Women with Early Breast 
Cancer 
Country Germany  International Egypt 
Study Type RCT  RCT RCT 
Data source     
Study Design     
Age Post-menopausal  Post-menopausal Post-menopausal 
Inclusions 
Women with histologically verified, grade 
1 to 3 invasive breast cancer (pT1-3, node 
negative, or up to nine tumour-infiltrated 
lymph nodes [pN0-2] and no distant 
metastases), who had undergone primary 
surgery (with or without radiotherapy) 
and had received 2 years of continuous 
adjuvant tamoxifen (20 or 30 mg/d) with 
disease recurrence 
 women with histologically proven operable invasive breast cancer who had 
completed primary surgery and chemotherapy (where given), and were 
candidates to receive hormonal adjuvant therapy. Patients with negative or 
unknown hormone-receptor status were included because hormone-
receptor-negative patients were thought to derive benefit from adjuvant 
therapy with a hormonal agent. 
Histologically confirmed operable invasive 
early breast carcinoma with positive 
oestrogen, or progesterone receptors, or 
both. Primary surgery was modified radical 
mastectomy or breast conserving surgery 
with axillary lymph-node dissection with 
resulting clear margins. There was no 
evidence of metastatic or recurrent disease; 
previous or concurrent cancer. Adequate 
hematologic, renal and hepatic functions 
were required 
Exclusions 
No information given  Patients were ineligible if there was any clinical evidence of metastatic 
disease; if chemotherapy was started more than 8 weeks after surgery or 
completed more than 8 weeks before starting randomised treatment (neo-
adjuvant chemotherapy was not allowed) or, in patients not receiving 
chemotherapy, if primary surgery was completed more than 8 weeks 
before starting randomised treatment; or if they had received hormonal 
therapy for breast-cancer prevention or for adjuvant treatment of breast 
cancer (except if tamoxifen treatment was started before surgery and 
received for less than 29 days, or if hormonal therapy was received before 
surgery in the context of a formal trial previously approved by the Steering 
Committee). Patients were not eligible if they were unwilling to stop any 
hormonal drug including HRT; if they had a previous history of invasive 
No information given 
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malignant disease (breast cancer at any time, other malignant disorders 
within the past 10 years excluding squamous or basal-cell carcinoma of the 
skin or carcinoma in situ of the cervix, adequately cone biopsied); or if the 
patient had any severe concomitant disease which would place the patient 
at unusual risk or confound the results of the trial. Patients were included o 
Intervention arm 
Tamoxifen (20 or 30mg) daily for 2 years 
followed by anastrozole (1mg) daily for 
another 3 years (n=445). Follow up began 
after initial tamoxifen. 
 Anastrozole only after surgery (n=3125) Tamoxifen (20mg) daily for 2 years followed 
by letrozole (2.5mg) daily for another 3 
years. Follow up began after initial 
tamoxifen. 
Reference arm 
Tamoxifen (20 or 30mg) daily for the 
remainder of their 5yr endocrine 
treatment following 2 years of initial 
tamoxifen (n=452). Follow up began after 
initial tamoxifen. 
 Tamoxifen only after surgery  (n=3116) Tamoxifen (20mg) daily for 3 years following 
2 years initial tamoxifen. Follow up began 
after initial tamoxifen. 
Primary end point Disease free survival  Disease free survival Disease free survival 
Follow up time 
Median follow up 30.1 months  Median follow up 100 months (range 0–126) Median follow up 41 months (range 15 to 62 
months)  
Statistical 
methods (if 
available for CVD 
outcome) 
Number of outcomes reported for 
adverse events.   
 Side-effects were summarised according to the hormone treatment first 
received. Except for other cancers, side-effect events were accrued up to 
14 days after stopping treatment. Information on new primary cancers was 
collected during and after trial treatment (before and after recurrence), but 
only summarised up to the point of recurrence. The comparisons of pre-
specified adverse events were based on a simple comparison of 
proportions, and Fisher’s exact two-sided p values were used when 
necessary. 
Number of outcomes reported for adverse 
events.   
Adjustments     
Relative risk taken 
from paper, or 
calculated from 
raw numbers 
Calculated  Calculated Calculated 
CVD outcome(s) Stroke  Stroke, MI, Thromboembolic events Stroke 
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Author Colleoni van de Velde Bliss 
Year 2011 2011 2012 
Title 
Analyses Adjusting for Selective Crossover Show 
Improved Overall Survival With Adjuvant Letrozole 
Compared With Tamoxifen in the BIG 1-98 Study 
Adjuvant tamoxifen and exemestane in early breast 
cancer (TEAM): a randomised phase 3 trial 
Disease-related outcomes with long-term follow-up: an 
updated analysis of the intergroup exemestane study 
Country International Europe International 
Study Type RCT RCT RCT 
Data source    
Study Design    
Age Post-menopausal Post-menopausal Post-menopausal 
Inclusions 
Patients were eligible for the study if they had tumours 
that were positive for oestrogen receptors, progesterone 
receptors, or both. Primary surgery with resulting clear 
margins and adequate hematologic, renal, and hepatic 
function were required. 
Histologically confirmed breast adenocarcinoma and 
locally assessed oestrogen-receptor-positive or 
progesterone-receptor-positive disease who had 
completed local treatment administered with curative 
intent.  Other eligibility criteria were invasive tumours of 
all sizes, with or without involvement of the lymph nodes 
(N0 to N3) and no evidence of metastatic disease. 
ER–positive/ER-unknown primary invasive breast cancer 
who remained disease-free and on treatment after 2 to 3 
years of tamoxifen, with adequate hematologic, renal, 
and liver function at the time of randomization 
Exclusions 
Evidence of metastatic disease; previous or concurrent 
cancer other than adequately treated non-invasive breast 
or cervical cancer or basal-cell or squamous-cell 
carcinoma of the skin within 5 years before 
randomization; receipt of adjuvant antioestrogen therapy 
for the primary breast cancer for at least 1 month; and 
treatment with systemic investigational drugs within 30 
days before randomization or topical investigational 
drugs within 7 days before randomization. 
Patients were excluded if they had substantial cardiac 
disease, other malignant diseases, or illnesses interfering 
with participation in the study. Further details have been 
previously reported. 
Presence of a tumour with known negative oestrogen-
receptor status; evidence of local relapse or a distant 
metastasis since the time of diagnosis; a clinically 
significant skeletal, cardiac, or endocrine disorder; and 
the use of hormone-replacement therapy within four 
weeks before randomization. Patients were also excluded 
if they had clinical evidence of severe osteoporosis or a 
history of a previous neoplasm other than carcinoma in 
situ of the cervix or basal-cell skin carcinoma or if they 
were taking concomitant anticoagulant agents, a 
selective oestrogen-receptor modulator other than 
tamoxifen, or any other form of hormonal therapy. The 
protocol required adequate treatment of primary 
disease, including postoperative radiotherapy 
in patients who had been treated with breast-preserving 
surgery. Neo-adjuvant chemotherapy was permitted 
according to a consistent policy within each centre. 
Patients were required to have started chemotherapy 
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within three months after diagnosis and to have begun 
receiving tamoxifen and radiotherapy within three 
months after the completion of chemotherapy. 
Intervention arm 
1) Letrozole (2.5mg) daily for 2 years followed by 
tamoxifen (25mg) daily for 3 years (n=1540), 2) 
Tamoxifen (25mg) daily for 2 years followed by letrozole 
(2.5mg) daily for 3 years (n=1548). Follow up began after 
initial 2 year treatment.. 
Tamoxifen (20 mg) daily for 2-3yrs followed by 
Exemestane (25 mg) daily for the remainder of the 5yrs 
(n=4868). Follow up for the whole period.  
25mg of exemestane daily for remainder of 5yr 
endocrine treatment following 2-3 years of tamoxifen 
(n=2105). Follow up began after initial tamoxifen. 
Reference arm 
1) Only tamoxifen (25mg) daily for 5 years (n=1548), 2) 
Only letrozole (2.5mg) daily for 5 years (n=1546). Follow 
up began after initial 2 year treatment. 
Exemestane (25 mg) daily for 5yrs (n=4898). Follow up 
for the whole period. 
20 or 30mg of tamoxifen daily for the remainder of their 
of 5yr endocrine treatment following 2-3 initial years of 
tamoxifen (n=2036). Follow up began after initial 
tamoxifen. 
Primary end point Disease free survival Disease free survival Disease free survival 
Follow up time Media follow up 74 months Median follow-up 5·1 years Median follow up 91 months (IQR=83-99.2 months) 
Statistical methods 
(if available for CVD 
outcome) 
Selective crossover then number of outcomes reported 
for adverse events.   
Number of outcomes reported for adverse events.   Kaplan-Meier plots, log-rank tests, and Cox proportional 
hazards models were used. 
Adjustments    
Relative risk taken 
from paper, or 
calculated from raw 
numbers 
Calculated Calculated Paper 
CVD outcome(s) Stroke, Heart failure, Thromboembolic events Arrhythmia, Heart failure, MI, Thromboembolic events Angina, Thromboembolic events 
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Author Pagani Hernandez 
Year 2014 2008 
Title Adjuvant Exemestane with Ovarian Suppression in 
Premenopausal Breast Cancer 
Tamoxifen Treatment in Danish Breast Cancer Patients 
and 5-Year Risk of Arterial Atherosclerotic Events: A Null 
Association 
Country International Denmark 
Study Type RCT Observational 
Data source  Danish Registries 
Study Design  Cohort 
Age Pre-menopausal 45-69 years old 
Inclusions 
Histologically proven operable breast cancer confined to 
the breast and ipsilateral axilla, with the exception of 
internal-mammary-node involvement detected by means 
of sentinel-node biopsy, and tumour that expressed 
oestrogen or progesterone receptors in at least 10% of 
the cells, as assessed with the use of 
immunohistochemical testing. Patients with synchronous 
bilateral hormone-receptor–positive breast cancer were 
eligible. Patients had undergone either a total 
mastectomy with subsequent optional radiotherapy or 
breast-conserving surgery with subsequent radiotherapy. 
Either axillary dissection or a negative sentinel-node 
biopsy was required. Macrometastasis in a sentinel node 
required axillary dissection or irradiation. 
Women eligible for the study were diagnosed with 
International Union Against Cancer stage I or stage II 
oestrogen receptor-positive breast cancer between 1990 
and 2004 at ages 45 to 69 years, as reported to the 
Danish Breast Cancer Cooperative Group (DBCG) clinical 
database 
Exclusions 
 
Women with no existing cardiovascular disease (defined 
using ICD-8 and ICD-10 codes) as of the date of breast 
cancer surgery 
Intervention arm 
In the TEXT study, 5 yrs of exemestane (25mg daily) plus 
triptorelin. In the SOFT study 5 yrs of exemestane plus 
ovarian suppression. Any tamoxifen during follow up (n=8232) 
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Reference arm 
In the TEXT study 5 yrs of tamoxifen (20mg daily) plus 
triptorelin. In the SOFT study 5 yrs of tamoxifen plus 
ovarian suppression.  
Unexposed to tamoxifen. Unlikely to have been 
prescribed AIs due to study period being before approval 
of AIs (n=8057) 
Primary end point Disease free survival Angina, MI, HF, stroke 
Follow up time Median follow up of 68 months Not reported 
Statistical methods 
(if available for CVD 
outcome) 
Number of outcomes reported for adverse events.   
Follow-up was initiated 3 months after the surgery date. 
Follow-up ended on December 31, 2005. Risks of events 
were analysed individually by year for the first 5 years of 
follow-up, and then cumulatively for Years 1 to 5. RRs 
and 95% confidence intervals were calculated as 
estimates of the association between tamoxifen therapy 
and incident CVD events. Cox proportional hazards 
models were used to estimate crude HRs and adjusted 
HRs controlling for confounding, for years 1 to 5 
individually, and for Years 5 to 10 taken together. The 
proportional hazards assumption was tested by adding a 
covariate to the model to represent the interaction 
between exposure and the log of survival time 
Adjustments 
 
Age group, diabetes, renal disease, hypertension, chronic 
obstructive pulmonary disease, radiation therapy, and 
chemotherapy 
Relative risk taken 
from paper, or 
calculated from raw 
numbers Calculated Paper 
CVD outcome(s) Stroke, MI, Thromboembolic events Angina, stroke, MI, heart failure 
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Appendix 2.6 – Bias assessment of RCTs 
Study Random sequence 
generation 
Allocation concealment Blinding Incomplete outcome 
data 
Selective reporting Other sources of bias 
Bliss 2012 1 - permuted blocks 0 1 - double blinded 1 - All patients included 1 - CVD events were 
coded according to 
criteria specified by an 
independent cardiologist 
1 - No other risks of bias 
Boccardo 2006 0 0 0 1 - All patients included 0 1 - No other risks of bias 
Coombes 2007 1 - permuted blocks 0 1 - double blinded 1 - 95% had full follow 
up 
0 1 - No other risks of bias 
Fisher 1999 0 0 0 1 - All patients included 0 1 - No other risks of bias 
Fisher 2001 1- biased coin 0 0 1 - 98% had full follow 
up 
0 1 - No other risks of bias 
Forbes 2008 1 - randomisation by 
computer 
1 - central allocation 0 0 0 1 - No other risks of bias 
Jakesz 2005 1 - randomisation by 
computer 
1 - central allocation 2 - open label trials  0 0 1 - No other risks of bias 
Kaufmann 2007 1 - randomisation by 
computer 
1 - central allocation 0 1 - 6 patients 
discontinued 
0 1 - No other risks of bias 
McDonald 1995 0 0 0 0 0 1 - No other risks of bias 
Colleoni 2011 1 - permuted blocks 0 1 - double blinded 1 - All patients included 0 1 - No other risks of bias 
Rutqvist 1993 0 0 0 1 - Outcome data taken 
from registries 
0 1 - No other risks of bias 
van de Velde 
2001 
1 - randomisation by 
computer 
1 - Only statistician and 
steering committee had 
access to unmasked data 
2 - open label trial 0 0 1 - No other risks of bias 
Abo-Touk 2010 1 - simple 
randomisation method 
0 0 1 - All patients included 0 1 - No other risks of bias 
Goss 2005 1 - minimisation 
method 
0 1 - double blinded 1 - All patients included 0 1 - No other risks of bias 
Pagani 2014 1 - permuted blacks 0 2 - open label trials  1 - All patients included 0 1 - No other risks of bias 
Bias assessment categories      
0 - No information given      
1 - Low risk of bias      
2 - High risk of bias      
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Appendix 2.7 – Bias assessment of observational studies 
 
Study Exposure definition Outcome/case definition Control selection Confounding Missing Data Censoring 
Abdel-Qadir 2016 2 - Only included women who were exposed to either 
AI or Tam for >90% of days dispensed 
2 - Used hospital records, but not 
clear what method used to define 
outcome 
N/A 1 - Adjustment for a wide range of 
confounders using IPTW 
0 - No information given 1 - Only censored at end 
of study  
Chen 2014 2 - Patients only needed one tamoxifen prescription 
to be defined as exposed 
1 - Use hospital records and outlines 
ICD-9 codes used 
N/A 2 - No adjustment for CVD related 
treatment, cancer severity, or other 
cancer treatments 
0 - No information given 1 - Only censored at end 
of study or death 
Haque 2016 2 - Patients only needed one tamoxifen prescription 
to be defined as exposed 
1 - Identified by medical records and 
validated by clinician 
N/A 1 - Adjustment for wide range of 
covariates and used IPTW 
1 - Missing data on BMI, but 
sensitivity analyses 
performed to assess the 
impact of this 
1 - Censored at death or 
termination of health 
plan membership 
Hernandez 2008 0 - Not enough information given 1 - Outcome defined by ICD 8 and 10 
codes 
N/A 1 - Adjustment for wide range of 
covariates 
0 - No information given 1 - Only censored at 
outcome or end of 
follow-up 
Hernandez 2009 0 - Not enough information given 1 - Outcome defined by ICD 8 and 10 
codes 
N/A 1 - Adjustment for wide range of 
covariates 
2 - A lot of missing BMI data 
and no explanation of how 
it is dealt with  
1 - Only censored at 
outcome or end of 
follow-up 
Ligibel 2012 2 - Ascertained through pharmacy data, but no 
information on how exposure begins 
1 - Outcome identified through 
hospital records 
N/A 2 - No adjustment for cancer severity 
or other cancer related treatments 
0 - No information given 1 - Only censored at 
outcome or end of 
follow-up 
Yang 2014 2 -Not clear when patient defined as exposed, and all 
breast cancer patients could be unexposed, even 
with ER- BC 
1 - based on ICD-9 from medical 
records 
N/A 2 - No adjustment for cancer severity 
or other cancer treatment 
0 - No information given 0 - No information given 
Bradbury 2005 2 - Patients are taken from a study population that 
include bladder, colorectal, and non-melanoma skin 
cancer patients, who would not be prescribed 
tamoxifen 
2 - Used GP records, but no indication 
of terms used to define the case 
1 - Three controls matched on 
date of IHD diagnosis, age, and 
study entry date 
2 - No adjustment for CVD related 
treatment, cancer severity, or other 
cancer treatments 
1 - Minimal missing data N/A 
Geiger 2004 1 - Exposure abstracted from medical records for 
cases and controls 
1 - Hospital records used 1 -Two controls matched on age 
and members of the same health 
maintenance organisation during 
their at-risk period 
2 - All risk factors adjusted for, but 
breast cancer therapies, smoking and 
some medical therapies through 
patient recall 
2 - Missing category fitted 
to deal with missing data 
N/A 
Geiger 2005 1 - Exposure abstracted from medical records for 
cases and controls 
1 - Hospital records used 1 -Two controls matched on age 
and members of the same health 
maintenance organisation during 
their at-risk period 
2 - All risk factors adjusted for, but 
breast cancer therapies, smoking and 
some medical therapies through 
patient recall 
2 - Missing category fitted 
to deal with missing data 
N/A 
Meier 1998 1 - Ascertained through computerised medical 
records 
1 - Based on hospital records 1 - Cancer free controls from 
GPRD population 
2 - No adjustment for cancer severity 
or other cancer treatment 
2 - Missing data category 
fitted 
N/A 
Bias assessment categories      
0 - No information given      
1 - Low risk of bias      
2 - High risk of bias      
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Appendix 2.8 - Meta-analysis of observational studies examining the risk of heart failure in 
tamoxifen users compared with non-users 
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Appendix 2.9 - Meta-analysis of RCTs examining the risk of thromboembolic events in AI users 
compared with tamoxifen  
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CHAPTER 3  
Appendix 3.1 – Patient and practice level data acceptability in CPRD (provided by CPRRD) 
Acceptable Patients 
Patients are labelled as ‘acceptable’ for use in research by a process that identifies and excludes 
patients with non-continuous follow up or patients with poor data recording that raises suspicion as 
to the validity of the that patients record. Patient data are checked, for the following issues: 
• An empty or invalid first registration date 
• An empty or invalid current registration date 
• Absence of a record for a year of birth 
• A first registration date prior to their birth year 
• A current registration date prior to their birth year 
• A transferred out reason with no transferred out date  
• A transferred out date with no transferred out reason  
• A transferred out date prior to their first registration date  
• A transferred out date prior to their current registration date  
• A current registration date prior to their first registration date  
• A gender other than Female/Male/Indeterminate  
• An age of greater than 115 at end of follow up 
• Recorded health care episodes in years prior to birth year 
• All recorded health care episodes have empty or invalid event dates 
• Registration status of temporary patients 
 
If any of these conditions are true then the patient is labelled unacceptable, and is not 
recommended for use in research. 
 
Up to standard date 
The overall quality of data in practices is mediated by use of an ‘up to standard’ (UTS) date, which is 
deemed as the date at which data in the practice is considered to have continuous high quality data 
fit for use in research. This is mediated by an analysis on the total data in the practice, which is 
refreshed every time a new collection for a practice is processed into the database. It is based on 
two central concepts: assurance of continuity in data recording (gap analysis), and avoidance of use 
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of data for which transferred out and dead patients have been removed (death recording). 
 
Gap Analysis 
To detect whether there are any meaningful gaps in the data it is necessary to look in more detail at 
single day gaps as well as longer gaps. A single day alone may reflect a situation where nothing was 
recorded that day at the practice, i.e. the practice was not open, such as on a bank holiday. A longer 
gap may reflect a situation where the practice did not offer a service and patients may have been 
treated elsewhere. If a meaningful gap is found, the earliest date after which there is no significant 
gap is identified. 
 
Death Recording 
It is expected that a standard number of deaths will be recorded at a practice over time. Assessment 
of gaps in death recording is performed taking the size of the practice into account. A safety margin 
is built in to account for both geographical and seasonal variation in death rates. If a meaningful gap 
is found, the earliest date after which there is no significant gap is identified. 
 
The UTS date is set to the latest of these dates for each practice. The CPRD recommend that 
analyses are performed on data following the practice UTS date.  
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CHAPTER 4  
Appendix 4.1 – CVD code list inclusion and exclusion criteria 
 
 
 
 
 
Outcome  Inclusion Exclusion 
Angina angina*, stenocard*, coronary*artery*spasm*, 
spasm*cor*artery*, card*syndrome*x*, 
cor*syndrome*x*, preinfarct* impending infarct* 
acute coronary insuff* 
fh*, no fh*, score*, vincent*, strepto*, herp*, 
abdominal*, ludwig*, bullosa haemor*, infarc*, 
therapy* 
MI *stemi*, *st*elevation*, *steami*, 
myocard*infarct, infarct*myocard*, acute*infarct, 
infarct*acute*, acute*mi*, mi*acute*, 
heart*infarct*, infarct*heart*, 
subendocard*infarct*, infarct*subendocard*, 
transmur*infarct*, infarct*transmur*, 
card*infarct*, infarct*card*, heart*attack*, 
attack*heart*, coronary*attack*, 
attack*coronary*, coronary*thrombosis*, 
thrombosis*coronary*, myocard*necro*, 
necro*myocard*, heart*necro*, necro*heart*, 
coron*necro*, necro*coron*, mural*thrombosis*, 
q*wave*  
family*, fh*, leukaemia*, systemic*, chemical*, 
tuberculosis*, alcohol*, colitis*, epidid*, treatment 
programme*, memory*, endophthal*, vesiculitis*, 
meningoc*, porphyria*, spinal*, anaemia*, 
compression*, meloidosis*, psychotic*, 
pericarditis*, miss*, dsmiv*, minority*, mibg*, 
abort*, abdomin*, uraemic*, nephritic*, test of 
motor impairment*, no *, normal*, scor*, stress 
study*, mibi study, quality indicator*, military*, 
disseminated demyel*, aminoglycoside* 
Revascularisation cor*by*pass*, by*pass*cor*, cardio*by*pass*, 
by*pass*cardio*, artery*by*pass*, 
by*pass*artery*, aorta*by*pass*, by*pass*aorta*, 
vein*by*pass*, by*pass*vein*, revascular*, 
coron*graft*, graft*coron*, percut*cor*int*, 
saphen*graft*, graft*saphen* 
*fh*, family*history*, presence*, rejection*, 
impotence*, cornea*, *revision*, complication*, 
planned, occlusion 
SCA cardiac*arrest*, arrest*cardiac*, electro*dissoc*, 
dissoc*electro*, cardio*arrest*, arrest*cardio*, 
circ*arrest*, arrest*circ*, resusc*cardio*, 
cardio*resusc*, asys*, defib*, vent*fib*, 
vent*tach*, cardiac massage* 
fh*, family*history*, ivf, pregna*, viral*, not*, 
tachycardia*, flutter*, fibrillation*, renewal*, 
resiting*, cardiovert*defib*, pacemaker* 
PVD extremit*, leg*, limb*, iliac*, femoral*, pedis*, 
tibial*, popliteal*, periphera*l, extremit*, 
peripheral*vascular*, peripheral*arter*, 
intermitt*claudicat*, peripheral*vascular*, 
peripheral*arter*, intermitt*claudicat*, 
thromboangiitis*obliter*, acrocyanosis*, 
acroparaesthes*, erythrocyanosis*, nothnagel*, 
schultze*, buerger*, erythromelalgia*, 
claudication*, peripher*angiopath*, 
aortoiliac*obstruction*, arter*ulcer*, 
peripher*ischaem*, leg*gangrene*, leg*ischaem*, 
ischaem*leg*, ischaem*ulcer*foot*, 
ischaem*foot*, ischaem*toe*, gangrene*foot*, 
peripheral*circul*disorder, ischaem*toe*, 
gangrene*toe*, failure*peripheral*circul*, 
peripher*circul*fail*, extrem*arter*atheroma*, 
foot*gangrene*, toe*gangrene*, 
peripheral*gangrene*, atherosclerosis, peripheral 
arterial*, peripheral vascular*, goldblatt*, 
athero*gangrene*, monkeberg*, endarterect*, 
angioplasty*, arteriosclerosis*, renal*stenosis*, 
arter*atherom*,  aorto*iliac*disease*, 
arteriosclerot*vascular*diseas* 
fh:, family*, symptom*, excluded*, no *, prevent*, 
advice*, screen*, buergers exercises*, arm or leg*, 
pulmonary*, cerebral*, coronary*, cor art*, 
complications of care*, pulmon art*, false*, 
pulmonary*, neurogenic*, vein*, lymph node*, 
congenital*, anomaly*, liver*, *valsalva*, 
radiological*, anomalies*, arter*venous*, 
inflammat*, syphili*, spasm* 
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Stroke stroke*, carotid*steno*, steno*carotid*, basil*steno*, 
steno*basil*, verteb*steno*, steno*verteb*, 
cereb*steno*, steno*cereb*, carotid*occlu*, 
occlu*carotid*, basil*occlu*, occlu*basil*, 
verteb*occlu*, occlu*verteb*, cereb*occlu*, 
occlu*cereb*, carotid*thrombo*, thrombo*carotid*, 
cereb*thrombo*, thrombo*cereb*, verteb*thrombo*, 
thrombo*verteb*, basil*thrombo*, thrombo*basil*, 
basil*infarct*, infarct*basil*, basal*infarct*, 
infarct*basal*, brain*infarct*, infarct*brain*, 
pontine*infarct*, infarct*pontine*, cereb*infarct*, 
infarct*cereb*, infarct*lobe*, lobe*infarct*, 
cereb*insuff*, insuff*cereb*, basil*insuff*, insuff*basil*, 
vertebral*insuff*, insuff*vertebral*, carotid*insuff*, 
insuff*carotid*, cereb*syndrom*, syndrom*cereb*, 
basil*syndrom*, syndrom*basil*, vertebral*syndrom*, 
syndrom*vertebral*, carotid*syndrom*, 
syndrom*carotid*, cva*, clot*brain*, brain*clot*, 
cereb*accident*, accident*cereb*, vascular*accident*, 
accident*vascular*, cereb*ischaem*, ischaem*cereb*, 
cereb*embol*, embol*cereb*, cran*embol*, 
embol*cran*, haemorr*brain*, brain*haemorr*, 
haemorr*cerebr*, cereb*haemorr*, haemorr*stroke*, 
stroke*haemorr*, basal*haemorr*, haemorr*basal*, 
bulbar*haemorr*, haemorr*bulbar*, capsule*haemorr*, 
haemorr*capsule*, pontine*haemorr*, 
haemorr*pontine*, cort*haemorr*, haemorr*cort*, 
cran*haemorr*, haemorr*cran*, dural*haematoma*, 
haematoma*dural*, dural*haemorr*, haemorr*dural*, 
brain*bleed*, bleed*brain*, cereb*bleed*, 
bleed*cereb*, brain*aneurys*, aneurys*brain*, 
cereb*aneurys*, aneurys*cereb* 
All codes were checked individually 
Arrhythima arrhythmia*, dysrhythmia*, bradyarrhytmia*, 
irregular*heartbeat*, tachycardia*, bradycardia*, 
atrial*flut*, cardiac*fibrillation*, atrial*fibrillation*, 
premature*atrial*contrad*, 
premature*ventric*contrad*, *junctional*rhythm*, 
artioventricular*block*    
fh*, family*history*, fetal*, pregnan*, 
neonatal*, hypsarrhyth*, excepted*, 
exception*, no *, cardiomyopathy*, 
excluded*, administration* 
HF *heart*fail*, fail*heart*, card*fail*, fail*card*, 
pulmon*oedema*, oedema*pulmon*, left*vent*fail*, 
fail*left*vent*, lvf*, card*asthma*, asthma*card*, 
right*vent*fail*, fail*right*vent*, rvf*, congesti*card*, 
card*congesti*, heart*congesti*, congesti*heart*, 
congesti*pulm*, pulm*congesti*, cor pulmonale*, new 
york heart assoc*class*, lvd*, vent*dys, rvd*, dys*vent*, 
malignant*hypert*, ccf*, cardiomyopath*, 
arrhythmogenic*dysplasia*, right*ventricular*dysplaisa* 
transplant*, mechanical*, post*operation*, 
complication*care*, no evidence*, 
neonatal*, postoperative*, screen*, 
information given*, advice*, hyperthermia*, 
asthma*, preferred*, discharge*, not 
available*, not indicated*, declined*, 
except*, weak heart*, fh*, family*history*, 
familial*, newborn*, alcoholic*, tachy* 
Pericarditis pericarditis*, serous*pericardi*, purulent*pericardi*, 
fibrinous*pericardi*, caseous*pericardi*, 
hemhorr*pericardi*, dressler* 
fh*, family*history*, dressler* 
VHD aortic*valve*stenosis*, mitral*valve*stenosis*, 
tricuspid*valve*stenosis*, pulmonary*valve*stenosis*, 
aortic*insuff*, mitral*insuff*, tricuspid*insuff*, 
pulmonary*insuff*, aortic*regurgit*, mitral*regurgit*, 
tricuspid*regurgit*, pulmonary*regurgit*, 
valvular*heart*, valv*dysplasia* 
fh, family*history*, surgery*, shock* 
DVT deep*vein*thrombo*, thrombosis*venous*, 
thrombus*veins*, deep*venous*thrombosis*, 
thrombophleb*iliac*, thrombophleb*intracranial sinus*" 
"*thrombophleb*cavernous sinus*, thrombo*venous 
sinus*" "*venous sinus*thrombo*, thrombophleb*vein*, 
portal vein*thrombo*, hepatic vein*thrombo*, 
thrombo*vena cava*, thromb*superior mesenteric 
vein* 
fh*, family*history*, no *, probability of*, 
probability score*, risk of*, screening*, 
prevention*, care pathway*, services 
admin*, saphenous*, superficial*, budd - * 
PE pulmonary*embol* fh*, family*history*, no *, probability of*, 
probability score*, risk of* 
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Appendix 4.2 – Angina code list 
Read Code Description Definite/possible/history 
of 
G33..00 angina pectoris Definite 
G330.00 angina decubitus Definite 
G330000 nocturnal angina Definite 
G330z00 angina decubitus nos Definite 
G33z.00 angina pectoris nos Definite 
G33z100 stenocardia Definite 
G33z200 syncope anginosa Definite 
G33z300 angina on effort Definite 
G33z600 new onset angina Definite 
G33z700 stable angina Definite 
G33zz00 angina pectoris nos Definite 
G34y000 chronic coronary insufficiency Definite 
Gyu3000 [x]other forms of angina pectoris Definite 
187..00 frequency of angina Possible 
661M000 angina self-management plan agreed Possible 
661N000 angina self-management plan review Possible 
662K400 angina self management plan commenced Possible 
8IEY.00 referral to angina plan self-management programme declined Possible 
8T04.00 referral to angina plan self-management programme Possible 
G311.11 crescendo angina Definite 
G311.13 unstable angina Definite 
G311.14 angina at rest Definite 
G311100 unstable angina Definite 
G311200 angina at rest Definite 
G31y000 acute coronary insufficiency Definite 
G33z000 status anginosus Definite 
G311300 refractory angina Definite 
G37..00 cardiac syndrome x Definite 
G331.00 prinzmetal's angina Definite 
G331.11 variant angina pectoris Definite 
G332.00 coronary artery spasm Definite 
14A5.00 h/o: angina pectoris History 
14AJ.00 h/o: angina in last year History 
662K.00 angina control History 
662K000 angina control - good History 
662K100 angina control - poor History 
662K200 angina control - improving History 
662K300 angina control - worsening History 
662K500 angina self management plan completed History 
662Kz00 angina control nos History 
G311400 worsening angina History 
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Appendix 4.3 – MI code list 
Read Code Description Definite/possible/histor
y of 
323..00 ecg: myocardial infarction Definite 
3235.00 ecg: subendocardial infarct Definite 
323Z.00 ecg: myocardial infarct nos Definite 
889A.00 diab mellit insulin-glucose infus acute myocardial infarct Definite 
G30..00 acute myocardial infarction Definite 
G30..11 attack - heart Definite 
G30..13 cardiac rupture following myocardial infarction (mi) Definite 
G30..14 heart attack Definite 
G30..15 mi - acute myocardial infarction Definite 
G30..17 silent myocardial infarction Definite 
G300.00 acute anterolateral infarction Definite 
G301.00 other specified anterior myocardial infarction Definite 
G301000 acute anteroapical infarction Definite 
G301100 acute anteroseptal infarction Definite 
G301z00 anterior myocardial infarction nos Definite 
G302.00 acute inferolateral infarction Definite 
G303.00 acute inferoposterior infarction Definite 
G304.00 posterior myocardial infarction nos Definite 
G305.00 lateral myocardial infarction nos Definite 
G306.00 true posterior myocardial infarction Definite 
G307.00 acute subendocardial infarction Definite 
G307000 acute non-q wave infarction Definite 
G308.00 inferior myocardial infarction nos Definite 
G309.00 acute q-wave infarct Definite 
G30B.00 acute posterolateral myocardial infarction Definite 
G30X.00 acute transmural myocardial infarction of unspecif site Definite 
G30y.00 other acute myocardial infarction Definite 
G30y000 acute atrial infarction Definite 
G30y100 acute papillary muscle infarction Definite 
G30y200 acute septal infarction Definite 
G30yz00 other acute myocardial infarction nos Definite 
G30z.00 acute myocardial infarction nos Definite 
G35..00 subsequent myocardial infarction Definite 
G350.00 subsequent myocardial infarction of anterior wall Definite 
G351.00 subsequent myocardial infarction of inferior wall Definite 
G353.00 subsequent myocardial infarction of other sites Definite 
G35X.00 subsequent myocardial infarction of unspecified site Definite 
G38..00 postoperative myocardial infarction Definite 
G380.00 postoperative transmural myocardial infarction anterior wall Definite 
G381.00 postoperative transmural myocardial infarction inferior wall Definite 
G383.00 postoperative transmural myocardial infarction unspec site Definite 
G384.00 postoperative subendocardial myocardial infarction Definite 
G38z.00 postoperative myocardial infarction, unspecified Definite 
Gyu3400 [x]acute transmural myocardial infarction of unspecif site Definite 
Gyu3500 [x]subsequent myocardial infarction of other sites Definite 
Gyu3600 [x]subsequent myocardial infarction of unspecified site Definite 
SP08V00 very mild acute rejection of renal transplant Definite 
G30..12 coronary thrombosis Possible 
G30..16 thrombosis - coronary Possible 
G30A.00 mural thrombosis Possible 
G31y100 microinfarction of heart Possible 
ZV71900 [v]observation for suspected myocardial infarction Possible 
G30X000 acute st segment elevation myocardial infarction Definite 
G307100 acute non-st segment elevation myocardial infarction Definite 
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14A3.00 h/o: myocardial infarct <60 History 
14A4.00 h/o: myocardial infarct >60 History 
14AH.00 h/o: myocardial infarction in last year History 
14AT.00 history of myocardial infarction History 
3232.00 ecg: old myocardial infarction History 
G310.00 postmyocardial infarction syndrome History 
G310.11 dressler's syndrome History 
G32..00 old myocardial infarction History 
G32..11 healed myocardial infarction History 
G32..12 personal history of myocardial infarction History 
G33z500 post infarct angina History 
G36..00 certain current complication follow acute myocardial infarct History 
G360.00 haemopericardium/current comp folow acut myocard infarct History 
G361.00 atrial septal defect/curr comp folow acut myocardal infarct History 
G362.00 ventric septal defect/curr comp fol acut myocardal infarctn History 
G364.00 ruptur chordae tendinae/curr comp fol acute myocard infarct History 
G365.00 rupture papillary muscle/curr comp fol acute myocard infarct History 
G366.00 thrombosis atrium,auric append&vent/curr comp foll acute mi History 
G501.00 post infarction pericarditis History 
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Appendix 4.4 – Revascularisation code list 
Read Code Description Definite/possible/history 
of 
790H300 revascularisation of wall of heart Definite 
792..11 coronary artery bypass graft operations Definite 
7920.00 saphenous vein graft replacement of coronary artery Definite 
7920.11 saphenous vein graft bypass of coronary artery Definite 
7920000 saphenous vein graft replacement of one coronary artery Definite 
7920100 saphenous vein graft replacement of two coronary arteries Definite 
7920200 saphenous vein graft replacement of three coronary arteries Definite 
7920300 saphenous vein graft replacement of four+ coronary arteries Definite 
7920y00 saphenous vein graft replacement of coronary artery os Definite 
7920z00 saphenous vein graft replacement coronary artery nos Definite 
7921.00 other autograft replacement of coronary artery Definite 
7921.11 other autograft bypass of coronary artery Definite 
7921000 autograft replacement of one coronary artery nec Definite 
7921100 autograft replacement of two coronary arteries nec Definite 
7921200 autograft replacement of three coronary arteries nec Definite 
7921300 autograft replacement of four of more coronary arteries nec Definite 
7921y00 other autograft replacement of coronary artery os Definite 
7921z00 other autograft replacement of coronary artery nos Definite 
7922.00 allograft replacement of coronary artery Definite 
7922.11 allograft bypass of coronary artery Definite 
7922000 allograft replacement of one coronary artery Definite 
7922100 allograft replacement of two coronary arteries Definite 
7922200 allograft replacement of three coronary arteries Definite 
7922300 allograft replacement of four or more coronary arteries Definite 
7922y00 other specified allograft replacement of coronary artery Definite 
7922z00 allograft replacement of coronary artery nos Definite 
7923.11 prosthetic bypass of coronary artery Definite 
7925.11 creation of bypass from mammary artery to coronary artery Definite 
7928200 percut translum balloon angioplasty bypass graft coronary a Definite 
792D.00 other bypass of coronary artery Definite 
792Dy00 other specified other bypass of coronary artery Definite 
792Dz00 other bypass of coronary artery nos Definite 
792E.00 percutaneous coronary intervention Definite 
792E000 emergency percutaneous coronary intervention Definite 
7A10.00 extraanatomic bypass of aorta Definite 
7A10100 bypass aorta by anastomosis axillary to femoral artery nec Definite 
7A10400 bypass aorta anastomosis axillary artery bi femoral arteries Definite 
7A10y00 other specified extraanatomic bypass of aorta Definite 
7A10z00 extraanatomic bypass of aorta nos Definite 
7A12.00 other bypass of bifurcation of aorta Definite 
7A12000 emerg bypass bifurc aorta by anast aorta to femoral artery Definite 
7A12100 bypass bifurc aorta by anastom aorta to femoral artery nec Definite 
7A12300 bypass bifurcation aorta by anastom aorta to iliac artery Definite 
7A12y00 other specified other bypass of bifurcation of aorta Definite 
7A12z00 other bypass of bifurcation of aorta nos Definite 
7A15.00 other emergency bypass of segment of aorta Definite 
7A15000 emerg bypass ascending aorta by anastom aorta to aorta nec Definite 
7A15300 emerg bypass infrarenal aorta by anastom aorta to aorta nec Definite 
7A15400 emerg bypass abdominal aorta by anastom aorta to aorta nec Definite 
7A15y00 other specified other emergency bypass of segment of aorta Definite 
7A15z00 other emergency bypass of segment of aorta nos Definite 
7A16.00 other bypass of segment of aorta Definite 
7A16000 bypass of ascending aorta by anastomosis aorta to aorta nec Definite 
7A16100 bypass of thoracic aorta by anastomosis aorta to aorta nec Definite 
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7A16300 bypass of infrarenal aorta by anastomosis aorta to aorta nec Definite 
7A16400 bypass of abdominal aorta by anastomosis aorta to aorta nec Definite 
7A16y00 other specified other bypass of segment of aorta Definite 
7A16z00 other bypass of segment of aorta nos Definite 
7A20100 intracranial bypass to carotid artery Definite 
7A20200 bypass to carotid artery nec Definite 
7A20700 intracranial bypass from carotid artery nec Definite 
7A26000 bypass of subclavian artery nec Definite 
7A26100 bypass of axillary artery nec Definite 
7A26700 bypass of brachial artery nec Definite 
7A30100 bypass of renal artery Definite 
7A33000 bypass of coeliac artery nec Definite 
7A33100 bypass of superior mesenteric artery nec Definite 
7A33200 bypass of inferior mesenteric artery nec Definite 
7A33H00 bypass of visceral branch of abdominal aorta nec Definite 
7A41.00 other bypass of iliac artery Definite 
7A41.11 other bypass of iliac artery by anastomosis Definite 
7A41100 bypass iliac artery by iliac/femoral artery anastomosis nec Definite 
7A41200 emerg bypass iliac artery by femoral/femoral art anast nec Definite 
7A41300 bypass iliac artery by femoral/femoral art anastomosis nec Definite 
7A41400 emerg bypass comm iliac art by aorta/com iliac art anast nec Definite 
7A41600 emerg bypass leg artery by aorta/com fem art anastomosis nec Definite 
7A41900 bypass common iliac artery by aorta/com iliac art anast nec Definite 
7A41B00 bypass leg artery by aorta/com femoral art anastomosis nec Definite 
7A41C00 bypass leg artery by aorta/deep femoral art anastomosis nec Definite 
7A41D00 bypass iliac artery by iliac/iliac artery anastomosis nec Definite 
7A41y00 other specified other bypass of iliac artery Definite 
7A41z00 other bypass of iliac artery nos Definite 
7A47.00 other emergency bypass of femoral artery or popliteal artery Definite 
7A47.12 other emergency bypass of common femoral artery Definite 
7A47.13 other emergency bypass of deep femoral artery Definite 
7A47.14 other emergency bypass of popliteal artery Definite 
7A47.15 other emergency bypass of superficial femoral artery Definite 
7A47.16 other emergency bypass of femoral artery Definite 
7A47200 emerg bypass femoral art by fem/pop a anast c vein graft nec Definite 
7A47300 emerg bypass pop art by pop/pop art anast c vein graft nec Definite 
7A47600 emerg bypass femoral art by fem/tib a anast c vein graft nec Definite 
7A47700 emerg bypass pop art by pop/tib art anast c vein graft nec Definite 
7A47B00 emerg bypass pop art by pop/peron art anast c vein graft nec Definite 
7A47C00 emerg bypass femoral artery by fem/fem art anastomosis nec Definite 
7A47D00 emerg bypass popliteal artery by pop/fem art anastomosis nec Definite 
7A47y00 other emergency bypass of femoral or popliteal artery os Definite 
7A47z00 other emergency bypass of femoral or popliteal artery nos Definite 
7A48.00 other bypass of femoral artery or popliteal artery Definite 
7A48.11 other bypass of femoral or popliteal artery by anastomosis Definite 
7A48.12 other bypass of common femoral artery Definite 
7A48.14 other bypass of femoral artery Definite 
7A48.15 other bypass of popliteal artery Definite 
7A48.16 other bypass of superficial femoral artery Definite 
7A48000 bypass femoral artery by fem/pop art anast c prosthesis nec Definite 
7A48100 bypass popliteal artery by pop/pop a anast c prosthesis nec Definite 
7A48200 bypass femoral artery by fem/pop art anast c vein graft nec Definite 
7A48300 bypass popliteal artery by pop/pop a anast c vein graft nec Definite 
7A48400 bypass femoral artery by fem/tib art anast c prosthesis nec Definite 
7A48500 bypass popliteal artery by pop/tib a anast c prosthesis nec Definite 
7A48600 bypass femoral artery by fem/tib art anast c vein graft nec Definite 
7A48700 bypass popliteal artery by pop/tib a anast c vein graft nec Definite 
7A48800 bypass femoral artery by fem/peron a anast c prosthesis nec Definite 
7A48900 bypass popliteal artery by pop/peron art anast c prosth nec Definite 
7A48A00 bypass femoral artery by fem/peron a anast c vein graft nec Definite 
7A48B00 bypass popliteal art by pop/peron art anast c vein graft nec Definite 
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7A48C00 bypass femoral artery by femoral/femoral art anastomosis nec Definite 
7A48D00 bypass popliteal artery by pop/fem artery anastomosis nec Definite 
7A48y00 other bypass of femoral artery or popliteal artery os Definite 
7A48z00 other bypass of femoral artery or popliteal artery nos Definite 
7A64.00 other bypass operations on vein Definite 
7A64y00 other specified bypass operation on vein Definite 
7A64z00 bypass operation on vein nos Definite 
7A66000 crossover graft of saphenous vein Definite 
7A66011 palma crossover graft of saphenous vein Definite 
7M36000 cardiopulmonary bypass Definite 
7M36400 modified ultrafiltration adjunct cardiopulmonary bypass Definite 
8L40.00 coronary artery bypass graft operation planned Possible 
SP07600 coronary artery bypass graft occlusion Definite 
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Appendix 4.5 - SCA code list 
Read Code Description Definite/possible/history of 
2241.00 o/e - collapse -cardiac arrest Definite 
7932111 cardiac massage - open Definite 
7937500 implantation of internal cardiac defibrillator Definite 
7L1H600 advanced cardiopulmonary resuscitation Definite 
853..00 cardiac massage - external Definite 
8531.00 closed cardiac massage alone Definite 
8532.00 closed cardiac massage+ventil. Definite 
8532.11 cardiopulmonary resuscitation Definite 
853Z.00 external cardiac massage nos Definite 
G575.00 cardiac arrest Definite 
G575.11 cardio-respiratory arrest Definite 
G575.12 asystole Definite 
G575000 cardiac arrest with successful resuscitation Definite 
G575200 electromechanical dissociation with successful resuscitation Definite 
G575300 electromechanical dissociation Definite 
G575z00 cardiac arrest, unspecified Definite 
SP11000 cardiac arrest as a complication of care Definite 
7937600 removal of internal cardiac defibrillator History 
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Appendix 4.6 - PVD code list 
Read Code Description Definite/possible/history 
of 
Q31y400 perinatal acrocyanosis Definite 
Gyu7400 [x]other specified peripheral vascular diseases Definite 
G73z012 vascular claudication Definite 
G73..00 other peripheral vascular disease Definite 
1M11100 ischaemic foot pain when walking Definite 
16I..00 claudication distance Definite 
C109F00 non-insulin-dependent d m with peripheral angiopath Definite 
7A49000 endarterectomy and patch repair of femoral artery Definite 
7A4B000 percutaneous transluminal angioplasty of femoral artery Definite 
G73y100 peripheral angiopathic disease ec nos Definite 
R055011 [d]peripheral circulatory failure Definite 
Pyu2B00 [x]oth specified cong malform of peripheral vascular 
system 
Definite 
7A42011 endarterectomy and patch repair of common iliac artery Definite 
C107z00 diabetes mellitus nos with peripheral circulatory disorder Definite 
G73z011 claudication Definite 
7A56600 percutaneous transluminal placement peripheral stent 
artery 
Definite 
7A42000 endarterectomy and patch repair of iliac artery Definite 
G732000 gangrene of toe Definite 
M271400 mixed venous and arterial leg ulcer Definite 
G73y000 diabetic peripheral angiopathy Definite 
G73..11 peripheral ischaemic vascular disease Definite 
C109F11 type ii diabetes mellitus with peripheral angiopathy Definite 
C109F12 type 2 diabetes mellitus with peripheral angiopathy Definite 
C108G00 insulin dependent diab mell with peripheral angiopathy Definite 
G702.00 extremity artery atheroma Definite 
G731z00 thromboangiitis obliterans nos Definite 
7A42111 endarterectomy of common iliac artery nec Definite 
G742z00 peripheral arterial embolism and thrombosis nos Definite 
7A44000 percutaneous transluminal angioplasty of iliac artery Definite 
C10FF00 type 2 diabetes mellitus with peripheral angiopathy Definite 
7A49300 endarterectomy of popliteal artery nec Definite 
G73y511 nothnagel's vasomotor acroparaesthesia Definite 
M271300 arterial leg ulcer Definite 
G731.00 thromboangiitis obliterans Definite 
C107100 diabetes mellitus, adult, + peripheral circulatory disorder Definite 
7A4B100 percutaneous transluminal angioplasty of popliteal artery Definite 
G731000 buerger's disease Definite 
7A49100 endarterectomy and patch repair of popliteal artery Definite 
G734.00 peripheral arterial disease Definite 
C10FF11 type ii diabetes mellitus with peripheral angiopathy Definite 
M271000 ischaemic ulcer diabetic foot Definite 
M271.12 ischaemic leg ulcer Definite 
G740.12 aortoiliac obstruction Definite 
G73y800 erythromelalgia Definite 
G700.11 aorto-iliac disease Definite 
G73y400 acroparaesthesia - schultze's type Definite 
1M11000 ischaemic foot pain at rest Definite 
C107.00 diabetes mellitus with peripheral circulatory disorder Definite 
G733.00 ischaemic foot Definite 
G73..13 peripheral ischaemia Definite 
R054300 [d]widespread diabetic foot gangrene Definite 
G73..12 ischaemia of legs Definite 
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38DJ.00 edinburgh claudication questionnaire Definite 
C107400 niddm with peripheral circulatory disorder Definite 
G73z.00 peripheral vascular disease nos Definite 
7A49200 endarterectomy of femoral artery nec Definite 
G73y600 acroparaesthesia - unspecified Definite 
G732.00 peripheral gangrene Definite 
C107300 iddm with peripheral circulatory disorder Definite 
G73y200 acrocyanosis Definite 
7A42100 endarterectomy of iliac artery nec Definite 
G73z000 intermittent claudication Definite 
R055000 [d]failure of peripheral circulation Definite 
G702z00 extremity artery atheroma nos Definite 
G73y700 erythrocyanosis Definite 
R054200 [d]gangrene of toe in diabetic Definite 
G73y.00 other specified peripheral vascular disease Definite 
2G63.00 ischaemic toe Definite 
G73yz00 other specified peripheral vascular disease nos Definite 
C107000 diabetes mellitus, juvenile +peripheral circulatory disorder Definite 
G73y500 acroparaesthesia - nothnagel's type Definite 
G732100 gangrene of foot Definite 
G73zz00 peripheral vascular disease nos Definite 
A3A0F00 gas gangrene-foot Definite 
C10EG00 type 1 diabetes mellitus with peripheral angiopathy Definite 
7A42012 iliac endarterectomy and patch Definite 
9hS0.00 excepted frm peripheral arterial dis qual ind: pt unsuitable Possible 
9N4h.00 dna - did not attend peripheral vascular disease clinic Possible 
8HlP.00 referred for peripheral artery disease assessment Possible 
9hS1.00 except frm peripheral arter dis qual indicat: inform dissent Possible 
9m10.00 peripheral vascular disease monitoring first letter History 
9m12.00 peripheral vascular disease monitoring third letter History 
14F7.00 h/o: arterial lower limb ulcer History 
9m1..00 peripheral vascular disease monitoring invitation History 
9m11.00 peripheral vascular disease monitoring second letter History 
662U.00 peripheral vascular disease monitoring History 
14NB.00 h/o: peripheral vascular disease procedure History 
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Appendix 4.7 – Stroke code list 
Read Code Description Definite/possible/history 
of 
G63..11 infarction - precerebral Definite 
G63y000 cerebral infarct due to thrombosis of precerebral arteries Definite 
G63y100 cerebral infarction due to embolism of precerebral arteries Definite 
G64..11 cva - cerebral artery occlusion Definite 
G64..12 infarction - cerebral Definite 
G64..13 stroke due to cerebral arterial occlusion Definite 
G640000 cerebral infarction due to thrombosis of cerebral arteries Definite 
G641000 cerebral infarction due to embolism of cerebral arteries Definite 
G64z.00 cerebral infarction nos Definite 
G64z.11 brainstem infarction nos Definite 
G64z.12 cerebellar infarction Definite 
G64z000 brainstem infarction Definite 
G64z200 left sided cerebral infarction Definite 
G64z300 right sided cerebral infarction Definite 
G64z400 infarction of basal ganglia Definite 
G676000 cereb infarct due cerebral venous thrombosis, nonpyogenic Definite 
G6W..00 cereb infarct due unsp occlus/stenos precerebr arteries Definite 
G6X..00 cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs Definite 
Gyu6300 [x]cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs Definite 
Gyu6400 [x]other cerebral infarction Definite 
Gyu6G00 [x]cereb infarct due unsp occlus/stenos precerebr arteries Definite 
G62..00 other and unspecified intracranial haemorrhage Definite 
G62z.00 intracranial haemorrhage nos Definite 
C154211 adrenocortical haemorrhage Definite 
G61..00 intracerebral haemorrhage Definite 
G61..11 cva - cerebrovascular accid due to intracerebral 
haemorrhage 
Definite 
G61..12 stroke due to intracerebral haemorrhage Definite 
G610.00 cortical haemorrhage Definite 
G611.00 internal capsule haemorrhage Definite 
G612.00 basal nucleus haemorrhage Definite 
G613.00 cerebellar haemorrhage Definite 
G614.00 pontine haemorrhage Definite 
G616.00 external capsule haemorrhage Definite 
G617.00 intracerebral haemorrhage, intraventricular Definite 
G618.00 intracerebral haemorrhage, multiple localized Definite 
G619.00 lobar cerebral haemorrhage Definite 
G61X.00 intracerebral haemorrhage in hemisphere, unspecified Definite 
G61X000 left sided intracerebral haemorrhage, unspecified Definite 
G61X100 right sided intracerebral haemorrhage, unspecified Definite 
G61z.00 intracerebral haemorrhage nos Definite 
Gyu6200 [x]other intracerebral haemorrhage Definite 
Gyu6F00 [x]intracerebral haemorrhage in hemisphere, unspecified Definite 
G601.00 subarachnoid haemorrhage from carotid siphon and 
bifurcation 
Definite 
G602.00 subarachnoid haemorrhage from middle cerebral artery Definite 
G60X.00 subarachnoid haemorrh from intracranial artery, unspecif Definite 
Gyu6000 [x]subarachnoid haemorrhage from other intracranial 
arteries 
Definite 
Gyu6E00 [x]subarachnoid haemorrh from intracranial artery, unspecif Definite 
2Ba2200 scpe class predom patt c.3 infarct of middle cerebral artery Definite 
9N0p.00 seen in stroke clinic Definite 
Fyu5700 [x]other vascular syndroms/brain in cerebrovasculr diseases Definite 
G66..00 stroke and cerebrovascular accident unspecified Definite 
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G66..11 cva unspecified Definite 
G66..12 stroke unspecified Definite 
G66..13 cva - cerebrovascular accident unspecified Definite 
G663.00 brain stem stroke syndrome Definite 
G664.00 cerebellar stroke syndrome Definite 
G665.00 pure motor lacunar syndrome Definite 
G667.00 left sided cva Definite 
G668.00 right sided cva Definite 
L440.11 cva - cerebrovascular accident in the puerperium Definite 
L440.12 stroke in the puerperium Definite 
1JA1000 suspected cerebrovascular accident Possible 
1JA1011 suspected stroke Possible 
661M700 stroke self-management plan agreed Possible 
8HBJ.00 stroke / transient ischaemic attack referral Possible 
8HHM.00 ref to multidisciplinary stroke function improvement service Possible 
8HTQ.00 referral to stroke clinic Possible 
8Hd6.00 admission to stroke unit Possible 
C315100 mitochond encephalopathy, lact acidosis & strokelike 
episode 
Possible 
7017000 evacuation of subdural haematoma Definite 
G621.00 subdural haemorrhage - nontraumatic Definite 
G622.00 subdural haematoma - nontraumatic Definite 
G623.00 subdural haemorrhage nos Definite 
7032000 evacuation of extradural haematoma Definite 
G620.00 extradural haemorrhage - nontraumatic Definite 
A94y600 rupture of syphilitic cerebral aneurysm Definite 
14A7.00 h/o: cva/stroke History 
14A7.11 h/o: cva History 
14A7.12 h/o: stroke History 
14AK.00 h/o: stroke in last year History 
1M4..00 central post-stroke pain History 
5C13.00 old cerebral infarction on imaging History 
661N700 stroke self-management plan review History 
662M.00 stroke monitoring History 
662M100 stroke 6 month review History 
662M200 stroke initial post discharge review History 
662e.00 stroke/cva annual review History 
662e.11 stroke annual review History 
662o.00 haemorrhagic stroke monitoring History 
7P24200 delivery of rehabilitation for stroke History 
9Om..00 stroke/transient ischaemic attack monitoring administration History 
9Om0.00 stroke/transient ischaemic attack monitoring first letter History 
9Om1.00 stroke/transient ischaemic attack monitoring second letter History 
9Om2.00 stroke/transient ischaemic attack monitoring third letter History 
9Om3.00 stroke/transient ischaemic attack monitoring verbal invitati History 
9Om4.00 stroke/transient ischaemic attack monitoring telephone 
invte 
History 
G64z100 wallenberg syndrome History 
G64z111 lateral medullary syndrome History 
G681.00 sequelae of intracerebral haemorrhage History 
G682.00 sequelae of other nontraumatic intracranial haemorrhage History 
G683.00 sequelae of cerebral infarction History 
G68X.00 sequelae of stroke,not specfd as h'morrhage or infarction History 
ZLEP.00 discharge from stroke serv History 
ZV12511 [v]personal history of stroke History 
ZV12512 [v]personal history of cerebrovascular accident (cva) History 
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Appendix 4.8 – Arrhythmia code list 
Read Code Description Definite/possible/history 
of 
3272.00 ecg: atrial fibrillation Definite 
3273.00 ecg: atrial flutter Definite 
793M100 perc transluminal ablation of atrial wall for atrial flutter Definite 
793M300 perc translum ablat conduct sys heart for atrial flutter nec Definite 
8OAD.00 provision of written information about atrial fibrillation Definite 
G573.00 atrial fibrillation and flutter Definite 
G573000 atrial fibrillation Definite 
G573100 atrial flutter Definite 
G573200 paroxysmal atrial fibrillation Definite 
G573300 non-rheumatic atrial fibrillation Definite 
G573400 permanent atrial fibrillation Definite 
G573500 persistent atrial fibrillation Definite 
G573600 paroxysmal atrial flutter Definite 
G573z00 atrial fibrillation and flutter nos Definite 
7936A00 implant intravenous pacemaker for atrial fibrillation Possible 
8CMW200 atrial fibrillation care pathway Possible 
8HTy.00 referral to atrial fibrillation clinic Possible 
2426.00 o/e - pulse rate tachycardia Definite 
2426.11 o/e - tachycardia Definite 
3282.00 ecg: ventricular tachycardia Definite 
G570.00 paroxysmal supraventricular tachycardia Definite 
G570000 paroxysmal atrial tachycardia Definite 
G570100 paroxysmal atrioventricular tachycardia Definite 
G570200 paroxysmal junctional tachycardia Definite 
G570300 paroxysmal nodal tachycardia Definite 
G570z00 paroxysmal supraventricular tachycardia nos Definite 
G571.00 paroxysmal ventricular tachycardia Definite 
G571.11 ventricular tachycardia Definite 
G572.00 paroxysmal tachycardia unspecified Definite 
G572000 essential paroxysmal tachycardia Definite 
G572z00 paroxysmal tachycardia nos Definite 
G57y700 sinus tachycardia Definite 
G57y900 supraventricular tachycardia nos Definite 
R050.00 [d]tachycardia, unspecified Definite 
R050.12 [d]postural orthostatic tachycardia syndrome (pots) Definite 
2422.00 o/e - pulse rate - bradycardia Definite 
2422.11 o/e - bradycardia Definite 
G57y000 persistent sinus bradycardia Definite 
G57y100 severe sinus bradycardia Definite 
R059.00 [d]sinus bradycardia Definite 
R05W.00 [d] bradycardia, unspecified Definite 
Ryu0600 [x]bradycardia, unspecified Definite 
327..00 ecg: supraventricular arrhythmia Definite 
328..00 ecg: ventricular arrhythmia Definite 
328Z.00 ecg: ventricular arrhythmia nos Definite 
G57..00 cardiac dysrhythmias Definite 
G57..11 cardiac arrhythmias Definite 
G577.00 sinus arrhythmia Definite 
G57y.00 other cardiac dysrhythmias Definite 
G57yA00 re-entry ventricular arrhythmia Definite 
G57yz00 other cardiac dysrhythmia nos Definite 
G57z.00 cardiac dysrhythmia nos Definite 
Gyu5a00 [x]other specified cardiac arrhythmias Definite 
1J62.00 suspected arrhythmia Possible 
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14AN.00 h/o: atrial fibrillation History 
14AP.00 history of ventricular tachycardia History 
14AQ.00 history of supraventricular tachycardia History 
14AR.00 history of atrial flutter History 
212R.00 atrial fibrillation resolved History 
662S.00 atrial fibrillation monitoring History 
6A9..00 atrial fibrillation annual review History 
9Os0.00 atrial fibrillation monitoring first letter History 
9Os1.00 atrial fibrillation monitoring second letter History 
9Os2.00 atrial fibrillation monitoring third letter History 
9Os3.00 atrial fibrillation monitoring verbal invite History 
9Os4.00 atrial fibrillation monitoring telephone invite History 
 
 
221 
 
 
Appendix 4.9 – HF code list 
Read Code Description Definite/possible/history 
of 
G343.00 ischaemic cardiomyopathy Definite 
G554.00 other primary cardiomyopathies Definite 
G554000 congestive cardiomyopathy Definite 
G554011 congestive obstructive cardiomyopathy Definite 
G554400 primary dilated cardiomyopathy Definite 
G554z00 other primary cardiomyopathy nos Definite 
G55y.11 secondary dilated cardiomyopathy Definite 
G551.00 hypertrophic obstructive cardiomyopathy Definite 
G554300 hypertrophic non-obstructive cardiomyopathy Definite 
Gyu5M00 [x]other hypertrophic cardiomyopathy Definite 
Gyu5N00 [x]other restrictive cardiomyopathy Definite 
G559.00 arrhythmogenic right ventricular cardiomyopathy Definite 
F391B00 cardiomyopathy in duchenne muscular dystrophy Definite 
G55..00 cardiomyopathy Definite 
G552.00 obscure african cardiomyopathy Definite 
G554100 constrictive cardiomyopathy Definite 
G554500 takotsubo cardiomyopathy Definite 
G554511 stress cardiomyopathy Definite 
G557.00 nutritional and metabolic cardiomyopathies Definite 
G557z00 nutritional and metabolic cardiomyopathy nos Definite 
G558.00 cardiomyopathy in disease ec Definite 
G558000 cardiomyopathy in friedreich's ataxia Definite 
G558100 cardiomyopathy in myotonic dystrophy Definite 
G558200 dystrophic cardiomyopathy Definite 
G558400 amyloid cardiomyopathy Definite 
G558z00 cardiomyopathy in diseases ec, nos Definite 
G55y.00 secondary cardiomyopathy nos Definite 
G55y000 cardiomyopathy due to drugs and other external agents Definite 
G55z.00 cardiomyopathy nos Definite 
Gyu5P00 [x]other cardiomyopathies Definite 
Gyu5R00 [x]cardiomyopathy in metabolic diseases ce Definite 
L186500 cardiomyopathy in the puerperium Definite 
1736.00 paroxysmal nocturnal dyspnoea Possible 
1J60.00 suspected heart failure Possible 
1O1..00 heart failure confirmed Definite 
23E1.00 o/e - pulmonary oedema Possible 
2JZ..00 on optimal heart failure therapy Possible 
388D.00 new york heart assoc classification heart failure 
symptoms 
Definite 
585f.00 echocardiogram shows left ventricular systolic 
dysfunction 
Definite 
585g.00 echocardiogram shows left ventricular diastolic 
dysfunction 
Definite 
661M500 heart failure self-management plan agreed Possible 
662f.00 new york heart association classification - class i Definite 
662g.00 new york heart association classification - class ii Definite 
662h.00 new york heart association classification - class iii Definite 
662i.00 new york heart association classification - class iv Definite 
679W100 education about deteriorating heart failure Possible 
679X.00 heart failure education Possible 
8B29.00 cardiac failure therapy Possible 
8CL3.00 heart failure care plan discussed with patient Possible 
8CMW800 heart failure clinical pathway Possible 
8H2S.00 admit heart failure emergency Definite 
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8HHz.00 referral to heart failure exercise programme Possible 
8HTL000 referral to rapid access heart failure clinic Possible 
8Hk0.00 referred to heart failure education group Possible 
9N0k.00 seen in heart failure clinic Possible 
9N2p.00 seen by community heart failure nurse Possible 
9N4s.00 did not attend practice nurse heart failure clinic Possible 
9N4w.00 did not attend heart failure clinic Possible 
9N6T.00 referred by heart failure nurse specialist Possible 
G400.00 acute cor pulmonale Definite 
G41z.11 chronic cor pulmonale Definite 
G58..00 heart failure Definite 
G58..11 cardiac failure Definite 
G580.00 congestive heart failure Definite 
G580.11 congestive cardiac failure Definite 
G580.12 right heart failure Definite 
G580.13 right ventricular failure Definite 
G580.14 biventricular failure Definite 
G580000 acute congestive heart failure Definite 
G580100 chronic congestive heart failure Definite 
G580200 decompensated cardiac failure Definite 
G580300 compensated cardiac failure Definite 
G581.00 left ventricular failure Definite 
G581.12 pulmonary oedema - acute Possible 
G581.13 impaired left ventricular function Definite 
G581000 acute left ventricular failure Definite 
G582.00 acute heart failure Definite 
G583.00 heart failure with normal ejection fraction Definite 
G583.11 hfnef - heart failure with normal ejection fraction Definite 
G583.12 heart failure with preserved ejection fraction Definite 
G584.00 right ventricular failure Definite 
G58z.00 heart failure nos Definite 
G58z.12 cardiac failure nos Definite 
G5yy900 left ventricular systolic dysfunction Definite 
G5yyA00 left ventricular diastolic dysfunction Definite 
G5yyB00 right ventricular diastolic dysfunction Definite 
G5yyD00 left ventricular cardiac dysfunction Definite 
G5yyE00 right ventricular systolic dysfunction Definite 
H465.00 chemical-induced pulmonary oedema Possible 
H54..00 pulmonary congestion and hypostasis Possible 
H541.00 pulmonary congestion Possible 
H541000 chronic pulmonary oedema Possible 
H541z00 pulmonary oedema nos Possible 
H54z.00 pulmonary congestion and hypostasis nos Possible 
H584.00 acute pulmonary oedema unspecified Possible 
H584z00 acute pulmonary oedema nos Possible 
R2y1000 [d]cardiorespiratory failure Definite 
ZRad.00 new york heart assoc classification heart failure 
symptoms 
Definite 
G580400 congestive heart failure due to valvular disease Definite 
G210.00 malignant hypertensive heart disease Definite 
G210000 malignant hypertensive heart disease without ccf Definite 
G210100 malignant hypertensive heart disease with ccf Definite 
G210z00 malignant hypertensive heart disease nos Definite 
G211100 benign hypertensive heart disease with ccf Definite 
G21z100 hypertensive heart disease nos with ccf Definite 
G230.00 malignant hypertensive heart and renal disease Definite 
G232.00 hypertensive heart&renal dis wth (congestive) heart 
failure 
Definite 
G234.00 hyperten heart&renal dis+both(congestv)heart and renal 
fail 
Definite 
G1yz100 rheumatic left ventricular failure Definite 
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H461.00 acute pulmonary oedema due to chemical fumes Possible 
Q48y100 congenital cardiac failure Definite 
14A6.00 h/o: heart failure History 
14AM.00 h/o: heart failure in last year History 
183B.00 worsening pulmonary oedema History 
2126400 heart failure resolved History 
662T.00 congestive heart failure monitoring History 
662W.00 heart failure annual review History 
662p.00 heart failure 6 month review History 
8CMK.00 has heart failure management plan History 
8HBE.00 heart failure follow-up History 
9On..00 left ventricular dysfunction monitoring administration History 
9On0.00 left ventricular dysfunction monitoring first letter History 
9On1.00 left ventricular dysfunction monitoring second letter History 
9On2.00 left ventricular dysfunction monitoring third letter History 
9On3.00 left ventricular dysfunction monitoring verbal invite History 
9On4.00 left ventricular dysfunction monitoring telephone invite History 
9Or..00 heart failure monitoring administration History 
9Or0.00 heart failure review completed History 
9Or1.00 heart failure monitoring telephone invite History 
9Or2.00 heart failure monitoring verbal invite History 
9Or3.00 heart failure monitoring first letter History 
9Or4.00 heart failure monitoring second letter History 
9Or5.00 heart failure monitoring third letter History 
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Appendix 4.10 – Pericarditis code list 
Read Code Description Definite/possible/history 
of 
AB40300 histoplasma capsulatum with pericarditis Definite 
AB41300 histoplasma duboisii with pericarditis Definite 
G501.00 post infarction pericarditis Definite 
G531.00 adhesive pericarditis Definite 
G531z00 adhesive pericarditis nos Definite 
G532.00 constrictive pericarditis Definite 
G532z00 constrictive pericarditis nos Definite 
Gyu5400 [x]pericarditis in other diseases classified elsewhere Definite 
N000400 systemic lupus erythematosus with pericarditis Definite 
A364100 meningococcal pericarditis Definite 
A742100 coxsackie pericarditis Definite 
A93y000 syphilitic pericarditis Definite 
A98y200 gonococcal pericarditis Definite 
G500000 acute pericarditis - coxsackie Definite 
G500100 acute pericarditis - meningococcal Definite 
G500300 acute pericarditis - tuberculous Definite 
G500311 tb - acute pericarditis Definite 
G500500 acute pericarditis - gonococcal Definite 
G50z111 viral pericarditis nos Definite 
G50z200 acute pericarditis - pneumococcal Definite 
G50z300 acute pericarditis - staphylococcal Definite 
G50z400 acute pericarditis - streptococcal Definite 
G010.00 acute rheumatic pericarditis Definite 
G50..00 acute pericarditis Definite 
G500.00 acute pericarditis in diseases ec Definite 
G500400 acute pericarditis - uraemic Definite 
G500z00 acute pericarditis in diseases ec nos Definite 
G50z.00 other and unspecified acute pericarditis Definite 
G50z000 acute pericarditis - unspecified Definite 
G50z100 acute idiopathic pericarditis Definite 
G50z500 acute purulent pericarditis unspecified Definite 
G50zz00 acute pericarditis nos Definite 
Gyu5000 [x]other forms of acute pericarditis Definite 
G10..00 chronic rheumatic pericarditis Definite 
G102.00 chronic rheumatic myopericarditis Definite 
G53yz11 chronic pericarditis Definite 
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Appendix 4.11 – VHD code list 
Read Code Description Definite/possible/history 
of 
G121.00 rheumatic aortic insufficiency Definite 
G121.12 aortic regurgitation - rheumatic Definite 
G122.00 rheumatic aortic stenosis with insufficiency Definite 
G541011 aortic insufficiency, non-rheumatic Definite 
G541012 aortic regurgitation, non-rheumatic Definite 
G541211 aortic insufficiency alone, cause unspecified Definite 
G541212 aortic regurgitation alone, cause unspecified Definite 
G541400 aortic valve stenosis with insufficiency Definite 
P63..00 congenital aortic valve stenosis Definite 
P64..00 congenital aortic valve insufficiency Definite 
P640.00 congenital aortic valve insufficiency, unspecified Definite 
P64z.00 congenital aortic valve insufficiency nos Definite 
G111.00 rheumatic mitral insufficiency Definite 
G111.12 mitral regurgitation - rheumatic Definite 
G112.00 mitral stenosis with insufficiency Definite 
G112.13 mitral stenosis with regurgitation Definite 
G113.00 nonrheumatic mitral valve stenosis Definite 
G131.00 mitral stenosis and aortic insufficiency Definite 
G131.14 mitral stenosis and aortic regurgitation Definite 
G132.00 mitral insufficiency and aortic stenosis Definite 
G132.13 mitral regurgitation and aortic stenosis Definite 
G133.11 mitral and aortic insufficiency Definite 
G133.12 mitral and aortic regurgitation Definite 
G540.12 mitral valve insufficiency Definite 
G540.14 mitral valve regurgitation Definite 
G540.16 mitral regurgitation Definite 
P66..00 congenital mitral insufficiency Definite 
G141100 rheumatic pulmonary insufficiency Definite 
G141200 rheumatic pulmonary stenosis and insufficiency Definite 
G543011 pulmonary insufficiency, non-rheumatic Definite 
G543012 pulmonary regurgitation, non-rheumatic Definite 
G543213 pulmonary insufficiency, cause unspecified Definite 
G543215 pulmonary regurgitation, cause unspecified Definite 
G543400 pulmonary valve stenosis with insufficiency Definite 
H585.00 trauma and post-operative pulmonary 
insufficiency 
Definite 
H585200 pulmonary insufficiency following trauma Definite 
G140100 rheumatic tricuspid insufficiency Definite 
G140111 tricuspid regurgitation - rheumatic Definite 
G140200 rheumatic tricuspid stenosis and insufficiency Definite 
G14021X rheumatic tricuspid stenosis and regurgitation Definite 
G140400 tricuspid insufficiency, cause unspecified Definite 
G140413 tricuspid regurgitation, cause unspecified Definite 
G140500 tricuspid stenosis and insufficiency, cause 
unspecified 
Definite 
G140514 tricuspid stenosis and regurgitation, cause 
unspecified 
Definite 
G542011 tricuspid insufficiency, non-rheumatic Definite 
G542012 tricuspid regurgitation, non-rheumatic Definite 
G542200 nonrheumatic tricuspid valve stenosis with 
insufficiency 
Definite 
G54z500 valvular heart disease Definite 
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Appendix 4.12 – DVT code list  
Read Code Description Definite/possible/history 
of 
1JH..00 suspected deep vein thrombosis Possible 
8HTm.00 referral to deep vein thrombosis clinic Possible 
G801.11 deep vein thrombosis Definite 
G801.13 dvt - deep vein thrombosis Definite 
G801900 thrombophlebitis of the dorsalis pedis vein Definite 
G801D00 deep vein thrombosis of lower limb Definite 
G801G00 recurrent deep vein thrombosis Definite 
G801H00 unprovoked deep vein thrombosis Definite 
G801J00 provoked deep vein thrombosis Definite 
G80y.11 phlebitis and/or thrombophlebitis of iliac vein Definite 
G80y400 thrombophlebitis of the common iliac vein Definite 
G80y500 thrombophlebitis of the internal iliac vein Definite 
G80y600 thrombophlebitis of the external iliac vein Definite 
G80y700 thrombophlebitis of the iliac vein unspecified Definite 
G80y800 phlebitis and thrombophlebitis of the iliac vein nos Definite 
G81..00 portal vein thrombosis Definite 
G820.11 hepatic vein thrombosis Definite 
G822.00 embolism and thrombosis of the vena cava Definite 
G822000 thrombosis of inferior vena cava Definite 
J420200 thrombus of the superior mesenteric veins Definite 
SP12200 post operative deep vein thrombosis Definite 
G801.00 deep vein phlebitis and thrombophlebitis of the leg Definite 
G801.12 deep vein thrombosis, leg Definite 
G801600 thrombophlebitis of the femoral vein Definite 
G801700 thrombophlebitis of the popliteal vein Definite 
G801800 thrombophlebitis of the anterior tibial vein Definite 
G801A00 thrombophlebitis of the posterior tibial vein Definite 
G801B00 deep vein thrombophlebitis of the leg unspecified Definite 
G801C00 deep vein thrombosis of leg related to air travel Definite 
G801E00 deep vein thrombosis of leg related to intravenous drug 
use 
Definite 
G801F00 deep vein thrombosis of peroneal vein Definite 
G801z00 deep vein phlebitis and thrombophlebitis of the leg nos Definite 
F05..00 phlebitis and thrombophlebitis of intracranial sinuses Definite 
F051.00 thrombosis of central nervous system venous sinuses Definite 
F051z00 thrombosis of central nervous system venous sinus nos Definite 
F053.00 thrombophlebitis of central nervous system venous 
sinuses 
Definite 
F053000 thrombophlebitis of cavernous sinus Definite 
F053100 thrombophlebitis of superior longitudinal venous sinus Definite 
F05z.00 phlebitis or thrombophlebitis of cns venous sinus nos Definite 
G676.00 nonpyogenic venous sinus thrombosis Definite 
14A8100 h/o: deep vein thrombosis History 
ZV12800 [v] personal history deep vein thrombosis History 
ZV12811 [v] personal history dvt- deep vein thrombosis History 
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Appendix 4.13 – Pulmonary Embolism code list 
Read Code Description Definite/possible/history 
of 
G401.00 pulmonary embolism Definite 
L43..00 obstetric pulmonary embolism Definite 
G401.12 pulmonary embolus Definite 
G401000 post operative pulmonary embolus Definite 
L430.00 obstetric air pulmonary embolism Definite 
7A09311 trendelenburg pulmonary embolectomy Definite 
L431.00 amniotic fluid pulmonary embolism Definite 
L432.00 obstetric blood-clot pulmonary embolism Definite 
L096400 pulmonary embolism following abortive pregnancy Definite 
L43..11 obstetric pulmonary embolus Definite 
L43z.00 obstetric pulmonary embolism nos Definite 
L431100 amniotic fluid pulmonary embolism - delivered Definite 
G401100 recurrent pulmonary embolism Definite 
L43z100 obstetric pulmonary embolism nos - delivered Definite 
L43zz00 obstetric pulmonary embolism nos Definite 
L43z000 obstetric pulmonary embolism nos, unspecified Definite 
L43yz00 other obstetric pulmonary embolism nos Definite 
1JC..00 suspected pulmonary embolism Possible 
14AC.00 h/o: pulmonary embolus History 
ZV12900 [v] personal history of pulmonary embolism History 
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Appendix 4.14 – HES ICD-10 and OPCS-4 code list for CVD outcomes 
Outcome  ICD-10/OPCS-4 codes 
Angina I20, I20.0, I20.1, I20.8, I20.9 
MI I21, I21.0, I21.1, I21.2, I21.3, I21.4, I21.9 
Revascularisation K234, K40, K401, K402, K403, K404, K408, K409, K41, K411, K412, K413, K414, K418, K419, 
K42, K421, K422, K423, K424, K428, K429, K46, K468, K469, K493, L16, L161, L162, L163, 
L168, L169, L20, L201, L202, L203, L204, L205, L206, L208, L209, L21, L211, L212, L213, 
L214, L215, L216, L218, L219, L292, L293, L296, L297, L371, L412, L451, L50, L501, L502, 
L503, L504, L505, L506, L508, L509, L51, L511, L512, L513, L514, L515, L516, L518, L519, 
L58, L581, L582, L583, L584, L585, L586, L587, L588, L589, L59, L591, L592, L593, L594, 
L595, L596, L597, L598, L599, L81, L818, L819, L831, Y731 
SCA I46, I46.0, I46.1, I46.9 
PVD I70.2, I70.20, I70.21, I73, I73.8, I73.9, I79.2 
Stroke I60, I60.0, I60.1, I60.2, I60.3, I60.4, I60.5, I60.6, I60.7, I60.8, I60.9, I61, I61.0, I61.1, I61.2, 
I61.3, I61.4, I61.5, I61.6, I61.8, I61.9, I62, I62.0, I62.1, I62.9, I63, I63.0, I63.1, I63.2, I63.3, 
I63.4, I63.5, I63.6, I63.8, I63.9, I64 
Arrhythmia I48, I49, I49.0, I49.1, I49.2, I49.3, I49.4, I49.5, I49.8, I49.9 
HF I25.5, I42, I42.0, I42.1, I42.2, I42.3, I42.4, I42.5, I42.6, I42.7, I42.8, I42.9, I43, I43.0, I43.1, 
I43.2, I43.8, I50, I50.0, I50.1, I50.9 
Pericarditis I30, I30.0, I30.1, I30.8, I30.9, I31, I31.0, I31.1, I31.2, I31.3, I31.8, I31.9, I32, I32.0, I32.1, 
I32.8 
VHD I05, I05.0, I05.1, I05.2, I05.8, I05.9, I06, I06.0, I06.1, I06.2, I06.8, I06.9, I07, I07.0, I07.1, 
I07.2, I07.8, I07.9, I08, I08.0, I08.1, I08.2, I08.3, I08.8, I08.9, I34, I34.0, I34.1, I34.2, I34.8, 
I34.9, I35, I35.0, I35.1, I35.2, I35.8, I35.9, I36, I36.0, I36.1, I36.2, I36.8, I36.9, I37, I37.0, 
I37.1, I37.2, I37.8, I37.9 
DVT I80.1, I80.2, I80.3 
Pulmonary Embolism I26, I26.0, I26.9 
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Appendix 4.15 - Concordance between events identified in CPRD and HES for the outcomes in which new 
codes were identified 
Outcome  Before 
or after 
code list 
update 
Women in 
study 
population 
Incident events 
when use both 
CPRD and HES 
(% of study 
population) 
Incident 
events 
identified 
form CPRD (% 
of total 
events) 
Incident 
events 
identified 
form HES (% 
of total 
events) 
Overlap 
between 
CPRD and 
HES (% of 
total 
events) 
Median 
time 
between 
events in 
CPRD and 
HES (days) 
Arrhythmia Before 9060 542 (5.98) 344 (63.47) 359 (66.24) 184 (33.95) 102.5 
After 8445 679 (8.04) 507 (74.67) 331 (48.75) 188 (27.69) 203.5 
Pericarditis Before 9986 22 (0.22) 1 (4.55) 22 (100.00) 1 (4.55) 12 
After 9983 27 (0.27) 9 (33.33) 22 (81.48) 4 (14.81) 12.5 
Valvular Heart 
Disease 
Before 9755 223 (2.29) 70 (31.39) 166 (74.44) 18 (8.07) 311.5 
After 9729 232 (2.38) 107 (46.12) 157 (67.67) 39 (16.81) 214 
Revascularisation Before 9916 44 (0.44) 21 (47.73) 37 (84.09) 14 (31.82) 5 
After 9901 47 (0.47) 35 (74.47) 37 (78.72) 25 (53.19) 3 
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Appendix 4.16 - Proportion of primary diagnoses in HES events, and corresponding primary 
diagnoses if event was a secondary diagnosis 
Outcome (ICD letter of 
outcome) 
Total number of events 
in HES 
Number of HES events 
that were the primary 
diagnosis (proportion of 
all HES events) 
ICD chapter of primary 
diagnosis, if event was 
secondary diagnosis 
Number of secondary 
diagnoses with same  
ICD chapter of primary 
diagnosis (proportion of 
all secondary diagnoses) 
Angina (I) 167 42 (25.10) A 2 (1.60) 
   C 8 (6.40) 
   D 2 (1.60) 
   E 5 (4.00) 
   G 1 (0.80) 
   H 9 (7.20) 
   I 36 (28.80) 
   J 10 (8.00) 
   K 11 (8.80) 
   M 9 (7.20) 
   N 9 (7.20) 
   R 15 (12.00) 
   S 7 (5.60) 
   Z 1 (0.80) 
MI (I) 132 79 (59.80) A 1 (1.90) 
   C 4 (7.50) 
   D 1 (1.90) 
   G 2 (3.80) 
   I 19 (35.80) 
   J 5 (9.40) 
   K 3 (5.70) 
   M 2 (3.80) 
   R 11 (20.80) 
   S 5 (9.40) 
SCA (I) 38 10 (26.30) A 1 (3.60) 
   C 1 (3.60) 
   D 1 (3.60) 
   E 1 (3.60) 
   G 1 (3.60) 
   I 8 (28.60) 
   J 7 (25.00) 
   K 4 (14.30) 
   N 1 (3.60) 
   R 2 (7.10) 
   T 1 (3.60) 
PVD (I) 41 10 (24.40) A 1 (3.20) 
   C 1 (3.20) 
   D 1 (3.20) 
   E 1 (3.20) 
   G 1 (3.20) 
   H 2 (6.50) 
   I 10 (32.30) 
   J 1 (3.20) 
   K 2 (6.50) 
   L 1 (3.20) 
   M 3 (9.70) 
   N 1 (3.20) 
   R 4 (12.90) 
   T 1 (3.20) 
   Z 1 (3.20) 
Stroke (I) 197 137 (69.50) C 5 (8.30) 
   E 1 (1.70) 
   G 5 (8.30) 
   H 2 (3.30) 
   I 16 (26.70) 
   J 8 (13.30) 
   M 4 (6.70) 
   N 1 (1.70) 
   R 10 (16.70) 
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   S 7 (11.70) 
   T 1 (1.70) 
Arrhythmia (I) 416 68 (16.30) A 12 (3.40) 
   C 26 (7.50) 
   D 6 (1.70) 
   E 7 (2.00) 
   F 2 (0.60) 
   G 3 (0.90) 
   H 4 (1.10) 
   I 80 (23.00) 
   J 57 (16.40) 
   K 31 (8.90) 
   L 7 (2.00) 
   M 19 (5.50) 
   N 26 (7.50) 
   R 43 (12.40) 
   S 20 (5.70) 
   T 4 (1.10) 
   Z 1 (0.30) 
HF (I) 322 75 (23.30) A 10 (4.00) 
   C 11 (4.50) 
   E 7 (2.80) 
   G 4 (1.60) 
   H 2 (0.80) 
   I 67 (27.10) 
   J 46 (18.60) 
   K 16 (6.50) 
   L 5 (2.00) 
   M 12 (4.90) 
   N 17 (6.90) 
   R 29 (11.70) 
   S 16 (6.50) 
   T 4 (1.60) 
   Z 1 (0.40) 
Pericarditis (I) 33 3 (9.10) A 1 (3.30) 
   C 8 (26.70) 
   I 9 (30.00) 
   J 6 (20.00) 
   K 1 (3.30) 
   N 1 (3.30) 
   R 3 (10.00) 
   T 1 (3.30) 
VHD (I) 192 17 (8.90) A 3 (1.70) 
   C 4 (2.30) 
   E 2 (1.10) 
   F 1 (0.60) 
   G 1 (0.60) 
   H 6 (3.40) 
   I 71 (40.60) 
   J 24 (13.70) 
   K 8 (4.60) 
   L 2 (1.10) 
   M 12 (6.90) 
   N 4 (2.30) 
   Q 1 (0.60) 
   R 21 (12.00) 
   S 11 (6.30) 
   T 3 (1.70) 
   Z 1 (0.60) 
DVT (I) 100 57 (57.00) A 1 (2.30) 
   C 7 (16.30) 
   D 1 (2.30) 
   G 1 (2.30) 
   I 12 (27.90) 
   J 2 (4.70) 
   K 4 (9.30) 
   L 2 (4.70) 
   M 4 (9.30) 
   N 3 (7.00) 
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   R 4 (9.30) 
   S 1 (2.30) 
   Z 1 (2.30) 
Pulmonary Embolism (I) 147 79 (53.70) A 4 (5.90) 
   B 1 (1.50) 
   C 12 (17.60) 
   D 2 (2.90) 
   G 1 (1.50) 
   I 10 (14.70) 
   J 10 (14.70) 
   K 5 (7.40) 
   M 6 (8.80) 
   N 3 (4.40) 
   R 11 (16.20) 
   S 2 (2.90) 
   T 1 (1.50) 
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CHAPTER 5 
Appendix 5.1 – Defining a breast cancer diagnosis 
Code list is available at https://doi.org/10.17037/DATA.177. All women with a breast cancer 
diagnosis in the study period were identified in order to define the study population.  A code list 
generated for a previous project was used, which included all breast cancer Read codes that fall 
under the C50 ICD-10 code. Clinical and referral files were then used to search for incident breast 
cancer diagnoses within the study period, that were more than a year after the women had entered 
the CPRD system (to ensure an incident event).  
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Appendix 5.2 – Identification of drug prescription codes 
CPRD assigns product codes to drugs prescribed by GPs. Information on the product name, British 
National Formulary (BNF) header, drug substance, strength, formulation, and route by which drug is 
given are also provided in the CPRD therapy file.  
 
The following algorithm was used to define code lists for drug prescriptions:  
 A list of inclusion search terms, which were synonyms of the drug and any related brand 
names, was agreed with the clinicians involved in the study  
 The CPRD product code dictionary was then searched to identify any codes with one of the 
search terms in the product name or drug substance field 
 Using a list of pre-specified terms and scanning the codes initially identified, a list of 
exclusion terms was created and applied 
 Codes and their descriptors were manually reviewed to decide if they were appropriate for 
the final code list  
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Appendix 5.3 - Ever exposure to endocrine therapy categorisation 
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Appendix 5.4 - Current exposure to endocrine therapy categorisation  
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Appendix 5.5 – Defining length endocrine therapy prescriptions 
Information on the quantity of drugs prescribed and the recommended number of pills to take per 
day (numeric daily dose, ndd) is in the therapy file of CPRD. From this, it is possible to calculate the 
intended length of prescription (ndd multiplied by quantity). However, some of the entries within 
these fields are unreliable. The following sections therefore explore the quantity and ndd of 
tamoxifen and AI prescriptions to identify unreliable entries and replace them with entries that are 
more realistic.  
Refinement of tamoxifen prescriptions 
There were 146,670 tamoxifen prescriptions given to those women within the linked CPRD and HES 
study population.  The ndd of these prescriptions ranged from 0 to 20, with a median ndd of 1. As 
99.95% of prescriptions had an ndd of 10 or less, and it is impossible to have an ndd of 0, all 
prescriptions with an ndd of 0 or greater than 10 were imputed with the median of 1. 
 
The quantity of drugs prescribed ranged from 1 to 900, with a median of 30. It is unlikely that 
tamoxifen is prescribed in quantities of less than 7 (0.16% of prescriptions were given in a quantity 
of less than 7) and an extremely high quantity of drugs are very unlikely (99.45% of prescriptions 
were given in a quantity of 300 or less). All prescriptions with quantities of less than 7, or more than 
300 were therefore imputed with the median quantity of 30 days.  
Refinement of AI prescriptions 
There were 244,776 AI prescriptions given to those women within the linked CPRD and HES study 
population. The ndd of these prescriptions ranged from 0 to 12, with a median ndd of 1. As 99.99% 
of prescriptions had an ndd of 10 or less, and it is impossible to have an ndd of 0, all prescriptions 
with an ndd of 0 or greater than 10 were imputed with the median of 1, similar to tamoxifen 
prescriptions above.   
 
The quantity of drugs prescribed ranged from 1 to 924 for each prescription, with a median of 28. As 
with tamoxifen, it is unlikely that AIs are prescribed in quantities of less than 7 (0.03% of 
prescriptions were given in a quantity of less than 7), or in extremely high quantities (99.93% of 
prescriptions were given in a quantity of 90 or less). All prescriptions with quantities of less than 7, 
or more than 90 were therefore imputed with the median quantity of 28 days. 
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Appendix 5.6 – Identification of clinical diagnosis codes 
CPRD 
CPRD uses Read codes to identify clinical events that have been diagnosed in primary care. Read 
codes are a coded thesaurus of clinical terms that have been used in the NHS since 1985, which 
provide a standard vocabulary by which clinicians can record patient findings and procedures in 
health and social care IT systems across primary and secondary care. Creation of Read code lists 
representing a certain disease allows identification of patients in CPRD with a diagnosis of that 
disease by merging the code lists with the patients’ raw data files.  
 
A systematic approach was used to define code lists in order to identify clinical diagnoses. The 
relevant dictionaries of codes were searched using STATA do files,[1] so that all decisions on 
inclusion and exclusion criteria were recorded and easily replicated.  
 
A code list for each clinical diagnosis was created using the following algorithm:  
 A list of inclusion search terms, which were synonyms of the medical event, was agreed 
through discussion with the clinical collaborators involved in the study.  
 The CPRD Read code dictionary was then searched to identify any codes with one of the 
search terms in the read term field, which is used to describe the Read code 
 Using a list of pre-specified terms and scanning the codes initially identified, a list of 
exclusion terms was created and applied 
 Codes and their descriptors were manually reviewed to decide if they were appropriate for 
the final code list  
 
HES 
HES uses ICD-10 codes to identify clinical events diagnosed in secondary care. ICD-10 codes are a 
comprehensive classification of causes of morbidity and mortality that is published by the World 
Health Organisation. The 10th revision of ICD codes was published in April 1995, and followed the 9th 
revision (ICD-9) that was published in 1975 and came into use in hospital health systems in 1979. 
Furthermore, OPCS-4 codes are used to classify interventions and procedures, and were originally 
published in 1987 by the Office of Population Censuses and Surveys, and was followed by a 4th 
revision in 1992. 
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CVD outcome events were identified in HES. Clinicians guided the creation of ICD-10 code lists 
relating to all CVD outcomes. OPCS-4 codes lists were also created to identify revascularisation 
procedures carried out in secondary care. These codes lists were then used to search for relevant 
diagnoses in the patients’ raw HES data.  
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Appendix 5.7 – Defining covariates 
All code lists are available at https://doi.org/10.17037/DATA.177.  
Diagnoses 
Code lists for clinical diagnoses were created using the algorithm for CPRD outlined in Appendix 6 
above. Once code lists were created, the following steps were taken to define covariates in the study 
population.  
 
Diabetes and rheumatoid arthritis 
Read code lists were used to search CPRD clinical and referral files to identify any women in the 
study population with a diabetes or rheumatoid arthritis diagnosis prior to index date. 
 
Chronic kidney disease 
Records of an eGFR reading by GPs were identified in the CPRD additional files. CKD was then 
established by calculating eGFR using the Chronic Kidney Disease Epidemiology Collaboration 
equation.[2] Serum creatinine measurements were not routinely isotope-dilution mass 
spectrometry-standardised until 2013. It was therefore assumed that all creatinine results were 
unstandardised and multiplied results with a correction factor of 0.95 before calculating eGFR 
without regard to ethnicity.[3] To avoid selection bias, an absent CKD category was included for 
those with no recorded serum creatinine result. The recording closest to, but before index date was 
used. 
 
Systolic and diastolic blood pressure 
No code lists were created to identify blood pressure as all information was in the CPRD additional 
file.  
CPRD Additional files were searched for instances of when blood pressure was recorded by the GP. 
The following algorithm to identified blood pressure records: 
 Drop record if systolic or diastolic <30 or >250  
 Drop if the record indicates it is a target blood pressure 
 Drop a duplicate if they indicate the same reading on the same day  
 If there are more than once sensible reading in the same day, calculate the mean  
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The following algorithm then assigned a systolic and diastolic blood pressure recording to all women 
with relevant records: 
 Take the nearest status in the period -1y to +1month from index if available (best option)  
 if not, then take nearest in the period +1month to +1y after index if available (second best 
option)  
 if not, then take any nearest before -1y from index if available (third best option) if not, then 
take nearest after +1y from index (least best option)  
 
Blood pressures were then categorised into the following categories.  
 Systolic – low and ideal (<120), pre-high (>=120 & <140), high (>=140)  
 Diastolic – low and ideal (<80), pre-high (>=80 & <90), high (>=90)  
 
Drug Prescriptions 
The algorithm presented in Appendix 2 was used to define drug prescription code lists.  
 
Once code lists were created, the CPRD therapy files were searched to identify women in the study 
population with a prescription of any of statins, ACE inhibitors, calcium channel blockers, 
angiotensin II receptor blockers, anti-platelets, or HRT prescriptions prior to index date  
 
Lifestyle measures 
A similar algorithm to that outlined for diagnoses above was used to create codes lists to identify 
lifestyle measures. The following steps were then taken to define covariates in the study population.  
Smoking status 
A Read code list was created to search for all records of a smoking status in the CPRD clinical file. 
Further available data from the additional file were also extracted, including the patients smoking 
“status” (yes, no or ex) and the “number of cigarettes per day” smoked. The following algorithm was 
then used to assign a smoking status to all women with relevant records.  
 
 Take the nearest status in the period -1y to +1month from index if available (best option)  
 if not, then take nearest in the period +1month to +1y after index if available (second best 
option)  
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 if not, then take any nearest before -1y from index if available (third best option)  
 if not, then take nearest after +1y from index (least best option)  
 
Smoking status was then categorised into non-smoker, current smoker, and ex-smoker.  
 
Alcohol status 
A Read code list was created to identify all records of alcohol usage in the CPRD clinical file. Further 
available data from the additional file were also extracted, including the patient’s alcohol drinking 
“status” (yes, no or ex) and the “units per week” consumed. The above algorithm used to define 
smoking status was also used to assign an alcohol status to all women with relevant records.  
 
Alcohol status was then categorised into non-drinker, current drinker, ex-drinker 
 
BMI 
No read code list was created as all information was available in the CPRD additional files.  
 
CPRD additional files were searched for records of women’s height and weight. BMI is calculated 
using patients weight in kilograms / (height in meters)2. The following algorithm, which was 
described in the paper by Bhaskaran et al. on BMI in the CPRD,[4] was used to identify for BMI 
records:  
 
 drop if 3+ measurements on the same day  
 if 2 measurements on same day: drop if >5cm (ht)/1kg (wt) difference, otherwise take the 
mean  
 initial pass, drop weights less than 2kg, heights less than 2 feet  
 drop records after end of follow-up but keeps those before start of follow-up  
 later, drops weights < 20kg, heights less than 4 or more than 7 feet  
 fill in missing heights using last observation carried forward or if no previous, first future 
height measurement 
 calculate a version of BMI directly from height and weight  
 drop BMIs <5 or >200 (but if CPRD and calculated version differ, and one is in the range 10-
100, use the one within this range)  
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 in general, prioritises calculated BMI, and only uses CPRD version if cannot be calculated (as 
no height measurement available at all)  
 
The above algorithm used to assign smoking status was then used to assign BMI status to all women 
with relevant records.  
 
BMI was categorised according to adult BMI cut-offs defined by the WHO, as underweight or healthy 
weight (BMI <24.9), overweight (BMI 25+), or obese (BMI ≥30).[5] 
 
Demographic measures 
Age 
As CPRD only supplies year of birth, the date of birth was set to 1st of July for all women. Age at index 
was then calculated and categorised into 54-59, 60-69, 70+ years.  
 
Index of multiple deprivation (IMD) 
CPRD supplies patient level IMD scores at the practice level for all patients. IMD combines a number 
of indicators, chosen to cover a range of economic, social and housing issues, into a single 
deprivation score.[6] This score was consolidated into quintiles, with a low quintile representing the 
least deprived, and a high quintile representing the most deprived.  
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Appendix 5.8 – Study design, covariate adjustment, and model selection alternatives 
Study design 
This study is a cohort study using prospectively collected data. It would also have been possible to 
set up a case control study within the CPRD. However, a cohort study enables the calculation of risk 
(which is informative for clinicians), allows modelling prospectively collected data and inclusion of 
time dependent variables (such as endocrine therapy treatment), and more suited to assessing 
causal relationships due to being less prone to bias (potential confounders measured at point of 
exposure in cohort studies instead of at outcome in non-nested case control studies). A cohort study 
was therefore more suited this research question and the data used in comparison with a case 
control study.  
 
Covariate adjustment 
All potential confounders were measured at baseline and were adjusted for in Cox regression model. 
Another possible approach could have been propensity score matching. A propensity score is the 
conditional probability of being treated given the vector of observed covariates. The patients in each 
exposure arm can then be matched based on the propensity score, with the aim of obtaining an 
unbiased estimate of treatment effect adjusted for the impact of given confounding factors. 
However, the propensity score relies on two major assumptions: the observed variables do not 
affect the clinician's decision that a patient will be treated (e.g. lifestyle factors to not affect the 
choice of endocrine therapy); and there are no unmeasured confounders (all the covariates 
potentially related to treatment assignment are known). The propensity score was not used in this 
study because we did not have information on other cancer treatments (such as chemotherapy and 
trastuzumab), which could be potential confounders of the exposure outcome association, so the 
assumption of no unmeasured confounders was not satisfied.  
 
Model selection 
Cox regression was used to model the effect of endocrine therapies on the risk of a range of CVD 
outcomes. Cox regression is a method for investigating the effect of several variables upon the time 
a specified event takes to happen. It also allows time dependent and time fixed covariates, which 
were essential when assessing this association as women could change their exposure from AIs to 
tamoxifen, or vice versa, and their exposure was updated in the models to indicate this change. 
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Another regression strategy could have been Poisson regression. However, Poisson regression 
models count data, which is not suitable in this context as we were only modelling the effect of 
endocrine therapies on incident CVD events. Poisson regression would have been suitable if we 
further explored the effect of treatment on the risk of multiple CVD events. Furthermore, time-to-
event techniques, such as survival analysis and Cox regression achieve greater efficiency and 
accuracy when modelling time varying covariates (such as exposure to endocrine therapy) in 
comparison with Poisson regression.  
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Appendix 5.9: STROBE flow diagram for inclusion in UK study  
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Appendix 5.10 - Crude rates, unadjusted HRs, and adjusted HRs by ever exposure to endocrine 
therapies for a range of clinical CVDs  
Outcome Ever 
exposure  
Number of 
Events 
Person years  
(1000s) 
Crude Rate  
(per 1000 Person-Years) 
Unadjusted HR  
(95% CI) 
Adjusted HR  
(95% CI) * 
Coronary Artery Disease Tamoxifen 93 13.54 6.87 (5.60, 8.41) 1 1 
 AI 131 12.87 10.18 (8.58, 12.08) 1.40 (1.06, 1.86) 1.29 (0.94, 1.76) 
Both 67 10.6 6.32 (4.98, 8.03) 0.95 (0.69, 1.31) 0.95 (0.68, 1.32) 
     Angina 
 
Tamoxifen 56 13.73 4.08 (3.14, 5.30) 1 1 
AI 80 13.15 6.09 (4.89, 7.58) 1.43 (1.00, 2.05) 1.31 (0.88, 1.97) 
Both 31 10.73 2.89 (2.03, 4.11) 0.70 (0.44, 1.10) 0.69 (0.43, 1.10) 
     MI 
 
Tamoxifen 32 14.6 2.19 (1.55, 3.10) 1 1 
AI 61 14.11 4.32 (3.36, 5.56) 1.73 (1.12, 2.68) 1.56 (0.96, 2.52) 
Both 39 11.24 3.47 (2.54, 4.75) 1.62 (1.01, 2.60) 1.62 (0.99, 2.63) 
     Revascularisation 
 
Tamoxifen 15 14.72 1.02 (0.61, 1.69) 1 1 
AI 20 14.3 1.40 (0.90, 2.17) 1.36 (0.69, 2.68) 1.84 (0.85, 4.02) 
Both 12 11.33 1.06 (0.60, 1.86) 0.99 (0.46, 2.11) 1.01 (0.46, 2.22) 
     SCA 
 
Tamoxifen 13 14.88 0.87 (0.51, 1.50) 1 1 
AI 21 14.53 1.45 (0.94, 2.22) 1.87 (0.83, 4.22) 1.65 (0.65, 4.19) 
Both 5 11.43 0.44 (0.18, 1.05) 0.73 (0.24, 2.19) 0.68 (0.22, 2.09) 
PVD Tamoxifen 35 14.64 2.39 (1.72, 3.33) 1 1 
 AI 41 14.08 2.91 (2.14, 3.96) 1.25 (0.77, 2.01) 1.31 (0.76, 2.25) 
 Both 22 11.23 1.96 (1.29, 2.97) 0.81 (0.45, 1.43) 0.86 (0.48, 1.57) 
Stroke 
 
Tamoxifen 91 14.45 6.30 (5.13, 7.73) 1 1 
AI 118 13.71 8.61 (7.19, 10.31) 1.22 (0.91, 1.63) 1.11 (0.81, 1.52) 
Both 88 10.98 8.02 (6.51, 9.88) 1.33 (0.98, 1.80) 1.25 (0.91, 1.71) 
Arrhythmia 
 
Tamoxifen 219 12.7 17.25 (15.11, 19.69) 1 1 
AI 287 11.52 24.90 (22.18, 27.96) 1.37 (1.14, 1.64) 1.37 (1.11, 1.68) 
Both 174 9.51 18.30 (15.77, 21.23) 1.07 (0.87, 1.32) 1.10 (0.89, 1.36) 
HF Tamoxifen 90 14.33 6.28 (5.11, 7.72) 1 1 
 AI 178 13.59 13.10 (11.31, 15.17) 1.87 (1.43, 2.45) 1.68 (1.24, 2.26) 
 Both 76 11.04 6.89 (5.50, 8.62) 1.12 (0.81, 1.55) 1.12 (0.80, 1.56) 
Pericarditis Tamoxifen 3 14.85 0.20 (0.07, 0.63) 1 1 
 AI 14 14.53 0.96 (0.57, 1.63) 3.96 (1.12, 14.03) 3.25 (0.86, 12.23) 
 Both 10 11.4 0.88 (0.47, 1.63) 4.29 (1.18, 15.61) 3.57 (0.95, 13.50) 
VHD Tamoxifen 66 14.54 4.54 (3.57, 5.78) 1 1 
 AI 114 13.93 8.18 (6.81, 9.83) 1.58 (1.15, 2.17) 1.30 (0.92, 1.85) 
 Both 52 11.14 4.67 (3.56, 6.13) 1.08 (0.74, 1.57) 0.98 (0.67, 1.43) 
VTE 
 
Tamoxifen 122 14.41 8.47 (7.09, 10.11) 1 1 
AI 116 13.4 8.66 (7.22, 10.38) 0.93 (0.71, 1.21) 0.82 (0.61, 1.10) 
Both 85 10.63 8.00 (6.47, 9.89) 0.91 (0.69, 1.22) 0.95 (0.71, 1.28) 
     DVT 
 
Tamoxifen 83 14.52 5.72 (4.61, 7.09) 1 1 
AI 62 13.78 4.50 (3.51, 5.77) 0.69 (0.48, 0.98) 0.63 (0.42, 0.92) 
Both 59 10.83 5.45 (4.22, 7.03) 0.98 (0.69, 1.38) 1.04 (0.73, 1.49) 
     PE 
 
Tamoxifen 48 14.75 3.25 (2.45, 4.32) 1 1 
AI 68 14.06 4.84 (3.81, 6.13) 1.39 (0.95, 2.04) 1.21 (0.79, 1.85) 
Both 33 11.19 2.95 (2.10, 4.15) 0.80 (0.51, 1.28) 0.78 (0.48, 1.25) 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); BMI 
(underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score (level 1-5 based on GP 
level IMD data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor blockers (ARB); 
diabetes; chronic kidney disease; rheumatoid arthritis; systolic blood pressure (low/normal, pre-high, high); diastolic blood pressure 
(low/normal, pre-high, high); history of VTE; history of non-venous CVD year of breast cancer diagnosis; time since index (<1yr, 1 to <3yrs, 3 to 
<5yrs, 5+yrs ); and current year. 
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Appendix 5.11 - Crude rates, unadjusted HRs, and adjusted HRs by current exposure to 
endocrine therapies for a range of clinical CVDs  
Outcome Ever exposure  Number of 
Events 
Person years 
(1000s) 
Crude Rate (per 1000 
Person-Years) 
Unadjusted HR 
(95% CI) 
Adjusted HR (95% 
CI)* 
Coronary Artery Disease Tamoxifen 67 10.42 6.43 (5.06, 8.17) 1 1 
 AI 137 15.57 8.80 (7.44, 10.41) 1.28 (0.94, 1.73) 1.19 (0.87, 1.64) 
Past with AI 49 6.49 7.55 (5.71, 9.99) 1.05 (0.72, 1.54) 1.09 (0.68, 1.74) 
Past Tam only 38 4.54 8.38 (6.10, 11.51) 1.10 (0.73, 1.67) 1.23 (0.74, 2.05) 
     Angina 
 
 
 
Tamoxifen 40 10.55 3.79 (2.78, 5.17) 1 1 
AI 79 15.85 4.98 (4.00, 6.21) 1.21 (0.82, 1.80) 1.12 (0.74, 1.70) 
Past with AI 28 6.59 4.25 (2.94, 6.16) 0.99 (0.60, 1.63) 1.20 (0.66, 2.18) 
Past Tam only 20 4.61 4.34 (2.80, 6.73) 0.95 (0.54, 1.68) 1.25 (0.63, 2.44) 
     MI 
 
 
 
Tamoxifen 27 11.16 2.42 (1.66, 3.53) 1 1 
AI 67 16.91 3.96 (3.12, 5.03) 1.39 (0.88, 2.18) 1.26 (0.78, 2.03) 
Past with AI 26 6.95 3.74 (2.55, 5.49) 1.28 (0.75, 2.20) 1.11 (0.57, 2.17) 
Past Tam only 12 4.92 2.44 (1.38, 4.29) 0.73 (0.36, 1.48) 0.67 (0.29, 1.52) 
     Revascularisation 
 
 
 
Tamoxifen 9 11.28 0.80 (0.42, 1.53) 1 1 
AI 21 17.13 1.23 (0.80, 1.88) 1.47 (0.67, 3.24) 1.67 (0.72, 3.86) 
Past with AI 9 7.01 1.28 (0.67, 2.47) 1.38 (0.54, 3.49) 1.30 (0.41, 4.12) 
Past Tam only 8 4.94 1.62 (0.81, 3.24) 1.75 (0.67, 4.56) 1.61 (0.50, 5.18) 
     SCA 
 
 
 
Tamoxifen 7 11.36 0.62 (0.29, 1.29) 1 1 
AI 20 17.35 1.15 (0.74, 1.79) 2.70 (0.90, 8.03) 2.28 (0.73, 7.11) 
Past with AI 5 7.1 0.70 (0.29, 1.69) 1.51 (0.37, 6.08) 1.53 (0.30, 7.80) 
Past Tam only 7 5.02 1.39 (0.66, 2.93) 3.01 (0.84, 10.73) 3.47 (0.70, 17.04) 
PVD Tamoxifen 26 11.19 2.32 (1.58, 3.41) 1 1 
 AI 45 16.9 2.66 (1.99, 3.57) 1.27 (0.75, 2.18) 1.37 (0.78, 2.42) 
 Past with AI 14 6.92 2.02 (1.20, 3.42) 0.92 (0.46, 1.86) 0.95 (0.40, 2.26) 
 Past Tam only 13 4.95 2.63 (1.53, 4.53) 1.28 (0.63, 2.58) 1.47 (0.62, 3.49) 
Stroke 
 
 
 
Tamoxifen 63 11.08 5.68 (4.44, 7.28) 1 1 
AI 131 16.47 7.95 (6.70, 9.44) 1.25 (0.91, 1.72) 1.16 (0.83, 1.62) 
Past with AI 63 6.76 9.32 (7.28, 11.94) 1.57 (1.09, 2.27) 1.56 (1.00, 2.43) 
Past Tam only 40 4.83 8.28 (6.07, 11.29) 1.31 (0.87, 1.98) 1.40 (0.86, 2.27) 
Arrhythmia 
 
 
 
Tamoxifen 142 9.74 14.58 (12.37, 17.19) 1 1 
AI 317 14.2 22.32 (19.99, 24.92) 1.46 (1.18, 1.80) 1.45 (1.17, 1.81) 
Past with AI 124 5.64 21.98 (18.43, 26.21) 1.52 (1.18, 1.96) 1.86 (1.38, 2.52) 
Past Tam only 97 4.14 23.40 (19.18, 28.56) 1.56 (1.19, 2.04) 1.90 (1.38, 2.62) 
HF Tamoxifen 65 10.97 5.93 (4.65, 7.56) 1 1 
 AI 169 16.37 10.32 (8.88, 12.00) 1.65 (1.21, 2.24) 1.48 (1.07, 2.04) 
 Past with AI 72 6.78 10.62 (8.43, 13.38) 1.66 (1.16, 2.37) 1.71 (1.11, 2.63) 
 Past Tam only 38 4.84 7.85 (5.71, 10.79) 1.19 (0.78, 1.82) 1.33 (0.81, 2.18) 
Pericarditis Tamoxifen 2 11.35 0.18 (0.04, 0.70) 1 1 
 AI 17 17.34 0.98 (0.61, 1.58) 4.85 (1.11, 21.23) 3.61 (0.80, 16.27) 
 Past with AI 7 7.09 0.99 (0.47, 2.07) 5.77 (1.19, 28.05) 3.09 (0.49, 19.59) 
 Past Tam only 1 5.02 0.20 (0.03, 1.41) 1.19 (0.11, 13.18) 0.65 (0.05, 8.92) 
VHD Tamoxifen 37 11.12 3.33 (2.41, 4.59) 1 1 
 AI 117 16.73 6.99 (5.83, 8.38) 1.84 (1.25, 2.70) 1.52 (1.02, 2.25) 
 Past with AI 40 6.87 5.82 (4.27, 7.94) 1.46 (0.92, 2.34) 1.18 (0.68, 2.03) 
 Past Tam only 38 4.9 7.76 (5.65, 10.67) 1.90 (1.18, 3.03) 1.66 (0.95, 2.91) 
VTE 
 
 
 
Tamoxifen 117 11.04 10.60 (8.84, 12.70) 1 1 
AI 110 16.07 6.84 (5.68, 8.25) 0.59 (0.45, 0.78) 0.58 (0.43, 0.77) 
Past with AI 69 6.51 10.60 (8.37, 13.42) 0.89 (0.65, 1.21) 1.22 (0.82, 1.80) 
Past Tam only 27 4.81 5.61 (3.85, 8.18) 0.48 (0.31, 0.74) 0.74 (0.45, 1.23) 
     DVT 
 
 
 
Tamoxifen 82 11.12 7.38 (5.94, 9.16) 1 1 
AI 68 16.49 4.12 (3.25, 5.23) 0.50 (0.36, 0.71) 0.50 (0.35, 0.72) 
Past with AI 38 6.64 5.72 (4.16, 7.86) 0.69 (0.46, 1.03) 0.83 (0.49, 1.40) 
Past Tam only 16 4.87 3.28 (2.01, 5.36) 0.39 (0.23, 0.68) 0.50 (0.26, 0.98) 
     Pulmonary Embolism Tamoxifen 43 11.29 3.81 (2.83, 5.14) 1 1 
AI 59 16.86 3.50 (2.71, 4.52) 0.84 (0.56, 1.26) 0.77 (0.50, 1.17) 
Past with AI 36 6.89 5.22 (3.77, 7.24) 1.24 (0.78, 1.96) 1.74 (0.99, 3.05) 
Past Tam only 11 4.96 2.22 (1.23, 4.01) 0.51 (0.26, 1.03) 0.84 (0.39, 1.83) 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); 
BMI (underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score (level 1-5 
based on GP level IMD data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor 
blockers (ARB); diabetes; chronic kidney disease; rheumatoid arthritis; systolic blood pressure (low/normal, pre-high, high); diastolic 
blood pressure (low/normal, pre-high, high); history of VTE; history of non-venous CVD year of breast cancer diagnosis; time since index 
(<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); and current year. 
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Appendix 5.12 - Adjusted HRs for association between ever exposure to endocrine therapies and 
risk of coronary artery disease, stratified by age, time since index, and prior CVD 
No 
Yes 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); BMI 
(underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score (level 1-5 based on GP level IMD 
data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor blockers (ARB); diabetes; chronic kidney 
disease; rheumatoid arthritis; systolic blood pressure (low/normal, pre-high, high); diastolic blood pressure (low/normal, pre-high, high); history of VTE; 
history of non-venous CVD year of breast cancer diagnosis; time since index (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); and current year. 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
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Appendix 5.13 - Adjusted HRs for association between ever exposure to endocrine therapies and 
risk of angina, stratified by age, time since index, and prior CVD 
No 
Yes 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); BMI 
(underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score (level 1-5 based on GP level IMD 
data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor blockers (ARB); diabetes; chronic kidney 
disease; rheumatoid arthritis; systolic blood pressure (low/normal, pre-high, high); diastolic blood pressure (low/normal, pre-high, high); history of VTE; 
history of non-venous CVD year of breast cancer diagnosis; time since index (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); and current year. 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
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Appendix 5.14 - Adjusted HRs for association between ever exposure to endocrine therapies and 
risk of MI, stratified by age, time since index, and prior CVD 
No 
Yes 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); BMI 
(underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score (level 1-5 based on GP level IMD 
data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor blockers (ARB); diabetes; chronic kidney 
disease; rheumatoid arthritis; systolic blood pressure (low/normal, pre-high, high); diastolic blood pressure (low/normal, pre-high, high); history of VTE; 
history of non-venous CVD year of breast cancer diagnosis; time since index (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); and current year. 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
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Appendix 5.15 - Adjusted HRs for association between ever exposure to endocrine therapies and 
risk of revascularisation, stratified by age, time since index, and prior CVD 
No 
Yes 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); BMI 
(underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score (level 1-5 based on GP level IMD 
data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor blockers (ARB); diabetes; chronic kidney 
disease; rheumatoid arthritis; systolic blood pressure (low/normal, pre-high, high); diastolic blood pressure (low/normal, pre-high, high); history of VTE; 
history of non-venous CVD year of breast cancer diagnosis; time since index (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); and current year. 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
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Appendix 5.16 - Adjusted HRs for association between ever exposure to endocrine therapies and 
risk of PVD, stratified by age, time since index, and prior CVD 
No 
Yes 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); BMI 
(underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score (level 1-5 based on GP level IMD 
data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor blockers (ARB); diabetes; chronic kidney 
disease; rheumatoid arthritis; systolic blood pressure (low/normal, pre-high, high); diastolic blood pressure (low/normal, pre-high, high); history of VTE; 
history of non-venous CVD year of breast cancer diagnosis; time since index <1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); and current year. 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
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Appendix 5.17 - Adjusted HRs for association between ever exposure to endocrine therapies and 
risk of stroke, stratified by age, time since index, and prior CVD 
No 
Yes 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); BMI 
(underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score (level 1-5 based on GP level IMD 
data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor blockers (ARB); diabetes; chronic kidney 
disease; rheumatoid arthritis; systolic blood pressure (low/normal, pre-high, high); diastolic blood pressure (low/normal, pre-high, high); history of VTE; 
history of non-venous CVD year of breast cancer diagnosis; time since index (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); and current year. 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
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Appendix 5.18 - Adjusted HRs for association between ever exposure to endocrine therapies and 
risk of arrhythmia, stratified by age, time since index, and prior CVD 
No 
Yes 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); BMI 
(underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score (level 1-5 based on GP level IMD 
data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor blockers (ARB); diabetes; chronic kidney 
disease; rheumatoid arthritis; systolic blood pressure (low/normal, pre-high, high); diastolic blood pressure (low/normal, pre-high, high); history of VTE; 
history of non-venous CVD year of breast cancer diagnosis; time since index (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); and current year. 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
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Appendix 5.19 - Adjusted HRs for association between ever exposure to endocrine therapies and 
risk of HF, stratified by age, time since index, and prior CVD 
No 
Yes 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); BMI 
(underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score (level 1-5 based on GP level IMD 
data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor blockers (ARB); diabetes; chronic kidney 
disease; rheumatoid arthritis; systolic blood pressure (low/normal, pre-high, high); diastolic blood pressure (low/normal, pre-high, high); history of VTE; 
history of non-venous CVD year of breast cancer diagnosis; time since index (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); and current year. 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
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Appendix 5.20 - Adjusted HRs for association between ever exposure to endocrine therapies and 
risk of VHD, stratified by age, time since index, and prior CVD 
No 
Yes 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); BMI 
(underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score (level 1-5 based on GP level IMD 
data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor blockers (ARB); diabetes; chronic kidney 
disease; rheumatoid arthritis; systolic blood pressure (low/normal, pre-high, high); diastolic blood pressure (low/normal, pre-high, high); history of VTE; 
history of non-venous CVD year of breast cancer diagnosis; time since index (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); and current year. 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
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Appendix 5.21 - Adjusted HRs for association between ever exposure to endocrine therapies and 
risk of VTE, stratified by age, time since index, and prior CVD 
* ** 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); BMI 
(underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score (level 1-5 based on GP level IMD 
data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor blockers (ARB); diabetes; chronic kidney 
disease; rheumatoid arthritis; systolic blood pressure (low/normal, pre-high, high); diastolic blood pressure (low/normal, pre-high, high); history of VTE; 
history of non-venous CVD year of breast cancer diagnosis; time since index (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); and current year. 
** p value from Wald test for interaction 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
* ** 
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Appendix 5.22 - Adjusted HRs for association between ever exposure to endocrine therapies and 
risk of DVT, stratified by age, time since index, and prior CVD 
No 
Yes 
* ** 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); BMI (underweight/healthy 
weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score (level 1-5 based on GP level IMD data); use of statins; use of ACE 
inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor blockers (ARB); diabetes; chronic kidney disease; rheumatoid arthritis; systolic 
blood pressure (low/normal, pre-high, high); diastolic blood pressure (low/normal, pre-high, high); history of VTE; history of non-venous CVD year of breast cancer 
diagnosis; time since index (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); and current year. 
** p value from Wald test for interaction 
 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
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Appendix 5.23 - Adjusted HRs for association between ever exposure to endocrine therapies and 
risk of PE, stratified by age, time since index, and prior CVD 
No 
Yes 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); BMI 
(underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score (level 1-5 based on GP level IMD 
data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor blockers (ARB); diabetes; chronic kidney 
disease; rheumatoid arthritis; systolic blood pressure (low/normal, pre-high, high); diastolic blood pressure (low/normal, pre-high, high); history of VTE; 
history of non-venous CVD year of breast cancer diagnosis; time since index (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); and current year. 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
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Appendix 5.24 - Characteristics of study population based on their initial exposure, 
before and after guideline changes 
 Before   After   
 Tamoxifen  AI Total Tamoxifen  AI Total 
N 2267 (100) 670 (100) 2937 (100) 2449 (100) 4619 (100) 7068 (100) 
Age (yrs)       
54-59 476 (21) 69 (10.3) 545 (18.6) 435 (17.8) 647 (14) 1082 (15.3) 
60-69 815 (36) 208 (31) 1023 (34.8) 1035 (42.3) 1764 (38.2) 2799 (39.6) 
70+ 976 (43.1) 393 (58.7) 1369 (46.6) 979 (40) 2208 (47.8) 3187 (45.1) 
Median (IQR) 68 (61-77) 74 (65-83) 69 (62-78) 68 (62-75) 69 (63-79) 69 (63-78) 
Year of breast cancer       
2002 579 (25.5) 72 (10.7) 651 (22.2) 0 (0) 0 (0) 0 (0) 
2003 605 (26.7) 123 (18.4) 728 (24.8) 0 (0) 0 (0) 0 (0) 
2004 571 (25.2) 186 (27.8) 757 (25.8) 0 (0) 0 (0) 0 (0) 
2005 512 (22.6) 289 (43.1) 801 (27.3) 0 (0) 0 (0) 0 (0) 
2006 0 (0) 0 (0) 0 (0) 467 (19.1) 370 (8) 837 (11.8) 
2007 0 (0) 0 (0) 0 (0) 386 (15.8) 448 (9.7) 834 (11.8) 
2008 0 (0) 0 (0) 0 (0) 380 (15.5) 495 (10.7) 875 (12.4) 
2009 0 (0) 0 (0) 0 (0) 290 (11.8) 533 (11.5) 823 (11.6) 
2010 0 (0) 0 (0) 0 (0) 223 (9.1) 586 (12.7) 809 (11.4) 
2011 0 (0) 0 (0) 0 (0) 216 (8.8) 619 (13.4) 835 (11.8) 
2012 0 (0) 0 (0) 0 (0) 210 (8.6) 539 (11.7) 749 (10.6) 
2013 0 (0) 0 (0) 0 (0) 174 (7.1) 504 (10.9) 678 (9.6) 
2014 0 (0) 0 (0) 0 (0) 93 (3.8) 451 (9.8) 544 (7.7) 
2015 0 (0) 0 (0) 0 (0) 10 (.4) 74 (1.6) 84 (1.2) 
BMI (kg/m2)       
<18 26 (1.1) 11 (1.6) 37 (1.3) 33 (1.3) 52 (1.1) 85 (1.2) 
18-24 808 (35.6) 211 (31.5) 1019 (34.7) 885 (36.1) 1408 (30.5) 2293 (32.4) 
25-29 757 (33.4) 208 (31) 965 (32.9) 792 (32.3) 1593 (34.5) 2385 (33.7) 
30-34 361 (15.9) 108 (16.1) 469 (16) 439 (17.9) 871 (18.9) 1310 (18.5) 
≥35 146 (6.4) 55 (8.2) 201 (6.8) 199 (8.1) 493 (10.7) 692 (9.8) 
Missing 169 (7.5) 77 (11.5) 246 (8.4) 101 (4.1) 202 (4.4) 303 (4.3) 
Median (IQR) 26 (23-30) 27 (23-30) 26 (23-30) 26 (23-30) 27 (24-31) 27 (24-31) 
Smoking status       
Never smoker 1235 (54.5) 332 (49.6) 1567 (53.4) 1188 (48.5) 2185 (47.3) 3373 (47.7) 
Current smoker 271 (12) 64 (9.6) 335 (11.4) 228 (9.3) 419 (9.1) 647 (9.2) 
Ex-smoker 733 (32.3) 261 (39) 994 (33.8) 1032 (42.1) 2006 (43.4) 3038 (43) 
Missing 28 (1.2) 13 (1.9) 41 (1.4) 1 (0) 9 (.2) 10 (.1) 
Alcohol use       
Non drinker 333 (14.7) 121 (18.1) 454 (15.5) 285 (11.6) 492 (10.7) 777 (11) 
Current 1569 (69.2) 409 (61) 1978 (67.3) 1750 (71.5) 3229 (69.9) 4979 (70.4) 
Ex-drinker 184 (8.1) 76 (11.3) 260 (8.9) 297 (12.1) 629 (13.6) 926 (13.1) 
Missing 181 (8) 64 (9.6) 245 (8.3) 117 (4.8) 269 (5.8) 386 (5.5) 
Systolic BP       
Low/ideal 215 (9.5) 62 (9.3) 277 (9.4) 315 (12.9) 538 (11.6) 853 (12.1) 
Pre-high 801 (35.3) 225 (33.6) 1026 (34.9) 1061 (43.3) 2102 (45.5) 3163 (44.8) 
High 1243 (54.8) 382 (57) 1625 (55.3) 1071 (43.7) 1972 (42.7) 3043 (43.1) 
Missing 8 (.4) 1 (.1) 9 (.3) 2 (.1) 7 (.2) 9 (.1) 
Diastolic BP       
Low/ideal 922 (40.7) 301 (44.9) 1223 (41.6) 1208 (49.3) 2348 (50.8) 3556 (50.3) 
Pre-high 1004 (44.3) 276 (41.2) 1280 (43.6) 984 (40.2) 1782 (38.6) 2766 (39.1) 
High 333 (14.7) 92 (13.7) 425 (14.5) 255 (10.4) 482 (10.4) 737 (10.4) 
Missing 8 (.4) 1 (.1) 9 (.3) 2 (.1) 7 (.2) 9 (.1) 
IMD category       
1 386 (17) 119 (17.8) 505 (17.2) 484 (19.8) 843 (18.3) 1327 (18.8) 
2 453 (20) 141 (21) 594 (20.2) 490 (20) 1073 (23.2) 1563 (22.1) 
3 431 (19) 124 (18.5) 555 (18.9) 494 (20.2) 930 (20.1) 1424 (20.1) 
4 541 (23.9) 142 (21.2) 683 (23.3) 511 (20.9) 794 (17.2) 1305 (18.5) 
5 456 (20.1) 144 (21.5) 600 (20.4) 470 (19.2) 978 (21.2) 1448 (20.5) 
Missing 0 (0) 0 (0) 0 (0) 0 (0) 1 (0) 1 (0) 
Statins before index 385 (17) 190 (28.4) 575 (19.6) 715 (29.2) 1713 (37.1) 2428 (34.4) 
ACEI before index 475 (21) 204 (30.4) 679 (23.1) 720 (29.4) 1619 (35.1) 2339 (33.1) 
CCB before index 510 (22.5) 204 (30.4) 714 (24.3) 685 (28) 1560 (33.8) 2245 (31.8) 
ARB before index 180 (7.9) 77 (11.5) 257 (8.8) 313 (12.8) 718 (15.5) 1031 (14.6) 
Anti-platelets before 
index 
516 (22.8) 245 (36.6) 761 (25.9) 616 (25.2) 1394 (30.2) 2010 (28.4) 
RA before index 52 (2.3) 26 (3.9) 78 (2.7) 86 (3.5) 111 (2.4) 197 (2.8) 
Diabetes before index 204 (9) 76 (11.3) 280 (9.5) 258 (10.5) 652 (14.1) 910 (12.9) 
CKD before index 464 (20.5) 218 (32.5) 682 (23.2) 403 (16.5) 872 (18.9) 1275 (18) 
Non-venous CVD before 
index 
455 (20.1) 235 (35.1) 690 (23.5) 576 (23.5) 1401 (30.3) 1977 (28) 
VTE before index 64 (2.8) 75 (11.2) 139 (4.7) 80 (3.3) 249 (5.4) 329 (4.7) 
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Appendix 5.25 - Sensitivity analysis – Adjusted HRs for current exposure to endocrine 
therapy for Arrhythmia, DVT, and HF, with different grace periods, where the grace 
period is the maximum gap in prescription coverage for exposure to be considered 
continuous 
 
Outcome Current 
exposure  
Adjusted HR – 1m 
grace (original) 
Adjusted HR – 3m 
grace 
Adjusted HR – 6m 
grace 
Adjusted HR – 1y 
grace 
Arrhythmia Tamoxifen 1 1 1 1 
 AI 1.46 (1.17, 1.82) 1.49 (1.20, 1.84) 1.45 (1.18, 1.79) 1.37 (1.12, 1.67) 
Past with AI 1.88 (1.39, 2.54) 1.74 (1.27, 2.39) 1.89 (1.36, 2.63) 1.72 (1.21, 2.44) 
Past Tam only 1.88 (1.37, 2.60) 1.90 (1.36, 2.66) 2.05 (1.46, 2.89) 1.91 (1.32, 2.74) 
DVT 
 
 
 
Tamoxifen 1 1 1 1 
AI 0.51 (0.35, 0.73) 0.53 (0.37, 0.75) 0.59 (0.42, 0.83) 0.62 (0.45, 0.87) 
Past with AI 0.83 (0.49, 1.41) 0.81 (0.46, 1.42) 0.42 (0.22, 0.81) 0.41 (0.20, 0.84) 
Past Tam only 0.50 (0.26, 0.98) 0.46 (0.23, 0.95) 0.33 (0.15, 0.70) 0.41 (0.19, 0.89) 
HF 
 
 
 
Tamoxifen 1 1 1 1 
AI 1.49 (1.08, 2.06) 1.49 (1.09, 2.03) 1.55 (1.14, 2.10) 1.54 (1.14, 2.09) 
Past with AI 1.72 (1.12, 2.65) 1.50 (0.96, 2.36) 1.41 (0.87, 2.27) 1.47 (0.89, 2.43) 
Past Tam only 1.31 (0.80, 2.15) 1.15 (0.69, 1.94) 1.18 (0.69, 2.01) 1.37 (0.79, 2.36) 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, 
ex-smoker); BMI (underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-
drinker); IMD score (level 1-5 based on GP level IMD data); use of statins; use of ACE inhibitors; use of calcium channel 
blockers (CCB); use of angiotensin II receptor blockers (ARB); diabetes; chronic kidney disease; rheumatoid arthritis; 
systolic blood pressure (low/normal, pre-high, high); diastolic blood pressure (low/normal, pre-high, high history of VTE; 
history of non-venous CVD ;  year of breast cancer diagnosis; time since index (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs ); and 
current year 
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Appendix 5.26 - Crude rates, unadjusted HRs, and adjusted HRs by ever exposure to endocrine 
therapies for a range of clinical CVDs, additionally adjusted for HRT use prior to index 
Outcome Ever 
exposure  
Number of 
Events 
Person years  
(1000s) 
Crude Rate  
(per 1000 Person-Years) 
Unadjusted HR  
(95% CI) 
Adjusted HR  
(95% CI) * 
Coronary Artery Disease Tamoxifen 93 13.54 6.87 (5.60, 8.41) 1 1 
 AI 131 12.87 10.18 (8.58, 12.08) 1.40 (1.06, 1.86) 1.29 (0.94, 1.76) 
Both 67 10.6 6.32 (4.98, 8.03) 0.95 (0.69, 1.31) 0.95 (0.68, 1.32) 
     Angina 
 
Tamoxifen 56 13.73 4.08 (3.14, 5.30) 1 1 
AI 80 13.15 6.09 (4.89, 7.58) 1.43 (1.00, 2.05) 1.31 (0.88, 1.97) 
Both 31 10.73 2.89 (2.03, 4.11) 0.70 (0.44, 1.10) 0.69 (0.43, 1.11) 
     MI 
 
Tamoxifen 32 14.6 2.19 (1.55, 3.10) 1 1 
AI 61 14.11 4.32 (3.36, 5.56) 1.73 (1.12, 2.68) 1.56 (0.96, 2.52) 
Both 39 11.24 3.47 (2.54, 4.75) 1.62 (1.01, 2.60) 1.62 (0.99, 2.63) 
     Revascularisation 
 
Tamoxifen 15 14.72 1.02 (0.61, 1.69) 1 1 
AI 20 14.3 1.40 (0.90, 2.17) 1.36 (0.69, 2.68) 1.84 (0.85, 4.01) 
Both 12 11.33 1.06 (0.60, 1.86) 0.99 (0.46, 2.11) 1.00 (0.46, 2.21) 
     SCA 
 
Tamoxifen 13 14.88 0.87 (0.51, 1.50) 1 1 
AI 21 14.53 1.45 (0.94, 2.22) 1.87 (0.83, 4.22) 1.65 (0.65, 4.19) 
Both 5 11.43 0.44 (0.18, 1.05) 0.73 (0.24, 2.19) 0.69 (0.22, 2.10) 
PVD Tamoxifen 35 14.64 2.39 (1.72, 3.33) 1 1 
 AI 41 14.08 2.91 (2.14, 3.96) 1.25 (0.77, 2.01) 1.31 (0.76, 2.25) 
 Both 22 11.23 1.96 (1.29, 2.97) 0.81 (0.45, 1.43) 0.87 (0.48, 1.57) 
Stroke 
 
Tamoxifen 91 14.45 6.30 (5.13, 7.73) 1 1 
AI 118 13.71 8.61 (7.19, 10.31) 1.22 (0.91, 1.63) 1.11 (0.81, 1.53) 
Both 88 10.98 8.02 (6.51, 9.88) 1.33 (0.98, 1.80) 1.25 (0.91, 1.70) 
Arrhythmia 
 
Tamoxifen 219 12.7 17.25 (15.11, 19.69) 1 1 
AI 287 11.52 24.90 (22.18, 27.96) 1.37 (1.14, 1.64) 1.37 (1.12, 1.69) 
Both 174 9.51 18.30 (15.77, 21.23) 1.07 (0.87, 1.32) 1.08 (0.87, 1.34) 
HF Tamoxifen 90 14.33 6.28 (5.11, 7.72) 1 1 
 AI 178 13.59 13.10 (11.31, 15.17) 1.87 (1.43, 2.45) 1.67 (1.24, 2.25) 
 Both 76 11.04 6.89 (5.50, 8.62) 1.12 (0.81, 1.55) 1.12 (0.81, 1.56) 
Pericarditis Tamoxifen 3 14.85 0.20 (0.07, 0.63) 1 1 
 AI 14 14.53 0.96 (0.57, 1.63) 3.96 (1.12, 14.03) 3.26 (0.86, 12.29) 
 Both 10 11.4 0.88 (0.47, 1.63) 4.29 (1.18, 15.61) 3.46 (0.92, 13.11) 
VHD Tamoxifen 66 14.54 4.54 (3.57, 5.78) 1 1 
 AI 114 13.93 8.18 (6.81, 9.83) 1.58 (1.15, 2.17) 1.31 (0.92, 1.86) 
 Both 52 11.14 4.67 (3.56, 6.13) 1.08 (0.74, 1.57) 0.97 (0.66, 1.42) 
VTE 
 
Tamoxifen 122 14.41 8.47 (7.09, 10.11) 1 1 
AI 116 13.4 8.66 (7.22, 10.38) 0.93 (0.71, 1.21) 0.82 (0.61, 1.10) 
Both 85 10.63 8.00 (6.47, 9.89) 0.91 (0.69, 1.22) 0.95 (0.71, 1.28) 
     DVT 
 
Tamoxifen 83 14.52 5.72 (4.61, 7.09) 1 1 
AI 62 13.78 4.50 (3.51, 5.77) 0.69 (0.48, 0.98) 0.62 (0.42, 0.92) 
Both 59 10.83 5.45 (4.22, 7.03) 0.98 (0.69, 1.38) 1.06 (0.74, 1.52) 
     PE 
 
Tamoxifen 48 14.75 3.25 (2.45, 4.32) 1 1 
AI 68 14.06 4.84 (3.81, 6.13) 1.39 (0.95, 2.04) 1.21 (0.80, 1.85) 
Both 33 11.19 2.95 (2.10, 4.15) 0.80 (0.51, 1.28) 0.76 (0.47, 1.23) 
*Adjusted the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); BMI 
(underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score (level 1-5 based on GP 
level IMD data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor blockers (ARB); 
diabetes; chronic kidney disease; rheumatoid arthritis; systolic blood pressure (low/normal, pre-high, high); diastolic blood pressure 
(low/normal, pre-high, high); history of VTE; history of non-venous CVD year of breast cancer diagnosis; time since index (<1yr, 1 to <3yrs, 3 to 
<5yrs, 5+yrs ); current year; and use of HRT. 
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Appendix 6.1 - Endocrine therapy billing codes 
 HCPCS NDC 
Tamoxifen S0187 00038060025, 00038060060, 00054483121, 00054483126, 00054483413, 00054483422, 
00054883125, 00054883425, 00093078210, 00093078256, 00093078405, 00093078406, 
00093078410, 00172565658, 00172565670, 00172565680, 00172565746, 00172565755, 
00172565760, 00172565770, 00310060018, 00310060075, 00310060412, 00310060430, 
00310060490, 00310073060, 00378014405, 00378014491, 00378027401, 00378027493, 
00440845092, 00440845130, 00440845160, 00440845192, 00555044603, 00555044605, 
00555044609, 00555044663, 00555090401, 00591223218, 00591223319, 00591223330, 
00591247319, 00591247330, 38779034101, 38779034103, 38779034108, 49452775301, 
51552083802, 51927297600, 53002103203, 53002103230, 54569038201, 54569038202, 
54569376501, 54569571600, 54569853100, 54569860200, 54868300401, 54868300402, 
54868300403, 54868300404, 54868428700, 54868428703, 54868428704, 57866661501, 
58016065760, 60346004832, 62991115101, 62991115103, 63304060060, 63304060130, 
63304060190, 63739026910, 63739026915, 00093078201, 00093078205, 00093078486, 
00172565649, 00172565780, 00310060025, 00310060060, 00310073130, 00440845030, 
00440845060, 00555090405, 00555090414, 00591223260, 00591247218, 00591247260, 
13632012301, 38779034104, 38779034105, 42254034390, 52372075601, 52372075602, 
54569038200, 54569376500, 54868300405, 54868428701, 54868428702, 55175550006, 
55289058530, 57866661801, 62991115104, 63304060028 
Aromatase 
inhibitors 
S0170 
S0156 
Anastrozole:   
00054016413, 00093753656, 00310020130, 00310020137, 00310020150, 00378603405, 
00378603477, 00781535631, 00904619546, 00904622961, 16571042103, 16729003510, 
16729003515, 16729003516, 21695099030, 35356027030, 38779227406, 38779255503, 
38779255504, 38779255506, 42043018003, 42291010530, 51079032301, 51079032306, 
51927443500, 51991062010, 51991062033, 54569573100, 54569619800, 54868500000, 
54868613000, 54868613001, 55111064730, 55175550503, 60258086603, 62756025013, 
62756025083, 63275993001, 63275993002, 63323012930, 66435041530, 67877017110, 
67877017130, 68084044811, 68084044821, 68258903501, 68382020906, 42254016130, 
60429028630, 60429028690, 60505298503, 63275993003, 63275993004, 63275993005, 
68382020910 
Exemestane:   
00054008013, 49999098630, 54569573200, 54868526100, 59762285801, 00009766304 
Letrozole:    
00054026913, 00078024915, 00093762056, 00378207105, 00378207193, 00603418016, 
16729003410, 35356040930, 51991075910, 51991075933, 54569571400, 54868415100, 
54868625200, 55111064630, 62756051183, 63323077230 
42254024330, 60505325503, 60505325508 
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Appendix 6.2 - Visualisation of potential categorisations in the ever exposure 
analysis 
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Appendix 6.3 - Visualisation of potential categorisations in the current exposure 
analysis 
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Appendix 6.4 - CVD outcome billing codes 
Composite outcomes 
Individual outcomes 
ICD 9 diagnosis and procedure 
codes CPT/HCPCS codes 
Coronary Artery Disease Angina  411.1, 413.1, 413.9  
Myocardial infarction  410.11, 410.01, 410.31, 410.21, 
410.41, 410.81, 410.51, 410.61, 
410.91, 410.71 
 
Revascularization procedures 36.0x, 36.1x, 36.2, 36.3 33140, 33510, 33511, 33512, 
33513, 33514, 33516, 33517, 
33518, 33519, 33521, 33522, 
33523, 33533, 33534, 33535, 
33536, 92920, 92924, 92928, 
92933, 92937, 92941, 92943, 
92980, 92981, 92982, 92984, 
92995, 92996, 92997, 92998 
Sudden cardiac arrest 427.5  
 Peripheral vascular disease 443.89, 443.9  
 Stroke (haemorrhagic and 
ischaemic)  
430.x, 431.x, 432.1, 432.0, 432.9, 
433.91, 433.21, 433.01, 433.11, 
433.31, 433.81, 434.01, 434.x,  
435.0, 
435.1, 435.3, 435.8, 435.9, 436.x 
 
 Arrhythmia 427.31, 427.32, 427.41, 427.42, 
427.61, 427.0, 427.69, 427.60, 
427.81, 427.89, 427.9     
 
 Heart failure HF - 428.1, 428.0, 428.20, 
428.21, 428.22, 428.23, 428.30, 
428.31, 428.32, 428.33, 428.40, 
428.41, 428.42, 428.43, 428.9 
Cardiomyopathy - 414.8, 425.4, 
425.11, 425.18, 425.0, 425.3, 
425.5, 425.9, 425.2, 425.8 
 
 Pericarditis 420.91, 420.90, 420.99, 423.1, 
423.2, 423.0, 423.9, 423.3, 423.8 
420.0 
 
 Valvular heart disease 394.0, 394.1, 394.2, 394.9, 
395.0, 395.1, 395.2, 395.9, 
397.0, 396.0, 396.1, 396.2, 
396.3, 397.9, 396.8, 396.9, 
424.0, 424.1, 424.2, 424.3 
 
VTE Deep venous thromboembolism 415.1x  
Pulmonary Embolism 415.0, 415.12, 415.13, 415.19  
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Appendix 6.5 - Covariate drugs billing codes  
Chemotherapy billing codes  
Drug Class HCPCS/CPT (variable) 
Taxanes C9127, C9431, J9170, J9171, J9264, J9265, Q0125    
Anthracyclines C9415, J9000, J9001, J9178, J9180  
Trastuzumab J9355    
Others 96408, 96409, 96410, 96411, 96412, 96413, 96414, 
96415, 96416, 96417, 96545, 96549,  C1167, C8953, 
C8954, C8955, C9214, C9240, C9257, C9280, C9414, 
C9418, C9420, C9421, C9425, C9438, C9440, G0359, 
G0360, G9021, G9022, G9023, G9024, G9025, G9026, 
G9027, G9028, G9029, G9030, G9031, G9032, J8520, 
J8521, J8530, J8560, J8999, J9035,  J9045, J9060, 
J9062, J9070, J9080, J9090, J9091, J9092, J9093, 
J9094, J9095, J9096, J9097, J9179, J9181, J9182,  
J9190, J9201, J9207, J9250, J9260, J9293,  J9360, 
J9390, J9999, Q0083, Q0084, Q0085 
Concomitant medication billing codes 
Drug class ATC codes 
Hypertensives C02      
Statins C10AA  (C10AA01-C10AA08)      
Ace Inhibitors C09AA  (C09AA01-C09AA16)       
Calcium Channel Blockers C08CA  (C08CA01-C08CA16, C08CA55) 
Angiotensin 2 receptor blocker C09CA  (C09CA01-C09CA09) 
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Appendix 6.6 - STROBE flow diagram for inclusion in US study  
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Appendix 6.7 - Adjusted HRs, events, and crude rate for the association between ever 
exposure to endocrine therapy and a range of clinical CVD outcomes 
 
Outcome Ever exposure Events, Follow-up, Rate (95% CI) 
(per 1000 pyears) * 
Unadjusted HR 
(95% CI) 
Adjusted HR  
(95% CI) 
Adjusted HR  
(95% CI)** 
Coronary Artery 
Disease 
 
Unexposed 318, 8.22, 38.70 (34.67, 43.19) 1.00 (   .,    .) 1.00 (   .,    .) 
1.34 (1.09, 1.66) 
Tamoxifen 129, 4.79, 26.95 (22.68, 32.03) 0.74 (0.60, 0.91) 0.74 (0.60, 0.92) 1.00 (   .,    .) 
AI 1059, 30.03, 35.26 (33.20, 37.45) 1.01 (0.89, 1.15) 0.96 (0.83, 1.10) 1.29 (1.06, 1.55) 
Both 118, 3.87, 30.51 (25.47, 36.54) 0.86 (0.69, 1.07) 0.89 (0.71, 1.10) 1.19 (0.92, 1.54) 
     Angina 
 
Unexposed 189, 8.40, 22.51 (19.52, 25.96) 1.00 (   .,    .) 1.00 (   .,    .) 1.13 (0.87, 1.46) 
Tamoxifen 87, 4.83, 18.00 (14.59, 22.21) 0.85 (0.66, 1.10) 0.88 (0.68, 1.14) 1.00 (   .,    .) 
AI 710, 30.61, 23.20 (21.55, 24.97) 1.06 (0.90, 1.26) 1.05 (0.89, 1.25) 1.19 (0.95, 1.50) 
Both 76, 3.97, 19.13 (15.28, 23.95) 0.89 (0.68, 1.17) 0.95 (0.72, 1.25) 1.07 (0.78, 1.46) 
     MI 
      
Unexposed 153, 9.39, 16.30 (13.91, 19.10) 1.00 (   .,    .) 1.00 (   .,    .) 2.29 (1.58, 3.33) 
Tamoxifen 38, 5.41, 7.02 (5.11, 9.65) 0.45 (0.31, 0.65) 0.44 (0.30, 0.63) 1.00 (   .,    .) 
AI 407, 34.29, 11.87 (10.77, 13.08) 0.90 (0.74, 1.10) 0.79 (0.64, 0.97) 1.81 (1.28, 2.58) 
Both 42, 4.35, 9.66 (7.14, 13.07) 0.71 (0.50, 1.01) 0.67 (0.47, 0.96) 1.53 (0.97, 2.42) 
     Revascularisation 
 
Unexposed 65, 9.40, 6.91 (5.42, 8.81) 1.00 (   .,    .) 1.00 (   .,    .) 1.60 (0.99, 2.57) 
Tamoxifen 25, 5.37, 4.66 (3.15, 6.89) 0.65 (0.41, 1.05) 0.63 (0.39, 1.01) 1.00 (   .,    .) 
AI 234, 34.29, 6.82 (6.00, 7.76) 0.92 (0.69, 1.23) 0.91 (0.68, 1.23) 1.46 (0.95, 2.24) 
Both 30, 4.33, 6.94 (4.85, 9.92) 0.93 (0.60, 1.46) 0.99 (0.63, 1.55) 1.57 (0.91, 2.72) 
     SCA 
 
 
Unexposed 80, 9.70, 8.25 (6.63, 10.27) 1.00 (   .,    .) 1.00 (   .,    .) 1.49 (0.96, 2.33) 
Tamoxifen 29, 5.50, 5.28 (3.67, 7.59) 0.69 (0.44, 1.07) 0.67 (0.43, 1.04) 1.00 (   .,    .) 
AI 222, 35.21, 6.31 (5.53, 7.19) 0.91 (0.69, 1.20) 0.78 (0.59, 1.04) 1.17 (0.78, 1.76) 
Both 28, 4.48, 6.25 (4.32, 9.05) 0.82 (0.52, 1.31) 0.80 (0.50, 1.28) 1.20 (0.69, 2.08) 
PVD Unexposed 331, 7.81, 42.40 (38.07, 47.23) 1.00 (   .,    .) 1.00 (   .,    .) 1.10 (0.91, 1.34) 
Tamoxifen 158, 4.56, 34.64 (29.64, 40.48) 0.89 (0.74, 1.08) 0.91 (0.75, 1.10) 1.00 (   .,    .) 
AI 1075, 28.85, 37.26 (35.10, 39.55) 1.05 (0.92, 1.19) 1.00 (0.87, 1.14) 1.10 (0.92, 1.31) 
Both 129, 3.81, 33.85 (28.48, 40.22) 0.91 (0.73, 1.12) 0.93 (0.75, 1.15) 1.02 (0.80, 1.30) 
Stroke 
 
Unexposed 404, 7.66, 52.76 (47.86, 58.16) 1.00 (   .,    .) 1.00 (   .,    .) 1.22 (1.02, 1.45) 
Tamoxifen 190, 4.65, 40.85 (35.43, 47.09) 0.85 (0.71, 1.02) 0.82 (0.69, 0.98) 1.00 (   .,    .) 
AI 1126, 28.82, 39.07 (36.85, 41.42) 0.93 (0.82, 1.05) 0.87 (0.76, 0.98) 1.05 (0.90, 1.24) 
Both 134, 3.72, 36.06 (30.44, 42.71) 0.84 (0.69, 1.03) 0.81 (0.66, 1.00) 0.99 (0.79, 1.24) 
Arrhythmia      
     
Unexposed 510, 5.97, 85.40 (78.30, 93.14) 1.00 (   .,    .) 1.00 (   .,    .) 1.34 (1.14, 1.58) 
Tamoxifen 222, 3.67, 60.49 (53.04, 69.00) 0.73 (0.62, 0.86) 0.75 (0.63, 0.88) 1.00 (   .,    .) 
AI 1640, 22.80, 71.92 (68.52, 75.48) 0.94 (0.85, 1.05) 0.91 (0.81, 1.01) 1.22 (1.05, 1.41) 
Both 189, 2.87, 65.90 (57.14, 76.00) 0.85 (0.71, 1.01) 0.88 (0.74, 1.04) 1.17 (0.96, 1.43) 
HF Unexposed 488, 6.77, 72.07 (65.95, 78.76) 1.00 (   .,    .) 1.00 (   .,    .) 1.15 (0.98, 1.36) 
Tamoxifen 233, 4.17, 55.90 (49.16, 63.56) 0.85 (0.72, 1.00) 0.87 (0.74, 1.02) 1.00 (   .,    .) 
AI 1368, 26.03, 52.56 (49.85, 55.42) 0.93 (0.83, 1.04) 0.84 (0.75, 0.94) 0.96 (0.83, 1.12) 
Both 167, 3.44, 48.56 (41.72, 56.51) 0.85 (0.71, 1.02) 0.83 (0.69, 1.00) 0.96 (0.78, 1.18) 
Pericarditis Unexposed 74, 9.48, 7.80 (6.21, 9.80) 1.00 (   .,    .) 1.00 (   .,    .) 2.69 (1.54, 4.71) 
Tamoxifen 16, 5.44, 2.94 (1.80, 4.80) 0.37 (0.21, 0.64) 0.37 (0.21, 0.65) 1.00 (   .,    .) 
AI 197, 34.48, 5.71 (4.97, 6.57) 0.74 (0.56, 0.98) 0.67 (0.50, 0.90) 1.81 (1.06, 3.08) 
Both 20, 4.43, 4.52 (2.91, 7.00) 0.55 (0.33, 0.93) 0.57 (0.34, 0.96) 1.53 (0.77, 3.05) 
VHD 
     
Unexposed 447, 6.08, 73.51 (67.00, 80.65) 1.00 (   .,    .) 1.00 (   .,    .) 1.24 (1.05, 1.47) 
Tamoxifen 205, 3.69, 55.62 (48.50, 63.78) 0.78 (0.66, 0.93) 0.81 (0.68, 0.96) 1.00 (   .,    .) 
AI 1513, 22.37, 67.63 (64.31, 71.13) 1.01 (0.90, 1.13) 0.98 (0.87, 1.09) 1.21 (1.04, 1.41) 
Both 175, 2.86, 61.13 (52.72, 70.90) 0.90 (0.75, 1.07) 0.94 (0.78, 1.13) 1.16 (0.94, 1.43) 
VTE 
      
Unexposed 78, 9.34, 8.35 (6.69, 10.43) 1.00 (   .,    .) 1.00 (   .,    .) 0.72 (0.51, 1.02) 
Tamoxifen 58, 5.41, 10.73 (8.30, 13.88) 1.39 (0.98, 1.97) 1.39 (0.98, 1.98) 1.00 (   .,    .) 
AI 284, 33.99, 8.36 (7.44, 9.39) 1.17 (0.90, 1.52) 1.11 (0.84, 1.46) 0.80 (0.59, 1.07) 
Both 54, 4.31, 12.54 (9.60, 16.37) 1.67 (1.16, 2.41) 1.71 (1.18, 2.47) 1.23 (0.83, 1.81) 
     DVT 
 
     
Unexposed 72, 9.36, 7.69 (6.11, 9.69) 1.00 (   .,    .) 1.00 (   .,    .) 0.71 (0.49, 1.02) 
Tamoxifen 54, 5.42, 9.97 (7.63, 13.01) 1.41 (0.98, 2.03) 1.42 (0.98, 2.04) 1.00 (   .,    .) 
AI 263, 34.05, 7.72 (6.85, 8.72) 1.18 (0.89, 1.56) 1.14 (0.86, 1.52) 0.81 (0.59, 1.09) 
Both 53, 4.31, 12.29 (9.39, 16.09) 1.79 (1.23, 2.60) 1.85 (1.26, 2.71) 1.31 (0.88, 1.94) 
     PE** 
     
Unexposed -, -, 0.93 (0.48, 1.78) 1.00 (   .,    .) 1.00 (   .,    .) 0.95 (0.32, 2.87) 
Tamoxifen -, -, 0.91 (0.38, 2.18) 1.02 (0.34, 3.06) 1.05 (0.35, 3.16) 1.00 (   .,    .) 
AI 29, 35.26, 0.82 (0.57, 1.18) 1.01 (0.47, 2.18) 0.80 (0.36, 1.79) 0.77 (0.29, 2.04) 
Both -, -, 0.22 (0.03, 1.58) 0.27 (0.03, 2.19) 0.26 (0.03, 2.08) 0.24 (0.03, 2.11) 
*Events and follow-up suppressed if number of events < 11 
**With reference category changed to ever tamoxifen 
† HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, other); SEER region (North 
East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); current calendar year; use 
of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, ACE inhibitors, calcium channel blockers, angiotensin receptor 
blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, diabetes, VTE, and non-venous CVD 
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Appendix 6.8 - Adjusted HRs, events, and crude rate for the association between 
current exposure to endocrine therapy and a range of clinical CVD outcomes 
Outcome Current exposure Events, Follow-up, Rate (95% 
CI)* (per 1000 pyears)  
Unadjusted HR 
(95% CI) 
Adjusted HR  
(95% CI) 
Coronary Artery 
Disease 
 
Unexposed 318, 8.22, 38.70 (34.67, 
43.19) 
1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 141, 5.25, 26.85 (22.76, 
31.66) 
0.77 (0.63, 0.94) 0.77 (0.63, 0.94) 
AI 807, 24.32, 33.19 (30.97, 
35.56) 
0.96 (0.84, 1.10) 0.89 (0.77, 1.02) 
Past with AI 316, 7.76, 40.71 (36.46, 
45.45) 
1.11 (0.95, 1.31) 1.11 (0.94, 1.32) 
Past Tam only 42, 1.35, 31.00 (22.91, 41.95) 0.78 (0.56, 1.08) 0.85 (0.61, 1.19) 
     Angina 
 
Unexposed 189, 8.40, 22.51 (19.52, 
25.96) 
1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 99, 5.33, 18.58 (15.26, 22.63) 0.88 (0.69, 1.13) 0.90 (0.70, 1.15) 
AI 561, 24.73, 22.69 (20.89, 
24.65) 
1.05 (0.88, 1.25) 1.03 (0.86, 1.23) 
Past with AI 188, 7.99, 23.54 (20.40, 
27.16) 
1.06 (0.86, 1.30) 1.10 (0.89, 1.36) 
Past Tam only 25, 1.37, 18.22 (12.31, 26.96) 0.83 (0.55, 1.27) 0.93 (0.61, 1.41) 
     MI 
 
Unexposed 153, 9.39, 16.30 (13.91, 
19.10) 
1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 40, 5.87, 6.82 (5.00, 9.29) 0.49 (0.34, 0.70) 0.47 (0.33, 0.67) 
AI 299, 27.59, 10.84 (9.68, 
12.14) 
0.83 (0.67, 1.02) 0.71 (0.57, 0.88) 
Past with AI 135, 9.03, 14.96 (12.63, 
17.70) 
1.06 (0.84, 1.35) 0.98 (0.77, 1.26) 
Past Tam only 13, 1.57, 8.29 (4.82, 14.28) 0.45 (0.25, 0.84) 0.46 (0.25, 0.85) 
     Revascularisation 
 
Unexposed 65, 9.40, 6.91 (5.42, 8.81) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 37, 5.82, 6.35 (4.60, 8.77) 0.92 (0.61, 1.38) 0.89 (0.59, 1.35) 
AI 185, 27.54, 6.72 (5.82, 7.76) 0.89 (0.66, 1.20) 0.89 (0.65, 1.21) 
Past with AI 60, 9.06, 6.62 (5.14, 8.53) 0.90 (0.63, 1.30) 0.89 (0.62, 1.30) 
Past Tam only 7, 1.56, 4.49 (2.14, 9.41) 0.56 (0.24, 1.29) 0.54 (0.23, 1.27) 
     SCA 
 
Unexposed 80, 9.70, 8.25 (6.63, 10.27) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 25, 5.96, 4.20 (2.83, 6.21) 0.59 (0.37, 0.94) 0.58 (0.36, 0.92) 
AI 150, 28.25, 5.31 (4.53, 6.23) 0.77 (0.57, 1.03) 0.64 (0.48, 0.87) 
Past with AI 87, 9.38, 9.28 (7.52, 11.44) 1.21 (0.88, 1.67) 1.11 (0.80, 1.54) 
Past Tam only 17, 1.60, 10.62 (6.60, 17.09) 1.30 (0.76, 2.22) 1.31 (0.76, 2.27) 
PVD Unexposed 331, 7.81, 42.40 (38.07, 
47.23) 
1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 156, 5.01, 31.16 (26.64, 
36.46) 
0.84 (0.69, 1.03) 0.85 (0.70, 1.03) 
AI 830, 23.42, 35.44 (33.11, 
37.93) 
1.01 (0.88, 1.15) 0.95 (0.82, 1.09) 
Past with AI 312, 7.50, 41.62 (37.25, 
46.51) 
1.09 (0.93, 1.28) 1.10 (0.93, 1.29) 
Past Tam only 64, 1.30, 49.07 (38.41, 62.69) 1.14 (0.86, 1.50) 1.21 (0.91, 1.60) 
Stroke 
 
Unexposed 404, 7.66, 52.76 (47.86, 
58.16) 
1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 197, 5.11, 38.52 (33.50, 
44.29) 
0.87 (0.73, 1.03) 0.83 (0.69, 0.99) 
AI 856, 23.48, 36.46 (34.10, 
38.99) 
0.88 (0.78, 1.00) 0.81 (0.71, 0.93) 
Past with AI 346, 7.29, 47.43 (42.69, 
52.70) 
1.06 (0.91, 1.23) 1.02 (0.87, 1.18) 
Past Tam only 51, 1.30, 39.13 (29.74, 51.48) 0.73 (0.53, 0.99) 0.73 (0.54, 1.00) 
Arrhythmia      
 
Unexposed 510, 5.97, 85.40 (78.30, 
93.14) 
1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 231, 4.09, 56.52 (49.68, 
64.30) 
0.71 (0.60, 0.83) 0.72 (0.61, 0.84) 
AI 1285, 18.65, 68.91 (65.24, 
72.78) 
0.91 (0.81, 1.01) 0.86 (0.77, 0.97) 
Past with AI 456, 5.62, 81.09 (73.98, 
88.89) 
1.02 (0.90, 1.17) 1.02 (0.89, 1.17) 
Past Tam only 79, 0.98, 80.35 (64.45, 
100.17) 
0.92 (0.73, 1.18) 0.99 (0.77, 1.26) 
HF Unexposed 488, 6.77, 72.07 (65.95, 
78.76) 
1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 217, 4.62, 47.00 (41.14, 
53.69) 
0.78 (0.66, 0.92) 0.77 (0.65, 0.91) 
AI 1058, 21.14, 50.04 (47.12, 
53.15) 
0.90 (0.80, 1.00) 0.79 (0.70, 0.89) 
Past with AI 412, 6.69, 61.59 (55.92, 
67.83) 
1.02 (0.89, 1.17) 0.99 (0.86, 1.14) 
Past Tam only 81, 1.19, 68.32 (54.95, 84.94) 0.96 (0.76, 1.23) 1.05 (0.82, 1.34) 
Pericarditis Unexposed 74, 9.48, 7.80 (6.21, 9.80) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 18, 5.89, 3.06 (1.93, 4.85) 0.41 (0.25, 0.70) 0.42 (0.25, 0.70) 
AI 159, 27.66, 5.75 (4.92, 6.72) 0.75 (0.56, 1.00) 0.67 (0.50, 0.90) 
Past with AI 50, 9.21, 5.43 (4.11, 7.16) 0.66 (0.46, 0.97) 0.65 (0.45, 0.96) 
Past Tam only -, -, 3.77 (1.69, 8.39) 0.41 (0.16, 1.01) 0.43 (0.17, 1.06) 
VHD 
 
Unexposed 447, 6.08, 73.51 (67.00, 
80.65) 
1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 224, 4.01, 55.84 (48.99, 
63.66) 
0.82 (0.69, 0.96) 0.82 (0.69, 0.97) 
AI 1181, 18.20, 64.91 (61.31, 
68.72) 
0.97 (0.87, 1.09) 0.92 (0.82, 1.04) 
Past with AI 423, 5.68, 74.43 (67.66, 
81.87) 
1.08 (0.94, 1.24) 1.11 (0.97, 1.28) 
Past Tam only 65, 1.03, 63.11 (49.49, 80.47) 0.83 (0.64, 1.09) 0.92 (0.70, 1.20) 
VTE 
 
Unexposed 78, 9.34, 8.35 (6.69, 10.43) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 75, 5.88, 12.75 (10.17, 15.99) 1.71 (1.23, 2.38) 1.68 (1.21, 2.35) 
AI 222, 27.31, 8.13 (7.13, 9.27) 1.15 (0.87, 1.51) 1.07 (0.81, 1.42) 
Past with AI 87, 8.95, 9.72 (7.88, 11.99) 1.28 (0.93, 1.76) 1.27 (0.91, 1.76) 
Past Tam only 12, 1.56, 7.68 (4.36, 13.52) 0.98 (0.53, 1.81) 1.04 (0.56, 1.92) 
     DVT 
 
Unexposed 72, 9.36, 7.69 (6.11, 9.69) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 71, 5.90, 12.04 (9.54, 15.20) 1.77 (1.26, 2.48) 1.74 (1.23, 2.46) 
AI 207, 27.35, 7.57 (6.60, 8.67) 1.17 (0.88, 1.55) 1.11 (0.83, 1.49) 
Past with AI 81, 8.96, 9.04 (7.27, 11.24) 1.29 (0.92, 1.80) 1.31 (0.93, 1.84) 
Past Tam only -, -, 7.03 (3.89, 12.69) 0.98 (0.52, 1.86) 1.04 (0.55, 1.98) 
     PE 
 
Unexposed -, -, 0.93 (0.48, 1.78) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen -, -, 0.67 (0.25, 1.78) 0.79 (0.24, 2.58) 0.77 (0.22, 2.53) 
AI 20, 28.27, 0.71 (0.46, 1.10) 0.86 (0.38, 1.95) 0.68 (0.29, 1.57) 
Past with AI -, -, 0.96 (0.50, 1.84) 1.14 (0.45, 2.91) 0.97 (0.37, 2.53) 
Past Tam only -, -, 1.25 (0.31, 4.98) 1.38 (0.30, 6.43) 1.51 (0.32, 7.14) 
*Events and follow-up suppressed if number of events < 11 
† HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, 
other); SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (<1yr, 1 
to <3yrs, 3 to <5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-
hypertensive drugs, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney 
disease, hypertension, diabetes, VTE, and non-venous CVD 
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Appendix 6.9 – Adjusted HRs for association between ever exposure to endocrine therapies 
and risk of coronary artery disease, stratified by age, time since index, and prior CVD 
* HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, other); 
SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (<1yr, 1 to <3yrs, 3 to 
<5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, 
ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, 
diabetes, VTE, and non-venous CVD 
** p value from Wald test for interaction 
66-74 
75-84 
No 
Yes 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
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Appendix 6.10 – Adjusted HRs for association between ever exposure to endocrine 
therapies and risk of angina, stratified by age, time since index, and prior CVD 
67-74 
74-84 
67-74 
74-84 
67-74 
74-84 
66-74 
75-84 
No 
Yes 
* HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, other); 
SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date <1yr, 1 to <3yrs, 3 to 
<5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, 
ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, 
diabetes, VTE, and non-venous CVD 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
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Appendix 6.11 – Adjusted HRs for association between ever exposure to endocrine 
therapies and risk of MI, stratified by age, time since index, and prior CVD 
66-74 
75-84 
No 
Yes 
* HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, other); 
SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (<1yr, 1 to <3yrs, 3 to 
<5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, 
ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, 
diabetes, VTE, and non-venous CVD 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3+yrs 
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Appendix 6.12 – Adjusted HRs for association between ever exposure to endocrine 
therapies and risk of revascularisation, stratified by age, time since index, and prior CVD 
66-74 
75-84 
No 
Yes 
* HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, other); 
SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (<1yr, 1 to <3yrs, 3 to 
<5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, 
ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, 
diabetes, VTE, and non-venous CVD 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3+yrs 
 
 
276 
 
Appendix 6.13 – Adjusted HRs for association between ever exposure to endocrine 
therapies and risk of SCA, stratified by age, time since index, and prior CVD 
67-74 
74-84 
66-74 
5
No 
Yes 
* HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, other); 
SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (<1yr, 1 to <3yrs, 3 to 
<5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, 
ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, 
diabetes, VTE, and non-venous CVD 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3+yrs 
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Appendix 6.14 – Adjusted HRs for association between ever exposure to endocrine 
therapies and risk of PVD, stratified by age, time since index, and prior CVD 
66-74 
75-84 
No 
Yes 
* HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, other); 
SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (<1yr, 1 to <3yrs, 3 to 
<5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, 
ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, 
diabetes, VTE, and non-venous CVD 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
 
278 
 
Appendix 6.15 – Adjusted HRs for association between ever exposure to endocrine 
therapies and risk of stroke, stratified by age, time since index, and prior CVD 
66-74 
75-84 
No 
Yes 
* HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, other); 
SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (<1yr, 1 to <3yrs, 3 to 
<5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, 
ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, 
diabetes, VTE, and non-venous CVD 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
1 to < 3yrs 
 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
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Appendix 6.16 – Adjusted HRs for association between ever exposure to endocrine 
therapies and risk of arrhythmia, stratified by age, time since index, and prior CVD 
67-74 
74-84 
 
 
6
5
No 
Yes 
* HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, other); 
SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date <1yr, 1 to <3yrs, 3 to 
<5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, 
ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, 
diabetes, VTE, and non-venous CVD 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3+yrs 
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Appendix 6.17 – Adjusted HRs for association between ever exposure to endocrine 
therapies and risk of HF, stratified by age, time since index, and prior CVD 
67-74 
74-84 
66-74 
5  
No 
Yes 
* HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, other); 
SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (<1yr, 1 to <3yrs, 3 to 
<5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, 
ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, 
diabetes, VTE, and non-venous CVD 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
1 to < 3yrs 
 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
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Appendix 6.18 – Adjusted HRs for association between ever exposure to endocrine 
therapies and risk of pericarditis, stratified by age, time since index, and prior CVD 
66-74 
75-84 
No 
Yes 
* HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, other); 
SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (<1yr, 1 to <3yrs, 3 to 
<5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, 
ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, 
diabetes, VTE, and non-venous CVD 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3+yrs 
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Appendix 6.19 – Adjusted HRs for association between ever exposure to endocrine 
therapies and risk of VHD, stratified by age, time since index, and prior CVD 
67-74 
74-84 
6
75-84 
No 
Yes 
* HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, other); 
SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (<1yr, 1 to <3yrs, 3 to 
<5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, 
ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, 
diabetes, VTE, and non-venous CVD 
** p value from Wald test for interaction 
* ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
3 to < 5yrs 
 
 
 
5+yrs 
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Appendix 6.20 – Adjusted HRs for association between ever exposure to endocrine 
therapies and risk of VTE, stratified by age, time since index, and prior CVD 
66-74 
75-84 
No 
Yes 
* HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, other); 
SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (<1yr, 1 to <3yrs, 3 to 
<5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, 
ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, 
diabetes, VTE, and non-venous CVD 
** p value from Wald test for interaction 
 * ** 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3+yrs 
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66-74 
75-84 
No 
Yes 
* HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, other); 
SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (<1yr, 1 to <3yrs, 3 to 
<5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, 
ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, 
diabetes, VTE, and non-venous CVD 
** p value from Wald test for interaction 
* ** 
Appendix 6.21 – Adjusted HRs for association between ever exposure to endocrine 
therapies and risk of DVT, stratified by age, time since index, and prior CVD 
< 1yr 
 
 
 
1 to < 3yrs 
 
 
 
3+yrs 
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Appendix 6.22 - Adjusted HRs for the association between ever exposure to endocrine therapy and 
a range of clinical CVD outcomes, directly comparing the risk in AI and tamoxifen users 
Outcome Ever tamoxifen vs 
unexposed to any 
endocrine therapy 
(original study 
population) 
Ever AI vs 
unexposed to any 
endocrine therapy 
(original study 
population) 
Ever AI vs ever 
tamoxifen 
(original study 
population) 
Ever AI vs ever tamoxifen 
(study population restricted 
to only those with 
tamoxifen/AI prescription) 
Coronary Artery Disease 0.74 (0.60, 0.92) 0.96 (0.83, 1.10) 1.29 (1.06, 1.55) 1.35 (1.13, 1.63) 
     Angina 0.88 (0.68, 1.14) 1.05 (0.89, 1.25) 1.19 (0.95, 1.50) 1.27 (1.01, 1.58) 
     MI 0.44 (0.30, 0.63) 0.79 (0.64, 0.97) 1.81 (1.28, 2.58) 1.88 (1.34, 2.64) 
     Revascularisation 0.63 (0.39, 1.01) 0.91 (0.68, 1.23) 1.46 (0.95, 2.24) 1.38 (0.91, 2.09) 
     SCA 0.67 (0.43, 1.04) 0.78 (0.59, 1.04) 1.17 (0.78, 1.76) 1.29 (0.87, 1.91) 
PVD 0.91 (0.75, 1.10) 1.00 (0.87, 1.14) 1.10 (0.92, 1.31) 1.13 (0.96, 1.34) 
Stroke 0.82 (0.69, 0.98) 0.87 (0.76, 0.98) 1.05 (0.90, 1.24) 1.07 (0.92, 1.25) 
Arrhythmia 0.75 (0.63, 0.88) 0.91 (0.81, 1.01) 1.22 (1.05, 1.41) 1.21 (1.05, 1.40) 
HF 0.87 (0.74, 1.02) 0.84 (0.75, 0.94) 0.96 (0.83, 1.12) 1.01 (0.87, 1.16) 
Pericarditis 0.37 (0.21, 0.65) 0.67 (0.50, 0.90) 1.81 (1.06, 3.08) 1.97 (1.18, 3.29) 
VHD 0.81 (0.68, 0.96) 0.98 (0.87, 1.09) 1.21 (1.04, 1.41) 1.25 (1.08, 1.45) 
VTE 1.39 (0.98, 1.98) 1.11 (0.84, 1.46) 0.80 (0.59, 1.07) 0.85 (0.64, 1.13) 
     DVT 1.42 (0.98, 2.04) 1.14 (0.86, 1.52) 0.81 (0.59, 1.09) 0.85 (0.63, 1.15) 
     PE 1.05 (0.35, 3.16) 0.80 (0.36, 1.79) 0.77 (0.29, 2.04) 0.95 (0.36, 2.48) 
† HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, 
other); SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (<1yr, 1 to 
<3yrs, 3 to <5yrs, 5+yrs ); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-
hypertensive drugs, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney 
disease, hypertension, diabetes, VTE, and non-venous CVD 
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Appendix 6.23 - Sensitivity analysis – Adjusted HRs for the association between current 
exposure to endocrine therapy and the risk of a rand of CVDs, with different grace periods, 
where the grace period is the maximum gap in prescription coverage for exposure to be 
considered continuous 
 
 
Outcome Current exposure  Adjusted HR – 1m grace 
(original) 
Adjusted HR – 3m grace Adjusted HR – 6m grace Adjusted HR – 1y grace 
Coronary Artery 
Disease 
 
Unexposed 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 0.77 (0.63, 0.94) 0.75 (0.62, 0.92) 0.78 (0.64, 0.95) 0.79 (0.66, 0.96) 
AI 0.89 (0.77, 1.02) 0.91 (0.79, 1.05) 0.92 (0.80, 1.06) 0.93 (0.81, 1.07) 
Past with AI 1.11 (0.94, 1.32) 1.08 (0.90, 1.28) 1.06 (0.87, 1.28) 1.02 (0.82, 1.27) 
Past Tam only 0.85 (0.61, 1.19) 0.85 (0.60, 1.22) 0.81 (0.55, 1.20) 0.78 (0.49, 1.23) 
     Angina 
 
Unexposed 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 0.90 (0.70, 1.15) 0.86 (0.67, 1.10) 0.90 (0.71, 1.15) 0.93 (0.74, 1.17) 
AI 1.03 (0.86, 1.23) 1.02 (0.86, 1.22) 1.03 (0.86, 1.22) 1.03 (0.87, 1.23) 
Past with AI 1.10 (0.89, 1.36) 1.11 (0.89, 1.39) 1.10 (0.86, 1.40) 1.10 (0.83, 1.45) 
Past Tam only 0.93 (0.61, 1.41) 0.98 (0.63, 1.52) 0.94 (0.58, 1.51) 0.74 (0.40, 1.36) 
     MI 
 
Unexposed 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 0.47 (0.33, 0.67) 0.49 (0.35, 0.70) 0.50 (0.36, 0.70) 0.49 (0.36, 0.68) 
AI 0.71 (0.57, 0.88) 0.73 (0.59, 0.91) 0.75 (0.61, 0.93) 0.77 (0.63, 0.95) 
Past with AI 0.98 (0.77, 1.26) 0.94 (0.72, 1.22) 0.91 (0.69, 1.21) 0.85 (0.61, 1.17) 
Past Tam only 0.46 (0.25, 0.85) 0.43 (0.22, 0.85) 0.39 (0.18, 0.84) 0.44 (0.19, 1.00) 
     Revascularisation 
 
Unexposed 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 0.89 (0.59, 1.35) 0.89 (0.59, 1.33) 0.84 (0.56, 1.27) 0.84 (0.56, 1.25) 
AI 0.89 (0.65, 1.21) 0.88 (0.65, 1.20) 0.89 (0.66, 1.20) 0.89 (0.66, 1.21) 
Past with AI 0.89 (0.62, 1.30) 0.90 (0.61, 1.34) 0.89 (0.58, 1.35) 0.84 (0.52, 1.36) 
Past Tam only 0.54 (0.23, 1.27) 0.53 (0.21, 1.31) 0.61 (0.24, 1.52) 0.66 (0.24, 1.83) 
     SCA 
 
Unexposed 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 0.58 (0.36, 0.92) 0.63 (0.41, 0.98) 0.66 (0.43, 1.02) 0.67 (0.44, 1.01) 
AI 0.64 (0.48, 0.87) 0.72 (0.54, 0.96) 0.73 (0.55, 0.98) 0.75 (0.57, 1.00) 
Past with AI 1.11 (0.80, 1.54) 0.93 (0.65, 1.34) 0.94 (0.64, 1.39) 0.87 (0.55, 1.36) 
Past Tam only 1.31 (0.76, 2.27) 1.24 (0.69, 2.25) 1.11 (0.57, 2.16) 1.34 (0.67, 2.70) 
PVD 
 
Unexposed 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 0.85 (0.70, 1.03) 0.84 (0.69, 1.01) 0.87 (0.72, 1.05) 0.93 (0.77, 1.11) 
AI 0.95 (0.82, 1.09) 0.97 (0.85, 1.12) 0.98 (0.86, 1.13) 0.99 (0.86, 1.13) 
Past with AI 1.10 (0.93, 1.29) 1.06 (0.89, 1.26) 1.01 (0.83, 1.22) 0.99 (0.80, 1.23) 
Past Tam only 1.21 (0.91, 1.60) 1.28 (0.96, 1.70) 1.29 (0.95, 1.75) 1.06 (0.72, 1.55) 
Stroke 
 
Unexposed 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 0.83 (0.69, 0.99) 0.82 (0.69, 0.98) 0.82 (0.69, 0.97) 0.83 (0.70, 0.98) 
AI 0.81 (0.71, 0.93) 0.82 (0.72, 0.93) 0.84 (0.74, 0.95) 0.85 (0.75, 0.96) 
Past with AI 1.02 (0.87, 1.18) 1.02 (0.87, 1.20) 0.99 (0.83, 1.17) 0.92 (0.75, 1.13) 
Past Tam only 0.73 (0.54, 1.00) 0.74 (0.53, 1.02) 0.77 (0.55, 1.09) 0.80 (0.55, 1.18) 
Arrhythmia      
 
Unexposed 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 0.72 (0.61, 0.84) 0.73 (0.63, 0.86) 0.75 (0.64, 0.87) 0.76 (0.65, 0.88) 
AI 0.86 (0.77, 0.97) 0.89 (0.79, 0.99) 0.89 (0.80, 1.00) 0.89 (0.80, 0.99) 
Past with AI 1.02 (0.89, 1.17) 0.98 (0.85, 1.13) 0.95 (0.81, 1.10) 0.96 (0.81, 1.15) 
Past Tam only 0.99 (0.77, 1.26) 0.94 (0.72, 1.22) 0.96 (0.73, 1.28) 1.11 (0.81, 1.50) 
HF 
 
Unexposed 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 0.77 (0.65, 0.91) 0.82 (0.70, 0.96) 0.82 (0.70, 0.96) 0.81 (0.69, 0.94) 
AI 0.79 (0.70, 0.89) 0.80 (0.71, 0.90) 0.82 (0.73, 0.92) 0.83 (0.74, 0.93) 
Past with AI 0.99 (0.86, 1.14) 0.96 (0.83, 1.12) 0.94 (0.80, 1.10) 0.95 (0.79, 1.14) 
Past Tam only 1.05 (0.82, 1.34) 1.01 (0.77, 1.31) 1.00 (0.76, 1.33) 1.06 (0.78, 1.46) 
Pericarditis 
 
Unexposed 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 0.42 (0.25, 0.70) 0.42 (0.25, 0.70) 0.42 (0.25, 0.69) 0.38 (0.23, 0.63) 
AI 0.60 (0.50, 0.90) 0.70 (0.52, 0.94) 0.69 (0.51, 0.93) 0.70 (0.52, 0.94) 
Past with AI 0.65 (0.45, 0.96) 0.57 (0.37, 0.88) 0.58 (0.37, 0.92) 0.50 (0.28, 0.89) 
Past Tam only 0.43 (0.17, 1.06) 0.48 (0.19, 1.20) 0.57 (0.23, 1.41) 0.76 (0.30, 1.89) 
VHD 
 
Unexposed 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 0.82 (0.69, 0.97) 0.82 (0.70, 0.97) 0.83 (0.71, 0.98) 0.82 (0.70, 0.96) 
AI 0.92 (0.82, 1.04) 0.93 (0.83, 1.05) 0.94 (0.84, 1.06) 0.95 (0.85, 1.07) 
Past with AI 1.11 (0.97, 1.28) 1.10 (0.95, 1.28) 1.13 (0.96, 1.32) 1.17 (0.97, 1.40) 
Past Tam only 0.92 (0.70, 1.20) 0.95 (0.72, 1.26) 0.85 (0.62, 1.16) 1.00 (0.71, 1.40) 
VTE 
 
Unexposed 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 1.68 (1.21, 2.35) 1.70 (1.22, 2.35) 1.68 (1.21, 2.32) 1.59 (1.15, 2.19) 
AI 1.07 (0.81, 1.42) 1.09 (0.83, 1.45) 1.09 (0.83, 1.44) 1.12 (0.85, 1.48) 
Past with AI 1.27 (0.91, 1.76) 1.19 (0.84, 1.68) 1.22 (0.84, 1.77) 1.10 (0.71, 1.69) 
Past Tam only 1.04 (0.56, 1.92) 0.90 (0.45, 1.80) 0.81 (0.37, 1.76) 0.94 (0.40, 2.16) 
     DVT 
 
Unexposed 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 1.74 (1.23, 2.46) 1.77 (1.26, 2.48) 1.75 (1.25, 2.45) 1.66 (1.19, 2.31) 
AI 1.11 (0.83, 1.49) 1.14 (0.85, 1.52) 1.14 (0.85, 1.52) 1.15 (0.87, 1.54) 
Past with AI 1.31 (0.93, 1.84) 1.22 (0.85, 1.75) 1.23 (0.83, 1.81) 1.18 (0.76, 1.84) 
Past Tam only 1.04 (0.55, 1.98) 0.88 (0.42, 1.83) 0.76 (0.33, 1.75) 0.85 (0.34, 2.13) 
     PE 
 
Unexposed 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 0.77 (0.22, 2.53) 0.74 (0.22, 2.44) 0.70 (0.21, 2.30) 0.65 (0.20, 2.14) 
AI 0.68 (0.29, 1.57) 0.71 (0.31, 1.64) 0.67 (0.29, 1.54) 0.77 (0.34, 1.74) 
Past with AI 0.97 (0.37, 2.53) 0.97 (0.34, 2.72) 1.23 (0.44, 3.47) 0.79 (0.21, 3.07) 
Past Tam only 1.51 (0.32, 7.14) 1.80 (0.38, 8.55) 2.19 (0.46, 10.41) 2.81 (0.59, 13.49) 
† HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, other); SEER region 
(North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs ); current 
calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, ACE inhibitors, calcium channel 
blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, diabetes, VTE, and non-venous CVD 
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Appendix 6.24 - Sensitivity analysis – Crude rates, unadjusted HRs, and adjusted HRs for the 
association between ever exposure to endocrine therapies and the risk of a range of clinical 
CVDs, excluding women over 85 
 Outcome Ever exposure Events, Follow-up, Rate (95% CI) 
(per 1000 pyears) * 
Unadjusted HR 
(95% CI) 
Adjusted HR  
(95% CI) 
Coronary Artery 
Disease 
 
Unexposed 177, 5.55, 31.86 (27.50, 36.92) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 96, 3.68, 26.08 (21.36, 31.86) 0.83 (0.65, 1.07) 0.85 (0.66, 1.10) 
AI 849, 25.84, 32.85 (30.71, 35.14) 1.06 (0.90, 1.25) 1.00 (0.84, 1.18) 
Both 91, 3.33, 27.30 (22.23, 33.53) 0.85 (0.66, 1.10) 0.88 (0.68, 1.15) 
     Angina 
 
Unexposed 111, 5.65, 19.64 (16.31, 23.65) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 69, 3.72, 18.55 (14.65, 23.49) 0.99 (0.73, 1.34) 1.03 (0.76, 1.39) 
AI 604, 26.30, 22.96 (21.20, 24.87) 1.19 (0.97, 1.47) 1.18 (0.96, 1.46) 
Both 62, 3.41, 18.20 (14.19, 23.35) 0.95 (0.69, 1.30) 1.01 (0.73, 1.39) 
     MI 
      
Unexposed 74, 6.32, 11.71 (9.33, 14.71) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 27, 4.13, 6.53 (4.48, 9.52) 0.55 (0.35, 0.86) 0.52 (0.33, 0.83) 
AI 298, 29.35, 10.15 (9.06, 11.38) 0.93 (0.71, 1.20) 0.80 (0.61, 1.04) 
Both 32, 3.71, 8.63 (6.11, 12.21) 0.74 (0.49, 1.14) 0.70 (0.46, 1.08) 
     Revascularisation 
 
Unexposed 46, 6.26, 7.34 (5.50, 9.80) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 24, 4.09, 5.86 (3.93, 8.74) 0.79 (0.48, 1.31) 0.75 (0.45, 1.25) 
AI 207, 29.27, 7.07 (6.17, 8.10) 0.94 (0.68, 1.31) 0.95 (0.68, 1.33) 
Both 26, 3.67, 7.08 (4.82, 10.39) 0.94 (0.57, 1.54) 1.01 (0.61, 1.67) 
     SCA 
 
 
Unexposed 40, 6.48, 6.17 (4.53, 8.42) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 18, 4.19, 4.29 (2.70, 6.81) 0.73 (0.42, 1.27) 0.74 (0.42, 1.31) 
AI 161, 30.07, 5.35 (4.59, 6.25) 0.88 (0.62, 1.26) 0.77 (0.54, 1.11) 
Both 20, 3.79, 5.28 (3.40, 8.18) 0.83 (0.48, 1.46) 0.89 (0.50, 1.57) 
PVD Unexposed 200, 5.43, 36.81 (32.05, 42.28) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 107, 3.57, 29.98 (24.81, 36.24) 0.84 (0.66, 1.07) 0.86 (0.68, 1.09) 
AI 847, 25.08, 33.77 (31.58, 36.13) 0.99 (0.85, 1.16) 0.96 (0.82, 1.13) 
Both 97, 3.28, 29.57 (24.23, 36.07) 0.83 (0.65, 1.07) 0.87 (0.67, 1.12) 
Stroke 
 
Unexposed 224, 5.33, 42.06 (36.90, 47.94) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 116, 3.68, 31.49 (26.25, 37.78) 0.77 (0.61, 0.97) 0.76 (0.60, 0.96) 
AI 879, 25.20, 34.88 (32.65, 37.27) 0.94 (0.81, 1.10) 0.88 (0.75, 1.03) 
Both 104, 3.24, 32.11 (26.50, 38.92) 0.84 (0.66, 1.07) 0.83 (0.65, 1.06) 
Arrhythmia      
     
Unexposed 328, 4.23, 77.46 (69.51, 86.31) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 155, 2.92, 53.08 (45.34, 62.13) 0.67 (0.55, 0.81) 0.69 (0.57, 0.84) 
AI 1346, 20.14, 66.85 (63.37, 70.51) 0.90 (0.79, 1.02) 0.86 (0.76, 0.98) 
Both 159, 2.53, 62.82 (53.78, 73.39) 0.82 (0.68, 1.00) 0.86 (0.71, 1.05) 
HF Unexposed 260, 4.88, 53.29 (47.19, 60.18) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 139, 3.34, 41.60 (35.23, 49.13) 0.78 (0.63, 0.96) 0.80 (0.65, 0.99) 
AI 1063, 23.01, 46.19 (43.50, 49.05) 0.92 (0.80, 1.06) 0.83 (0.72, 0.95) 
Both 126, 3.06, 41.12 (34.53, 48.97) 0.79 (0.64, 0.99) 0.78 (0.63, 0.98) 
Pericarditis Unexposed 51, 6.37, 8.01 (6.09, 10.54) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 12, 4.16, 2.89 (1.64, 5.08) 0.33 (0.17, 0.64) 0.35 (0.18, 0.67) 
AI 155, 29.46, 5.26 (4.50, 6.16) 0.63 (0.45, 0.87) 0.55 (0.39, 0.76) 
Both 17, 3.75, 4.53 (2.82, 7.29) 0.54 (0.31, 0.94) 0.54 (0.31, 0.96) 
VHD 
     
Unexposed 283, 4.33, 65.37 (58.19, 73.45) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 163, 2.93, 55.63 (47.71, 64.86) 0.88 (0.72, 1.07) 0.90 (0.74, 1.10) 
AI 1245, 19.65, 63.35 (59.93, 66.97) 1.02 (0.89, 1.16) 0.98 (0.86, 1.12) 
Both 143, 2.53, 56.44 (47.91, 66.49) 0.88 (0.72, 1.08) 0.92 (0.75, 1.14) 
VTE 
      
Unexposed 49, 6.26, 7.83 (5.92, 10.36) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 37, 4.13, 8.96 (6.49, 12.37) 1.18 (0.76, 1.82) 1.17 (0.76, 1.81) 
AI 225, 29.10, 7.73 (6.78, 8.81) 1.03 (0.75, 1.42) 1.00 (0.72, 1.38) 
Both 42, 3.66, 11.46 (8.47, 15.51) 1.53 (1.00, 2.34) 1.56 (1.01, 2.40) 
     DVT 
 
     
Unexposed 44, 6.27, 7.02 (5.23, 9.44) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen 36, 4.14, 8.71 (6.28, 12.07) 1.28 (0.82, 2.01) 1.27 (0.81, 2.00) 
AI 206, 29.16, 7.07 (6.16, 8.10) 1.05 (0.75, 1.46) 1.03 (0.73, 1.45) 
Both 41, 3.67, 11.18 (8.23, 15.18) 1.66 (1.07, 2.57) 1.70 (1.09, 2.66) 
     PE 
     
Unexposed -, -, 0.92 (0.41, 2.06) 1.00 (   .,    .) 1.00 (   .,    .) 
Tamoxifen -, -, 0.24 (0.03, 1.69) 0.26 (0.03, 2.17) 0.27 (0.03, 2.27) 
AI 25, 30.11, 0.83 (0.56, 1.23) 0.96 (0.39, 2.36) 0.84 (0.33, 2.14) 
Both -, -, 0.26 (0.04, 1.86) 0.31 (0.04, 2.57) 0.31 (0.04, 2.67) 
*Events and follow-up supressed if number of events < 11 
† HRs adjusted for: year of breast cancer diagnosis; age at index date (66-74, 75-84); race (White, Black Asian, Hispanic, Native American, 
other); SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date 
(<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs ); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, 
statins, anti-hypertensive drugs, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, 
chronic kidney disease, hypertension, diabetes, VTE, and non-venous CVD 
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CHAPTER 7 
 
Appendix 7.1 – HRs for the association between ever AI use compared with 
ever tamoxifen use and a range of clinical CVD outcomes, first unadjusted, 
then individually adjusted for antiplatelet use 
Outcome Adjustments HR (95% CI) Percentage difference 
between crude and 
adjusted (%) 
Coronary artery 
disease 
Crude  1.40 (1.06, 1.86) 4.3 
 Adjusted for 
antiplatelet use 
1.34 (1.01, 1.77)  
Angina Crude  1.43 (1.00, 2.05) 7 
 Adjusted for 
antiplatelet use 
1.33 (0.93, 1.90)  
MI Crude  1.73 (1.12, 2.68) 4 
 Adjusted for 
antiplatelet use 
1.66 (1.07, 2.57)  
Revascularisation Crude  1.36 (0.69, 2.68) 4.4 
 Adjusted for 
antiplatelet use 
1.30 (0.66, 2.57)  
SCA Crude  1.87 (0.83, 4.22) 1.6 
 Adjusted for 
antiplatelet use 
1.84 (0.82, 4.16)  
PVD Crude  1.25 (0.77, 2.01) 1.6 
 Adjusted for 
antiplatelet use 
1.23 (0.76, 1.99)  
Stroke Crude  1.22 (0.91, 1.63) 2.5 
 Adjusted for 
antiplatelet use 
1.19 (0.89, 1.59)  
Arrhythmia Crude  1.37 (1.14, 1.64) 2.2 
 Adjusted for 
antiplatelet use 
1.34 (1.11, 1.61)  
HF Crude  1.87 (1.43, 2.45) 6.4 
 Adjusted for 
antiplatelet use 
1.75 (1.34, 2.29)  
Pericarditis Crude  3.96 (1.12, 14.03) 1.3 
 Adjusted for 
antiplatelet use 
3.91 (1.10, 13.89)  
VHD Crude  1.58 (1.15, 2.17) 3.8 
 Adjusted for 
antiplatelet use 
1.52 (1.11, 2.10)  
VTE Crude  0.92 (0.71, 1.20) 1.1 
 Adjusted for 
antiplatelet use 
0.91 (0.70, 1.19)  
DVT Crude  0.69 (0.48, 0.98) 1.4 
 Adjusted for 
antiplatelet use 
0.68 (0.48, 0.97)  
PE Crude  1.39 (0.95, 2.04) 0 
 Adjusted for 
antiplatelet use 
1.39 (0.95, 2.03)  
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Appendix 7.2 – Adjusted HRs for the association between current exposure to endocrine therapy and a range of clinical CVD outcomes in restricted 
analyses in both the UK and US  
†Adjusted for: year of breast cancer; age at index date (66-74, 75-84, 85+); time since index date (<1yr, 1 to <3yrs, 3 to <5yrs, 5+yrs); current calendar year; use of statins; use of ACE inhibitors; use of calcium channel 
blockers; use of angiotensin receptor blockers; rheumatoid arthritis; chronic kidney disease; diabetes; VTE; and non-venous CVD 
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Appendix 7.3 – HF QOF Read code list 
Read code Read term 
585f.00 echocardiogram shows left ventricular systolic dysfunction 
662f.00 new york heart association classification - class i 
662g.00 new york heart association classification - class ii 
662h.00 new york heart association classification - class iii 
662i.00 new york heart association classification - class iv 
G58..00 heart failure 
G58..11 cardiac failure 
G5yy900 left ventricular systolic dysfunction 
G5yyD00 left ventricular cardiac dysfunction 
G1yz100 rheumatic left ventricular failure 
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